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CHAPTER	I		INTRODUCTION		Overview	In	all	domains	of	 life,	 cellular	 function	depends	upon	appropriate	regulation	of	the	genes	encoded	in	the	DNA	genome.		Historically,	this	regulation	was	described	in	terms	of	the	“central	dogma”	of	molecular	biology	(Crick,	1970)	whereby	DNA	is	transcribed	into	RNA,	which	is	in	turn	translated	into	proteins,	the	functional	workhorses	of	the	cell.	 	This	simplistic	 view	 of	 molecular	 biology	 –	 simplistic	 in	 the	 sense	 that	 the	 central	 dogma	primarily	 applies	 to	 coding	 RNA	 (messenger	 RNAs	 (mRNA))	 and	 not	 non-coding	 RNAs	(transfer	RNA	 (tRNA),	 ribosomal	RNA	 (rRNA),	 small	 non-coding	RNAs	 (ncRNA)	 and	 long	non-coding	 RNA	 (lncRNAs))	 which	 perform	 important	 cellular	 functions	 without	 being	translated	into	proteins	–	provides	an	important	framework	to	understand	how	the	cell	can	regulate	the	expression	of	the	DNA	genome.		Specifically,	gene	activity	can	be	increased	or	decreased	 based	 on	 processes	 that	 regulate	 the	 synthesis	 or	 degradation	 of	 RNA	(transcription),	the	conversion	of	RNA	to	protein	(translation)	or	the	activity	or	stability	of	the	 protein	 product.	 	 At	 the	 cellular	 level,	 appropriate	 gene	 regulation	 dictates	 cellular	function	 and	 identity,	 which	 is	 especially	 important	 in	 multicellular	 organisms.		Considering	the	human	genome	consists	of	approximately	3	billion	base	pairs	encoding	at	least	20,000	mRNA	genes	that	must	be	coordinately	and	differentially	regulated	in	all	of	the	tissue	 types	 of	 the	 body,	 the	 importance	 of	 gene	 regulation	 in	 cellular	 and	 organismal	
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function	 cannot	 be	 overstated	 (International	 Human	 Genome	 Sequencing	 Consortium,	2004).	 The	 focus	of	 this	dissertation	 is	 on	 the	 regulation	of	 the	 transcription	process,	the	first	step	in	the	gene	regulatory	pathway.	In	yeast	and	metazoans,	transcription	of	the	nuclear	 genome	 is	 performed	 by	 three	 DNA-dependent	 RNA	 polymerases	 (Vannini	 and	Cramer,	 2012).	 	RNA	polymerase	 I	 (Pol	 I)	 transcribes	 the	28s	 and	18s	 rRNA	genes;	RNA	polymerase	II	(Pol	II)	transcribes	the	mRNA	genes	as	well	as	certain	ncRNA	and	lncRNAs	genes;	and	RNA	polymerase	III	(Pol	III)	transcribes	the	5s	rRNA	gene,	the	tRNA	genes	and	certain	ncRNA	genes.		The	transcription	process	for	all	of	these	RNA	polymerases	includes	three	 distinct	 steps,	 each	 of	 which	 is	 a	 target	 for	 important	 modes	 of	 regulation:		transcription	 initiation,	elongation	and	 termination.	 	More	specifically,	 I	will	 focus	on	 the	regulation	of	transcription	initiation	of	the	mRNA	genes	by	Pol	II,	in	particular	the	role	the	general	 transcription	 factor	 and	 coactivator	 TFIID	 plays	 in	 Pol	 II	 transcription	 initiation.		Functional	 similarities	 between	 eukaryotic	 Pol	 II	 transcription	 and	 prokaryotic	transcription	are	discussed.			In	 addition,	 the	 work	 presented	 herein	 was	 performed	 in	 the	 model	 system	
Saccharomyces	 cerevisiae,	 also	 known	 as	 baker’s	 yeast.	 	 While	 certain	 differences	 exist	between	yeast	and	higher	eukaryotic	systems	with	regard	to	transcription	initiation	(some	of	 which	 will	 be	 described	 in	 detail	 below),	 the	 vast	 majority	 of	 the	 proteins	 and	 gene	structures	 that	 play	 important	 roles	 in	 transcription	 regulation	 are	 highly	 evolutionarily	conserved	at	the	amino	acid,	structure	and	functional	levels.	 	Furthermore,	S.	cerevisiae	 is	an	 excellent	 model	 organism	 for	 hypothesis	 testing	 due	 to	 its	 short	 doubling	 time	 (90	minutes)	and	facile	genetics,	without	which	my	project	would	not	have	been	possible.		
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Structure	of	an	mRNA	Gene	The	 structures	 of	mRNA	genes	 include	both	 the	 sequences	 that	 are	 critical	 for	regulating	 transcription	 initiation,	 elongation	 and	 termination	 as	 well	 as	 the	 coding	sequence	 that	 is	 recognized	 by	 the	 translational	 machinery	 to	 synthesize	 the	 encoded	protein	product	(Figure	1.1).	 	 	Transcription	 initiation	 is	guided	by	two	structures	within	the	mRNA	gene	sequence:	 	 the	enhancer/silencer	and	 the	core	promoter.	 	Enhancers	are	sequences	 that	 function	 to	 stimulate	 transcription	 while	 silencers	 are	 sequences	 that	repress	 transcription.	 	 In	 general,	 while	 the	 core	 promoter	 is	 positioned	 5’	 of	 the	transcription	start	site	(TSS)	and	oriented	in	a	manner	to	direct	transcription	through	the	mRNA	 transcription	 unit,	 the	 enhancer/silencer	 is	 not	 constrained	 by	 these	 position	 or	orientation	limitations	(Li	et	al.,	2016).		Enhancers/silencers	can	be	located	often	kilobases	to	 megabases	 away	 from	 the	 TSS	 and	 these	 sequences	 can	 be	 5’	 of	 the	 TSS,	 within	 the	transcription	unit	 such	 as	within	 introns	 or	 3’	 of	 the	 transcription	 termination	 sequence	(TTS).	 	 However,	 in	 S.	 cerevisiae,	 likely	 as	 a	 result	 of	 a	 more	 compact	 genome,	enhancers/silencers	 are	 known	 as	 upstream	 activating	 sequences	 (UAS)	 or	 upstream	repressing	sequences	(URS)	and	are	located	5’	to	the	core	promoter,	often	within	1000bp	of	 the	TSS	 (Hahn	and	Young,	2011).	 	These	sequences	are	collections	of	binding	sites	 for	trans-acting	 factors.	 	 These	 trans-acting	 factors	 can	 both	 stimulate	 transcription	 (trans-activators)	and	repress	transcription	(trans-repressors).	In	 most	 eukaryotic	 systems	 including	 metazoans	 and	 the	 fission	 yeast	
Schizosaccharomyces	 pombe,	 which	 has	 been	 argued	 based	 on	 sequence	 conservation	 to	more	similar	to	metazoans	than	to	budding	yeast	(Sipiczki,	2000),	the	core	promoter	is		
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Figure	 1.1.	 	 Structure	 and	 regulation	 of	 an	 mRNA	 gene.	 	 A	 model	 for	 the	 structure	 of	 a	eukaryotic	gene	is	presented.		Within	the	DNA	genome,	housed	in	the	nucleus,	a	gene	consists	of	the	cis-elements	 that	 regulate	 the	association	between	RNA	polymerase	 II	 and	 the	 transcription	unit,	including	 the	 transcription	 start	 site	 (TSS)	and	 the	 transcription	 termination	 site	 (TTS).	 	The	 cis-regulatory	elements	 include	the	enhancer/silencer	and	the	core	promoter.	A	number	of	sequence	elements	within	the	core	promoter	have	been	identified,	the	most	common	of	which	are	displayed.		These	elements	are	often	not	all	present	within	the	same	core	promoter	but	are	displayed	as	such	for	 simplicity.	 	The	 transcription	unit	often	 includes	protein	coding	exons	 interspersed	with	non-coding	introns.		The	first	exon	begins	with	the	transcription	start	site	while	the	final	exon	contains	the	TTS	and	a	polyadenylation	sequence.	 	RNA	polymerase	II	uses	the	DNA	template	to	transcribe	the	RNA	 from	 the	TSS	 to	 the	TTS	and	past	until	 the	polymerase	 is	 subject	 to	active	 transcription	termination	 mechanisms	 (not	 discussed	 here).	 	 The	 resulting	 mRNA	 is	 post-transcriptionally	 7-methylguanisine	 (7meG)	 capped	 at	 its	 5’	 end	 and	 polyadenylated	 at	 its	 3’	 end.	 	 The	 resulting	transcript,	including	the	intron,	is	the	pre-mRNA	and	it	is	maintained	in	the	nucleus.		The	intron	is	spliced	 out	 of	 the	 pre-mRNA	 to	 form	 the	 mature	 mRNA,	 which	 then	 exits	 the	 nucleus.	 	 Protein	translation	 occurs	 in	 the	 cytosol	 where	 ribosomes,	 reading	 from	 the	 start	 codon	 (initiator	methionine)	 to	 the	 stop	 codon,	 synthesize	 the	 protein	 product.	 	 Importantly,	 each	 step	 of	 the	process	 is	 subject	 to	 regulation	 including	 transcription,	 post-transcriptional	 processing,	 nuclear	export	 and	 translation.	 	 BREu=	 TFIIB	 recognition	 element	 upstream,	 BREd=	 TFIIB	 recognition	element	downstream,	INR=	initiator	element,	MTE=	motif-ten	element,	DPE=downstream	promoter	element.		
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located	approximately	30bp	5’	of	the	transcription	start	site.		However,	in	S.	cerevisiae	the	core	promoter	location	varies	between	40bp	and	120bp	upstream	of	the	TSS	likely	because	of	inherent	differences	in	yeast	Pol	II	(Li	et	al.,	1994).	 	The	core	promoter	is	a	degenerate	sequence	 containing	 several	 documented	 binding	 elements:	 	 the	 TATA-box,	 the	 initiator	(INR),	 the	 downstream	 promoter	 element	 (DPE),	 the	 motif-ten	 element	 (MTE)	 and	 the	TFIIB	recognition	element	(BRE),	among	others	that	have	been	identified	for	specific	gene	classes	(Burke	and	Kadonaga,	1997;	Deng	and	Roberts,	2006;	Kadonaga,	2012;	Lagrange	et	al.,	 1998;	 Lim	 et	 al.,	 2004;	 Smale	 and	 Baltimore,	 1989;	 Thomas	 and	 Chiang,	 2006).	 Core	promoters	 do	 not	 contain	 consensus	 sequences	 for	 all	 of	 these	 binding	 elements	 but	instead	contain	some	combination	of	these	elements.		Other	than	the	TATA-box,	none	of	the	other	 core	 promoter	 elements	 have	 been	 unambiguously	 identified	 in	 the	 yeast	 system.		Furthermore,	only	20%	of	genes	contain	consensus	TATA-boxes	while	the	remaining	genes	have	 historically	 been	 considered	 TATA-less	 (Basehoar	 et	 al.,	 2004)	 although	 recent	studies	 have	 demonstrated	 that	 the	majority	 of	 yeast	 core	 promoters	 contain	 TATA-like	elements	(Rhee	and	Pugh,	2012).		The	functions	of	these	core	promoter	elements	and	how	they	interface	with	the	RNA	polymerase	II	transcription	machinery	will	be	described	more	below.	 Following	 transcription	 initiation	 by	 RNA	 polymerase	 II,	 the	 polymerase	 will	transcribe	 the	 entire	 transcription	 unit.	 	 This	 transcription	 unit	 contains	 the	 TSS,	 the	 5’	untranslated	 region	 (UTR),	 a	 start	 codon	 (AUG,	 initiator	methionine),	 a	 stop	 codon,	 a	 3’	UTR	and	a	TTS.		In	addition,	mRNA	genes	are	divided	into	introns	and	exons.	 	Introns	are	non-coding	sequences	that	are	interspersed	between	coding	exons.		These	introns	must	be	excised	 from	 the	RNA	and	 the	exons	must	be	 ligated	 together	 to	 form	 the	mature	mRNA	
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that	 can	be	 transported	out	 of	 the	nucleus	 and	used	 as	 a	 template	 for	 protein	 synthesis.		The	sequence	encompassed	by	the	translation	start	and	stop	codon	of	the	mature	mRNA	is	the	open	reading	frame	(ORF).		The	translation	machinery	initiates	protein	synthesis	at	the	start	 codon	 and	 terminates	 at	 the	 stop	 codon	 to	 synthesize	 the	 protein	 encoded	 by	 the	mRNA.		Once	RNA	polymerase	II	has	completed	transcription	of	the	3’	UTR	and	terminated	transcription,	it	is	free	to	reinitiate	on	the	same	mRNA	gene	or	move	to	a	different	mRNA	gene	and	begin	an	entirely	new	transcription	cycle	(Hahn,	2004).		The	RNA	Polymerase	II	General	Transcription	Factors	and	Their	Relation	to	Prokaryotic	Transcription	In	 prokaryotes,	 RNA	 polymerase	 (RNAP)	 holoenzyme	 can	 specifically	 bind	 to	promoter	 sequences	 and	 accurately	 initiate	 transcription	 (Murakami,	 2015).	 	 RNAP	holoenzyme	 is	 composed	 of	 6	 subunits:	 σ,	ω,	α (two	 copies),	 β	 and	 β’.	 	 While	 w	 is	 not	essential	 for	 RNAP	 function,	 the	 remaining	 five	 polypeptides	 are	 all	 that	 is	 required	 for	transcription	 initiation.	 	 The	 eukaryotic	 transcription	 machinery	 is	 exponentially	 more	complicated.	 	As	mentioned	above,	 instead	of	one	RNAP,	 eukaryotes	have	3	nuclear	RNA	polymerases	(Roeder	and	Rutter,	1969).		In	addition,	eukaryotes	contain	mitochondrial	and	chloroplast	RNA	polymerases	 that	 are	 responsible	 for	 transcription	 of	 the	mitochondrial	and	 chloroplast	 genomes	 (Arnold	 et	 al.,	 2012;	 Börner	 et	 al.,	 2015).	 	 Plants	 contain	 two	additional	RNA	polymerase	 (RNA	polymerase	 IV	 and	RNA	Polymerase	V)	 that	 transcribe	the	genes	encoding	non-coding	RNAs	 that	 are	 involved	 in	gene	 silencing	 functions	 (Haag	and	Pikaard,	2011).	 	The	 increased	complexity	of	 the	eukaryotic	 transcription	machinery	provides	 a	 vast	 increase	 in	 the	 modes	 through	 which	 eukaryotes	 can	 regulate	 gene	
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expression,	likely	allowing	for	evolution	of	the	many	diverse	and	highly	complex	metazoan	and	plant	species.			Focusing	 solely	 on	mRNA	 gene	 transcription,	 Pol	 II	 cannot	 perform	 promoter	specific	transcription	on	its	own	(Weil	et	al.,	1979).		Instead,	six	additional	protein	factors	are	 required	 for	Pol	 II	 to	 initiate	 transcription	 (Flores	 et	 al.,	 1992;	Reinberg	 et	 al.,	 1987;	Reinberg	 and	 Roeder,	 1987a).	 	 These	 co-factors	 are	 known	 as	 the	 general	 transcription	factors:	transcription	factor	for	RNA	polymerase	II	A	(TFIIA),	TFIIB,	TFIID,	TFIIE,	TFIIF	and	TFIIH.	 	These	six	along	with	Pol	 II	 form	the	pre-initiation	complex	(summarized	 in	Table	1.1),	 which	 is	 required	 for	 promoter-specific	 transcription	 by	 Pol	 II	 (Figure	 1.2).	 The	functions	and	subunit	structures	of	each	of	the	transcription	factors	and	Pol	II	are	briefly	described	below:	
TFIID:	 	 TFIID	 is	 a	 multi-protein	 complex	 containing	 14	 conserved	 subunits.		These	 subunits	 include	 TATA-box	 binding	 protein	 (TBP)	 and	 13	 TBP-associated	 factors	(Taf1à13).	 	While	TBP	 is	 required	 for	 transcription	by	all	 three	nuclear	DNA-dependent	RNA	polymerases,	TFIID	specifically	 functions	with	RNA	polymerase	 II	 (Kim	and	Roeder,	1994).		In	S.	cerevisiae,	TFIID	contains	an	extra	subunit,	Taf14,	that	is	also	a	component	of	6	other	 transcription	 related	 complexes	 including	 the	 general	 transcription	 factor	 TFIIF	(Cairns	et	al.,	1996;	Henry	et	al.,	1994;	John	et	al.,	2000;	Kabani	et	al.,	2005;	Lim	et	al.,	2007;	Sanders	et	al.,	2002b).	 	 In	addition	to	being	a	multi-subunit	complex,	several	of	the	TFIID	subunits	 are	 present	 at	 2	moles	 per	mole	 of	 TFIID	 including	 Tafs	 5,	 6,	 9,	 10,	 12	 and	 14	(potentially	greater	than	2	moles	per	mole	of	TFIID)	(Sanders	et	al.,	2002a).		Thus,	TFIID	is	composed	of	at	least	19	individual	polypeptides,	depending	on	the	species	(Tora,	2002).		In	
S.	 cerevisiae,	 with	 the	 exception	 of	 TAF14,	 all	 of	 the	 genes	 encoding	 TFIID	 subunits	 are	
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single-copy	 essential	 genes	(Klebanow	 et	 al.,	 1997,	 1996;	Moqtaderi	 et	 al.,	 1996;	 Poon	 et	al.,	 1995;	Ray	 et	 al.,	 1991;	Reese	et	 al.,	 1994;	 Sanders	 and	 Weil,	2000).	 	 taf14	 null	 cells	 display	 a	slow	 growth	 phenotype	 and	temperature	 sensitive	 (Ts)	growth.							 TFIID	 serves	 two	known	 transcription	 initiation	functions:		promoter	recognition	and	transcription	co-activation	(Albright	and	Tjian,	2000).		As	 indicated	 by	 its	 name,	 TBP	 binds	 to	 the	 TATA-box	 in	 gene	 core	 promoters.	 	 TBP-promoter	 association	 is	 absolutely	 required	 for	 PIC	 formation	 because	 the	 rest	 of	 the	general	 transcription	 factors	 cannot	 specifically	 associate	with	 the	 core	 promoter	 in	 the	absence	of	TBP	(Buratowski	et	al.,	1989).		In	this	sense,	TBP	most	resembles	σ	factor	from	prokaryotic	RNAP.	 	The	σ	 subunit	of	RNAP	is	required	to	recognize	the	core	promoter	 in	prokaryotic	 gene	 promoters	 (Sugiura	 et	 al.,	 1970).	 	 Without	 σ,	 RNAP	 cannot	 perform	promoter-specific	 transcription.	 	 When	 core	 promoters	 contain	 consensus	 TATA-boxes,	TBP	 can	 function	 independently	 of	Tafs	 to	 nucleate	PIC	 formation.	 In	 fact,	 TBP	has	been	used	extensively	for	in	vitro		
	
Table	1.1:	The	RNA	polymerase	II	General	Transcription	
Factors	in	S.	cerevisiae.		Subunits	and	molecular	weights	of	general	 transcription	factors.	 	 In	total,	 the	PIC	 is	composed	of	~49	polypeptides	that	amounts	to	~2.5	MDa	in	size,	not	including	 additional	 co-activators	 such	 as	 SAGA	 and	mediator,	 or	 DNA.	 	 Values	 derived	 from	 Saccharomyces	Genome	Database.	
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transcription	with	purified	components	(He	et	al.,	2016;	Murakami	et	al.,	2013;	Myers	et	al.,	1997).		However,	in	the	absence	of	a	consensus	TATA-box,	TFIID	Tafs	are	likely	to	play	an	important	role	in	core	promoter	recognition	through	direct	binding	to	sequence	elements	within	the	core	promoter	(Figure	1.3).	When	TBP	is	associated	with	TFIID,	TBP	is	incapable	of	binding	to	DNA	because	the	Taf1	N-terminal	Domain	(TAND)	binds	to	the	DNA	binding	cleft	 of	 TBP	 and	mimics	 TATA-DNA	 (Bai	 et	 al.,	 1997;	 Kokubo	 et	 al.,	 1998;	 Kotani	 et	 al.,	1998).		This	repression	of	TBP	binding	can	be	alleviated	through	the	binding	of	TFIIA.			Prokaryotes	 utilize	 alternative	 σ	 factors	 that	 have	 different	 core	 promoter	binding	 specificities	 to	 regulate	 different	 transcriptional	 programs.	 	 These	 alternative	 σ	factors	allow	prokaryotes	 to	 respond	 to	external	 stress	or	nutrient	availability	or	 initiate	alternative	 expression	 programs	 distinct	 from	 vegetative	 growth	 such	 as	 in	 response	 to	viral	infection	or	sporulation	(Burgess	et	al.,	1969;	Duffy	and	Geiduschek,	1977;	Fox	et	al.,	1976;	Haldenwang	et	al.,	1981;	Haldenwang	and	Losick,	1980,	1979).		Similarly,	eukaryotes	also	 contain	 alternate	 forms	 of	 both	 Tafs	 and	 TBP	 that	 are	 required	 for	 expression	 of	transcription	programs	within	differentiated	tissue	types.	 	For	example,	drosophila	testes	express	cannonball/can	(Taf5	paralog),	no	hitter/nht	(Taf4	paralog),	meiosis	I	arrest/mia	(Taf6	 paralog),	 spermatocyte	 arrest/sa	 (Taf8	 paralog)	 and	 ryan	 express/rye	 (Taf12	paralog)	(Hiller	et	al.,	2004).		Alternative	forms	of	TBP	(TBP-related	factors	or	TRFs)	have	functional	roles	in	muscle	cell-specific	transcriptional	programs	as	well	as	transcription	of	the	ribosomal	protein	genes	in	drosophila	and	human	cells	(Deato	et	al.,	2008;	Wang	et	al.,	2011).		However,	a	recent	study	by	the	labs	of	Tora	and	Puri	have	called	into	question	the	role	of	TRF2	in	muscle	cell	differentiation	(Malecova	et	al.,	2016).		Regardless,	the	current	model	 in	 the	 field	 is	 that	alternative	TFIID	subunits	play	specialized	roles	 to	 increase	the	
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functional	 diversity	 within	 tissue	 types	 of	 multi-organ	 species	 and	 allow	 for	 the	increasingly	complex	modes	of	gene	regulation	that	are	not	required	in	prokaryotes.	The	other	function	of	TFIID	is	to	serve	as	a	transcription	co-activator	(Pugh	and	Tjian,	1990).		In	this	role,	TFIID	directly	interacts	with	trans-activator	proteins	(Chen	et	al.,	1994;	Garbett	et	al.,	2007;	Gill	et	al.,	1994;	Goodrich	et	al.,	1993;	Hoey	et	al.,	1993;	Liu	et	al.,	2009;	Tanese	et	al.,	1991;	Thut	et	al.,	1995).		While	the	exact	mechanism(s)	of	how	TFIID-activator	interactions	stimulate	transcription	has	not	been	well	explored,	the	predominant	model	is	known	as	“recruitment”	(Pugh	and	Tjian,	1991,	1990,	Sauer	et	al.,	1995a,	1995b).		While	recruitment	is	an	imprecise	term,	TFIID	recruitment	refers	to	the	concept	whereby	TFIID-core	 promoter	 DNA	 binding	 affinity	 is	 weak	 in	 the	 absence	 of	 a	 trans-activator	protein	 leading	 to	 an	 inability	 of	 TFIID	 to	 promote	 PIC	 formation	 and	 transcription	initiation.		However,	trans-activator	binding	to	the	cis-linked	enhancer	can	facilitate	TFIID	association	 with	 the	 core	 promoter,	 which	 can	 be	 achieved	 through	 either	 direct	 trans-activator-TFIID	 binding	 that	 results	 in	 cooperative	 binding	 to	 the	 core	 promoter	 or	indirectly	 through	 a	 protein	 intermediate	 that	 interacts	 with	 both	 TFIID	 and	 the	 trans-
	
Figure	 1.3:	 Association	 of	 TFIIB	 and	 TFIID	 with	 core	 promoter	 sequence	
elements.	 	 Contacts	made	 by	 TBP,	 Tafs	 and	 TFIIB	with	 core	 promoter	 are	 shown.		Protein-DNA	 contacts	 identified	 by	 various	 methods	 including	 protein-DNA	 cross-linking	and	DNaseI	footprinting.	
	 12	
activator	 (Johnson	 et	 al.,	 2002;	 Sauer	 et	 al.,	 1995a).	 	 Ultimately,	 an	 increase	 in	 TFIID-promoter	 DNA	 binding	 affinity	 leads	 to	 an	 increase	 in	 TFIID	 residency	 on	 promoters	resulting	 in	 stimulation	 of	 PIC	 formation.	 	 Prokaryotes	 utilize	 similar	 mechanisms	 to	stimulate	 RNAP	 association	 with	 promoters.	 	 For	 example,	 catabolite	 activator	 protein	(CAP)	 binds	 to	 cis-linked	DNA	 sequences	 upstream	of	 the	 core	 promoter	 and	 stimulates	RNAP-promoter	association	through	direct	interaction	with	the	C-terminal	domain	of	the	α	subunit	(Heyduk	et	al.,	1993).	
TFIIA:		TFIIA	is	composed	of	two	polypeptides	in	yeast,	Toa1	and	Toa2	(Ranish	and	Hahn,	1991).		Both	TOA1	and	TOA2	are	single	copy	essential	genes	(Ranish	et	al.,	1992).		In	metazoans,	the	large	subunit	of	TFIIA	is	synthesized	as	single	polypeptide	(TFIIAαβ)	but	post-translationally	 processed	 to	 form	 a	 three	 subunit	 complex,	 TFIIAα,	 β,	 γ  (Ma	 et	 al.,	1993;	 Zhou	 et	 al.,	 2006).	 	 Biochemically,	 TFIIA	 directly	 binds	 to	 TBP	 and	 can	 stabilize	binding	of	TBP	to	DNA	although	TFIIA	does	not	display	significant	DNA	binding	activity	on	its	 own	 (Yokomori	 et	 al.,	 1994).	 	 In	 addition,	 TFIIA	 has	 been	 shown	 to	 serve	 an	 anti-repressor	 function	 by	 displacing	 interactions	 between	 the	 Taf1-TAND	 and	 the	 TBP	DNA	binding	 domain,	 allowing	 TBP	 to	 access	 DNA	 (Ozer	 et	 al.,	 1998).	 	 Furthermore,	 TFIIA	directly	interacts	with	trans-activator	proteins	and	can	stimulate	activated	transcription	in	a	TFIID-dependent	manner	(Kobayashi	et	al.,	1995;	Ozer	et	al.,	1996).	 	Despite	the	role	of	TFIIA	 in	activated	transcription,	when	TBP	 is	substituted	 for	TFIID,	TFIIA	 is	not	required	for	 in	 vitro	 transcription	 performed	 with	 purified	 Pol	 II	 and	 the	 rest	 of	 the	 general	transcription	factors	(Murakami	et	al.,	2013).	
TFIIB:		SUA7	encodes	TFIIB	in	S.	cerevisiae	(Pinto	et	al.,	1992).		SUA7	is	a	single	copy	 essential	 gene.	 TFIIB	 is	 the	 one	 general	 transcription	 factor	 that	 is	 composed	 of	 a	
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single	 polypeptide	 instead	 of	 a	 multi-subunit	 complex.	 	 Similar	 to	 TFIIA,	 TFIIB	 can	 also	stabilize	 TBP-DNA	 binding	 (Imbalzano	 et	 al.,	 1994).	 	 TFIIB	 mediates	 the	 interaction	between	 TBP	 and	 Pol	 II	 (Barberis	 et	 al.,	 1993;	 Buratowski	 et	 al.,	 1989;	 Buratowski	 and	Zhou,	1993;	Killeen	et	al.,	1992;	Maldonado	et	al.,	1990).	 	This	 interaction	between	TFIIB	and	Pol	II	also	stimulates	Pol	II	transcription	initiation	activity	and	TSS	selection	(Pardee	et	al.,	1998).		TFIIB	may	also	function	to	maintain	the	transcription	bubble	(He	et	al.,	2016).	
TFIIE:	 	 TFIIE	 is	 composed	 of	 two	 polypeptides,	 Tfa1	 and	 Tfa2	 (Feaver	 et	 al.,	1994).	 	 	TFIIE	forms	a	heterotetramer	in	solution	(Inostroza	et	al.,	1991).	 	Both	TFA1	and	
TFA2	are	single	copy	essential	genes.		TFIIE	binds	directly	to	both	Pol	II	and	TFIIH	(Maxon	et	 al.,	 1994).	 	 Binding	 of	 TFIIE	 to	 TFIIH	 stimulates	 TFIIH	 enzymatic	 activity	 (described	below)	(Lu	et	al.,	1992;	Ohkuma	and	Roeder,	1994).	 	 In	addition,	TFIIE	is	thought	to	help	Pol	II	maintain	an	open	transcription	bubble	(Buratowski	et	al.,	1991;	Forget	et	al.,	2004;	Holstege	et	al.,	1996;	Plaschka	et	al.,	2016).	
TFIIF:	 	TFIIF	 is	composed	of	 three	polypeptides	 in	S.	cerevisiae,	Tfg1,	Tfg2	and	Tfg3	(Henry	et	al.,	1992).	 	Tfg3	 is	 identical	 to	Taf14.	TFG1	and	TFG2	are	both	single	copy	essential	genes	(Henry	et	al.,	1994).	 	In	metazoans,	Tfg3	is	not	present	in	TFIIF	(Flores	et	al.,	1989).		TFIIF	is	tightly	associated	with	Pol	II	(Rani	et	al.,	2004)	and	functions	in	a	similar	manner	 to	 TFIIB	 in	 the	 sense	 that	 it	 is	 important	 for	 Pol	 II	 incorporation	 into	 the	 pre-initiation	complex	(Flores	et	al.,	1991),	initiation	of	transcription	and	TSS	selection	(Ghazy	et	al.,	2004).		TFIIF	can	also	stimulate	transcription	elongation	(Conaway	et	al.,	2000).	
TFIIH:	 	TFIIH	is	a	ten	subunit	complex	and	in	S.	cerevisiae	 is	composed	of	Ssl2,	Rad3,	Tfb1,	Tfb2,	Ssl1,	Tfb3,	Ccl1,	Tfb4,	Kin28	and	Tfb5	(Murakami	et	al.,	2012;	Ranish	et	al.,	 2004;	 Svejstrup	 et	 al.,	 1994).	 	With	 the	 exception	 of	TFB5,	 all	 of	 the	 genes	 encoding	
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TFIIH	 subunits	 are	 essential	 for	 viability	 (Feaver	 et	 al.,	 1997;	Gileadi	 et	 al.,	 1992;	Gulyas	and	Donahue,	1992;	Higgins	et	al.,	1983;	Naumovski	and	Friedberg,	1983;	Park	et	al.,	1992;	Simon	et	al.,	1986;	Valay	et	al.,	1993;	Yoon	et	al.,	1992).		TFIIH	has	two	enzymatic	activities	that	 are	 critical	 for	 transcription	 initiation.	 	 First,	 Ssl2	 acts	 as	 a	 helicase	 and	 melts	 the	promoter	DNA	such	that	Pol	II	can	begin	scanning	for	the	transcription	start	site	(Guzder	et	al.,	 1994).	 	 Prokaryotic	 RNAP	 contains	 this	 helicase	 activity	within	 the	σ	 and	β	 subunits	(Fisher	 and	 Blumenthal,	 1980;	Wigneshweraraj	 et	 al.,	 2003).	 	 Second,	 Kin28	 has	 kinase	activity	 and	 phosphorylates	 Ser5	 and	 Ser7	 in	 the	 heptad	 repeat	 of	 the	 Rpb1	 C-terminal	domain	 (CTD)	 (Komarnitsky	 et	 al.,	 2000;	 Lu	 et	 al.,	 1992)	 (importance	 of	 the	 Ser5	modification	 is	 described	more	below).	 	 As	mentioned	 above,	 direct	 interaction	between	TFIIE	and	TFIIH	stimulates	the	enzymatic	activities	of	TFIIH.	
Pol	II:	Pol	II	contains	12	subunits,	Rpb1-Rpb12	(Edwards	et	al.,	1990;	Kolodziej	et	al.,	1990;	Treich	et	al.,	1992;	Vannini	and	Cramer,	2012;	Woychik	et	al.,	1993).		With	the	exception	of	Rpb4	and	Rpb9,	all	of	the	Pol	II	subunits	are	essential	for	life	(Woychik	et	al.,	1993,	1991;	Woychik	and	Young,	1989).		The	three	nuclear	RNA	polymerases	all	contain	a	10	subunit	 catalytic	 core,	 five	of	which	are	 shared	among	 the	polymerases:	 	Rpb5,	Rpb6,	Rpb8,	Rpb10	and	Rpb12.		Rpb6	is	similar	to	ω,	both	subunits	serve	structural	roles	within	the	RNA	polymerase	 (Minakhin	 et	 al.,	 2001).	 	Together,	Rpb1	and	Rpb2	 compromise	 the	active	center,	which	contains	the	nucleotide	binding	pocket	and	catalyzes	phosphodiester	bond	 formation	 (Riva	 et	 al.,	 1987),	 and	 are	 similar	 to	 the	β’	 and	β	 subunits,	 respectively	(Allison	et	al.,	1985;	Cramer	et	al.,	2001;	Sweetser	et	al.,	1987).		Subunits	Rpb3	and	Rpb11	are	 the	 remaining	 subunits	 of	 the	 catalytic	 core	 and	most	 resemble	 the	 two	α	 subunits	(Zhang	and	Darst,	1998).		Rpb4	and	Rpb7	are	less	stably	associated	with	the	catalytic	core.		
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These	 subunits	 are	 critical	 for	 transcription	 initiation	 (Edwards	 et	 al.,	 1991)	 but	 are	thought	to	dissociate	during	transcription	elongation	(Mosley	et	al.,	2013).		Pol	II	also	has	another	accessory	factor	that	is	important	for	transcription	elongation,	TFIIS	(Rappaport	et	al.,	 1987;	Reinberg	and	Roeder,	1987b;	 Sekimizu	et	 al.,	 1979).	 	This	 accessory	 factor	 can	stimulate	 the	 RNA	 cleavage	 activity	 of	 Rpb9	 as	 a	 mechanism	 to	 backtrack	 during	transcriptional	stalling	(Awrey	et	al.,	1997;	Reines,	1992).		The	additional	subunits	of	Pol	I	(A49)	and	Pol	 III	(C37,	C53	C82,	C34	and	C31)	function	 in	a	similar	manner	to	TFIIE	and	TFIIF,	as	described	above	(Carter	and	Drouin,	2010;	Geiger	et	al.,	2010;	Kuhn	et	al.,	2007).		 The	Rpb1	C-Terminal	Domain	A	unique	characteristic	of	Pol	II	is	the	C-terminal	domain	(CTD)	of	Rpb1	(Allison	et	al.,	1985).	 	Rpb1,	 the	 largest	subunit	 in	Pol	 II,	contains	a	repeating	sequence	known	as	the	 heptad	 repeat	 (Tyr1Ser2Pro3Thr4Ser5Pro6Ser7)	 at	 its	 C-terminus.	 	 The	 repeat	 length	varies	 by	 species	 with	 S.	 cerevisiae	 containing	 26	 repeats	 and	 mammals	 containing	 52	repeats,	although	many	of	the	mammalian	heptad	repeats	are	non-consensus	in	sequence	(Corden	 et	 al.,	 1985;	 Nonet	 et	 al.,	 1987;	Wintzerith	 et	 al.,	 1992).	 	While	 not	 all	 of	 these	repeats	are	essential	for	life,	partial	truncation	of	the	CTD	results	in	Ts	growth	in	yeast	and	strains	harboring	a	complete	deletion	of	 the	Rpb1	CTD	are	 inviable	 (Allison	et	al.,	1988).		Similar	mutations	in	metazoan	cells	cause	loss	in	viability	(Zehring	et	al.,	1988).			Importantly,	 the	 Rpb1	 CTD	 is	 the	 target	 for	 significant	 post-translational	modification	(Zaborowska	et	al.,	2016).		Both	proline	residues	are	subject	to	isomerization	(Hanes,	 2014)	 while	 the	 remaining	 consensus	 residues	 can	 be	 both	 phosphorylated	(Kolodziej	 et	 al.,	 1990)	and	glycosylated	 (Kelly	 et	 al.,	 1993).	 	 Some	of	 the	non-consensus	
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residues	in	the	mammalian	CTD	can	be	ubiquitylated	(Li	et	al.,	2007),	methylated	(Sims	et	al.,	2011)	and	acetylated	(Voss	et	al.,	2015).	 	 In	general,	site-specific	phosphorylation	has	been	 most	 intensively	 studied.	 	 For	 example,	 ChIP-seq	 studies	 have	 shown	 that	 Ser5	phosphorylation	 (Ser5-p)	 is	 localized	closest	 to	 the	5’	end	of	 the	 transcription	unit	while	Ser2	 is	 localized	more	 towards	 the	 3’	 end	 of	 the	 transcription	 unit	 (Komarnitsky	 et	 al.,	2000).		Ser5-p	is	catalyzed	by	the	Kin28	subunit	of	TFIIH	while	Ser2	is	phosphorylated	by	the	Bur1/Bur2	and	Ctk1	kinases	 (Keogh	et	 al.,	 2003;	Lee	and	Greenleaf,	 1991;	Qiu	et	 al.,	2009).			 Using	 a	 truncated	 Rpb1	 CTD	 in	 S.	 pombe,	 Schwer	 and	 Shuman	 exhaustively	characterized	 the	 contribution	 of	 each	 residue	 of	 the	 heptad	 repeat	 to	 life	 (Schwer	 and	Shuman,	 2011).	 	 Importantly,	 they	 show	 that	 Ser5	 is	 essential	 for	 life.	 	 However,	 the	function	of	this	residue	can	be	largely	bypassed	if	an	mRNA	capping	enzyme	is	fused	to	the	Rpb1	CTD.		Thus,	a	major	function	of	Ser5-p	is	the	recruitment	of	mRNA	capping	enzymes	(Cho	 et	 al.,	 1997;	McCracken	 et	 al.,	 1997a).	 	While	 prokaryotes	do	not	 cap	 their	mRNAs,	eukaryotes	 use	 a	 5’	 7-methylguanosine	 (7meG)	 cap	 that	 serves	 to	 both	 protect	 the	 RNA	from	 5’	 to	 3’	 nuclease	 digestion	 as	 well	 as	 provide	 a	 binding	 site	 for	 the	 translation	machinery	(see	Figure	1.1)	(Both	et	al.,	1975;	De	Kloet	and	Andrean,	1976;	Muthukrishnan	et	 al.,	 1975;	Wei	 and	 Moss,	 1975).	 	 Thus,	 this	 cap	 is	 a	 critical	 RNA	 post-transcriptional	modification	for	eukaryotic	translation.			Also,	 in	Schwer	and	Shuman’s	work,	 they	demonstrate	Ser2	can	be	mutated	 to	alanine.	 	 However,	 mutating	 Ser2	 to	 the	 phosphomimetic	 Glu	 results	 in	 lethality.	 	 This	residue	it	thought	to	play	a	significant	role	in	co-transcriptional	splicing	and	transcription	termination	 including	 recruitment	of	 the	polyadenlyation	machinery	 (Barillà	 et	 al.,	 2001;	
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Gu	 et	 al.,	 2013;	McCracken	 et	 al.,	 1997b).	 	 mRNA	 polyadenylation	 is	 thought	 to	 play	 an	important	role	in	RNA	stability	as	well	as	translation	activity		(Dreyfus	and	Régnier,	2002).		While	eukaryotes	contain	polyA	sequences	between	50-200nt	(see	Figure	1.1),	prokaryotes	do	 contain	 polyA	 sequences	 but	 they	 are	 less	 than	 10	 nucleotides	 and	 are	 thought	 to	promote	RNA	degradation	rather	than	stability.				Role	of	Co-activators	in	Transcription	Initiation	While	 the	 general	 transcription	 factors	 and	 Pol	 II	 are	 sufficient	 for	 basal	transcription	 in	 vitro,	 PIC	 formation	 in	 vivo	 requires	 communication	 between	 enhancer	bound	 trans-activators	 and	 proteins	 at	 the	 core	 promoter.	 	 In	 addition	 to	 TFIID,	 two	additional	co-activator	complexes	contribute	importantly	to	general	transcription	initiation	mechanisms:	 the	Spt-Ada-Gcn5-acetyltransferase	(SAGA)	complex	and	Mediator	(Grant	et	al.,	 1997;	Kim	et	al.,	 1994).	 	 SAGA,	a	 complex	composed	of	at	 least	20	different	 subunits,	shares	the	Taf	5,	6,	9,	10	and	12	subunits	with	TFIID	including	(Grant	et	al.,	1998).	 	SAGA	can	 also	 chaperone	 TBP	 to	 mRNA	 gene	 core	 promoters	 (Dudley	 et	 al.,	 1999).	 	 The	mechanisms	 by	 which	 SAGA	 contributes	 to	 transcription	 activation	 include	 direct	interaction	between	SAGA	subunits	Tra1	with	trans-activators	including	Gal4	(Bhaumik	et	al.,	2004)	and	Gcn4	(Fishburn	et	al.,	2005),	chromatin	based	mechanisms	(described	more	below)	and	aids	in	the	recruitment	of	mediator	(Bryant	and	Ptashne,	2003;	Larschan	and	Winston,	2005).	Given	 the	 shared	 subunits,	 TBP	 chaperone	 activities	 and	 activator	 binding	activities,	 TFIID	 and	 SAGA	 are	 believed	 to	 play	 complementary	 roles.	 	 Genome-wide	analyses	have	demonstrated	that	SAGA	is	the	pre-dominant	co-activator	on	stress	response	
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genes	(around	10%	of	yeast	genes)	which	often	contain	consensus	TATA-boxes	such	as	the	
GAL	genes,	the	PHO	genes	and	genes	that	respond	to	amino	acid	starvation	(Gcn4-regulated	genes)	 (Huisinga	 and	Pugh,	 2004).	 	Meanwhile,	 TFIID	dominates	 the	 other	 90%	of	 yeast	gene	 promoters,	 which	 predominantly	 lack	 consensus	 TATA-boxes.	 	 The	 terms	 “TFIID-dominated”	and	“SAGA-dominated”	are	used	pervasively	in	the	literature	to	describe	which	complex	 is	more	 responsible	 for	 the	 regulation	of	 a	 gene.	 	However,	 recent	 studies	have	expanded	 the	 role	 SAGA	 plays	 in	 regulating	 TFIID-dominated	 genes.	 	 Using	 4-thiouracil	RNA	pulse	labeling	in	cells	containing	either	WT	SAGA	or	deletion	of	subunits	required	for	SAGA	structural	integrity	(Spt7	and	Spt20),	Tora	and	colleagues	showed	that	RNA	synthesis	was	dramatically	reduced	in	TFIID-dominated	genes	despite	near	WT	levels	of	steady-state	transcripts	 (Bonnet	 et	 al.,	 2014).	 	 Thus,	 SAGA	 appears	 to	 play	 an	 important	 role	 in	 the	transcription	 for	 all	 yeast	 and	human	Pol	 II	 transcribed	 genes.	 	 	 Furthermore,	Hahn	 and	colleagues	recently	demonstrated	that	Taf1	also	occupies	SAGA-dominated	genes	using	the	newly	developed	chromatin	endogenous	cleavage	and	high	throughput	sequencing	(ChEC-seq)	 method	 (Grünberg	 et	 al.,	 2016;	 Zentner	 et	 al.,	 2015).	 	 Altogether,	 TFIID	 and	 SAGA	appear	to	have	significant	functional	overlap	that	will	need	to	be	explored	further	in	future	research.			Mediator	 is	 another	multisubunit	 complex	containing	at	 least	21	subunits	 in	S.	
cerevisiae.	 Kornberg	 and	 colleagues	 discovered	 Mediator	 as	 a	 biochemical	 activity	 that	could	alleviate	the	ability	of	Gal4-VP16	to	interfere	with	the	ability	of	other	trans-activators	to	 stimulate	 transcription	 (Kelleher	 et	 al.,	 1990).	 	 Co-incident	 with	 the	 Kornberg	 lab’s	discovery,	 Richard	 Young	 and	 colleagues	 genetically	 identified	 mutations	 in	 several	Mediator	subunits	(not	known	as	Mediator	subunits	at	the	time)	that	could	suppress	the	Ts	
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phenotype	of	strains	harboring	a	 truncated	C-terminal	domain	of	Rpb1	(Thompson	et	al.,	1993).	 	 Subsequently,	 both	 the	 Kornberg	 lab	 and	 the	 Young	 lab	 have	 postulated	 that	Mediator	 and	 Pol	 II	 come	 together	 to	 form	 the	 Pol	 II	 holoenzyme	 that	 is	 required	 for	transcription	 initiation	 in	vivo	(Koleske	 and	 Young,	 1994).	 	Mediator	 has	 been	 shown	 to	contribute	to	all	phases	of	the	transcription	cycle	–	initiation,	elongation	and	termination	–	by	physically	and	functionally	interacting	with	all	of	the	general	transcription	factors,	TFIIS	and	 Pol	 II	 (Allen	 and	 Taatjes,	 2015;	 Baek	 et	 al.,	 2006;	 Conaway	 and	 Conaway,	 2013;	Guglielmi	 et	 al.,	 2007;	 Johnson	 and	 Carey,	 2003;	 Kremer	 et	 al.,	 2012;	Malik	 et	 al.,	 2007;	Mukundan	and	Ansari,	2011;	Sakurai	et	al.,	1996;	Sakurai	and	Fukasawa,	1998;	Takagi	et	al.,	2006;	Takahashi	et	al.,	2011;	Wery	et	al.,	2004).				 The	Role	of	Chromatin	and	Nucleosome	Positioning	in	Transcription	Regulation	While	 much	 of	 the	 work	 done	 to	 define	 the	 components	 required	 for	transcription	initiation	has	been	performed	using	naked	DNA,	the	eukaryotic	DNA	genome	is	packaged	into	structures	called	chromatin	(Olins	and	Olins,	2003).		The	building	block	of	chromatin	 is	 the	 nucleosome:	 	 ~147bp	 of	 DNA	 wrapped	 around	 a	 histone	 octamer	composed	 of	 two	 copies	 of	 heterodimeric	 pairs	 of	 histones	 H2A/H2B	 and	 H3/H4	(Kornberg,	 1974;	 Luger	 et	 al.,	 1997).	 	 In	 general,	 the	 nucleosome	 is	 inhibitory	 to	transcription	 because	 most	 DNA	 binding	 proteins	 are	 unable	 to	 bind	 their	 cognate	 cis-elements	when	 it	 is	wrapped	around	 the	histone	octamer.	 	However,	 core	promoters	 for	constitutively	 active	 genes	 are	 contained	within	 a	 region	 known	 as	 the	 nucleosome	 free	region	(NFR)	(Choder	et	al.,	1984;	Jakobovits	et	al.,	1980;	Saragosti	et	al.,	1980,	p.	40).		This	NFR	is	maintained	through	two	likely	interdependent	mechanisms:		first,	ATP-	dependent	
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chromatin	 remodelers	 such	 as	 RSC,	 Swi/Snf	 and	 Ino80	 can	 slide	 histones	 upstream	 and	downstream	of	 the	 core	promoter	 leaving	 it	open	 (Lorch	and	Kornberg,	2015;	Yen	et	 al.,	2012)	 and	 second,	binding	of	 the	 general	 transcription	 factors	 and	Pol	 II	 can	occupy	 the	core	promoter	and	thus	prevent	nucleosome	formation.		Targeting	of	these	ATP-dependent	chromatin	 remodelers	 to	 chromatin	 is	 thought	 to	 occur	 through	 pioneer	 transcription	factors	(Swinstead	et	al.,	2016).	 	These	factors	can	bind	to	chromatinized	DNA	enhancers	(Cirillo	et	al.,	2002,	1998)	and	recruit	ATP-dependent	remodelers	to	open	up	the	chromatin	leading	to	gene	activation	(Figure	1.4)	(Hu	et	al.,	2011;	L.	Wang	et	al.,	2014).			Recently,	the	labs	of	Pugh	and	Korber	used	purified	components	in	an	attempt	to	reconstitute	the	distribution	of	chromatin	on	yeast	genomic	DNA	(Krietenstein	et	al.,	2016).		They	 observed	 that,	 in	 the	 presence	 of	 global	 transcription	 regulators	 (Abf1/Reb1),	chromatin-remodeling	enzymes	(RSC,	INO80,	ISW2	and	ISW1a)	order	the	nucleosomes	in	a	sequential	 process.	 	 This	 process	 entails	 clearing	 of	 the	 nucleosome	 free	 region,	establishing	 the	 appropriate	 positioning	 of	 the	 +1	 nucleosome	 and	 arranging	 the	downstream	nucleosomes	 to	 have	 the	 appropriate	 internucleosomal	 spacing.	 	While	 this	study	made	significant	progress	toward	defining	the	mechanism	of	nucleosome	positioning	genome	 wide,	 none	 of	 assays	 the	 labs	 of	 Korber	 and	 Pugh	 used	 ever	 reconstituted	 the	nucleosome	 positioning	 observed	 in	 vivo	 and,	 thus,	 only	 informs	 us	 of	 the	 contributions	that	ATP-dependent	chromatin	remodelers	can	make.		To	truly	test	their	model,	they	need	to	 perform	 these	 studies	 in	 cells	 with	 conditionally	 (Anchor	 Away	 or	 auxin-inducible	degron)	 depleted	 chromatin	 remodeling	 enzymes,	 either	 individually	 or	 in	 combination,	and	map	nucleosome	positioning	genome-wide	(Haruki	et	al.,	2008;	Nishimura	et	al.,	2009).		
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The	PHO5	System	as	a	Model	for	Chromatin-Dependent	Gene	Activation	Arguably,	 the	 most	 well	 characterized	 system	 with	 regard	 to	 chromatin	remodeling	 as	 a	 gene	 activation	 mechanism	 is	 the	 activation	 of	 the	 PHO5	 gene	 in	 S.	
cerevisiae	 (Korber	 and	 Barbaric,	 2014).	 	 Specifically,	 under	 inorganic	 phosphate	 rich	conditions,	PHO5	 is	 repressed.	 	 Repression	 is	 achieved	 through	 two	mechanisms.	 	 First,	nucleosomes	occlude	one	of	 the	binding	sites	 for	 the	Pho4	trans-activator	and	the	TATA-box	(Almer	et	al.,	1986;	Almer	and	Hörz,	1986;	Barbarić	et	al.,	1996;	Bergman	et	al.,	1986;	Bergman	 and	 Kramer,	 1983;	 Venter	 et	 al.,	 1994).	 	 Second,	 Pho4	 is	 sequestered	 to	 the	cytosol	through	phosphorylation	(Kaffman	et	al.,	1998,	1994;	O’Neill	et	al.,	1996).			
PHO5	activation	is	achieved	through	the	following	mechanism.		Under	inorganic	phosphate	starvation	conditions,	Pho4	is	no	longer	phosphorylated	(Schneider	et	al.,	1994),	can	enter	the	nucleus	and	bind	cooperatively	with	Pho2	at	its	cognate	binding	site	on	PHO5	(Barbaric	et	al.,	1998).	 	Pho4	can	then	direct	remodeling	of	 the	histones	within	the	PHO5	core	 promoter	 by	 ATP-dependent	 chromatin	 remodeling	 complexes	 exposing	 a	 second	Pho4	binding	site	and	the	TATA-box	(Barbaric	et	al.,	2007;	Gregory	et	al.,	1999;	Svaren	et	al.,	 1994).	 	 SAGA	 is	 also	 critically	 important	 for	 this	 process	 serving	 two	 distinct	 roles:		histone	 acetylation	 through	 its	 Gcn5	 subunit	 and	 a	 TBP	 chaperone	 function	 through	 its	Spt3	 subunit	 (Barbaric	 et	 al.,	 2003;	 Brownell	 et	 al.,	 1996,	 p.	 5;	 Gregory	 et	 al.,	 1998).		Together,	 SAGA	 and	 chromatin	 remodelers	 activate	 the	 PHO5	 promoter	 such	 that	 PIC	formation	can	occur	and	Pol	II	can	initiate	transcription.	In	this	example,	nucleosomes	play	a	 direct	 role	 in	 repressing	 transcription	 by	 occluding	 the	 TATA-box	 and	 preventing	association	 of	 TBP	 and	 subsequent	 PIC	 formation.	 	 In	 support	 of	 this	model,	 Adkins	 and	Tyler	have	shown	that	if	histone	chaperones	involved	in	reassembling	nucleosomes	at	the	
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PHO5	 promoter	 are	 disrupted,	 even	 under	 repressive	 conditions	 where	 both	 Pho2	 and	Pho4	are	displaced	 from	the	promoter,	 transcription	continues	(Adkins	and	Tyler,	2006).		This	data	highlights	the	importance	of	DNA	accessibility	to	transcription	activation.		 Histone	Post-Translational	Modification	and	Transcription	Activation	Alternatively,	 nucleosomes	 also	 play	 a	 role	 in	 transcription	 activation	 and	promoter	specific	transcription.	 	Histones	contain	unstructured	regions	that	protrude	out	of	 the	 nucleosome	 known	 as	 histone	 tails.	 	 These	 tails	 are	 heavily	 post-translationally	modified	 (PTM)	by	methylation,	phosphorylation,	 acylation	 (most	 commonly	acetylation)	and	ubiquitylation,	among	other	PTMs	(Hottiger,	2015;	Shilatifard,	2006).	 	The	dominant	model	 for	 how	 these	 histone	 marks	 regulate	 transcription	 is	 that	 co-activator	 and	 co-repressor	proteins	recognize	these	marks	and	stimulate	either	PIC	formation	or	chromatin	condensation,	 respectively,	 to	 make	 gene	 promoters	 less	 accessible.	 	 For	 transcription	activation,	the	+1	nucleosome	(the	nucleosome	immediately	downstream	of	the	NFR)	is	a	hub	for	post-translational	modification	(Figure	1.4).	For	example,	Rad6/Bre1	ubiquitylates	lysine	 123	 of	 H2B	 (H2Bub123)	 at	 the	 +1	 nucleosome	 (Dover	 et	 al.,	 2002;	 Hwang	 et	 al.,	2003;	 Sun	 and	Allis,	 2002;	Wood	 et	 al.,	 2003).	 	 This	H2Bub123	mark	 is	 required	 for	 the	SET1/COMPASS	 complex	 to	 tri-methylate	 lysine	 4	 on	 histone	 H3	 (Krogan	 et	 al.,	 2002;	Miller	 et	 al.,	 2001)	 (H3K4me3;	 see	Figure	1.4).	 	 The	H3K4me3	mark	 is	 highly	 correlated	with	actively	transcribing	genes	(Briggs	et	al.,	2001;	Roguev	et	al.,	2001;	Santos-Rosa	et	al.,	2002;	 Strahl	 et	 al.,	 1999).	 	 Both	 the	 plant	 homeobox	 domain	 (PHD)	 finger	 in	 the	 TFIID	subunit	 Taf3	 as	 well	 as	 the	 Tudor	 domain	 of	 Sgf29	 in	 SAGA	 can	 specifically	 bind	 to	H3K4me3	(Bian	et	al.,	2011;	Vermeulen	et	al.,	2007).		Furthermore,	active	genes	are	highly		
	 23	 	
	 24	
enriched	 in	acetylation	on	histones	H3	and	H4.	 	Three	of	 the	major	acetyltransferases	 in	yeast	 are	 Nucleosomal	 Acetyltransferase	 of	 Histone	 H3	 (NuA3)	 (John	 et	 al.,	 2000),	Nucleosomal	 Acetyltransferase	 of	 Histone	 H4	 (NuA4)	 (Allard	 et	 al.,	 1999)	 and	 the	 Gcn5	acetyltransferase	 containing	 SAGA	 and	 transcriptional	 ADAptor	 (ADA)	 co-activatorcomplexes	 (Grant	 et	 al.,	 1997),	 all	 three	 of	 which	 play	 a	 role	 in	 stimulating	transcription	 activation.	 One	 of	 the	 lysines	 Gcn5	 acetylates	 is	 lysine	 9	 of	 histone	 H3	(H3K9ac),	 another	 mark	 that	 is	 localized	 to	 the	 5’	 ends	 of	 genes	 and	 correlated	 with	actively	transcribed	genes	(Bonnet	et	al.,	2014;	Cieniewicz	et	al.,	2014;	Grant	et	al.,	1999;	Ruiz-García	et	al.,	1997).	 	The	Taf1	subunit	of	TFIID	contains	a	doublebromo	domain	that	directly	 interacts	 with	 acetylated	 histones	 (Jacobson	 et	 al.,	 2000)	 and	 Taf14	 has	 been	shown	 to	 preferentially	 interact	with	 acetylated	 histone	H3	 over	 unmodified	 histone	H3	including	H3K9ac	(Shanle	et	al.,	2015).		Based	on	these	biochemical	activities,	the	simplest	model	 is	 that	 both	 TFIID	 and	 SAGA	 can	 recognize	 histone	 marks,	 which	 results	 in	stimulation	of	TBP-promoter	binding	and	PIC	formation.	Post-translational	 modification	 of	 histone	 tails	 can	 also	 repress	 spurious	transcription	 (Figure	 1.5).	 	 For	 example,	 in	 the	 wake	 of	 actively	 transcribing	 Pol	 II,	intragenic	nucleosomes	are	both	acetylated	(a	mark	of	active	transcription)	as	well	as	di-	and	tri-methylated	on	lysine	36	of	H3	(H3K36me)	by	Set2	(Kizer	et	al.,	2005;	Krogan	et	al.,	2003b;	Strahl	et	al.,	2002),	which	 is	bound	to	 the	Ser2-p	 form	of	 the	Rpb1	CTD	(Li	et	al.,	2003).	 	 Acetylated	 histones	 are	 readily	 removed	 and/or	 exchanged	 with	 other	 histones	potentially	resulting	in	free	DNA	and	subsequent	PIC	formation	at	cryptic	core	promoters	at	 the	 3’	 end	 of	 genes	 (Schwabish	 and	 Struhl,	 2004;	 Venkatesh	 et	 al.,	 2012).	 	 	 	 This	H3K36me	mark	is	recognized	by	the	Rpd3S	histone	deacetylase	complex,	which	acts	to		
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remove	the	acetylation	mark	(Carrozza	et	al.,	2005;	Keogh	et	al.,	2005).		Functionally,	this	represses	 spurious	 initiation	 of	 transcription	 within	 intragenic	 regions.	 	 Thus,	 these	observations	 have	 led	 to	 the	 model	 that,	 within	 the	 context	 of	 a	 transcribed	 gene,	nucleosomes	play	an	active	repressive	role	in	minimizing	transcription	initiation	outside	of	the	core	promoter.		However,	nucleosome	modifications	such	as	acetylation	and	H3K4me3	at	the	+1	nucleosome	stimulate	PIC	formation	at	the	core	promoter.		The	Structure	of	the	15-Subunit	TFIID	Complex	As	described	above,	TFIID	is	critical	for	regulating	transcription	of	90%	of	mRNA	genes	 likely	 through	 its	 co-activator	 function	 as	 well	 as	 its	 ability	 to	 recognize	 both	promoter	 DNA	 and	 active	 histone	marks.	 	 As	 such,	 the	 elucidation	 of	 the	 structure	 and	biochemical	properties	of	TFIID	will	shed	light	on	how	this	complex	accomplishes	its	role	in	transcription	regulation.			
	S.	 cerevisiae	 TFIID	 (scTFIID)	 is	 a	 1.2	 megadalton	 15-subunit	 complex	 (Figure	1.5)	(Sanders	et	al.,	2002a).		Prior	to	joining	the	lab,	our	lab	in	collaboration	with	the	lab	of	Patrick	 Schultz	 from	 the	 IGBMC	 (Institut	 Génétique	 Biologie	 Moléculaire	 Cellulaire)	 in	Strasbourg,	 France	 had	 described	 the	 structure	 of	 yeast	 TFIID	 using	 cryo-electron	microscopy	 at	 approximately	 25	Angstrom	 resolution	 (Papai	 et	 al.,	 2010).	 	 The	 shape	 of	TFIID	can	be	divided	into	4	lobes:	lobe	A,	lobe	B,	lobe	C	(containing	C1	and	C2	subdomains)	and	lobe	D	(Figure	1.6).		These	lobes	form	an	asymmetric	structure	that	could	be	described	as	a	catcher’s	mitt.		Lobe	B	forms	the	smaller	thumb	part	of	the	mitt,	lobe	C1	and	C2	form	the	base	of	 the	palm	and	 lobe	A	and	 lobe	D	 form	the	 top	part	of	 the	mitt	where	 the	 four	fingers	would	be	located.		The	interface	of	these	lobes	is	the	cleft	of	the	complex	where	the	
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DNA	associates.	Through	this	work,	our	lab	along	with	the	Schultz	lab	was	able	to	identify	the	rough	location	of	all	the	Tafs	(with	the	exception	of	Taf14)	using	electron	microscopy	techniques	 coupled	 with	 immunolabeling	 and	 difference	 mapping	 (Leurent	 et	 al.,	 2004,	2002;	Papai	et	al.,	2009).		Two	copies	of	Taf5	form	the	scaffold	of	the	molecule	onto	which			other	TFIID	subunits	assemble.		The	N-terminal	domains	(NTDs)	of	Taf5	are	located	in	lobe	C1	and	C2	while	the	C-terminal	WD40	motifs	are	located	in	both	the	A	lobe	and	the	B	lobe.		Lobe	A	also	contains	Taf1,	Taf3,	Taf6,	Taf7,	Taf8,	Taf9,	Taf10,	Taf11	and	Taf13.		Lobe	B	also	contains	Taf3,	Taf4,	Taf12,	Taf6,	Taf9,	Taf11	and	Taf13.		Lobe	D	contains	the	C-terminus	of	Taf2.		The	remaining	Taf2	density	extends	throughout	the	central	part	of	the	molecule	with	its	N-terminus	positioned	between	 lobe	C2	 and	 lobe	B.	 	 The	TAND	of	Taf1	 extends	 from	
	
Figure	1.6:	TFIID	Subunit	Stoichiometry	and	Structure.	 	A.		Purified	TFIID	separated	on	a	SDS-PAGE	gel.		Subunits	(Taf1àTaf14	and	TBP)	were	visualized	by	Sypro	Ruby	gel	stain.		B.		Schematic	of	 TFIID	 structure	 based	 on	 immunolabeling	 and	 difference	 mapping.	 	 Note:	 	 Location	 of	 Taf14	within	 the	 complex	 is	 currently	 unknown.	 	 C.	 	 Stoichiometry	 of	 the	 subunits	 within	 the	 TFIID	complex	 (mole	 subunit/mole	 TFIID).	 	 Values	 based	 on	 staining	 measurements	 and	 in	 vivo	immunoprecipitation	measurements.		
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lobe	A	to	lobe	C1	where	it	binds	to	TBP,	which	is	located	in	the	central	cleft	of	the	molecule.		In	addition	to	the	Taf5	NTDs,	lobe	C1	and	C2	also	contain	Taf4,	Taf8,	Taf10	and	Taf12.	In	 general,	 the	 stoichiometry	 and	 biochemical	 binding	 data	 for	 the	 TFIID	subunits	are	in	agreement	with	the	identified	positions	within	the	TFIID	structure.		Many	of	these	subunits	contain	what	 is	known	as	a	histone-fold	domain,	which	allows	 for	specific	heterodimerization	among	the	TFIID	subunits.	 	The	TFIID	histone	fold	pairs	include	Taf3-Taf10,	 Taf4-12,	 Taf6-9,	 Taf8-10	 and	Taf11-13	 	 (Birck	 et	 al.,	 1998;	 Gangloff	 et	 al.,	 2001b;	Hisatake	et	al.,	1995;	Selleck	et	al.,	2001;	Werten	et	al.,	2002).			With	the	exception	of	Taf3	that	localizes	to	lobe	B,	all	of	the	histone	fold	domain-containing	Tafs	localize	to	lobes	that	contain	their	cognate	binding	partners.		However,	the	stoichiometry	of	the	complex	and	the	locations	for	Taf3,	Taf8,	Taf11	and	Taf13	subunits	are	inconsistent	if	the	structure	of	TFIID	is	monolithic.		First,	Taf3,	Taf8,	Taf11	and	Taf13	are	present	in	one	mole	per	mole	of	TFIID	so	they	should	not	be	present	in	multiple	copies,	as	the	immunolabeling	might	suggest.	It	is	possible	 that	 Taf3	 and	 the	Taf11-Taf13	 heterodimer	 can	 bind	 to	 both	 lobe	A	 and	 lobe	B	while	 Taf8	 can	 bind	 to	 both	 lobe	 A	 and	 lobe	 C.	 	 This	 possibility	 would	 result	 in	 TFIID	assembly	 isomers	 that	 could	 explain	 the	 immunolabeling	 results.	 	 To	 more	 accurately	determine	 the	 location	 of	 all	 of	 the	 TFIID	 subunits	 and	 if	 these	 isomers	 exist,	we	would	need	a	TFIID	cryoEM	or	x-ray	crystallographic	structure	with	improved	resolution.			Recently,	 the	Nogales	 lab	published	 two	 cryoEM	 structures	 of	 human	TFIID	 in	complex	with	promoter	DNA	and	TFIIA	 (Cianfrocco	 et	 al.,	 2013;	 Louder	 et	 al.,	 2016).	 	 In	their	first	report,	Nogales	and	colleagues	suggested	a	lobe	of	TFIID	is	highly	mobile,	capable	of	 moving	 from	 one	 side	 of	 the	 molecule	 to	 the	 other,	 further	 confounding	 our	understanding	of	 the	TFIID	structure.	 	 In	 their	 second	report,	Nogales	et	al.	 refined	 their	
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structure	 by	 docking	 existing	 crystal	 structure	 data	 or	 homology	 models	 (Taf2	 in	particular)	into	the	structure	and	refining	the	amino	acids	to	fit	the	densities	observed	in	the	cryoEM	reconstruction.		Using	this	method,	they	were	able	to	resolve	TBP,	TFIIA,	Taf2,	Taf7	and	parts	of	Taf1	and	Taf6	at	the	atomic	level.	They	also	speculate	about	the	position	of	 Taf8,	 although	 the	 resolution	 of	 the	 structure	 makes	 it	 difficult	 to	 conclude	 with	confidence	that	the	density	is	truly	Taf8.		The	rest	of	the	structure	is	not	at	a	high	enough	resolution	 to	 determine	 the	 location	 of	 the	 remaining	 subunits	 and,	 therefore,	 does	 not	solve	 the	 discrepancy	 related	 to	 the	 position	 of	 Taf3,	 Taf8	 and	 the	 Taf11-Taf13	heterodimer.	Furthermore,	Nogales	and	colleagues	could	not	locate	any	of	the	histone	fold	domain-containing	 heterodimers	 in	 her	 structures	 and	 suggests	 that	 TFIID	 undergoes	 a	significant	 rearrangement	 once	 either	 completely	 assembled	 or	 bound	 to	 promoter	DNA/TFIIA.					 In	parallel	with	the	Nogales	work,	the	labs	of	Imre	Berger,	Lazlo	Tora	and	Patrick	Schultz	 began	 to	 reconstitute	 the	 human	 TFIID	 complex	 using	 purified	 Taf	 subunits	(Bieniossek	et	al.,	2013).		They	attempted	to	begin	with	Taf5	as	the	scaffold.		However,	Taf5	is	insoluble	when	expressed	in	E.	coli	or	Sf9	cells.		To	overcome	this	hurdle,	they	discovered	that	Taf5,	Taf6	and	Taf9,	when	co-expressed,	from	a	soluble	and	stable	complex.		They	used	this	complex	as	the	scaffold	onto	which	they	could	assemble	several	TFIID	subunits.		First,	Taf5-Taf6-Taf9	 complex	 can	 associate	 with	 the	 Taf4-Taf12	 heterodimer	 to	 form	 a	 5-Taf	complex.	 	Consistent	with	this	observation,	using	siRNA	knockdown	of	Taf1,	the	Tjian	lab	was	able	to	isolate	a	similar	5-Taf	complex	from	drosophila	S2	cells	(Wright	et	al.,	2006).		The	 Schultz	 lab	went	 on	 to	 determine	 the	 structure	 of	 this	 5-Taf	 complex	using	 cryoEM.		This	 complex	 contains	 two	 copies	 of	 each	 subunit	 and	 is	 arranged	 as	 a	 symmetrical	
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complex,	 inconsistent	 with	 the	 asymmetric	 structure	 of	 TFIID.	 	 Berger	 and	 colleagues	termed	this	5-Taf	complex	as	the	TFIID	core.		Once	the	core	was	formed,	Berger	et	al.	could	add	 a	 Taf8-Taf10	 complex	 resulting	 in	 an	 7-Taf	 assembly.	 	 Addition	 of	 this	 Taf8-Taf10	complex	 to	 the	 5-Taf	 TFIID	 core	 complex	 breaks	 its	 symmetry	 such	 that	 the	 structure	begins	to	resemble	TFIID	and	can	be	docked	into	the	yeast	TFIID	complex	structure.		As	a	result,	Berger	and	Schultz	have	proposed	that	the	TFIID	assembly	pathway	is	regulated	by	the	association	of	this	Taf8-Taf10	complex	with	the	TFIID	core	and	this	break	in	symmetry	is	 important	for	the	final	steps	of	TFIID	assembly.	 	These	data	were	further	supported	by	the	identification	of	a	cytoplasmic	Taf2-Taf8-Taf10	subcomplex	that	is	distinct	from	TFIID	and	whose	 entry	 into	 the	 nucleus	 is	 regulated	 by	 the	Taf8	 nuclear	 localization	 sequence	and	 importin-α1	 (Trowitzsch	 et	 al.,	 2015).	 	 This	 Taf2-Taf8-Taf10	 complex	 can	 also	associate	 and	 co-purify	 with	 the	 5-Taf	 TFIID	 core	 suggesting	 that	 the	 Taf2-Taf8-Taf10	submodule	may	 stimulate	 this	 conformational	 change	and	 subsequent	TFIID	assembly	 in	
vivo.	 	 	Additional	TFIID	structural	 intermediates	generated	 in	vitro	and,	 if	possible,	 in	vivo	would	help	to	understand	the	TFIID	assembly	pathway.	When	 comparing	 the	 structures	 generated	 by	 our	 lab	 in	 collaboration	 with	Patrick	Schultz,	the	collaboration	of	Berger	and	Schultz,	and	the	Nogales	lab,	there	remain	some	discrepancies.	Neither	 the	5-Taf	TFIID	core	nor	 the	8-Taf	complex	could	be	docked	into	 the	 Nogales	 human	 TFIID	 structure.	 	 In	 fact,	 in	 the	 Nogales	 structure,	 the	 subunits	constituting	 the	 5-Taf	 core	 appeared	 to	 be	 the	most	 disordered	 region	 of	 her	 structure.		Furthermore,	Nogales	 and	 colleagues	 could	 not	 dock	 any	 of	 the	 crystal	 structures	 of	 the	histone	fold	heterodimers.	Even	though	they	could	identify	the	position	of	Taf6,	she	could	not	 detect	 the	 Taf6/Taf9	 heterodimer.	 	 This	 led	 Nogales	 et	 al.	 to	 speculate	 that	 TFIID	
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undergoes	 a	 dramatic	 rearrangement	where	 the	 histone	 fold	 domain	 Tafs	 are	 separated	into	two	distinct	domains,	one	of	which	is	exceptionally	mobile.		These	results	may	reflect	a	rearrangement	 stemming	 from	 this	 break	 in	 asymmetry	 described	 by	 the	 work	 of	 the	Berger	 and	 Schultz	 labs.	 	 As	mentioned	 above,	 this	 could	be	 consistent	with	 observation	Nogales	and	colleagues	made	that	an	entire	domain	of	TFIID	dissociates	from	one	part	of	the	complex	and	reassociates	with	another	part	of	the	complex.		It	is	important	to	note	that	the	 labs	 of	Weil	 and	 Schultz	never	 observed	 these	 structural	 rearrangements	 in	 scTFIID,	either	by	itself	or	in	complex	with	TFIIA	and	promoter	DNA.		In	addition,	the	Nogales	TFIID	model	 was	 not	 supported	 by	 either	 genetic	 (i.e.	 GFP	 or	 MBP	 tags	 or	 domain	 deletion	variants)	 or	 biochemical	 (i.e.	 immunolabeling)	 labeling	 or	 chemical	 cross-linking/mass	spectrometry	 techniques	 that	 could	 help	 to	 unambiguously	 identify	 the	 location	 of	 these	subunits.	 	 While	 these	 new	 structural	 studies	 are	 exciting	 and	 could	 lead	 to	 important	revelations	 about	 the	 subunit	 architecture	 of	 TFIID	 as	 well	 as	 provide	 some	 functional	implications	 that	 could	 be	 dissected	 biochemically	 and	 genetically,	 our	 understanding	 of	the	TFIID	structure	still	remains	quite	poor.		 TFIID	Functions	as	a	Transcription	Co-activator	and	Binds	the	Core	Promoter	Functionally,	 the	Tjian	 lab	has	been	 instrumental	 in	establishing	TFIID	as	a	co-activator.		In	their	early	investigations,	Tjian	and	colleagues	formed	TBP-Taf	subcomplexes	and	used	these	complexes	for	in	vitro	transcription	reactions	and	DNA	binding	studies	with	and	 without	 various	 trans-activator	 proteins.	 	 Using	 TFIID	 depleted,	 partially	 purified	general	 transcription	 factors,	 Tjian	 et	 al.	 demonstrated	 that	 a	 TBP/Taf1/Taf2/Taf4	complex,	in	the	presence	of	the	trans-activator	Sp1,	could	stimulate	transcription	from	an	
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enhancer/promoter	DNA	containing	Sp1	binding	sites	(Chen	et	al.,	1994).		This	stimulation	did	 not	 occur	 with	 TBP	 only,	 a	 TBP/Taf1/Taf2	 complex	 or	 a	 TBP/Taf1/Taf4	 complex.		These	 workers	 then	 demonstrated	 that	 Sp1	 directly	 interacts	 with	 Taf4.	 Using	 similar	experimental	 paradigms,	 Tjian	 and	 colleagues	 have	 demonstrated	 direct	 interaction	between	the	trans-activator	NTF-1	and	Tafs	2	and	6,	the	trans-activator	p53	with	Taf6	and	Taf9	and	the	 trans-activator	c-Jun	with	Taf1	and	Taf6	(Thut	et	al.,	1995).	 	These	protein-protein	 interaction	 assays	 were	 complemented	 with	 in	 vitro	 transcription	 functional	approaches	 showing	 activator-TFIID	 Taf	 dependent	 transcription	 stimulation.	 	 But,	 the	Tjian	 lab	 did	 not	 follow	 up	 these	 results	 with	 iterative	 complementary	 genetic	 and	biochemical	 dissection	 of	 these	 Taf-trans-activator	 interactions	 to	 determine	 how	 they	contribute	 to	 gene	 regulatory	 mechanism	 in	 vivo.	 	 	 While	 the	 Tjian	 lab’s	 work	 was	performed	with	metazoan	TFIID,	the	Weil	 lab	has	demonstrated	that	in	S.	cerevisiae	Rap1	directly	interacts	with	TFIID	through	Tafs	4,	5	and	12	supporting	a	role	for	TFIID	as	a	co-activator	 across	 all	 eukaryotes	 (Garbett	 et	 al.,	 2007;	 Layer	 et	 al.,	 2010;	 Layer	 and	Weil,	2013).	 	 Furthermore,	 the	Weil	 lab	 demonstrated	 that	 the	 interaction	 between	 Rap1	 and	TFIID	 was	 sensitive	 to	 mutagenesis	 and	 important	 for	 the	 regulation	 of	 the	 ribosomal	protein-encoding	 genes.	 	 Altogether	 these	 data	 implicate	 a	 direct	 interaction	 between	trans-activator	and	TFIID	as	a	mechanism	for	activated	transcription.	 	Moreover,	multiple	Tafs	can	directly	 interact	with	distinct	trans-activators	providing	multiple	hubs	for	trans-activator/co-activator	communication	(Chen	et	al.,	1994;	Hoey	et	al.,	1993;	Liu	et	al.,	2009;	Thut	et	al.,	1995).	TFIID	 also	 plays	 a	 critical	 role	 in	 promoter	 recognition	 through	 direct	interactions	between	TFIID	Tafs	and	both	core	promoter	DNA	elements	as	well	as	modified	
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histones	associated	with	active	transcription	(described	in	detail	in	the	next	section).		The	Smale	 lab	 first	 demonstrated	 that	 TFIID	 directly	 and	 functionally	 interacts	 with	 the	initiator	 (INR)	 core	 promoter	 element	 (Kaufmann	 and	 Smale,	 1994).	 	 Functional	 assays	performed	 by	 Smale	 and	 colleagues	 focused	 on	 identifying	 a	 co-factor	 that	 could	 help	stimulate	 transcription	 from	 the	 terminal	 deoxynucleotidyl	 transferase	 core	 promoter	fragment	engineered	 to	contain	a	consensus	TATA	box	and	either	a	WT	or	a	mutant	 INR	element	 (Kaufmann	 et	 al.,	 1998,	 1996).	 	 Impetus	 for	 these	 experiments	 derived	 from	 a	failure	 in	 the	 field	 to	 observe	 robust	 INR-dependent	 stimulation	 of	 transcription	 with	purified	 components	 when	 this	 stimulation	 had	 been	 observed	 using	 nuclear	 extracts	(Smale	 and	 Baltimore,	 1989).	 	 Ultimately,	 Smale	 and	 colleagues	 purified	 an	 activity	 that	could	 stimulate	 transcription	 in	 an	 INR-dependent	manner.	 	 He	 dubbed	 the	 protein	 that	displayed	this	activity	CIF150	and,	surprisingly,	this	protein	displayed	similar	reactivity	to	antibodies	raised	against	drosophila	Taf2	(Kaufmann	et	al.,	1996).	 	Concurrent	with	these	studies,	 Tjian	 and	 Verrijzer	 demonstrated	 that	 Taf2	 can	 directly	 bind	 to	DNA	 and,	 using	DNaseI	 footprinting,	 demonstrated	 that	 Taf2	 binding	 resulted	 in	 significant	hypersensitivity	 around	 the	 TSS	 and	 protection	 immediately	 downstream	 of	 the	 TSS,	 a	position	 that	 is	 in	 close	 proximity	 to	 the	 INR	 (Verrijzer	 et	 al.,	 1995,	 1994).	 	 Ultimately,	Chalkley	 and	 Verrizjer	 advanced	 these	 results	 by	 performing	 systematic	 evolution	 of	ligands	by	exponential	 enrichment	 (SELEX)	with	a	Taf1/Taf2	complex	and	demonstrated	that	the	preferred	specificity	was	for	the	INR	(Chalkley	and	Verrijzer,	1999).		The	Kadonaga	lab	performed	similar	footprinting	analyses	as	well	as	protein-DNA	cross-linking	to	identify	that	 Tafs	 6	 and	 9	 directly	 interact	 with	 the	 DPE	 core	 promoter	 element	 (Burke	 and	Kadonaga,	1997).	 	Also,	TFIID	 footprints,	performed	with	either	metazoan	or	yeast	TFIID	
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using	either	DNaseI	or	hydroxyl	radical	DNA	cleavage	methods,	span	between	60bp	to	up	to	 100bp	 in	 length	 (Juven-Gershon	 et	 al.,	 2006;	 Sanders	 et	 al.,	 2002a).	 	While	metazoan	TFIID	 footprints	 tend	 to	 display	 robust	 protection	 from	 DNA	 cleavage	 agents,	 scTFIID	shows	an	increase	in	DNaseI	hypersensitivity.	Functionally,	the	binding	of	TFIID	to	downstream	promoter	elements	has	raised	concerns	about	how	Pol	II	can	traverse	the	DNA	when	TFIID	may	sterically	hinder	access	to	the	 TSS.	 	 From	 a	 Taf2	 perspective,	 this	 concern	 is	 underscored	 by	 the	 fact	 that	 in	metazoans,	 the	 initiator	 is	 also	 the	 site	 of	 transcription	 initiation,	 with	 the	 starting	nucleotide	residing	directly	within	the	Taf2	binding	site.		Two	labs	have	provided	evidence	that	TFIID	structural	rearrangement	and	dissociation	from	the	INR	is	important	for	Pol	II	to	clear	 the	 promoter	 and	 engage	 in	 productive	 transcription.	 	 First,	 cross-linking,	footprinting	 and	 in	vitro	 transcription	 studies	 by	 the	 Goodrich	 and	Kugel	 labs	 suggested	that	 following	 recruitment	 of	 Pol	 II	 to	 the	 PIC,	 TFIID	 undergoes	 a	 slow	 isomerization	(Yakovchuk	et	al.,	2010).		This	isomerization	may	result	in	a	change	in	TFIID	structure	that	is	more	permissive	for	Pol	II	to	engage	the	DNA	and	transcribe	the	gene.		Second,	Tjian	and	colleagues	 identified	 a	 small	 molecule	 that	 targeted	 a	 predicted	 intrinsically	 disordered	region	 (IDR)	 of	 the	 Taf2	 C-terminus	 (Zhang	 et	 al.,	 2015).	 	 They	 utilized	 this	 inhibitor	 to	interrogate	 the	mechanism	 of	 Taf2	 action	 using	 in	 vitro	 transcription	 as	 a	 read-out.	 The	Tjian	 group	 observed	 that	 this	 inhibitor	 did	 not	 block	 TFIID	 association	 with	 promoter	DNA,	but	instead	it	enhanced	it.		As	a	result,	if	the	inhibitor	was	used	prior	to	the	first	round	of	 transcription	 (pre-Pol	 II	 addition),	 transcription	 was	 inhibited,	 presumably	 because	TFIID	could	not	undergo	the	isomerization	step	proposed	by	Yakovchuk	et	al.		However,	if	the	inhibitor	was	used	after	the	first	round	of	transcription,	transcription	re-initiation	was	
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not	 impacted.	 	Together,	 these	biochemical	 studies	have	 led	 to	a	putative	model	 for	Taf2	action	whereby	 it	 is	 important	 for	 promoter	 recognition	 and	 Pol	 II	 association	 but	 then	must	dissociate	from	or	alter	its	DNA	contacts	such	that	Pol	II	can	escape	the	promoter	and	engage	 in	 productive	 transcription	 initiation.	 	 However,	 as	 of	 yet,	 there	 have	 been	 no	studies	to	determine	if	this	mechanism	is	operative	and/or	important	in	vivo	because	Taf2	has	not	been	molecularly	genetically	dissected	in	any	system.			 Differences	between	Metazoan	and	Yeast	TFIID	Despite	 the	 functional	 similarities	 between	 metazoan	 and	 scTFIID	 described	above,	 the	TFIID	subunits	do	display	significant	differences.	A	comparison	of	 the	scTFIID	and	the	human	TFIID	subunits	is	provided	in	Figure	1.7	(Bai	et	al.,	1997;	Birck	et	al.,	1998;	Durso	 et	 al.,	 2001;	 Gangloff	 et	 al.,	 2001b;	 Hisatake	 et	 al.,	 1995;	 Klebanow	 et	 al.,	 1997;	Matangkasombut	et	al.,	2000;	Papai	et	al.,	2009;	Scheer	et	al.,	2012;	Werten	et	al.,	2002)..		Of	note,	several	functional	domains	that	exist	in	human	TFIID	Tafs	are	not	conserved	in	the	scTFIID	 homologs.	 	 For	 example,	 while	 human	 Taf3	 contains	 a	 PHD	 finger	 involved	 in	H3K4me3	binding	(described	above),	scTaf3	does	not	contain	this	domain	(Gangloff	et	al.,	2001a).		In	addition,	human	Taf1	is	a	213kDa	protein	that,	in	addition	to	structural	domains	required	for	Taf1-Taf	and	Taf1-TBP	interactions,	contains	two	kinase	domains	at	its	N-	and	C-termini,	 an	 acetyltransferase	 domain	 and	 a	 doublebromo	 domain,	 which	 binds	 to	acetylated	histones	(Bai	et	al.,	1997;	Dikstein	et	al.,	1996;	Mizzen	et	al.,	1996;	Poon	et	al.,	1995).	 	scTaf1	is	only	a	121kDa	protein.	 	Sequence	alignments	have	demonstrated	scTaf1	corresponds	 to	 the	N-terminal	 half	 of	 hTaf1.	 	 Thus,	 based	 on	 homology,	 scTaf1	 contains	only	one	of	the	kinase	domains,	which	has	never	been	shown	to	possess	phosphorylation		
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Figure	 1.7:	 	 Conservation	 and	 Domain	 Structure	 of	 the	 Evolutionarily	 Conserved	 TFIID	 Subunits.		Schematics	 of	 the	 primary	 structures	 of	 TFIID	 subunits	 for	 human	 (h)	 and	 Saccharomyces	 cerevisiae	 (sc).		Black	indicates	regions	of	homology.		White	boxes	or	empty	regions	indicate	regions	of	dissimilar	or	missing	sequences,	respectively.		Schematics	derived	from	alignments	of	primary	amino	acid	sequence	using	ClustalW	analysis	in	MacVector.		Domains	are	labeled.		Kin	=	Kinase,	TAND	=	Taf1	N-Terminal	Domain,	HAT	=	histone	acetyltransferase,	 IDR	 =	 intrinsically	 disordered	 region,	 WD40	 repeats	 =	 40	 amino	 acid	 stretches	 with	characteristic	Tryptophan-Aspartic	Acid	repeats,	HEAT	repeats	=	domains	common	to	Huntingtin,	Elongation	factor	3,	protein	phosphatase	2A	and	Tor1,	HFD	=	histone	 fold	domain.	 	CORE	=	highly	conserved	 	(~90%)	TBP	C-terminal	sequence.		Sequence	information	derived	from	UniProt.		
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activity,	 and	 the	 acetyltransferase	 domain,	 which	 only	 possess	 weak	 acetyltransferase	activity.	To	account	for	this	missing	doublebromo	domain,	Buratowski	and	colleagues	has	suggested	 that	 the	TFIID	 accessory	protein	Bdf1,	which	 contains	 a	 doublebromo	domain	that	binds	to	acetylated	H3	and	H4	in	vivo	(Ladurner	et	al.,	2003),	is	the	missing	C-terminal	piece	 of	 Taf1	 (Matangkasombut	 et	 al.,	 2000).	 	 Furthermore,	 genome-wide	 chromatin	precipitation	 (ChIP)	 analyses	 have	 demonstrated	 that	 Bdf1	 and	 Taf1	 share	 similar	occupancy	 profiles	 on	 gene	 promoters	 (Rhee	 and	 Pugh,	 2012).	 Still,	 if	 Bdf1	 does	 in	 fact	functionally	 correspond	 to	 the	missing	 Taf1	 C-terminus,	 then	 the	 question	 remains	why	human	 evolution	 favored	 a	 Taf1	 protein	 containing	 a	 covalently	 fused	 doublebromo	domain	while	S.	cerevisiae	favored	a	Taf1	protein	that	weakly	associates	with	Bdf1.		There	are	two	likely	scenarios	that	could	explain	this	phenomenon.	 	First,	S.	cerevisiae	utilizes	a	mechanism	 not	 required	 in	 humans	 to	modulate	 the	 interaction	 between	 Taf1	 and	 Bdf1	which	 could	 regulate	 transcription	 activation	 potential.	 	 Second,	 in	 S.	 cerevisiae	 Bdf1	 is	required	 in	 multiple	 transcription	 related	 complexes	 while	 in	 humans	 its	 particular	function	 is	 only	 required	 in	 the	 Taf1	 C-terminus.	 	 Both	 scenarios	 are	 supported	 by	experimental	 evidence	 including	 that	 Bdf1	 is	 subject	 to	 phosphorylation	 (Sawa	 et	 al.,	2004),	Bdf1	is	also	associated	with	the	SWR-C	complex	(Krogan	et	al.,	2003a)	and	Bdf1	can	associate	with	chromatin	independent	of	TFIID	(Ladurner	et	al.,	2003).	The	other	major	difference	between	scTFIID	and	its	metazoan	homologs	is	that	scTFIID	contains	a	fifteenth	subunit,	Taf14	(Henry	et	al.,	1994).		In	S.	cerevisiae,	Taf14	is	a	stoichiometric	member	or	associated	protein	 for	at	 least	7	different	 transcription	related	complexes:		the	general	transcription	factors	TFIID	and	TFIIF	(Henry	et	al.,	1994;	Kabani	et	al.,	2005;	Sanders	et	al.,	2002b);	the	Mediator	co-activator	complex	(Henry	et	al.,	1994;	Lim	
	 38	
et	 al.,	 2007;	 Sanders	et	 al.,	 2002b);	 the	ATP-dependent	 chromatin	 remodeling	 complexes	Swi/Snf	(Cairns	et	al.,	1996;	Sanders	et	al.,	2002b),	Ino80	(Kabani	et	al.,	2005;	Sanders	et	al.,	2002b)	and	RSC	(Kabani	et	al.,	2005);	and	the	histone	acetylation	complex	NuA3	(John	et	al.,	2000;	Kabani	et	al.,	2005;	Sanders	et	al.,	2002b).		Until	recently,	the	role	Taf14	played	in	these	complexes	was	largely	unknown.		TAF14	is	not	an	essential	gene	although	strains	that	 are	 taf14	 null	 display	 slow	 growth	 and	 a	 temperature	 sensitive	 phenotype.	 	 The	N-terminus	 of	 Taf14	 contains	 an	 evolutionarily	 conserved	 YEATS	 domain,	 named	 after	 the	proteins	 that	 contain	 this	 domain:	 Yaf9,	 ENL,	 AF9,	 Taf14,	 Sas5	 (Schulze	 et	 al.,	 2009).		However,	this	N-terminal	YEATS	domain	is	dispensable	for	growth	with	minimal	impact	on	growth	rate	or	 thermoresistance	(Schulze	et	al.,	2010).	The	Taf14	C-terminus	 is	 required	for	interaction	with	the	transcription	related	complexes	listed	above.		Deletion	of	the	Taf14	C-terminus	 phenocopies	 a	 taf14	 null	 strain.	 	 Together,	 these	 data	 suggest	 that	 the	 C-terminal	 domain	 plays	 a	 critical	 role	 in	 the	 function	 of	 these	 transcription	 related	complexes	 that	 is	 distinct	 from	 the	 function	 of	 the	 YEATS	 domain.	 	 Still,	 the	 role	 of	 the	YEATS	 domain	 in	 transcription	 is	 likely	 conserved	 between	 S.	 cerevisiae	 and	 humans	considering	both	ENL	and	AF9	are	members	of	the	human	super	elongation	complex	(Lin	et	al.,	2010).			In	the	last	two	years,	scientific	interest	in	YEATS	domain	containing	proteins	has	increased	because	both	Taf14	and	AF9	were	shown	to	specifically	bind	to	the	histone	tail	of	acetylated	lysine	9	of	H3	(H3K9ac),	a	histone	modification	that	is	highly	correlated	with	the	promoters	 of	 actively	 transcribing	 genes	 (Li	 et	 al.,	 2014;	 Shanle	 et	 al.,	 2015).	 	 Further	structural	and	biochemical	analyses	demonstrated	that	the	YEATS	domains	for	Taf14	and	AF9	contain	unusually	large	hydrophobic/aromatic	binding	pockets	that	can	accommodate	
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larger	 histone	 acylation	 marks	 including	 propionylation,	 butyrylation	 and	 crotonylation	(Andrews	et	al.,	2016;	Y.	Li	et	al.,	2016;	Tan	et	al.,	2011;	Zhang	et	al.,	2016).	 	 In	 fact,	 the	binding	affinity	of	Taf14	and	AF9	to	crotonyl-lysine	(Kd=10µM)	is	substantially	higher	than	acetyl	 lysine	 (Kd=150µM).	 	Similar	 to	H3K9ac,	 crotonylated	 lysine	9	of	H3	(H3K9cr)	also	correlates	with	 promoters	 of	 actively	 transcribing	 genes.	 	 Altogether,	 these	 observations	suggest	 that	 one	 important	 role	 of	 Taf14	 in	 transcription	 regulation	 is	 its	 ability	 to	 bind	modified	 chromatin	 allowing	 the	 complexes	 with	 which	 it	 associates	 to	 regulate	transcription.	 	 In	 support	of	 this	hypothesis,	Taf14	mutants	 that	are	defective	 in	H3K9ac	and	 H3K9cr	 binding	 display	 defects	 in	 steady-state	 RNA	 transcripts	 for	 DNA	 repair	pathways	 and	 cell	 cycle	 signaling	 pathways.	 	 Still,	 two	 issues	 remain	 with	 regard	 to	understanding	 the	 role	of	Taf14	 in	 transcription	regulation.	 	First,	 considering	Taf14	 is	a	stoichiometric	member	or	associated	protein	of	multiple	transcription	related	complexes,	it	is	 impossible	to	know	how	a	mutation	in	the	YEATS	domain	of	Taf14	specifically	 impacts	the	function	of	any	one	of	those	complexes.		Second,	considering	the	Taf14	YEATS	domain	is	dispensable	 for	normal	growth,	what	 is	 the	 function	of	 the	Taf14	C-terminus?	 	Does	 it	mediate	 interactions	 between	 the	 different	 proteins	within	 each	 complex	 (intra-complex	interactions),	bridge	interactions	between	different	proteins	in	different	complexes	(inter-complex	 interactions)	 or	 serve	 some	 other	 function	 such	 as	 stimulate	 proper	 folding	 or	mask	 domains	 that	 are	 inhibitory	 if	 exposed	 in	 the	 wrong	 cellular	 context.	 	 Ultimately,	despite	these	exciting	advancements	 in	our	understanding	of	Taf14	function,	 its	role	 in	S.	
cerevisiae	remains	quite	poorly	understood.	While	differences	in	TFIID	function	have	not	been	identified	with	regard	to	the	ability	 of	 specific	 Tafs	 to	 bind	 to	 DNA,	 the	 core	 promoter	 architecture	 is	 significantly	
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different	 between	 S.	 cerevisiae	 and	 metazoans.	 	 As	 described	 above,	 metazoan	 core	promoters	contain	several	elements	that	are	directly	bound	by	TFIID	subunits,	functionally	stimulate	transcription	in	a	TFIID-dependent	manner	or	both.		Those	elements	include	the	BREu,	BREd,	INR,	the	DPE,	the	downstream	core	element	(DCE)	and	the	motif	10	element	(MTE)	 (Figures	 1.2	 and	 1.3)(Lewis	 et	 al.,	 2000).	 	 None	 of	 these	 elements	 have	 been	unambiguously	identified	in	S.	cerevisiae.	 	In	addition,	studies	that	demonstrate	that	yeast	Tafs	bind	DNA	do	not	show	that	these	Tafs	bind	with	any	sequence	specificity	(Shao	et	al.,	2005).	 	Given	that	~80%	of	S.	cerevisiae	genes	do	not	contain	a	consensus	TATA	box,	one	must	question	how	scTFIID	specifically	binds	the	core	promoter.	 	Of	course,	scTFIID	Tafs	could	bind	to	the	core	promoter	in	a	sequence	specific	manner	but	the	cognate	cis-elements	are	 too	 degenerate	 to	 identify	 using	 bioinformatic	methods.	 	 Otherwise,	 there	 exist	 two	likely,	potentially	interdependent	mechanisms	that	could	answer	this	conundrum.			First,	TFIID	promoter	occupancy	could	be	directed	by	 its	 co-activator	 function,	meaning	that	TFIID	interaction	with	enhancer-bound	transactivators	could	direct	TFIID	to	TFIID-dominated	gene	core	promoters.		In	support	of	this	hypothesis,	Struhl	and	colleagues	have	 demonstrated	 TATA-containing,	 SAGA-dominated	 enhancer/promoters	 can	 be	converted	 to	 TFIID-dominated	 enhancer/promoters	 by	 fusing	 the	 enhancer	 of	 a	 TFIID-dominated	gene	to	the	core	promoter	from	a	SAGA-dominated	gene	(Mencía	et	al.,	2002).		The	Green	lab	has	made	similar	observations	(Li	et	al.,	2002).		These	data	suggest	that	the	core	promoter	does	not	necessarily	dictate	whether	a	gene	 is	TFIID-dominated	or	SAGA-dominated	 in	 S.	 cerevisiae.	 	 Furthermore,	 our	 lab	 has	 published	 structural	 data	 where	TFIID,	 when	 in	 complex	 with	 enhancer/promoter	 DNA	 (both	 the	 enhancer/promoter	fragments	used	by	Struhl	and	colleagues	as	well	as	from	the	native	RPS1A	gene),	the	trans-
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activator	Rap1	and	TFIIA,	appears	to	make	direct	contacts	with	TFIID	along	the	cleft	of	the	molecule	near	TBP	and	in	lobe	D	near	the	Taf2	C-terminus.	On	the	other	hand,	the	Ptashne	lab	 came	 to	 the	opposite	 conclusion.	 	 Ptashne	 and	 colleagues	 suggest	 that	 activators	 can	stimulate	the	association	of	both	SAGA	and	TFIID	to	promoters	but	the	promoter	 is	what	dictates	which	co-activator	is	required	for	activation	(Cheng	et	al.,	2002).	 	Thus,	the	roles	enhancers	 and	 promoters	 play	 in	 coordinating	 activator-co-activator	 communication	 are	still	poorly	understood.	Second,	TFIID	promoter	binding	could	result	from	the	ability	of	TFIID	to	interact	with	the	+1	nucleosome.	Rhee	and	Pugh	have	shown	that	the	distance	from	the	location	of	the	 PIC	 to	 the	 +1	 nucleosome	 is	much	more	 uniform	 across	 TFIID-dominated	 genes	 and	much	 less	uniform	across	SAGA-dominated	genes.	 	 	They	 speculate	 that	TFIID	acts	 like	a	ruler,	measuring	the	distance	between	its	interaction	with	the	+1	nucleosome	on	one	side	of	 the	 molecule	 and	 where	 the	 TATA-box	 (either	 consensus	 or	 non-consensus)	 is	positioned	 on	 the	 other	 side	 of	 the	 molecule.	 	 In	 this	 second	 model,	 TFIID-chromatin	binding	 activities	 are	 essential.	 	 Thus,	 Taf14-H3K9ac	 or	 Taf14-H3K9cr	 interactions	 and	Taf1-Bdf1	 interaction	 would	 be	 particularly	 important	 for	 TFIID	 promoter	 binding	function.		In	both	cases,	TFIID	can	still	interact	with	DNA	through	TBP,	non-specific	or	low	specificity	 Taf-DNA	 interactions	 or	 both;	 however,	 the	 ability	 of	 TFIID	 to	 specifically	associate	with	 the	 promoter	 is	 directed	 by	 activator	 and/or	 +1	 nucleosome	 interactions	and	not	 by	TBP-TATA	binding.	 	 In	 fact,	 both	models	 are	 consistent	with	 the	 observation	that	TATA-like	sequences	are	present	in	essentially	all	S.	cerevisiae	genes	(Rhee	and	Pugh,	2012)	because	TFIID-Tafs	could	act	to	position	TBP	in	close	proximity	to	low	affinity	TATA-like	sequences.			
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Alternatively,	it	is	possible	that	TBP-DNA	binding,	in	the	context	of	TFIID,	is	not	required	for	TFIID-dependent	transcription.		Two	lines	of	evidence	support	this	hypothesis.		Multiple	groups	have	shown	that	in	strains	containing	a	tbpts	allele,	following	temperature	shift,	Taf	occupancy	for	TFIID-dominated	genes	does	not	change	while	both	TBP	occupancy	and	Pol	II	occupancy	is	markedly	decreased	(Li	et	al.,	2000;	Mencía	et	al.,	2002,	p.	1).		Such	data	 demonstrate	 that	 Taf	 stability	 on	 genes	 (off	 rate)	 is	 not	 significantly	 changed	 upon	TBP	inactivation	but	it	does	not	show	that	TFIID	can	associate	with	gene	promoters	in	the	absence	 of	 TBP.	 Hahn	 and	 colleagues	 attempted	 to	 address	 this	 problem,	 to	 a	 certain	extent,	by	identifying	TBP	variants	that	displayed	a	reduction	in	the	ability	to	bind	DNA	and	failed	to	support	SAGA-dominated	gene	transcription	but	did	not	display	a	significant	loss	in	 TFIID-dominated	 gene	 transcription	 (Kamenova	 et	 al.,	 2014).	 	 Using	 TBP-inactivated	transcription	 extracts,	 addition	 of	 these	 TBP	 variants	 could	 reconstitute	 in	 vitro	transcription	of	a	RPS5	reporter	gene	(does	not	contain	a	consensus	TATA)	but	could	not	fully	reconstitute	 in	vitro	 transcription	of	a	HIS4	reporter	gene	(does	contain	a	consensus	TATA).	 	 These	 results	 suggest	 that	 TBP	 binding	 is	 not	 required	 for	 transcription	 of	 the	TFIID-dependent	RPS5	gene	and	could	support	an	increased	role	for	TFIID-DNA	binding	in	
RPS5	 gene	 transcription.	 	 However,	 Hahn	 et	 al.	 also	 states	 that	 he	 observed	 no	 TFIID-specific	DNA	binding,	which	directly	contradicts	DNaseI	footprinting	data	published	by	our	laboratory	(Sanders	et	al.,	2002a).			
Ultimately,	the	preponderance	of	data	supports	a	role	for	both	TBP-DNA	binding,	even	 to	 non-consensus	 TATA	 sequences,	 as	 well	 as	 TFIID-Taf	 DNA	 binding	 in	 promoter	recognition.	 	 Nonetheless,	 the	 field	will	 have	 to	 seriously	 address	 the	Hahn	 lab’s	 data	 to	understand	 the	 role	 of	 TBP	 and	 Tafs	 in	 TFIID-dependent	 transcription	 and	 promoter	
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recognition.		Importantly,	we	need	to	generate	separation-of-function	variants	in	Tafs	that	specifically	 disrupt	 Taf-DNA	 binding	 or	 Taf-chromatin	 binding	 without	 impacting	 other	essential	Taf	 functions.	 	With	 these	 reagents,	we	 can	determine	 the	 role	of	Taf-promoter	interactions	on	TFIID’s	functions	including	promoter	recognition	(i.e.	DNA	binding	in	vitro	and	promoter	occupancy	in	vivo)	and	transcription	activation	activity	(i.e.	RNA	output	both	
in	vivo	and	in	vitro).	
	 The	Role	of	Taf2,	a	Putative	INR	Binding	Protein,	in	TFIID	Biology	As	 described	 above,	 Taf2	 appears	 to	 play	 a	 significant	 role	 in	 TFIID-promoter	recognition	based	on	its	ability	to	bind	to	the	metazoan	INR	element.		However,	other	than	
in	 vitro	 biochemical	 data	 demonstrating	 Taf2	 DNA	 binding	 activity,	 we	 have	 minimal	understanding	 of	 how	Taf2	 functions	 in	 the	 context	 of	 TFIID.	 	 In	 fact,	 structure-function	analyses	of	Taf2	have	never	been	performed	in	any	system	so	we	do	not	even	understand	the	 domain	 structure	 of	 this	 critically	 important	 protein.	 	 Based	 on	 this	 dearth	 of	information,	 I	 decided	 to	 focus	 my	 dissertation	 research	 on	 the	 function	 of	 Taf2	 in	 S.	
cerevisiae.			While	we	do	not	 know	much	 about	Taf2	 function,	 several	 labs	have	published	descriptive	findings	regarding	Taf2	in	S.	cerevisiae.	 	To	identify	 important	protein-protein	interactions,	 two	 methods	 are	 commonly	 used	 in	 S.	 cerevisiae.	 	 First,	 2-hybrid	 genetic	screens	 are	 commonly	 used.	 	 Two	 studies	 that	 utilized	 2-hybrid	 screens	 have	 identified	potential	Taf2-TFIID	subunit	interaction	in	yeast.		The	first	study	described	a	genome-wide	2-hybrid	screen	to	identify	proteins	that	could	interact	with	Taf14	(Kabani	et	al.,	2005).		In	this	 study,	 while	 no	 data	 were	 shown,	 Kabani	 et	 al.	 reported	 that	 a	 Taf2	 aa	 1313-1407	
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fragment	 interacts	with	Taf14.	 	 The	 second	 study,	 performed	by	 Stargell	 and	 colleagues,	used	a	directed	2-hybrid	screen	approach	where	each	TFIID	subunit	was	screened	against	every	other	TFIID	subunit	to	create	a	TFIID	interaction	map	(Yatherajam	et	al.,	2003).		This	study	 found	 that	 a	Taf2-Gal4DBD	 fusion	 interacted	 strongly	with	a	Taf4-Gal4AD	 fusion	and	interacted	weakly	with	Taf3-Gal4AD	fusion	and	a	Taf8-Gal4AD	fusion.		Alternatively,	a	Taf2-Gal4AD	 fusion	 only	 interacted	 weakly	 with	 Taf7-Gal4DBD	 and	 Taf10-Gal4DBD	 fusions.		Importantly,	Taf14	was	not	assayed	in	this	study.		While	not	performed	with	yeast	Tafs,	an	
Arabidopsis	TFIID	subunit	directed	2-hybrid	screen	showed	that	a	Taf2-Gal4DBD	fusion	only	weakly	interacted	with	a	Taf1-Gal4AD	fusion	and	found	no	observable	interaction	with	any	other	Tafs	(Lawit	et	al.,	2007).		The	second	method	commonly	used	to	identify	interacting	proteins	is	to	purify	the	protein	in	question	along	with	any	other	associated	proteins	and	perform	 proteomics	 analysis.	 	 The	 Weil	 lab	 created	 affinity	 purified	 antibodies	 against	every	 TFIID	 subunit	 and	 used	 these	 antibodies	 to	 immunopurify	 each	 protein	 from	 a	partially	purified	chromatographic	fraction	(Sanders	et	al.,	2002b).		Immunopurification	of	Taf2	 of	 course	 purified	 TFIID	 subunits	 but	 also	 specifically	 purified	 the	 cleavage	 and	polyadenylation	specificity	factor	(CPSF).	 	None	of	the	other	immunopurifications	showed	enrichment	in	CPSF	suggesting	that	Taf2	may	directly	interact	with	CPSF	or	perform	other	functions	 outside	 of	 TFIID	 in	 the	 CPSF	 complex.	 	 One	 other	 study	 indicated	 that	 CPSF	interacts	 with	 TFIID	 (Dantonel	 et	 al.,	 1997),	 so,	 taken	 together,	 it	 is	 possible	 that	 CPSF	interacts	 with	 TFIID	 through	 Taf2.	 	 Considering	 our	 interest	 in	 the	 Weil	 lab	 is	 on	transcription	initiation	mechanism,	the	interaction	between	Taf2	and	CPSF	was	not	further	explored.	
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At	the	start	of	this	project,	the	existence	of	a	Taf2-Taf8-Taf10	complex	in	humans	had	not	yet	been	discovered.	 	However,	 the	Weil	 lab	had	generated	some	data	to	suggest	that	Taf2	 and	Taf8	 likely	 form	a	 subcomplex	 in	S.	cerevisiae.	 Post-doc	Madhu	Singh	used	immunoprecipitation	 of	 deletion	 variants	 of	 Taf1	 to	 identify	 the	 domains	 involved	 with	Taf1-TFIID	subunit	interactions	(Singh	et	al.,	2004).		He	found	that	three	deletion	variants	in	Taf1	 (aa	deletions:	Δ300-367,	Δ365-435	and	Δ430-495)	 could	 co-precipitate	 all	 of	 the	TFIID	 subunits	 as	 efficiently	 as	 WT	 Taf1	 with	 the	 exception	 of	 Taf2,	 Taf8	 and	 Taf14.		Surprisingly,	Taf10	did	not	show	a	defect	in	co-precipitation	in	these	Taf1	deletion	variants.		Similarly,	 Post-doc	 Manish	 Tripathi	 purified	 TFIID	 using	 a	 Taf1-TAP	 tag	 protocol.	 	 This	Taf1-TAP	 purified	 TFIID	 consistently	 resulted	 in	 substoichiometric	 levels	 of	 Taf2	 in	 the	complex	(Papai	et	al.,	2009).		These	preparations	were	used	to	identify	the	location	of	Taf2	in	the	TFIID	complex,	as	described	above.		However,	upon	closer	inspection,	both	Taf8	and	Taf14	 were	 substoichiometric	 in	 these	 TFIID	 preparations	 while	 Taf10	 levels	 were	unchanged.		These	data	suggest	that	instead	of	the	Taf2-Taf8-Taf10	subcomplex	that	exists	in	 metazoans,	 S.	 cerevisiae	 may	 have	 a	 Taf2-Taf8-Taf14	 complex.	 	 This	 hypothesis	 is	consistent	 with	 both	 biochemical	 data	 in	 metazoans	 which	 shows	 that	 Taf2	 directly	interacts	with	Taf8	and	not	Taf10	and	genetic	data	in	yeast	which	shows	that	the	histone	fold	 domain	 of	 Taf8	 is	 not	 essential	 for	 life	whereas	 the	 C-terminal	 portion	 of	 Taf8	 (the	domain	for	Taf2-Taf8	interaction	in	metazoans)	is	essential	for	life	(Gangloff	et	al.,	2001b).	The	 role	 of	 Taf2	 in	 regulating	 TFIID-dependent	 transcription	 regulation	 in	 S.	
cerevisiae	is	even	less	well	understood.		As	mentioned	above,	TAF2	is	a	single	copy	essential	gene	 (Ray	 et	 al.,	 1991).	 	 Thus,	 the	 best	 way	 to	 study	 essential	 gene	 function	 is	 through	conditional	loss-of-function	methods.	 	While	in	recent	years	new,	less	invasive	techniques	
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have	been	developed	 such	as	Anchor	Away	 (Haruki	 et	 al.,	 2008)	 and	 the	 auxin	 inducible	degron	(Nishimura	et	al.,	2009),	historically	yeast	biologists	have	used	Ts	variants,	which	can	be	abruptly	 inactivated	following	shift	 to	the	non-permissive	temperature.	Green	and	colleagues	created	Ts	alleles	for	all	of	the	TFIID	Tafs,	performed	acute	heat	inactivation	and	used	microarrays	to	determine	which	genes	were	misregulated	upon	acute	inactivation	of	the	 TFIID	 subunit	 (Shen	 et	 al.,	 2003).	 	 The	 results	 for	 Taf2	 were	 not	 particularly	informative	for	a	few	reasons.		First,	the	time	it	took	to	achieve	growth	arrest	for	the	strain	containing	 a	 taf2ts	 allele	 was	 the	 slowest	 of	 all	 the	 strains	 harboring	 Taf	 Ts	 alleles	suggesting	that	acute	heat	inactivation	was	the	least	efficient	for	the	taf2ts	allele	harboring	strain.		Based	on	this	result,	not	surprisingly,	Green	and	colleagues’	results	suggested	that	Taf2	 only	 contributed	 to	 the	 regulation	 of	 3%	 of	 yeast	 genes	 whereas	 another	 TFIID-specific	 subunit,	 Taf8,	 contributed	 to	 the	 regulation	 of	 51%	of	 yeast	 genes.	 	 Considering	Taf2	and	Taf8	likely	interact	within	the	TFIID	complex,	it	is	highly	unlikely	that	Taf2	only	contributes	to	3%	of	yeast	genes.		In	addition,	the	study	that	generated	this	taf2ts	allele	did	not	work	 to	determine	 the	mechanism	through	which	 this	allele	disrupted	Taf2	 function.		Thus,	 it	 is	possible	 that	 this	particular	taf2ts	allele	does	result	 in	a	disregulation	of	3%	of	yeast	genes	because	a	certain	function	that	is	essential	for	the	regulation	of	those	genes	is	inactivated	whereas	 the	 rest	 of	 Taf2	 function	 remains	 intact.	 	 The	 other	 data	 point	 that	could	 illuminate	 Taf2	 function	 was	 derived	 from	 a	 ChIP-microarray	 study	 using	 a	 taf1ts	allele	(Ohtsuki	et	al.,	2010).		In	this	study,	Kokubo	and	et	al.	acutely	heat	inactivated	strains	carrying	either	TAF1	or	a	taf1ts	allele	and	then	perform	ChIP-array	on	every	TFIID	subunit.		They	 found	 that	on	 certain	genes,	upon	gene	heat	 inactivation,	 strains	 carrying	 the	 taf1ts	allele	 displayed	 significant	 reductions	 in	 occupancy	 of	 Taf1	 and	 the	 rest	 of	 the	 TFIID	
	 47	
specific	Tafs	when	compared	to	the	TAF1	strain,	with	the	exception	of	Taf2.		Indeed,	when	comparing	the	two	strains,	Taf2	occupancy	did	not	change	or	increased.	 	The	result	could	indicate	 that	Taf2	can	stably	associate	with	 the	promoter	 in	 the	absence	of	Taf1	 function	whereas	the	rest	of	the	TFIID	subunits	cannot.		While	this	is	consistent	with	Taf2	having	a	DNA	binding	activity,	on	its	own	this	result	is	merely	suggestive.			Another	 strong	 impetus	 for	 investigating	 Taf2	 came	 from	 an	 observation	 the	Weil	 lab	made	when	describing	 the	structure	of	 the	 transactivator	Rap1	 in	complex	with	enhancer/promoter	DNA,	TFIIA	and	TFIID	(Papai	et	al.,	2010).	 	This	structure	 implicated	Taf2	 in	 direct	 Taf2-promoter	 DNA	 binding	 to	 a	 sequence	 downstream	 of	 the	 TATA-box.		This	 result	 suggests	 that	 scTaf2	 may	 also	 have	 DNA	 binding	 activity	 similar	 to	 the	metazoan	Taf2-INR	binding	function.				 Specific	Aims	Considering	 Taf2	 had	 never	 been	 subjected	 to	 structure-function	 analysis,	 I	believed	 that	 a	 systematic	 molecular	 genetic	 dissection	 of	 TAF2	would	 be	 an	 important	contribution	to	our	understanding	of	TFIID	biology.		This	project	had	the	promise	to	define	the	 domain	 structure	 of	 Taf2,	 which	 of	 those	 domains	 are	 essential	 for	 viability,	 which	other	TFIID	subunits	Taf2	binds	in	the	complex	and	if	those	interactions	are	necessary	for	Taf2	function	and	the	importance	of	Taf2-DNA	binding	to	TFIID	function.			To	address	these	goals,	I	proposed	two	specific	aims:		Aim	 1:	 	 Develop	 methods	 to	 purify	 Taf2	 mutant	 forms,	 both	 as	 individual	polypeptides	as	well	as	in	the	context	of	TFIID.	
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Aim	 2:	 Perform	 a	molecular	 genetic	 dissection	 of	 Taf2	 to	 identify	 domains	 or	individual	amino	acids	that	are	critical	for	Taf2	function	in	vivo	and	in	vitro.  
The	results	of	 the	studies	 to	achieve	 these	aims	are	documented	 in	Chapters	2	and	3	of	this	dissertation. 
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CHAPTER	II		METHOD	DEVELOPMENT	FOR	THE	PURIFICATION	OF	WILD-TYPE	AND	MUTANT	TAF2	AS	BOTH	A	SOLUBLE	PROTEIN	AND	WITHIN	THE	TFIID	COMPLEX		Current	Requirements	and	Difficulties	Involved	with	Purification	of	Taf2	and	TFIID		 Considering	 Taf2	 is	 a	 component	 of	 the	 multi-subunit	 TFIID	 complex,	 the	simplest	and	most	straightforward	method	of	deciphering	the	biochemical	activities	of	Taf2	vis-à-vis	Taf2-DNA	 interactions	or	Taf2-protein	 interactions	 is	by	using	purified	proteins.		These	 studies	 can	 be	 performed	 with	 holoTFIID	 using	 protein-DNA	 label	 transfer	approaches,	 as	 performed	 by	 the	 Buratowski	 laboratory	 (Auty	 et	 al.,	 2004),	 or	 through	chemical	 cross-linking/mass-spectrometry.	 	While	 crude	 extracts	 containing	 exogenously	expressed	 Taf2	 without	 any	 other	 TFIID	 subunits	 could	 also	 be	 employed,	 the	 most	versatile	and	most	easily	interpretable	approach	is	to	work	with	purified	Taf2.				When	 I	 entered	 the	Weil	 laboratory,	 no	 protocols	 existed	 for	 the	 purification	 of	 full	length	soluble	Taf2.		As	described	above,	Taf2	functions	involve	both	DNA	binding	and	Taf-Taf	interactions.	When	generating	Taf2	antigen	for	anti-Taf2	antibodies,	previous	Weil	lab	members	collaborated	to	make	His6-TEVcleavage	site-Taf2	baculovirus.		They	used	this	virus	to	infect	High	Five	cells	(Trichoplusia	ni)	and	express	Taf2.		When	they	generated	Taf2	using	this	method,	full	length	Taf2	accumulated	at	the	lowest	level	of	any	other	Taf	expressed	in	this	manner.		Furthermore,	they	used	denaturing	methods	to	purify	the	protein	so	I	had	no	information	 with	 regard	 to	 the	 solubility	 of	 the	 generated	 protein.	 	 Considering	 these	experiments	were	performed	nearly	10	years	prior	to	when	I	joined	the	lab,	I	decided	that	I	
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should	attempt	all	methods	at	my	disposal	to	generate	purified	Taf2	including	expressing	the	 protein	 and/or	 protein	 fragments	 using	 Escherichia	 coli,	 baculoviral	 infection	 or	galactose	(Gal)	induction	methods	in	S.	cerevisiae.		 In	addition,	to	truly	study	Taf2	function	in	transcription	mechanism,	Taf2	should	be	studied	in	the	context	of	TFIID.		For	example,	if	I	were	to	generate	a	Taf2	variant	with	a	documented	 separation-of-function	 molecular	 phenotype	 such	 as	 a	 loss	 of	 DNA	 binding	activity	or	a	loss	in	the	ability	to	interact	with	one	TFIID	subunit	but	not	with	the	rest	of	the	complex,	then	I	should	be	able	to	purify	Taf2-mutant	TFIID	and	assay	its	function	using	in	
vitro	 transcription.	 	 However,	 generating	 purified	 TFIID	 remains	 a	 significant	 hurdle.		Current	 literature	 suggests	 that	TFIID	 is	 the	most	difficult	 general	 transcription	 factor	 to	purify.	 	 Specifically,	 tandem	 affinity	 purification	 (TAP)-tagging	 purification	 procedures	have	 increased	 the	 accessibility	 and	 efficiency	 of	 purification	 of	 yeast	 multi-subunit	complexes	(Rigaut	et	al.,	1999).		RNA	polymerase	II	is	highly	abundant	and	easily	purified	using	 the	 TAP-tag	 procedure	 (Borggrefe	 et	 al.,	 2001).	 Kornberg	 and	 colleagues	 have	developed	 genetic	 and	 biochemical	methods	 to	 purify	milligram	 quantities	 of	 TFIIH	 and	TFIIF,	respectively	(Murakami	et	al.,	2012).		Recombinant	TFIIA,	TFIIB	and	TFIIE	can	all	be	expressed	 and	 purified	 from	E.	 coli.	 	 But,	 the	 standard	 TAP-purification	method	 has	 not	proven	effective	for	TFIID	because	the	resulting	material	is	substoichiometric	for	Taf2,	Taf8	and	Taf14.		In	addition,	using	Weil	lab	published	HA-immunopurification	methods	to	purify	TFIID	 results	 in	 a	 yield	 of	 ~1mg/2.5kg	 of	 yeast	 pellet.	 	 Purifying	 TFIIH,	 the	 next	 most	difficult	general	transcription	factor	to	purify,	with	the	TAP-tag	method	yields	~8mg/2.5kg	of	 yeast	 pellet,	 an	 8-fold	 difference.	 	 In	 addition,	 the	 financial	 cost	 of	 the	 TFIID	 HA-immunopurification	 procedure	 is	 considerably	 more	 expensive	 than	 the	 TAP-tag	
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purification	procedure.		To	overcome	both	the	financial	and	yield	difficulties	involved	with	the	HA-immunopurification	procedure,	I	employed	two	distinct	strategies:		1)	reconstitute	TFIID	 using	 recombinant	 protein	 expression	 technologies	 and	 2)	 improve	 the	 TAP-tag	purification	 protocol	 to	 eliminate	 the	 purification	 step	 that	 results	 in	 disruption	 of	 Taf2,	Taf8	and	Taf14	from	the	complex.		 METHODS		Expression	Vector	Design	and	Cloning	All	 cloning	 was	 performed	 using	 restriction	 enzyme-based	 methods.		Appropriate	 restriction	 ends	 were	 added	 to	 all	 cloned	 sequences	 using	 PCR	with	 either	
Pyrococcus	woesei	 DNA	polymerase	 as	 described	 (Dabrowski	 and	Kur,	 1998)	 or	Q5	DNA	polymerase	 according	 to	 manufacturers	 instructions	 (NEB).	 	 Individual	 details	 for	 each	cloned	 fragment	 will	 be	 described	 below.	 	 Both	 plasmid	 DNA	 and	 PCR-generated	 DNA	fragments	were	digested	with	the	appropriate	restriction	enzymes,	dephosphorylated	with	Antarctic	 phosphatase	 (NEB)	 and	 gel	 purified	 using	 Qiagen	 Gel	 Extraction	 buffers	 with	either	 Qiagen	 gel	 extraction	 columns	 or	 Denville	 Scientific	 gel	 extraction	 columns,	according	 to	 manufacturers	 instructions.	 	 The	 digested	 plasmid	 DNA	 was	 ligated	 to	 the	digested	PCR	product	 in	a	5µL	reaction	containing	approximately	a	3	 to	1	molar	 ratio	of	PCR	product	to	plasmid	DNA.		Total	mass	of	plasmid	DNA	was	~10-20ng	per	reaction	with	varying	amounts	of	PCR	product	depending	on	the	size	of	the	fragment.	 	 	In	addition,	this	reaction	 contained	 1x	 T4	 DNA	 ligase	 buffer	 and	 100units	 of	 T4	 DNA	 ligase	 (NEB).	 	 The	ligation	 reactions	 were	 allowed	 to	 proceed	 for	 2hrs	 to	 overnight	 at	 room	 temperature	
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(~20o)	prior	to	transformation	into	competent	E.	coli	(cell	manipulations	described	below).		Isolated	 recombinant	 expression	 plasmids	 were	 analyzed	 by	 restriction	 digestion	 to	confirm	 the	 presence	 of	 the	 correct	 sized	 inserts.	 	 Plasmids	 containing	 the	 correct	 sized	inserts	were	sequence	verified.		For	expression	 in	E.	coli,	 all	Taf2	variants	were	expressed	as	N-terminal	Hisx6-tagged	 proteins	 using	 pET28a	 (Novagen).	 	 Full	 length	 and	 TAF2	 fragments	 were	 all	engineered	to	contain	an	in-frame	5’	SpeI	restriction	enzyme	cut	site	and	SalI	cut	site	at	the	3’	end.		Six	Taf2	protein	fragments	were	generated:		full	length	Taf2	(aa	1-1407),	Taf2	aa	1-407,	 Taf2	 aa	 1-1007,	 Taf2	 aa	 401-1007,	 Taf2	 aa	 401-1407	 and	Taf2	 aa	 1001-1407.	 	 The	multiple	cloning	site	(MCS)	of	pET28a	contained	the	restriction	enzyme	cut	sites	for	NheI	and	XhoI.	 	NheI	is	in-frame	with	the	N-terminal	His6-tag	of	pET28a	and	the	NheI	digested	overhang	is	compatible	for	the	digested	overhang	for	a	SpeI	digested	fragment.		Similarly,	a	XhoI	digested	overhang	is	compatible	with	the	SalI	digested	overhang.	For	expression	using	baculovirus	infected	Sf9	cells,	all	of	the	TFIID	subunits	were	individually	cloned	into	pFASTBac1	or	pFASTBAC	HTc	(Invitrogen)	as	untagged	expression	cassettes,	 N-terminally	 tagged	 HA3-PreScission	 site	 (3Cpro)-	 expression	 cassettes	 or	 N-terminally	 tagged	 FLAG3-TEV	 protease	 cleavage	 site	 (TEVpro)-	 expression	 cassettes.	 The	3Cpro	 site	 and	 the	 TEVpro	 site	 are	 protease	 recognition	 sequences	 for	 the	 3C	 and	 TEV	proteases,	 respectively.	 	These	enzymes	can	be	used	 to	 liberate	 the	 tag	 from	the	purified	protein.	 	All	of	 the	TFIID	subunits	ORF	sequences,	with	 the	exception	of	TAF2	which	was	subcloned	as	a	5’-SpeI-TAF2-SalI-3’	 fragment	as	described	above,	were	synthesized	using	PCR	 from	 either	 existing	 plasmids	 containing	 the	 TFIID	 subunit	 sequence	 or	 from	 yeast	genomic	 DNA.	 	 The	 restriction	 enzymes	 cut	 sites	 for	 each	 of	 the	 TFIID	 subunits	 are	 as	
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follows:	 	 5’-SpeI-TAF1-XhoI-3’,	 5’-NheI-TAF3-KpnI-3’,	 5’-SpeI-TAF4-HindIII-3’,	 5’-SpeI-TAF5-Xho-3’,	5’-SpeI-TAF6-HindIII-3’,	5’-SpeI-TAF7-XhoI-3’,	5’-NheI-TAF8-SphI-3’,	5’-NheI-
TAF9-KpnI-3’,	 5’-SpeI-TAF10-HindIII-3’,	 5’-SpeI-TAF11-XhoI-3’,	 5’-NheI-TAF12-KpnI-3’,	 5’-NheI-TAF13-KpnI-3’,	 5’-SpeI-TAF14-XhoI-3’	 and	5’-SpeI-SPT15(TBP)-XhoI-3’.	 	 All	 of	 the	5’	restriction	enzyme	cut	sites	were	in-frame	with	the	start	codons	of	the	TFIID	subunit	ORFs.		The	 design	 intent	was	 to	 have	 complementary	 restriction	 enzyme	 sites	 for	 both	 cloning	into	a	single	MCS	and	into	a	dual	expression	vector	system	such	as	the	one	described	below	for	yeast	overexpression.		For	the	HA3-3Cpro-tag	and	the	FLAG3-TEVpro-tag,	complementary	oligos	(top	strand	and	bottom	strand)	for	each	tag	were	annealed	together	to	form	“cut”	5’-RsrII-	 HA3-3Cpro-NheI-3’	 and	 a	 5’-RsrII-	 FLAG3-TEVpro-NheI-3’.	 	 When	 annealed	 together,	the	ends	of	 these	oligos	mimic	overhangs	that	would	be	generated	by	restriction	enzyme	digestion	and	 can	be	 ligated	with	 compatible	overhang	ends.	 	To	 create	double	 stranded	DNA	 fragments	 for	 cloning	 of	 synthesized	 oligos	 into	 plasmids,	 10µg	 of	 both	 top	 and	bottom	 strand	 oligos	 were	 phosphorylated	 by	 T4	 PNK	 (NEB)	 per	 manufacturers	instructions	in	separate	reactions	and	mixed	together.		The	reactions	were	then	put	in	a	pot	of	water	and	heated	to	a	boil	with	a	Bunsen	burner.		Once	the	water	was	vigorously	boiling,	the	pot	was	removed	from	the	heat	and	allowed	to	cool	slowly	on	the	benchtop	to	allow	the	two	oligos	to	anneal.		The	annealed	double	stranded	DNA	was	separated	on	a	1x	TBE,	1.5%	agarose	gel,	stained	with	ethidium	bromide	and	the	most	intense	band	was	excised	and	gel	purified	 as	 described	 above.	 This	 procedure	 was	 used	 to	 anneal	 and	 purify	 all	complementary	 oligos	 described	 in	 this	 dissertation.	 	 For	 both	 tags,	 the	NheI	 restriction	enzyme	cut	site	is	in-frame	with	the	tag.		To	clone	the	tagged	variants	into	pFASTBac	HTc,	the	plasmids	were	digested	with	RsrII	and	an	appropriate	3’	restriction	end	for	the	subunit	
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to	be	cloned	(XhoI	(SalI	compatible),	KpnI,	SphI,	HindIII).	 	The	cut	vector,	either	the	HA3-3Cpro-tag	or	 the	FLAG3-TEVpro-tag	and	the	TFIID	subunit	ORF	was	 ligated	together	 in	a	3-piece	ligation	reaction	to	form	the	expression	plasmid	containing	tagged	TAF	variant.		For	untagged	variants,	the	TFIID	ORFs	were	ligated	into	the	corresponding	restriction	sites	in	the	 pFASTBac1	 MCS	 with	 the	 exception	 of	 TAF2.	 	 For	 TAF2,	 the	 5’-SpeI-TAF2-SalI-3’	fragment	was	 ligated	 into	the	SpeI	and	XhoI	restriction	ends	of	 the	pFASTBac1	MCS	such	that	the	TAF2	ORF	would	be	in	the	correct	orientation	in	the	plasmid.	The	 pFASTBac	 plasmid	 series	works	within	 the	 Bac-to-Bac	 protein	 expression	system	 (Invitrogen).	 	 This	 system	 required	 the	 DH10Bac	 E.	 coli	 strain.	 	 This	 strain	expresses	 a	 baculovirus	 shuttle	 vector	 (bacmid)	 that	 encodes	 the	 proteins	 required	 for	efficient	 virus	 production	 and	 a	 helper	 plasmid	 that	 helps	 transpose	 the	 pFASTBac	expression	sequence	into	the	bacmid.		DH10Bac	competent	cells	were	generated	using	the	Inoue	 method	 (Inoue	 et	 al.,	 1990).	 	 Recombinant	 bacmids	 were	 generated	 according	 to	manufacturers	instructions	and	transfected	into	Sf9	cells	(described	below).	For	expression	in	S.	cerevisiae,	TAF2	and	tagged-TAF2	variants	were	cloned	into	p425GAL1	(Mumberg	et	 al.,	 1994).	 	 First,	 the	 same	SpeI	 to	 SalI	 full	 length	Taf2	 fragment	was	cloned	into	p425GAL1	at	the	SpeI	to	SalI	restriction	sites	within	the	MCS.		This	plasmid	was	 used	 to	 overexpress	 an	 untagged	 variant	 of	 Taf2.	 	 However,	 in	 order	 to	 purify	overexpressed	Taf2	from	yeast,	 two	distinct	MBP-tagged	Taf2	constructs	were	generated,	one	with	a	maltose	binding	protein	(MBP)	tag	at	the	N-terminus	of	Taf2	and	the	other	with	an	MBP	 tag	 at	 the	 C-terminus	 of	 Taf2.	 	 To	 generate	 the	N-terminal	MBP	 tag,	 PCR	 based	cloning	methods	were	used	to	amplify	the	MBP	coding	sequence	from	the	pLM302	plasmid,	a	 plasmid	 obtained	 from	 the	 Vanderbilt	 Center	 for	 Structural	 biology.	 	 pLM302	 is	 a	
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derivative	 of	 pET27	 (Novagen)	 engineered	 to	 contain	 MBP	 (derived	 from	 pMAL	 (NEB))	followed	 by	 the	 3Cpro	 site	 and	 a	 multiple	 cloning	 site.	 	 The	 primers	 used	 to	 clone	 MBP	introduced	 an	 XbaI	 restriction	 end	 at	 the	 5’	 end	 of	 the	MBP	 coding	 sequence	 and	 an	 in-frame	 SpeI	 restriction	 end	 at	 the	 3’	 end	 of	 the	 3Cpro	 site.	 	 Two	MBP-3Cpro	 variants	were	generated	in	this	manner,	one	with	a	stop	codon	for	purification	of	just	MBP-3Cpro	(termed	MBP	hereafter)	and	one	without	a	stop	codon	for	purification	of	MBP-3Cpro-Taf2	(termed	MBP-Taf2	hereafter).	 	The	PCR	generated	MBP	DNA	fragments	were	cloned	 into	 the	SpeI	restriction	site	 in	p425GAL1	(Mumberg	et	al.,	1994).	 	DNA	cleaved	with	XbaI	generates	a	compatible	end	with	SpeI	digested	DNA.	 	After	verification	 that	 the	MBP	was	cloned	 into	the	p425GAL1	plasmid	correctly,	the	full	length	SpeI	to	SalI	Taf2	fragment	was	cloned	into	p425GAL1	MBP		(no	stop	codon)	cut	with	SpeI	to	SalI	restriction	endonucleases	to	generate	the	p425GAL1	MBP-TAF2	plasmid.		For	the	3’	MBP-tag,	using	PCR,	a	TAF2	3’	fragment	was	generated	 containing	 a	 5’	 HindIII	 restriction	 end	 and	 an	 in-frame	 AvrII	 restriction	 end	without	 a	 stop	 codon.	 	 The	 5’	 HindIII	 end	 was	 generated	 using	 a	 naturally	 occurring	internal	HindIII	site	within	the	TAF2	coding	region	(+3303).	 	The	MBP	tag	was	generated	by	adding	a	5’	in-frame	AvrII	restriction	end,	inserting	a	stop	codon	at	the	end	of	the	MBP	coding	sequence	and	adding	a	3’	SalI	 restriction	end.	 	 Initially,	 this	 tag	was	cloned	 into	a	p415TAF2	 plasmid,	 a	 derivative	 of	 pRS415	 (Sikorski	 and	 Hieter,	 1989)	 containing	 the	enhancer/promoter	 and	 ORF	 of	 the	 TAF2	 gene.	 	 The	 p415TAF2	 plasmid	 was	 digested	HindIII	to	SalI	to	remove	the	3’	end	of	the	TAF2	coding	region.		This	digested	plasmid	was	then	 ligated	 to	 both	 the	 HindIII-TAF2-AvrII	 fragment	 and	 the	 AvrII-MBP(STOP)-SalI	fragments	in	a	3-piece	ligation.		The	resulting	plasmid	was	p415TAF2	TAF2-MBP.		However,	this	plasmid	did	not	have	a	3Cpro	cleavage	site	between	TAF2	and	MBP	so	the	MBP	tag	could	
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not	be	cleaved	off.		To	insert	a	3Cpro	site,	complementary	oligonucleotides	(top	strand	and	bottom	 strand)	 were	 generated	 that	 encoded	 5’-SpeI-SacI-His6-3Cpro-SpeI-3’	 insert	 and	annealed	as	described	above.	The	annealed	oligos	were	 then	 ligated	 into	p415TAF2-MBP,	which	 had	 been	 linearized	 with	 AvrII.	 	 AvrII	 overhangs	 are	 compatible	 with	 SpeI	overhangs.		Considering	the	oligo	could	be	ligated	into	the	plasmid	in	either	direction,	the	SacI	restriction	end	was	included	to	determine	the	orientation	of	the	insert	in	an	analytical	restriction	 digestion.	 	 Both	 the	 5’-SpeI-TAF2-MBP-SalI-3’	 and	 the	 5’-SpeI-TAF2-SacI-His6-3Cpro-MBP-SalI-3’	 fragments	were	 then	 subcloned	 into	p425GAL1	 at	 the	SpeI	 to	 SalI	 sites	within	its	MCS.		The	p425GAL1	TAF2-His6-3Cpro-MBP	construct	was	used	for	overexpression	by	Gal	induction.		The	protein	product	generated	by	this	plasmid	will	be	described	as	Taf2-MBP	hereafter.	In	addition	to	overexpressing	Taf2	by	GAL	induction,	a	multi-protein	expression	system	 was	 designed	 based	 on	 the	 bi-directional	 GAL1-GAL10	 enhancer/promoter	sequence	 for	 the	purpose	of	Taf2-TFIID	 subunit	 co-expression	 and	purification	 (Burgers,	1999;	Gerik	 et	 al.,	 1997).	 	This	Gal	 induction	expression	 system	 is	 a	 two-plasmid	 system	(Figure	2.1).	 	Both	plasmids	were	derived	 from	pBluescript	 II	SK+	 (Agilent).	 	Plasmid	#1	was	 designed	 as	 the	 yeast	 expression	 plasmid,	 containing	 a	 2µm	 origin	 of	 replication,	 a	selectable	marker	 and	 an	MCS	 containing	 7-	 and	 8-bp	 restriction	 endonuclease	 cut	 sites	(BlpI,	RsrII,	PmeI	and	PacI).		Three	variants	of	Plasmid	#1	were	generated,	one	containing	a	
TRP1	 selectable	marker	 (pJFTRP1),	 one	 containing	 a	 LEU2	 selectable	marker	 (pJFLEU2)	and	one	containing	a	URA3	selectable	marker	(pJFURA3).	The	2µm	replication	site	was	PCR	amplified	 from	 pRS425	 (Christianson	 et	 al.,	 1992),	 engineered	 to	 contain	 5’	 and	 3’	 KpnI	ends	and	cloned	into	the	KpnI	restriction	site	within	pBluescript	II	SK+.		TRP1,	URA3	and	
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Figure	 2.1:	 	 Multi-ORF	 Overexpression	 System	 for	 S.	 cerevisiae.	 	 Diagram	 of	 elements	engineered	into	donor	and	acceptor	plasmids.		*	=	Three	different	acceptor	donors	were	generated:	pJFTRP1,	pJFLEU2,	pJFURA3.		
LEU2	were	PCR	amplified	 from	pRS424,	pRS426	and	pRS425,	 respectively,	engineered	 to	have	SpeI	to	XhoI	restriction	ends	and	ligated	into	pBluescript	II	SK+	at	the	SpeI	and	XhoI	restriction	sites	within	 its	MCS.	 	A	Not1	–	BlpI	–	RsrII	–	PmeI	–	PacI	–	NotI	 fragment	was	generated	from	complementary	oligos	(top	strand	and	bottom	strand)	as	described	above	and	ligated	into	pBluescript	II	SK+	at	the	NotI	restriction	site	within	its	MCS.		These	7-	to	8-bp	 restriction	 enzyme	 cut	 sites	 would	 be	 used	 as	 the	 entry	 point	 for	 the	 multi-TFIID	subunit	dual	overexpression	cassettes,	described	below.			Plasmid	#2	(pJFGDUAL)	was	an	entry	plasmid	to	which	the	TFIID	subunits	were	initially	cloned.		This	plasmid	was	engineered	in	stages.		Step	#1,	the	MCS	of	pBluescript	II	SK+	was	replaced	with	an	MCS	containing	the	following	restriction	enzyme	cut	sites:	Blp1-
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RsrII-PmeI-PacI-EcoRI-SalI-KpnI-SphI-BglII-NheI-SpeI-BamHI-HindIII-XhoI-EcoRV-PacI-PmeI-RsrII-BlpI-SacI.	 	Step	#2,	 the	GAL1-GAL10	bi-direction	enhancer/promoter	was	PCR	amplified	 from	genomic	DNA,	engineered	 to	 include	a	5’	NheI	end	and	a	3’	 SpeI	end	and	ligated	into	these	same	restriction	sites	within	the	new	MCS.		Step	#3,	the	CYC1	terminator	(CYC1term)	sequence	was	PCR	amplified	from	p415ADH	and	engineered	to	have	two	sets	of	restriction	 ends.	 	 The	 first	 variant	 contained	 XhoI	 and	 EcoRV	 5’	 and	 3’	 restriction	 ends,	respectively.	 	 The	 second	 variant	 contained	 SalI	 to	 EcoRI	 5’	 and	 3’	 restriction	 ends,	respectively.	 	These	 fragments	were	sequentially	 cloned	 into	plasmid	#2	 to	complete	 the	plasmid.		The	result	is	a	plasmid	with	two	distinct	MCS’s	to	which	TFIID	subunit	ORFs	can	be	 cloned	 (see	 Figure	 2.1).	 	 As	 an	 alternative	 to	 using	 the	CYC1term	 sequences,	 the	 TFIID	subunits	TAF1,	TAF3,	TAF4,	TAF5,	TAF6,	TAF7,	TAF8,	TAF9,	TAF10,	TAF11,	TAF12,	TAF13,	
TAF14	and	SPT15	were	PCR	amplified	from	genomic	DNA	including	~100bp	beyond	the	3’	UTR	 sequence.	 	 Coordinates	 for	 the	 end	 of	 the	 transcription	 unit	 for	 these	 genes	 was	derived	from	RNAseq	data	from	the	yeast	genome	(Nagalakshmi	et	al.,	2008).		In	addition,	a	5’-SpeI-His6-MBP-3Cpro-NheI-3’	 fragment	 and	 a	 5’-His6-GST-3Cpro-3’	 fragment	 were	generated	through	PCR	from	pLM302	and	pBG101	plasmids.	 	pBG101	was	acquired	from	the	Vanderbilt	Center	for	Structural	Biology.		pBG101	was	constructed	in	a	similar	manner	as	pLM302	except	the	GST	sequence	derived	from	pGEX	(GE	Healthcare).			Ultimately,	several	multi-TFIID	subunit	expression	plasmids	were	generated.		As	mentioned	above,	TFIID	subunits	that	were	known	to	 interact	were	cloned	into	the	same	expression	 cassette.	 	 For	 example,	 Taf1	 and	 Taf7	were	 cloned	 into	 the	 same	 expression	cassette	(Bhattacharya	et	al.,	2014;	Singh	et	al.,	2004;	H.	Wang	et	al.,	2014).				Plasmids	that	included	the	CYC1term	were:	pJFURA3	TAF5;	pJFURA3	TAF11,TAF13;	pJFLEU2	TAF8,TAF10;	
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pJFLEU2	 His6-MBP-3Cpro-TAF1,TAF7;	 pJFLEU2	 TAF1,TAF7;	 pJFLEU2	 TBP,TAF2;	 pJFLEU2	
TBP,	His6-MBP-3Cpro-TAF2	pJFLEU2	TAF4,	HA3-3Cpro-TAF12;	pJFTRP1	TAF6,TAF9;	pJFTRP1	
His6-GST-3Cpro-TAF8,	 TAF10;	 pJFTRP1	 His6-MBP-3Cpro-TAF8,TAF10;	 pJFTRP1	 His6-GST-
3Cpro-TAF3,TAF10;	 pJFTRP1	 His6-MBP-3Cpro-TAF3,TAF10;	 pJFTRP1	 TBP,TAF2;	 pJFTRP1	
TAF5;	 pJFTRP1	 His6-GST-3Cpro-TAF1,TAF7;	 pJFTRP1	 His6-MBP-3Cpro-TAF1,TAF7;	 pJFTRP1	
TAF1,TAF7.	 	 The	 plasmids	 containing	 native	 TAF	 terminator	 sequences:	 	 pJFTRP1	TAF6,	
TAF9;	pJFTRP1	TAF6,	TAF9,	TAF5,	TAF14;	pJFTRP1	TAF6,	TAF9,	TAF5,	TAF14,	TAF8,	TAF10;	pJFTRP1	TAF6,	TAF9,	TAF5,	TAF14,	TAF8,	TAF10,	TAF4,	TAF12;	pJFTRP1	TAF6,	TAF9,	TAF5,	
TAF14,	 TAF8,	 TAF10,	 TAF4,	 HA3-3CproTAF12;	 pJFURA3	 TAF11,	 TAF13;	 pJFURA3	 TAF11,	
TAF13,	TAF3,	TAF10;	and	pJFURA3	TAF11,	TAF13,	TAF3,	TAF10,	TAF1,	TAF7.		 Bacterial,	Yeast	and	Insect	Cell	Growth	Manipulations	
E.	 coli	 manipulations	 -	 DH5α	 was	 used	 for	 all	 cloning	 and	 propagation	 of	plasmids.		DH5α	competent	cells	were	acquired	from	the	Vanderbilt	Molecular	and	Cellular	Biology	core.		Cells	were	grown	in	Luria-Bertani	(LB)	broth	(1%	w/v	Tryptone,	0.5%	yeast	extract	 and	 0.5%	 sodium	 chloride).	 	 During	 transformation	 reactions,	 cells	 were	resuspended	 in	 Super	 Optimal	 broth	 with	 Catabolite	 repression	 (SOC)	 medium	 (2%	tryptone,	 0.5%	 yeast	 extract,	 10mM	 sodium	 chloride,	 2.5mM	 potassium	 chloride,	 10mM	magnesium	chloride,	10mM	magnesium	sulfate	and	20mM	glucose).	 	 	 	All	 transformation	reactions	were	performed	using	1.5mL	snap	cap	tubes.		For	simply	propagating	plasmids,	a	modified	one-minute	transformation	protocol	was	used	(Golub,	1988).		Briefly,	50-200ng	of	plasmid	DNA	was	added	to	10uL	of	competent	cells	that	had	been	thawed	on	ice.		The	cells	were	immediately	heat	shocked	at	42o	for	30s.		The	cells	were	then	resuspended	in	100µL	
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of	SOC	medium.		If	the	plasmid	resistance	marker	encoded	β-lactamase	(AmpR),	the	entire	reaction	was	immediately	plated	to	LB	+	100mg/mL	Ampicillin	agar	plates.		However,	if	the	plasmid	resistance	cassette	encoded	the	kanamycin	resistance	enzyme	(KanR),	the	reaction	was	incubated	at	37o	for	30min	prior	to	plating	to	LB	+	50mg/mL	Kanamycin.		For	ligation	reactions,	the	entire	5µL	ligation	reaction	(set-up	described	below)	was	mixed	with	50uL	of	competent	 cells	 thawed	on	 ice.	 	The	 cells	were	 then	 incubated	on	 ice	 for	15-30min,	heat	shocked	at	42o	for	30s.		After	5min	rest	on	ice,	the	cells	were	resuspended	in	500µL	of	SOC	and	incubated	on	a	tiltboard	at	30o.		After	1hour,	20-40%	of	the	reaction	was	plated	on	LB	+	the	appropriate	antibiotic	(Ampicillin	or	Kanamycin).		Plated	cells	were	incubated	at	either	37o	 for	 14-20hrs	 or	 30o	 for	 24-36hrs	 prior	 to	 isolating	 individual	 colonies.	 To	 isolate	plasmids,	 individual	 colonies	 were	 grown	 in	 5mL	 of	 LB	 +	 appropriate	 antibiotic	 at	 37o	overnight	 (12-16	 hours)	 shaking	 at	 250rpm.	 	 For	 small-scale	 plasmid	 purifications,	 the	entire	5mL	of	cells	were	harvested	by	centrifugation	in	a	Beckman	Coulter	J6-HC	centrifuge	for	 5min	 at	 4.2k	 rpm	 at	 room	 temperature.	 	 The	 supernatant	 was	 discarded	 and	 the	plasmid	 DNA	 was	 harvested	 using	 Qiagen	 Mini-Prep	 kit	 according	 to	 manufacturers	instructions.		Alternatively,	the	buffers	from	the	Qiagen	Mini-Prep	kit	were	used	along	with	the	purification	columns	from	Denville	Scientific.		For	large-scale	plasmid	purifications,	the	entire	5mL	of	 cells	were	used	 to	 inoculate	250mL	of	LB	+	 the	appropriate	antibiotic	and	grown	at	37o	for	12	hours	shaking	at	250rpm.		The	cells	were	harvested	in	J6-HC	for	5min	at	 4.2k	 rpm	 at	 room	 temperature.	 	 The	 supernatant	was	 discarded	 and	 the	 pellets	were	either	immediately	processed	or	stored	at	-80o	until	ready	to	process.		DNA	was	harvested	from	the	pellet	using	Qiagen	Maxi-Prep	filter	kit	according	to	manufacturers	instructions.	
	 61	
Recombinant	 proteins	 were	 expressed	 in	 E.	 coli	 Rosetta2	 (DE3)	 strains	(Novagen).	 	Competent	cells	were	generated	using	the	Inoue	method	(Inoue	et	al.,	1990).		For	 transformation,	 20-50mL	 of	 Rosetta2	 (DE3)	 competent	 cells,	 thawed	 on	 ice,	 were	mixed	with	~500ng	of	 plasmid	DNA.	 	 The	 cells	were	 incubated	on	 ice	 for	 30-45min	 and	heat	shocked	at	42o	for	30s.		After	5min	rest	on	ice,	the	cells	were	mixed	with	500µL	of	SOC	medium	and	incubated	on	a	tiltboard	at	30o.		After	1hour,	40-80%	of	cells	were	plated	to	LB	+	34µg/mL	(dissolved	in	ethanol)	Chloramphenicol	+	50µg/mL	Kanamycin	agar	plates	and	grown	at	37o	overnight	(12-16)	hours.		When	expressing	proteins,	individual	colonies	were	picked	 to	5mL	of	LB	+	34µg/mL	Chloramphenicol	+	50µg/mL	Kanamycin	 liquid	medium	and	grown	overnight	at	37o	shaking	at	250rpm.		The	overnight	grown	culture	was	used	to	inoculate	 fresh	LB	+	34µg/mL	Chloramphenicol	+	50µg/mL	Kanamycin	 liquid	medium	to	an	optical	density	at	600nm	(OD600)=0.1.	 	The	liquid	culture	was	grown	at	37o	shaking	at	250rpm	to	an	OD600=0.6-0.9	and	 then	 the	 temperature	was	subsequently	 lowered	 to	30o.		After	 15min	 to	 allow	 the	 temperature	 to	 equilibrate,	 1M	 isopropyl	 β-D-1-thiogalactopyranoside	(IPTG)	was	added	to	the	cultures	to	a	final	concentration	at	1mM	to	induce	protein	 expression.	 	 Induction	was	 allowed	 to	proceed	 for	 4hours	 at	 30o	 prior	 to	harvest.	 	 Cells	were	harvested	by	 centrifugation	 in	 a	 J6-HC	 centrifuge	 for	10min	at	4200	rpm	at	room	temperature	(20o).		For	small-scale	inductions	(5-50mL),	the	supernatant	was	discarded	and	the	pellets	were	immediately	stored	at	-80o.		For	large-scale	inductions,	the	pellets	were	resuspended	 in	 fresh	LB,	 transferred	 to	50mL	conical	 tubes	and	centrifuged	again.		The	supernatant	was	discarded	and	the	pellets	were	stored	at	-80o.	
Sf9	 Cell	 Manipulations	 –	 Spotoptera	 frugiperda	 (Sf9)	 cells	 were	 obtained	 from	Invitrogen	Gibco	Catalog	No.	11496-015.		The	cells	were	received	on	dry	ice,	thawed	at	37o	
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until	the	residual	ice	just	completed	melting	and	used	to	inoculate	25mL	of	SF900	II	serum	free	 medium	 (SFM)	 (Invitrogen)	 +	 100U/mL	 Penicillin/Streptomycin	 antibiotic	 (Gibco),	pre-warmed	to	room	temperature.		For	normal	passage	and	cell	growth,	the	cultures	were	grown	in	SF900	II	SFM	+	100U/mL	Penicillin/Streptomycin	antibiotic	at	28o	in	250mL	vent	closed	 shaker	 flasks,	 shaking	 100-125rpm.	 	 All	 cell	measurements	were	 performed	with	trypan	 blue	 to	 distinguish	 between	 living	 and	 dead	 cells	 and	 counted	 with	 a	hemocytometer.	 	Once	the	original	inoculum	reached	2x106	cells/mL,	the	cell	volume	was	gradually	 increased	 so	 the	 cell	 concentration	was	1x106	 cells/mL	 in	100mL	medium	and	allowed	to	continue	to	grow.		Once	the	cells	doubled	two	additional	times	(~48	hrs),	half	of	the	 culture	 was	 used	 to	 make	 freezer	 stocks	 (20x107	 cells	 in	 total).	 	 The	 cells	 were	centrifuged	 for	 5min	 at	 1k	 rpm	 in	 J6-HC.	 	 To	 make	 the	 freezing	 medium,	 10mL	 of	supernatant	(conditioned	medium)	was	mixed	with	10mL	of	fresh	SF900	II	SFM	containing	14%	DMSO	and	placed	on	ice.		The	rest	of	the	supernatant	was	discarded	and	the	cells	were	resuspended	in	freezing	medium	at	a	final	concentration	of	1x107	cells/mL.		The	cells	were	distributed	to	2mL	screw	cap	cryogenic	vials	and	stored	at	-80o.			The	rest	of	the	cells	were	split	 to	 1x106	 cells/mL	 and	 allowed	 to	 continue	 to	 grow.	 	 Cells	were	 only	maintained	 in	continuous	culture	for	a	maximum	of	3	months	prior	to	thawing	a	fresh	vial	of	cells.	For	bacmid	transfection,	actively	growing	cells	were	diluted	to	5x105	cells/mL	in	SF900	 II	 SFM	 and	 5mL	were	 plated	 to	 T25	 Nunclon	 vent	 closed	 flasks	 (ThermoFisher).		Cells	 were	 allowed	 to	 adhere	 for	 1	 hour	 at	 room	 temperature,	 during	 which	 the	transfection	reactions	were	prepared.		In	two	separate	sterile	1.5mL	snap	cap	tubes,	8µL	of	Cellfectin	II	reagent	(Life	Technologies)	were	mixed	with	100µL	of	SF900	II	SFM	and	10µL	of	 Bacmid	mini-prep	were	mixed	with	 100µL	 of	 SF900	 II	 SFM.	 	 The	 two	 solutions	were	
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mixed	together	and	DNA:lipid	transfection	reagent	complex	was	allowed	to	form	for	30min.		The	transfection	reaction	was	added	to	2.8mL	of	SF900	II	SFM.		Once	the	cells	adhered,	the	residual	medium	was	aspirated	from	the	T25	flasks,	the	cells	were	washed	once	with	3mL	of	SF900	II	SFM	and	the	transfection	solution	was	overlayed	onto	the	cell	monolayer.		The	cells	 were	 then	 incubated	 at	 28o	 for	 5hrs.	 	 After	 5	 hours,	 the	 transfection	 solution	 was	aspirated	 from	 the	 cells,	 6mL	of	 SF900	 II	 SFM	was	 added	 to	 the	 cells	 and	 the	 cells	were	incubated	at	28o	 for	60hrs.	After	60hrs,	 the	viral	 supernatant	was	harvested	and	 filtered	through	0.45µm	filter	into	sterile	15mL	conical	tubes.		This	original	viral	supernatant	(Vo)	was	used	to	amplify	the	virus.			In	order	 to	amplify	 the	virus	 for	protein	expression,	250µL	of	Vo	was	added	 to	2x100mL	of	Sf9	cells	at	a	concentration	of	1x106	cells/mL	in	two	shaker	flasks	and	allowed	to	grow	under	the	following	growth	paradigm.		Ideally,	the	cells	would	double	2	to	4	times	and	then	arrest.		Following	arrest,	the	cells	would	significantly	swell	in	size.		Once	the	cells	take	 on	 this	 characteristic	 phenotype,	 the	 cells	 were	 allowed	 to	 produce	 virus	 for	 an	additional	24	hours	prior	to	harvesting	the	virus.		If	the	cells	reached	5x106	cells/mL	prior	to	 showing	 any	 sign	 of	 arrest,	 the	 cells	 were	 split	 1:2	 into	 fresh	medium	 until	 the	 cells	arrested.	 	 The	 final	 cell	 concentration	 at	 the	 time	 of	 arrest	was	 ideally	 between	 3-6x106	cells/mL.	 	 The	 entire	process	would	 take	between	3-7	days.	 The	 virus	was	harvested	by	centrifuging	the	cells	at	1k	rpm	for	5min	in	a	J6-HC	centrifuge	at	room	temperature.	 	The	supernatant	was	filtered	with	a	0.45µm	bottle	top	filter	assembly	into	sterile	plastic	bottles.		This	amplified	virus	(V1)	could	then	be	used	for	protein	expression.	To	determine	the	viral	titer	of	V1,	the	end-point	dilution	method	was	employed.		This	method	identifies	the	tissue	culture	infectious	dose	at	50%	(TCID50)	as	described	by	
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Reed	and	Muench	(Reed	and	Muench,	1938).		In	essence,	the	V1	virus	is	serially	diluted	and	then	each	dilution	is	used	to	infect	multiple	wells	(experimental	replicates)	of	plated	cells.		Over	5-7	days,	 the	 infected	replicates	will	 show	severe	cytological	effects	or	die	whereas	uninfected	 replicates	 will	 look	 normal	 and	 healthy.	 	 High	 concentrations	 of	 V1	 will	completely	infect	all	of	the	experimental	replicates	while	low	concentration	will	not	infect	any	of	the	experimental	replicates.	However,	in	the	middle	of	the	dilution	series,	a	few	viral	dilutions	will	result	in	a	mix	of	infected	and	uninfected	replicates.		These	dilutions	bracket	the	 end-point	 and	 are	 used	 to	 determine	 the	 infectious	 units.	 	 In	 general,	 the	 viral	amplification	procedure	highlighted	above	resulted	in	viral	titers	between	1x108	to	1x109	infectious	units/mL.	For	protein	expression,	cells	were	infected	at	a	multiplicity	of	infection	(MOI)	of	~5	of	each	virus.		MOI	is	calculated	based	on	the	relationship	between	infectious	units	and	total	cells.	 	For	example,	 if	one	wanted	to	infect	108	cells	at	an	MOI	of	5,	then	s/he	would	need	to	infect	with	5x108	infectious	units.		In	essence,	this	insures	that	greater	than	90%	of	cells	 are	 infected	with	 the	 virus	 and	maximizes	 protein	 expression.	 	 Upon	 infection,	 cell	growth	 arrests	 and	 the	 cells	 display	 the	 characteristic	 swollen	 phenotype	 after	 24-36	hours.	 	 Cells	were	 harvested	 after	 48-60hrs	 of	 infection	 by	 centrifugation	 at	 1k	 rpm	 for	5min	 in	 J6-HC	 at	 room	 temperature.	 	 The	 supernatant	was	 discarded	 and	 the	 cells	were	washed	 in	 1x	phosphate-buffered	 saline	 (PBS),	 pH	7.4	 and	 spun	 again.	 	 The	 supernatant	was	discarded	and	the	cells	were	stored	at	-80o.	
Yeast	 Manipulations	 –	 BY4741,	 BY4743	 (Brachmann	 et	 al.,	 1998),	 BY4741	
trp1Δ::KANMX6	and	FM113	(Gary	and	Burgers,	1995)	was	used	for	overexpression	of	TFIID	subunits.	 	 YLSTAF1	was	 used	 for	 Taf1-TAP	TFIID	 purification	 (Papai	 et	 al.,	 2009).	 	 Both	
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strains	 were	 propagated	 in	 YPD	 (1%	 w/v	 yeast	 extract,	 2%	 w/v	 peptone,	 2%	 w/v	dextrose),	either	plate	or	 liquid,	 for	normal	maintenance.	 	 	All	 strains	were	grown	at	30o	shaking	 at	 250rpm.	 For	 TFIID	 purification,	 YLSTAF1	 was	 grown	 to	 approximately	 mid-logarithmic	(mig-log)	phase.		Mid-log	phase	was	determined	experimentally	by	performing	growth	curves	with	each	strain	to	determine	the	inflection	point	at	which	time	exponential	growth	begins	to	slow	prior	to	stationary	phase.		Synthetic	complete	(SC)	medium	(0.67%	w/v	 yeast	 nitrogen	 base	 without	 amino	 acids,	 2%	 w/v	 dextrose	 (or	 1%	 w/v	 raffinose	where	 indicated),	 0.2%	 w/v	 amino	 acid	 dropout	 mix)	 without	 (-)	 Leucine	 (Leu),	 Uracil	(Ura)	or	Tryptophan	(Trp)	or	a	combination	of	the	three,	where	appropriate,	was	used	to	grow	strains	transformed	with	expression	plasmids.			All	 transformations	 were	 performed	 using	 the	 lithium	 acetate/PEG/salmon	sperm	carrier	DNA	transformation	protocol	(Gietz	and	Schiestl,	2007).		Briefly,	single	yeast	colonies	were	used	to	inoculate	YPD	and	grown	overnight	at	30o	shaking	at	250rpm.		The	following	 day,	 the	 overnight	 culture	 was	 used	 to	 inoculate	 2.5mL	 per	 transformation	reaction	of	YPD	to	an	OD600	of	approximately	0.2	and	cells	were	allowed	to	grow	for	5hours	at	 30o	 shaking	 at	 250	 rpm.	 	 Cell	 pellets	 were	 harvested	 by	 centrifugation	 in	 J6-HC	centrifuge,	 spinning	 at	 4.2k	 rpm	 for	 5min	 at	 room	 temperature.	 	 The	 supernatant	 was	discarded	and	the	pellet	was	washed	with	1.25mL	sterile	deionized	distilled	H2O	(ddH2O)	per	 transformation	 reaction	 and	 centrifuged	 as	 above.	 	 Again,	 the	 supernatant	 was	discarded	the	cell	pellet	was	resuspended	in	transformation	master	mix:	120µL	50%	w/v	polyethylene	 glycol	 (PEG)	 MW	 3350,	 18µL	 1M	 lithium	 acetate,	 18µL	 sterile	 ddH2O	 and	25µL	2mg/mL	single	 stranded	salmon	sperm	DNA;	 total	of	180µL	per	 reaction.	 	The	 cell	transformation	mix	was	then	transferred	to	1.5mL	snap	cap	tubes	containing	the	plasmid	
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DNA	of	 interest.	 	For	both	individual	transformations	(1	plasmid)	and	co-transformations	(up	to	3	plasmids),	a	minimum	of	50ng	of	each	plasmid	was	used.		A	no	plasmid	control	was	always	 to	used	to	ensure	 the	reagents	used	were	 free	of	contaminating	DNA	or	cells	 that	are	 prototrophic	 for	 the	 essential	 nutrient	 missing	 from	 the	 selection	 plates	 (Leucine,	Uracil	or	Tryptophan).	 	The	transformation	reaction	was	then	incubated	at	42o	for	40min	for	heat	shock.		Following	the	heat	shock	incubation,	the	cells	were	pelleted	at	5k	rpm	for	2min	 in	a	 table-top	mini-centrifuge	 (Eppendorf	Centrifuge	5417C).	 	The	supernatant	was	discarded	 and	 the	 pellet	 was	 resuspended	 in	 500µL	 of	 sterile	 ddH2O.	 	 For	 single	transformations,	10%	of	the	reactions	was	plated	to	SC	–	Leu,	Ura	or	Trp	agar	and	grown	at	30o	 for	 36-48	 hrs.	 	 For	 co-transformations,	 80%	 of	 the	 transformation	 reactions	 were	plated	to	SC	–	the	appropriate	combination	of	Leu,	Ura	or	Trp	agar	and	grown	at	30o	for	36-48	hours.			If	the	“no	DNA	control”	reaction	resulted	in	no	transformants,	I	would	proceed	with	the	experimental	transformations.	Colonies	that	grew	on	selective	media	agar	were	used	to	inoculate	5mL	of	SC	–	appropriate	 nutrient	 and	 grown	 at	 30o	 with	 shaking	 at	 250rpm	 overnight.	 	 For	 Gal	induction,	1mL	of	overnight	culture	was	diluted	1:10	in	sterile	ddH2O	and	centrifuged	in	J6-HC	for	5min	at	4.2k	rpm.		The	supernatant	was	discarded	and	the	cells	were	resuspended	in	5mL	of	SC	(+1%	w/v	raffinose)	–	appropriate	nutrient	and	grown	at	30o	with	shaking	at	250	 rpm	 overnight.	 	 The	 raffinose	 grown	 culture	 was	 used	 to	 inoculate	 fresh	 raffinose	medium	 to	 an	 OD600=1	 and	 grown	 to	 an	 OD600	 between	 2-3	 prior	 to	 galactose	 addition.		Once	the	cells	reached	OD600=2-3,	galactose	was	added	to	a	final	concentration	of	2%	w/v.		For	small-scale	induction,	20%	w/v	galactose	liquid	was	used	to	induce	the	cultures.	 	For	large-scale	 induction,	 solid	 galacose	 was	 used	 to	 induce	 the	 cultures.	 	 Inductions	 were	
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allowed	 to	 proceed	 for	 between	 2	 and	 8	 hours	 (4hrs	 was	 optimal)	 at	 30o	 shaking	 at	250rpm.	 	 Following	 induction,	 cells	 were	 centrifuged	 at	 4.2k	 rpm	 for	 5min	 in	 J6-HC	centrifuge	at	room	temperature.	 	The	cell	pellets	were	washed	in	ddH2O.	 	For	small-scale	inductions,	the	cells	were	transferred	to	2mL	snap-cap	tubes,	centrifuged	for	1min	at	14k	rpm	 in	 table-top	 mini-centrifuge	 and,	 after	 discarding	 the	 supernatant,	 immediately	processed	 for	 immunoblotting	 (described	below).	 	 For	 large-scale	 inductions,	 the	 cells	 in	ddH2O	wash	were	distributed	to	50mL	conical	tubes	and	centrifuged	again	as	above.	 	The	supernatant	was	discarded	the	cell	pellets	were	stored	at	-80o	prior	to	purification.			It	 was	my	 observation	 that	 growth	 of	 cells	 in	 raffinose	 is	 particularly	 finicky.		The	doubling	time	of	cells	grown	in	raffinose	is	quite	slow,	~3hrs	instead	of	the	standard	90min.	 	 In	 addition,	 cells	 that	 are	 allowed	 to	 reach	 stationary	 phase	 growth	 have	 a	significant	and	unpredictable	 lag	 time	before	they	can	resume	doubling	 in	 fresh	raffinose	medium.		Thus,	it	is	imperative	that	the	cells	be	actively	growing	in	raffinose	for	timing	of	the	experiments	to	be	consistent.		 	Analytical	Immunoblotting	for	Overexpressed	Protein	Detection	To	 determine	 if	 the	 bacmids	 effectively	 recombined	 such	 that	 they	 could	produce	 TFIID	 subunits,	 anti-TFIID	 subunit	 immunoblots	 were	 performed.	 	 Following	transfection	of	 the	 recombinant	bacmid	 into	 Sf9	 cells,	 the	 cells	were	washed	off	 the	T25	flasks	 with	 the	 virus	 conditioned	 medium	 and	 pelleted	 by	 centrifugation	 at	 1k	 rpm	 for	5min	in	J6-HC	centrifuge	at	room	temperature.		The	cell	pellet	was	resuspended	in	500µL	of	 1x	 lithium	 dodecyl	 sulfate	 (LDS)	 NuPAGE	 buffer	 (Invitrogen)	 with	 100mM	 DTT	 and	heated	 at	 75o	 for	 10min.	 	 Between	 0.5%	 and	 2%	 of	 the	 cell	 extract	 was	 used	 for	
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immunoblotting.			To	determine	if	TFIID	subunits	were	overexpressed	upon	Gal	induction,	total	cell	protein	was	extracted	from	2OD600	units	of	cells	of	early	to	mid-log	grown	culture	using	 sodium	 hydroxide	 based	 lysis	 (Kushnirov,	 2000).	 	 In	 both	 instances,	 cell	 extracts	were	 separated	 via	 SDS-PAGE	 using	 4-12%	 NuPAGE	 Bis-Tris	 gradient	 gels	 (Life	Technologies),	 run	 with	 1x	 MOPS	 running	 buffer	 and	 electro-transferred	 to	 PVDF	membranes	 using	 a	 wet	 transfer	 system.	 	 Polyclonal	 anti-Taf	 and	 anti-TBP	 antibodies	(Papai	 et	 al.,	 2010,	 2009;	 Sanders	 et	 al.,	 2002b;	 Singh	 et	 al.,	 2004)	 were	 used	 in	 the	following	manner.	 	 All	 antibodies	were	 diluted	 in	 1%	non-fat	milk	 (Carnation)	 in	 1x	 tris	buffered	saline	(25mM	Tris-HCl	pH	7.5,	150mM	NaCl).		The	antibody	dilutions	used	are	as	follows:	 anti-Taf1	 1:1000,	 anti-Taf2	 full	 length	 1:500,	 anti-Taf2	 N-term	 peptide	 1:1000,	anti-Taf2	 C-term	 peptide	 1:1000,	 anti-Taf3	 1:1000,	 anti-Taf4	 1:1000,	 anti-Taf5	 1:2500,	anti-Taf6	1:1000,	 anti-Taf7	1:5000,	 anti-Taf8	1:2000,	 anti-Taf9	1:500,	 anti-Taf10	1:2500,	anti-Taf11	 1:1000,	 anti-Taf12	 1:5000,	 anti-Taf13	 1:500,	 anti-Taf14	 1:5000	 and	 anti-TBP	1:2500.	 	Anti-HA	horseradish	peroxidase	(HRP)	conjugate	 (3F10)	antibody	was	procured	from	 Roche	 and	 used	 at	 1:5000	 dilution.	 	 Goat	 anti-Rabbit	 (Fc)	 HRP	 conjugate	 was	procured	 from	ThermoFisher	 and	 used	 at	 1:10,000	 dilution.	 Protein	 signal	was	 detected	using	Amersham	ECL	Western	Blotting	Detection	Reagent	(GE	Healthcare)	and	exposed	to	Blue	Basic	Double	Emulsion	Autoradiography	Film	(GeneMate).				 Recombinant	Protein	Purification	All	purification	steps	were	performed	at	4o	or	on	ice	unless	noted.		For	each	His6-Taf2	expression	construct	(full	length	Taf2	(aa1-1407),	Taf2	aa1-407,	Taf2	aa1-1007,	Taf2	aa401-1007,	 Taf2	 aa401-1407,	 Taf2	 aa1001-1407),	 approximately	 3-5g	 of	 E.	 coli	 pellets	
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were	generated	from	1L	of	induced	E.	coli	cultures.		The	cell	pellets	were	lysed	in	40mL	of	
E.	coli	 lysis	buffer	(20mM	Tris-HCl	pH	7.9,	200mM	NaCl,	20mM	imidazole,	0.1%	Triton	X-100,	 10%	 glycerol,	 1mM	 DTT	 and	 1x	 protease	 inhibitors)	 in	 the	 presence	 of	 approx.	100µg/mL	 lysozyme.	 Lysates	 were	 sonicated	 and	 insoluble	 material	 was	 pelleted	 by	spinning	 at	 14k	 rpm	 in	 Sorvall	 RC	 5C	 Plus	 centrifuge	 with	 an	 SS-34	 rotor	 for	 15min.		Soluble	lysate	was	then	bound	in	batch	to	2mL	of	Ni2+-NTA	agarose	(Qiagen)	for	2	hours	at	4o	 with	 mixing.	 	 Ni2+-NTA	 agarose	 and	 bound	 proteins	 were	 transferred	 to	 disposable	20mL	 chromatography	 columns	 (Bio-Rad)	 and	were	washed	 in	 column	 format	with	 >10	column	volumes	of	E.	coli	lysis	buffer.		Proteins	were	eluted	with	elution	buffer	(lysis	buffer	without	 T4	 lysozyme	 but	 with	 200mM	 imidazole)	 and	 peak	 fractions	 were	 collected.		Quantity	and	purity	of	purified	material	were	assessed	by	SDS-PAGE	followed	by	coomassie	brilliant	blue	staining	(0.1%	coomassie	brilliant	blue,	50%	methanol	and	10%	acetic	acid).	For	purification	of	Taf2	and	TFIID	subcomplexes	from	Sf9	cells,	between	2x108	and	1x109	cells	were	infected	with	baculovirus	according	to	the	paradigm	described	above.		Baculoviral	 infections	 were	 performed	 with	 HA3-3Cpro-Taf2	 expressing	 virus;	 a	combination	of	Taf1,	HA3-3Cpro-Taf2	and	TBP	expressing	viruses;	a	combination	of	Taf4	and	HA3-3Cpro-Taf12	 expressing	 viruses;	 a	 combination	 of	 Taf4,	 Taf5	 and	 HA3-3Cpro-Taf12	expressing	 virus;	 a	 combination	 of	 HA3-3Cpro-Taf5,	 Taf6	 and	 Taf9	 expression	 viruses;	 a	combination	 of	 Taf4,	 Taf5,	 Taf6,	 Taf9	 and	 HA3-3Cpro-Taf12	 expressing	 viruses;	 a	combination	of	Taf3,	Taf4,	Taf5,	Taf6,	Taf9,	Taf10	and	HA3-3Cpro-Taf12	expressing	viruses;	a	 combination	 of	 Taf4,	 Taf5,	 Taf6,	 Taf8,	 Taf9,	 Taf10	 and	 HA3-3Cpro-Taf12	 expressing	viruses;	 a	 combination	 of	 Taf3,	 Taf4,	 Taf5,	 Taf6,	 Taf8,	 Taf9,	 Taf10	 and	 HA3-3Cpro-Taf12	expressing	viruses;	a	combination	of	Taf3,	Taf4,	Taf5,	Taf6,	Taf9,	Taf10,	Taf11,	HA3-3Cpro-
	 70	
Taf12	 and	 Taf13	 expressing	 viruses;	 a	 combination	 of	 Taf3,	 Taf4,	 Taf5,	 Taf6,	 Taf8,	 Taf9,	Taf10,	Taf11,	HA3-3Cpro-Taf12	and	Taf13	expressing	viruses;	and	a	combination	of	all	TFIID	subunit	 expressing	 viruses,	 all	 of	 which	 expressed	 untagged	 TFIID	 subunits	 with	 the	exception	 of	 the	HA3-3Cpro-Taf12-expressing	 virus.	 	 The	 infected	 cells	were	 aliquoted	 for	trial	purifications	(2x107	cells)	or	for	preparative	scale	purifications	(2x108).		For	each	type	of	purification,	the	following	Sf9	lysis	buffer	was	used:		20mM	HEPES-KOH	pH	7.9,	200mM	KOAc,	 10%	glycerol,	 0.1%	NP40	 substitute,	 2mM	DTT,	0.2mM	PMSF,	2mM	Benzamidine-HCl,	 1mM	 EDTA,	 1µg/mL	 pepstatin	 A,	 2.5µg/mL	 aprotinin	 and	 2.5µg/mL	 leupeptin.	 	 In	small-scale	 purification,	 pellets	 were	 resuspended	 in	 1mL	 of	 lysis	 buffer	 and	 lysed	 by	sonication.		Cell	debris	was	removed	by	centrifugation	at	14k	rpm	for	15min	in	the	tabletop	mini-centrifuge.		The	supernatant	was	mixed	with	20-60µg	of	12CA5	monoclonal	antibody	(anti-HA)	covalently	cross-linked	to	proteinA	sepharose	(Invitrogen)	at	4mg/mL	antibody	to	bead	volume	for	3hrs	on	a	tiltboard.		Following	binding,	the	beads	were	washed	2x	with	1mL	of	ice-cold	lysis	buffer.		The	bound	protein	complexes	were	then	eluted	with	600ng	of	3C	protease	in	50µL	lysis	buffer	at	room	temperature	with	intermittent	mixing.		The	eluted	material	was	then	visualized	with	SDS-PAGE	followed	by	coomassie	brilliant	blue	staining	and	immunoblotting.		For	large-scale	purification,	2x108	cells	were	resuspended	in	20mL	of	
Sf9	 lysis	buffer	and	lysed	by	sonication.	 	Cellular	debris	was	removed	by	centrifugation	at	14k	rpm	in	Sorvall	RC	5C	Plus	centrifuge	with	an	SS-34	rotor	for	15min.		The	supernatant	was	mixed	with	 4mg	 of	 12CA5	 antibody	 crosslinked	 to	 1mL	 of	 proteinA	 sepharose	 and	allowed	to	bind	on	tiltboard	for	3hrs.	 	Following	binding,	the	beads	were	transferred	to	a	10mL	disposable	chromatography	column	(Bio-Rad)	and	washed	with	>10	bed	volumes	of	lysis	buffer.	The	column	was	capped	and	subjected	to	3C	elution	overnight	on	a	 tiltboard	
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with	1mL	of	elution	buffer	at	concentration	of	100ng	3C	protease/mL.		The	3C	eluate	was	extracted	 from	the	beads	by	centrifugation	at	1k	rpm	for	5min	 in	 J6-HC	centrifuge	 into	a	15mL	screw	cap	conical	tube	(Denville	Scientific).		The	eluate	was	further	purified	using	a	Superose6	 gel	 filtration	 column.	 	 Final	 purified	 material	 was	 analyzed	 by	 SDS-PAGE	followed	by	SyproRuby	gel	staining.	 	The	gels	were	imaged	using	PharosFX	Scanner	(Bio-Rad).	
Purification	 of	 Taf2	 variants	 from	 S.	 cerevisiae:	 MBP-Taf2	 and	 Taf2-MBP	 were	expressed	in	BY4741	by	Gal	induction	as	described	above	and	3g	of	cell	pellet/1L	of	culture	was	harvested.	 For	purification,	 all	manipulations	were	performed	at	4o	 or	on	 ice	unless	specified.		Thirty	grams	of	cell	pellet	were	lysed	in	30mL	of	Taf2	purification	buffer	(20mM	HEPES-KOH,	 500mM	potassium	 acetate,	 0.5%	NP40	 substitute,	 10%	 glycerol,	 2mM	DTT,	and	2X	protease)	using	glass	bead	lysis.		Lysate	was	then	centrifuged	at	14k	rpm	in	Sorvall	RC	 5C	Plus	 centrifuge	with	 an	 SS-34	 rotor	 for	 15min	 and	 soluble	 cell	 extract	was	mixed	with	5mL	of	DE-52	resin	equilibrated	in	Taf2	purification	buffer	for	10min	with	mixing	at	20o.	 	DE-52	 flowthrough	was	 then	diluted	with	20mM	HEPES-KOH	pH	7.9,	10%	glycerol,	1mM	 DTT	 and	 1X	 protease	 inhibitors	 to	 reduce	 the	 potassium	 acetate	 and	 the	 NP40	substitute	 concentration	 to	 200mM	 and	 0.2%,	 respectively,	 and	 bound	 to	 5mL	 amylose	resin	 (NEB)	 in	 batch	 with	mixing	 for	 2	 hours.	 	 The	 amylose	 resin-bound	 proteins	 were	transferred	 to	 a	 disposable	 chromatography	 column,	 washed	 with	 >10	 column	 volumes	amylose	wash	 buffer	 (20mM	HEPES-KOH	pH	7.9,	 200mM	potassium	acetate,	 0.1%	NP40	substitute,	10%	glycerol,	1mM	DTT	and	1X	protease	 inhibitors).	MBP-Taf2	and	Taf2-MBP	were	 eluted	 with	 wash	 buffer	 +	 10mM	 maltose	 and	 peak	 fractions	 were	 collected.		Alternatively,	Taf2	was	eluted	with	lab	generated	3C	protease	at	100ng/mL	concentration	
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at	 4o	 for	 16hrs.	 	 MBP-Taf2	 or	 free	 Taf2	 was	 further	 purified	 using	 a	 MonoQ	 column	(Pharmacia).	 	Peak	eluate	 fractions	 from	the	amylose	resin	purification	were	 loaded	onto	MonoQ	 with	 BA200	 (BA	 =	 20mM	 HEPES-KOH	 pH	 7.9,	 10%	 glycerol,	 1mM	 DTT	 and	 1x	protease	inhibitors	with	variable	concentrations	of	potassium	acetate,	eg.	BA200	contains	200mM	 potassium	 acetate).	 	 Proteins	 were	 eluted	 with	 a	 linear	 gradient	 of	 BA200	 to	BA1500.	 	 Peak	 fractions	 eluted	 at	 approx.	 BA1200.	 	 Peak	 fractions	 were	 pooled	 and	dialyzed	extensively	against	dialysis	buffer.	 	HA1-Taf1	and	Taf1-TAP	TFIID	Purification		HA1-Taf1	TFIID	was	purified	essentially	as	described	(Poon	et	al.,	1995;	Sanders	et	al.,	2002a)	with	the	following	modifications.		Woontner	extracts	(Woontner	et	al.,	1991)	were	dialyzed	against	20mM	HEPES-KOH	pH	7.9,	50mM	potassium	acetate,	20%	glycerol,	5mM	 DTT,	 1X	 protease	 inhibitor	 mix	 (0.1mM	 PMSF,	 1mM	 Benzamidine	 HCl,	 2.5mg/mL	aprotinin,	 2.5mg/mL	 leupeptin,	 1mg/mL	 pepstatinA)	 until	 the	 dialysate	 reached	 a	conductivity	 equivalent	 to	BA300.	 	Dialyzed	 extract	 derived	 from	a	maximum	of	300g	of	yeast	 cell	 pellet	 was	 chromatographed	 over	 a	 200mL	 Bio-Rex70	 100-200	mesh	 column.		For	immunopurification,	10%	SurfactAmps	NP40	was	added	to	Bio-Rex70	1M	fraction	to	a	final	 concentration	of	0.2%.	 	The	Bio-Rex70	1M	 fraction	was	 subsequently	diluted	1:2	 in	BA0,	ethidium	bromide	was	added	to	final	concentration	of	50µg/mL	and	subjected	to	anti-HA	affinity	chromatography	with	10mg	of	anti-HA	12CA5	mAb	covalently	coupled	to	2.5mL	proteinA	 sepharose	 beads	 (Life	 Technologies)	 at	 4o	 for	 16	 hours	 with	 mixing.	 	 Bound	proteins	were	transferred	to	a	10mL	disposable	chromatography	column,	washed	with	>5	column	 volumes	 of	 BA300	with	 0.1%,	 SurfactAmps	NP40,	 >5	 column	 volumes	 of	 BA300	
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with	 0.01%	 SurfactAmps	 NP40	 and	 >5	 column	 volumes	 of	 BA300	 with	 0.001%	SurfactAmps	NP40.	 	 TFIID	was	 eluted	 from	 the	 column	 two	 times	with	 2.5mL	of	 elution	buffer	 (BA300	with	 0.001%	SurfactAmps	NP40	plus	 2mg/mL	HA1	 peptide)	 for	 30min	 at	20o	 with	 mixing.	 	 The	 HA1	 peptide	 eluate	 was	 immediately	 subjected	 to	 ion	 exchange	chromatography	on	a	1.2mL	UnoS	column	(Bio-Rad).		Following	binding	of	the	HA1	peptide	eluate,	the	UnoS	column	was	washed	with	>5	column	volumes	of	BA300	and	then	subjected	to	a	linear	gradient	of	BA300	to	BA1000.		TFIID	elutes	at	approx.	BA650.		 Taf1-TAP	 TFIID	 was	 purified	 according	 to	 a	 modified	 tandem	 affinity	purification	protocol.		The	following	protocol	was	performed	multiple	times	with	different	amounts	of	yeast	cell	pellet	with	comparable	results.		One	kilogram	of	YLSTAF1	pellet	was	resuspended	 in	 500mL	 of	 3X	 TAP	 buffer	 (0.45M	 Tris-Acetate	 pH	 7.8,	 0.15M	 potassium	acetate,	 60%	glycerol,	 3mM	DTT,	 3mM	EDTA,	 3x	 protease	 inhibitors)	 and	 lysed	by	 glass	bead	beating.	 	Then,	 the	salt	concentration	of	 the	 lysate	was	adjusted	with	5M	potassium	acetate	 to	 a	 conductivity	 equivalent	of	300mM	potassium	acetate	 and	 centrifuged	at	42k	rpm	in	Beckman	Optima	LE-80K	Ultracentrifuge	with	a	45-Ti	rotor	 for	90min.	 	The	post-ribosomal	 supernatant	 was	 collected,	 avoiding	 the	 turbid	 material	 at	 the	 bottom	 of	 the	centrifugation	 tube	 and	 aliquoted	 for	 both	 analytical	 and	 large-scale	 purification.	 	 The	~800mL	of	post-ribosomal	 supernatant	was	bound	 to	80mL	 IgG	Sepharose	Fast	Flow,	 in	batch,	at	4o	for	2hr	with	mixing.	 	Following	binding,	the	IgG	sepharose	and	bound	protein	was	 washed	 extensively	 in	 IgG	 Sepharose	 Binding	 buffer	 (20mM	 Tris-Acetate	 pH	 7.8,	300mM	potassium	acetate,	10%	glycerol,	0.5mM	EDTA,	1mM	DTT,	1x	protease	inhibitors).		TFIID	was	eluted	 from	the	 IgG	sepharose	 in	100mL	of	 IgG	Sepharose	Binding	buffer	plus	TEV	protease	at	250ng/mL	for	2	hours	at	4o.	 	 	Following	TEV	elution	from	IgG	sepharose,	
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the	eluate	was	immediately	subjected	to	cation	exchange	chromatography.		The	TEV	eluate	was	 loaded	onto	 the	UnoS	column	at	a	 rate	of	1mL/min	with	BA300	buffer	 (BA	=	20mM	HEPES-KOH	 pH	 7.9,	 10%	 glycerol,	 1mM	 DTT	 and	 1x	 protease	 inhibitors	 with	 variable	concentrations	of	potassium	acetate,	eg.	BA300	contains	300mM	potassium	acetate).		After	loading	 the	 protein	 onto	 the	 UnoS	 column,	 the	 column	 was	 washed	 with	 >5	 column	volumes	of	BA300	and	then	the	protein	was	eluted	with	a	10	column	 linear	salt	gradient	from	 BA300	 to	 BA1000.	 TFIID	 elutes	 at	 approx.	 BA650.	 	 Purification	 fractions	 were	analyzed	 for	 conductivity	 to	 determine	 the	 salt	 concentration,	 immunoblotting	 and	SyproRuby	gel	staining.	 	RESULTS		Full	Length	Soluble	Taf2	Could	Only	Be	Purified	from	S.	cerevisiae	In	order	 to	purify	soluble	 full-length	Taf2	 for	 in	vitro	biochemical	assays,	 three	different	recombinant	expression	systems	were	employed.		First,	full	length	Taf2	and	Taf2	fragments	were	expressed	in	and	purified	from	E.	coli	as	His6	N-terminally	tagged	protein	variants	 (Figure	 2.2a).	 	 While	 all	 protein	 variants	 accumulated	 upon	 IPTG	 induction,	expression	 attempts	 for	 all	 of	 the	 fragments	 that	 contained	 an	 intact	 Taf2	 C-terminus	resulted	 in	 reduced	protein	 accumulation	 in	E.	coli	whole	 cell	 extracts	 (data	not	 shown).		Upon	 Ni2+-NTA	 agarose	 purification,	 the	 yield	 of	 soluble	 Taf2	 aa	 401-1407	 and	 Taf2	 aa	1001-1407	fragments	was	considerably	lower	than	the	Taf2	aa	1-407,	Taf2	aa	1-1007	and	Taf2	 aa	 401-1007	 fragments.	 	 Furthermore,	 the	 yield	 of	 full	 length	 Taf2	was	 essentially	non-existent.	Attempts	to	purify	full	length	Taf2	using	either	alternative	tags	(MBP)	or	by		
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Figure	2.2:	 	Recombinant	Taf2	Protein	Production	 from	Various	Sources.	A.	Partially	purified	His6-tagged	Taf2	variants,	expressed	in	E.	coli	and	purified	via	Ni2+-NTA	agarose,	are	presented.		The	peak	 fractions	 were	 analyzed	 via	 SDS-PAGE	 and	 coomassie	 brilliant	 blue	 (CBB)	 staining.	 	 Red	asterisks	 indicate	 unit	 length	 Taf2	 products.	 B.	 Anti-Taf2	 immunoblot	 depicting	 protein	overexpression	of	Taf2	forms	in	S.	cerevisiae	and	Sf9	cells.		C.		SDS-PAGE	and	CBB	staining	of	amylose	resin	purified	Taf2-MBP.	 	D.	 	Proteolytic	cleavage	of	Taf2-MBP	with	between	2	and	15ng/µL	of	3C	protease	to	remove	the	MBP	tag.		E.	 	SDS-PAGE	and	CBB	staining	analysis	of	amylose	resin	purified	MBP-Taf2.		F.	Proteolytic	cleavage	of	MBP-Taf2	with	2ng/µL	3C	protease	to	remove	the	MBP	tag.			
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employing	 a	 denaturing	 purification	 followed	 by	 a	 renaturation	 step	 failed	 to	 yield	 any	soluble	full	length	Taf2	(data	not	shown).		In	addition,	attempts	to	use	these	Taf2	fragments	in	DNA	binding	 assays	 failed	 to	 yield	 any	DNA	binding	 activity	 (data	not	 shown).	 	These	results	convinced	me	that	E.	coli	was	not	a	viable	organism	for	production	of	Taf2.		Thus,	I	began	to	explore	alternative	avenues	of	recombinant	protein	purification.	Recent	 successes	 in	 reconstituting	 milligram	 quantities	 of	 recombinant	 TFIID	subcomplexes	(Bieniossek	et	al.,	2013;	Trowitzsch	et	al.,	2015)	as	well	as	transcriptionally	active	TFIIH	(Fukuda	et	al.,	2001)	using	baculoviral	infection	of	insect	cells	suggested	that	this	method	 of	 recombinant	 protein	 expression	 and	 purification	 could	 prove	 productive.		Furthermore,	the	Tjian	lab	had	employed	baculovirus-based	methods	to	express	and	purify	drosophila	Taf2	(Chen	et	al.,	1994).		Unfortunately,	attempts	at	expressing	full	length	Taf2	in	insect	cells	resulted	in	a	soluble	but	truncated	Taf2	protein	product	(Figure	2.2b).	 	Our	lab	had	previously	derived	anti-Taf2	N-	and	C-terminal	peptide	affinity	purified	antibodies	for	the	purposes	of	 immunolabeling	Taf2	 in	the	TFIID	complex	(Papai	et	al.,	2010,	2009).		These	 reagents	 were	 used	 to	 determine	 that	 the	 truncated	 region	 of	 Taf2	 lied	 at	 its	 C-terminus	 (data	 not	 shown).	 	 I	 hypothesized	 that	 co-expression	 of	 Taf2	with	 other	 TFIID	subunits	may	protect	the	Taf2	C-terminus	from	degradation.		Thus,	to	test	this	hypothesis,	Taf2	was	co-expressed	with	Taf1,	Taf1	and	TBP	and	with	all	of	 the	TFIID	subunits	at	one	time.		These	efforts	failed	to	produce	full	length	Taf2	in	insect	cells	(data	not	shown).		Thus,	insect	 cell	 expression	was	 ruled	 out	 as	 a	 feasible	method	 to	 produce	 full	 length	 soluble	Taf2.	 Considering	 neither	 E.	 coli	 nor	 Sf9	 cells	 naturally	 produce	 yeast	 Taf2,	 I	hypothesized	that	the	most	effective	way	of	producing	recombinant	Taf2	may	be	through	
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expression	in	its	native	organism,	S.	cerevisiae.	 	The	work	of	Peter	Burgers	and	colleagues	had	 previously	 demonstrated	 that	 multi-protein	 complexes	 could	 be	 overexpressed	 and	purified	 from	 S.	 cerevisiae	 to	 great	 effect	 using	 a	 high-copy	 plasmid	 Gal	 induction-based	system	 (Gerik	 et	 al.,	 1997).	 	 Gal	 induction	of	 full	 length	Taf2,	 either	 in	untagged	 form	or	containing	 an	 MBP-tag	 at	 either	 its	 N-terminus	 or	 its	 C-terminus	 resulted	 in	 significant	protein	 overexpression	 (Figure	 2.2b	 and	 data	 not	 shown).	 	 Furthermore,	 amylose	 resin	purification	of	this	overexpressed	Taf2	resulted	in	highly	pure	full	length	MBP-tagged	Taf2	(Figure	2.2c,e).		Attempts	to	remove	the	MBP	tag	by	3C	protease	cleavage	were	successful	to	varying	degrees.		Specifically,	cleavage	of	amylose	resin-bound	Taf2-3Cpro-MBP	resulted	in	 liberation	 of	 the	majority	 of	 the	 Taf2	 protein	 from	 the	 resin.	 	 However,	 the	 liberated	protein	was	a	mixture	of	free	Taf2	and	residual	Taf2-3Cpro-MBP	(Figure	2.2d).		Attempts	at	prolonged	digestion	 of	 free	 protein	 in	 solution	with	 higher	 concentration	 of	 3C	protease	failed	to	achieve	greater	than	a	50:50	mix	of	free	Taf2	to	Taf2-MBP.		Alternatively,	cleavage	of	MBP-Taf2	with	 3C	 protease	 resulted	 in	 far	more	 efficient	 cleavage	 resulting	 in	 a	 near	complete	 cleavage	 and	 liberation	 of	 free	 Taf2	 (Figure	 2.2f).	 	 As	 a	 result,	 the	 MBP-Taf2	variant	was	used	for	in	vitro	biochemical	experiments	(described	in	Chapter	III).		 Progress	on	Generating	an	Alternative	TFIID	Purification	Strategy	
Generating	 Recombinant	 TFIID	 in	 Sf9	 Cells	 -	 In	 addition	 to	 generating	 soluble	Taf2,	a	goal	of	 this	dissertation	was	to	develop	a	method	for	 facile	purification	of	mutant	forms	 of	 TFIID,	 specifically	 to	 test	 the	 function	 of	 mutant	 Taf2	 in	 TFIID	 function.	 	 As	described	 above,	 current	 protocols	 for	 purification	 of	 TFIID	 are	 both	 time	 and	 cost	intensive.	 	 Thus,	 if	 I	 could	 develop	 a	 method	 where	 TFIID	 could	 be	 generated	 using	
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recombinant	 expression	 technologies	 such	 that	 milligram	 quantities	 of	 TFIID	 could	 be	produced	from	as	 little	as	one	 liter	of	 insect	cell	culture	or	10	 liters	of	yeast	cell	cultures	instead	 of	 the	 200-300	 liters	 currently	 required,	 this	 technological	 development	 would	dramatically	 increase	 the	ability	of	 scientists	 to	 genetically	 and	biochemically	dissect	 the	function	of	TFIID.	While	attempting	to	express	Taf2	in	Sf9	cells	either	by	itself	or	in	complex	with	other	TFIID	subunits,	 I	 generated	baculoviruses	encoding	all	of	 the	yeast	TFIID	subunits.		With	the	exception	of	Taf2,	each	baculovirus	induced	the	expression	of	the	encoded	TFIID	subunits	at	high	levels	without	any	obvious	N-	or	C-terminal	truncations	(Figure	2.3a).		To	begin	to	construct	recombinant	TFIID,	mixtures	of	virus	encoding	different	TFIID	subunits	were	 used	 to	 infect	 Sf9	 cells	 to	 form	 subcomplexes	 that	 could	 be	 subsequently	 purified.		Initially,	attempts	were	made	to	reconstitute	the	5-Taf	TFIID	core	complex	(Tafs	4,	5,	6,	9	and	12),	described	by	the	Berger	and	Schultz	labs	for	human	TFIID,	to	determine	if	I	could	replicate	published	data	(Bieniossek	et	al.,	2013).		According	to	the	Berger	and	Schultz	labs’	observations,	Taf4	and	Taf12	do	not	co-purify	with	Taf6	or	Taf9	in	the	absence	of	Taf5.		To	test	this	observation,	Sf9	cells	were	infected	with	baculovirus	encoding	Taf4	and	HA3-3Cpro-Taf12;	Taf4,	Taf6,	Taf9	and	HA3-3Cpro-Taf12;	or	Taf4,	Taf5,	Taf6,	Taf9	and	HA3-3Cpro-Taf12	and	subjected	to	anti-HA	immunopurification	(Figure	2.3b).		The	results	of	the	purification	demonstrated	 that	 in	 all	 three	 experimental	 conditions,	 levels	 of	 Taf4	 and	 Taf12	 in	 the	extract	 were	 depleted	 upon	 anti-HA	 immunopurification	 and	 enriched	 in	 the	immunopurified	material	 (Figure	2.3c	and	data	not	shown).	 	However,	 levels	of	Taf6	and	Taf9	were	 only	 depleted	 from	 the	 extract	 and	 enriched	 in	 the	 immunopurified	material	when	Taf5	was	also	co-expressed	(Figure	2.3c	and	data	not	shown).		The	resulting	5-Taf	
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Figure	2.3:	 	Reconstitution	of	Yeast	5-Taf	TFIID	Core	by	Sf9	 Cell	 Co-Infection.	 	A.	Anti-TFIID	subunit	immunoblots	of	Sf9	cells	singly	infected	with	recombinant	baculovirus	encoding	the	TFIID	subunits.	 	B.	 	 SDS-PAGE	and	CBB	 staining	of	 immunopurified	Taf	 subcomplexes	 generated	by	 co-infection	 of	 Sf9	 cell	 with	 recombinant	 baculoviruses	 encoding	 TAF4	 and	 HA3-3Cpro	 (HA)-TAF12;	
TAF4,	TAF6,	TAF9	and	HA3-3Cpro	(HA)-TAF12;	or	TAF4,	TAF5,	TAF6,	TAF9	and	HA3-3Cpro	(HA)-TAF12.		
C.	 	Immunoblots	of	Sf9	cell	lysates	and	immunopurified	material	following	co-infection	with	either	
TAF4,	TAF6,	TAF9	and	HA3-3Cpro	(HA)-TAF12	or	TAF4,	TAF5,	TAF6,	TAF9	and	HA3-3Cpro	(HA)-TAF12-encoding	baculoviruses.	 	 Input	 lysate	or	 lysates	 following	binding	 to	either	5	or	15µL	of	4mg/mL	anti-HA-coupled	proteinA	sepharose	were	assayed	for	Taf12	and	Taf9	as	a	measure	of	antigen	and	co-purifying	 protein	 depletion,	 respectively.	 	 Proteins	 bound	 to	 anti-HA	 beads	 were	 assayed	 to	demonstrate	level	of	enrichment	in	the	pull-down.	D.	 	SyproRuby	gel	stain	of	highly	purified	5-Taf	TFIID	core	complex	derived	from	Sf9	cell	co-infection.			
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TFIID	 core	 complex	 was	 then	 subjected	 to	 size-exclusion	 chromatography	 for	 further	purification.	 	 This	 analysis	 separated	 the	 intact	 5-Taf	 complex	 from	 excess	 Taf4-Taf12	complex	 and	 revealed	 that	 the	 5-Taf	 complex	 displays	 equal	 stoichiometry	 for	 all	 of	 the	different	 components	 (Figure	 2.3d).	 	 These	 results	 recapitulated	 the	 Schultz	 and	 Berger	labs’	 published	 data	 and	 suggest	 that	 the	 yeast	 TFIID	 core	 likely	 assembles	 in	 a	 similar	manner	to	the	human	TFIID	core	complex.	Also,	according	to	the	Berger	and	Schultz	labs,	addition	of	Taf8	and	Taf10	to	the	TFIID	 core	 is	 important	 for	 a	 conformational	 change	 in	 the	 complex.	 	They	hypothesized	that	this	structural	transition	is	critical	for	the	assembly	of	the	holo-TFIID	complex.		Thus,	to	recapitulate	their	ability	to	form	the	7-Taf	complex	(5-Taf	TFIID	core	+	Taf8	and	Taf10),	I	co-infected	Sf9	cells	with	viruses	encoding	all	of	the	5-Taf	TFIID	core	complex	constituents	as	well	as	viruses	encoding	Taf8	and	Taf10.		This	7-Taf	complex	was	subjected	to	anti-HA	immunopurification	 and	 size-exclusion	 chromatography.	 	 While	 I	 was	 able	 to	immunopurify	 a	 7-Taf	 complex,	 this	 complex	 displayed	 characteristics	 of	 protein	aggregation.		First,	despite	achieving	near	complete	cleavage	of	the	HA3-3Cpro-tag	on	Taf12	when	purifying	 the	5-Taf	TFIID	core	complex,	 the	7-Taf	 complex	displayed	both	a	mix	of	cleaved	 and	 uncleaved	 Taf12	 (data	 not	 shown).	 	 Second,	 this	 7-Taf	 complex	 would	 not	enter	the	size-exclusion	chromatography	column	matrix	but	instead	eluted	within	the	void	volume	of	the	column	(data	not	shown).		While	additional	Tafs	could	be	added	to	this	7-Taf	assembly,	namely	Taf3,	Taf11	and	Taf13,	all	of	these	complexes	displayed	the	same	signs	of	aggregation.	 	 In	an	effort	 to	create	 larger	Taf	assemblies	 that	did	not	display	 this	protein	aggregation	phenotype,	Sf9	cells	were	infected	with	viruses	encoding	the	5-Taf	TFIID	core	complex	constituents	
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and	either	Tafs	3	and	10	or	Tafs	3,	10,	11	 and	 13.	 	 The	 resulting	 complexes	were	 subjected	 to	 anti-HA	immunopurification	 and	 size-exclusion	chromatography.		Unlike	the	Taf8/Taf10	 containing	 subcomplexes,	both	the	5-Taf	TFIID	core	+	Taf	3	and	10	(7Taf)	complex	as	well	as	the	5-Taf	TFIID	 core	 +	 Taf	 3,	 10,	 11	 and	 13	(9Taf)	 complex	 entered	 the	 size-exclusion	 chromatography	 column	and	eluted	as	a	homogeneous	complex	(data	 not	 shown).	 	 When	 analyzing	these	complexes	by	SDS-PAGE	and	gel	staining	 (Figure	 2.4a),	 with	 the	exception	 of	 Taf13,	 all	 of	 the	 TFIID	subunits	 ran	 at	 the	 same	 mobility	 as	TFIID	 purified	 from	 S.	 cerevisiae.		Taf13	appeared	to	migrate	at	a	faster	mobility	likely	due	to	proteolysis.		In	addition,	neither	complex	 displayed	 the	 stoichiometry	 observed	 in	 TFIID	 purified	 from	 S.	 cerevisiae.		Specifically,	Taf3,	Taf11	and	Taf13	are	thought	to	be	one	mole	per	mole	of	TFIID	while	Tafs	4,	5,	6,	9,	10	and	12	are	thought	to	be	two	moles	per	mole	of	TFIID.		The	recombinant	TFIID	subcomplexes	display	an	approximate	subunit	stoichiometry	of	1:1	for	all	of	the	subunits.				
	
Figure	2.4:	 	Reconstitution	of	Taf	Subcomplexes	 in	
Sf9	cells.	 	A.		SyproRuby	stain	of	highly	purified	native	HA1-Taf1	TFIID	from	S.	cerevisiae	and	Taf	subcomlexes	from	baculovirally	co-infected	Sf9	cells.		B.	Sf9	cells	co-infected	 with	 baculoviruses	 encoding	 every	 TFIID	subunit	were	subjected	to	anti-HA	immunopurification,	as	 described	 in	 Methods	 section.	 	 Both	 input	 (lysate)	and	purified	material	were	analyzed	by	immunobloting	with	anti-Taf	and	anti-TBP	IgGs.	
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Attempts	at	adding	additional	TFIID	subunits	to	this	complex	were	unsuccessful	for	several	reasons.		First,	when	infecting	with	all	15	viruses,	production	of	both	Taf1	and	the	truncated	form	of	Taf2	severely	decreased	(Figure	2.4b).	 	Second,	addition	of	Taf8,	as	described	 above	 caused	 the	 complexes	 to	 adopt	 biochemical	 phenotypes	 suggestive	 of	protein	aggregation	(data	not	shown).		Third,	despite	being	expressed	at	high	levels,	Tafs	7	and	14	 and	TBP	 failed	 co-purify	with	 the	 9Taf	 complex	 (Figure	 2.4b).	 	 Regardless,	 these	results	represent	significant	progress	in	attempts	to	generate	recombinant	TFIID.		
	
Generating	 Recombinant	 TFIID	 in	 S.	 cerevisiae	 -	 Considering	 that	 yeast	 were	capable	of	overexpressing	large	quantities	of	soluble	Taf2	by	Gal	induction,	I	hypothesized	that	 I	 could	 instead	 use	 multi-subunit	 overexpression	 in	 yeast	 to	 generate	 recombinant	TFIID.	 	 Taking	 a	 similar	 approach	 as	 described	 for	 Sf9	 cells,	 the	 goal	 would	 be	 to	dramatically	 overexpress	 every	 TFIID	 subunit	 in	 the	 same	 cell	 at	 the	 same	 time.	 	 This	would	allow	native	yeast	protein	assembly	pathways	to	construct	the	TFIID	complex	in	vivo	leading	to	dramatically	increased	yield.			To	 this	 end,	 I	 constructed	 a	 two-plasmid	 system	 (Figure	 2.1;	 described	 in	Methods).	The	 rationale	 for	 this	 two-plasmid	 system	was	 that	one	plasmid	would	be	 the	donor	 plasmid	 and	 the	 other	 plasmid	 would	 the	 acceptor	 plasmid.	 	 The	 donor	 plasmid	(pJFGDUAL)	would	 contain	 a	 fully	 competent	 dual	 expression	 cassette	 to	which	 I	would	clone	the	ORFs	of	two	distinct	TFIID	subunits.		The	acceptor	plasmid	(pJFLEU2,	pJFTRP1	or	pJFURA3)	 would	 contain	 a	 high	 copy	 origin	 of	 replication	 and	 the	 selectable	 marker	required	 for	 growth	 in	 amino	 acid	 drop	 out	medium.	 	 In	 addition,	 the	 acceptor	 plasmid	
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would	 contain	 four	 distinct	 restriction	enzyme	 sites	 that	 could	 be	 used	 as	entry	 points	 for	 the	 dual	 expression	cassette.		In	theory,	a	single	acceptor	 plasmid	 could	 overexpress	 8	TFIID	 subunits.	 	 By	 using	 multiple	plasmids	 with	 different	 selectable	markers,	all	of	the	TFIID	subunits	could	be	 expressed	 in	 the	 same	 cell	 at	 the	same	time.	The	 initial	 plasmid	 design	included	 two	 CYC1term	 sequences	 for	each	 dual	 expression	 cassette.	 	 Using	these	 plasmids,	 overexpression	 of	 one	or	two	TFIID	subunits	in	a	single	cell	at	the	 same	 time	 was	 highly	 successful	(Figure	 2.5).	 	 Furthermore,	 expressing	two	and	three	different	plasmids	in	the	same	 cell	 did	 not	 markedly	 diminish	total	protein	output.	 	However,	despite	repeated	 attempts	 to	 create	 multiple	 dual	 expression	 cassettes	 into	 the	 same	 acceptor	plasmids,	I	was	never	able	to	produce	the	correct	sized	plasmid.		In	fact,	the	plasmids	that	were	purified	from	E.	coli	showed	significant	recombination	(data	not	shown).			In	the	one	
	
Figure	 2.5:	 	 Multi-subunit	 Overexpression	 in	
Yeast.	 	 Yeast	 strains	 harboring	 individual	 or	combinations	 of	 galactose	 inducible	 dual	 expression	plasmids	were	harvested	before	 (Un)	and	after	4hrs	of	galactose	induction	(In).	 	Whole	cell	extracts	were	analyzed	 by	 immunoblotting	with	 anti-Taf	 and	 anti-TBP	 IgGs.	 	 Numbers	 correspond	 to	 Tafs	 encoded	 in	dual	expression	cassette	 (e.g.	4=Taf4).	 	H=HA3-3Cpro-	tag.		**	=	loss	of	signal	because	of	inappropriate	cut	in	PVDF	membrane.		
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case	 where	 a	 plasmid	 was	 generated	 that	purportedly	contained	 four	Tafs	 in	 the	same	plasmid,	Gal	 induction	experiments	revealed	that	only	three	of	the	Tafs	were	expressed,	likely	 as	 a	 result	 of	 recombination	 (data	not	shown).		These	results	led	me	to	hypothesize	that	 recombination	 was	 a	 result	 of	 the	multiple	 copies	 of	 the	 CYC1term	 in	 the	 dual	expression	 cassettes.	 	 Indeed,	 despite	ultimately	 having	 success	 generating	 the	pJFGDUAL	 plasmid,	 I	 initially	 had	 difficulty	ligating	 the	 second	 copy	of	 the	CYC1term	 into	the	dual	expression	cassette	and	subsequently	sequencing	the	plasmid.	As	an	alternative	to	the	CYC1term,	I	re-	cloned	all	of	the	TFIID	subunits	(except	for	Taf2)	 such	 that	 they	 would	 contain	 ~100bp	 beyond	 the	 documented	 3’	 untranslated	sequence.		Then,	the	Taf	ORF	+	terminator	sequences	were	ligated	into	pJFGDUAL	sans	the	
CYC1term	 sequences	 and	 the	 resulting	 dual	 expression	 cassettes	 were	 transferred	 to	 the	acceptor	plasmids.		This	change	in	plasmid	design	then	allowed	me	to	insert	multiple	dual	expression	 cassettes	 into	 the	 same	 acceptor	 plasmid.	 To	 determine	 if	 the	 native	termination	 sequences	 were	 as	 effective	 as	 the	 CYC1term	 sequence,	 overexpression	 of	acceptor	 plasmids	 containing	 CYC1term	 sequences	 with	 Taf6	 and	 Taf9	 was	 compared	 to	overexpression	 of	 acceptor	 plasmids	 containing	 the	 native	 Taf6	 and	 Taf9	 terminator	sequences	 (Figure	 2.6).	 	While	 the	 CYC1term	 sequences	 performed	 better	 than	 the	 native	
	
Figure	 2.6:	 	 Comparison	 of	 Protein	 Output	
Between	 CYC1	 and	 Native	 Terminator	
Containing	 Expression	 Vectors.	 	 S.	cerevisiae	strains	 harboring	 an	 empty	 vector	 and	 dual	expression	 plasmids	 encoding	 TAF6	 and	 TAF9	containing	 either	 the	 CYC1term	 or	 the	 natural	
TAF6/TAF9	 terminators	 were	 induced	 with	galactose	 for	2,	4	or	8	hrs.	 	Whole	cell	extracts	derived	 from	 the	 induced	 cells	 were	 analyzed	by	 immunoblotting	with	 anti-Taf	 and	 anti-TBP	IgGs	
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terminator	sequences,	considering	I	was	unable	to	express	more	than	two	TFIID	subunits	in	a	single	acceptor	plasmid	containing	the	CYC1term	sequences,	I	moved	forward	with	the	native	 terminator	 sequences.	 	 Three	 acceptor	 plasmids,	 and	 associated	 intermediate	plasmids,	 were	 generated	 that	 contained	 all	 of	 the	 TFIID	 subunits.	 	 The	 following	 dual	expression	cassettes	were	sequentially	cloned	into	pJFTRP1:		1)	Taf6	and	Taf9,	2)	Taf5	and	Taf14,	3)	Taf8	and	Taf10	and	4)	Taf4	and	(HA3-3Cpro-)Taf12.		The	following	dual	expression	cassettes	were	 sequentially	 cloned	 into	pJFURA3:	1)	Taf11	and	Taf13,	2)	Taf3	and	Taf10	and	3)	Taf1	and	Taf7.		MBP-3Cpro-Taf2	and	TBP	were	cloned	into	the	pJFGDUAL	containing	the	CYC1term	sequences	and	the	dual	expression	cassette	was	inserted	into	pJFLEU2.		All	of	these	plasmids	were	transformed	into	yeast	in	combination	or	individually	and	tested	for	ability	to	overexpress	TFIID	subunits	by	Gal	induction	(Figure	2.7).	 	Overall,	I	was	able	to	observe	 significant	 protein	 induction	 for	 all	 of	 the	 TFIID	 subunits	 when	 they	 were	expressed	on	a	single	plasmid	or	in	two	plasmid	combinations.		However,	I	did	not	observe	induction	of	all	of	the	TFIID	subunits	in	the	three-plasmid	combination.		In	addition,	when	focusing	 on	 the	 Tafs	 encoded	 in	 the	 first	 dual	 expression	 cassettes	 introduced	 into	 the	acceptor	 plasmids	 (Taf6	 and	 Taf9	 or	 Taf11	 and	 Taf13),	 as	 additional	 dual	 expression	cassettes	were	 introduced	 into	 the	 acceptor	plasmid,	 the	 level	 of	 protein	 overexpression	was	significantly	reduced.		In	totality,	these	results	demonstrate	that	in	separate	strains,	I	could	achieve	significant	overexpression	of	all	of	the	TFIID	subunits;	however,	I	could	not	achieve	significant	overexpression	of	all	of	the	TFIID	subunits	in	the	same	strain.	
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Figure	2.7:		Iterative	Addition	of	Dual	Expression	Cassettes	for	Overexpression	of	All	TFIID	
Subunits	 in	 the	 Same	 Cell	 at	 the	 Same	 Time.	 	 S.	 cerevisiae	 strains,	 transformed	 with	 multi-subunit	 overexpression	 plasmids	 either	 individually	 or	 in	 combination,	 were	 harvested	 pre-galactose	 induction	(Un)	or	after	4hrs	galactose	 induction	(In).	 	Whole	cell	extracts	derived	from	these	strains	were	subjected	to	immunoblotting	with	anti-Taf	and	anti-TBP	IgGs.		Overexpression	plasmids	were	 derived	 from	 dual	 expression	 cassettes	 containing	 the	 native	 terminators	 for	 all	TFIID	subunits	with	the	exception	of	the	MBP-TAF2,TBP	(SPT15)	encoding	plasmid.		Plasmid	1	(P1)	was	derived	from	iteratively	integrating	dual	galactose	inducible	expression	cassettes	encoding	1)	Tafs	6	and	9,	2)	Tafs	5	anad	14,	3)	Tafs	8	and	10	and	4)	Taf4	and	(HA3-3Cpro)-Taf12.		Plasmid	2	(P2)	was	derived	from	iteratively	integrating	dual	galactose	inducible	exrpression	cassettes	encoding	1)	Tafs	11	and	13,	2)	Tafs	3	and	10	and	3)	Tafs	1	and	7.	 	Purified	TFIID	was	 included	as	a	positive	control.		Un	=	uninduced,	In	=	induced,	H=	HA3-3Cpro-tag	,	M=MBP-3Cpro-tag,	*=non-specific	band.		
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Alternative	 Taf1-TAP	 TFIID	 Purification	 Optimization	 –	 As	 an	 alternative	 to	generating	 recombinant	 TFIID	 or	 purifying	 TFIID	 using	 our	 anti-HA	 immunopurification	lab	 protocol,	 I	 hypothesized	 that	 if	 I	 were	 to	 optimize	 the	 Taf1-TAP	 TFIID	 purification	protocol,	 then	 I	 would	 be	 able	 to	 at	 least	 decrease	 the	 cost	 of	 TFIID	 purification.	 	 IgG	sepharose	 is	 significantly	 less	 expensive	 than	 anti-HA	 (12CA5)	 covalently	 coupled	 to	proteinA	sepharose.	 	 In	addition,	 rabbit	 IgG	can	easily	be	covalently	coupled	 to	cyanogen	bromide	activated	sepharose	4B	beads	in-house,	decreasing	the	cost	further	(March	et	al.,	1974).		The	challenge	with	optimizing	this	protocol	is	that	I	would	need	to	figure	out	how	to	eliminate	the	step	that	results	in	dissociation	of	Taf2,	Taf8	and	Taf14	from	the	complex	To	 determine	 which	 step	 is	 likely	 to	 result	 in	 dissociation	 of	 Taf2,	 Taf8	 and	Taf14,	 I	 investigated	the	unpublished	data	of	Post-doc	Manish	Tripathi	who	had	 invested	extensive	time	and	energy	into	the	purification	of	Taf1-TAP	TFIID.		When	looking	through	his	data,	I	observed	that	he	had	already	identified	the	step	in	the	purification	that	leads	to	Taf2,	 Taf8	 and	 Taf14	 dissociation,	 he	 just	 had	 not	 realized	 it.	 	 In	 the	 first	 step	 of	 the	purification,	 he	 was	 able	 to	 bind	 Taf1-TAP	 TFIID	 to	 IgG	 sepharose	 and	 elute	 with	 TEV	protease	without	any	 loss	of	Taf2.	 	However,	 in	 the	next	step	(calmodulin	sepharose),	he	observed	 that	 if	he	used	 too	high	of	a	 salt	 concentration,	Taf2	would	dissociate	 from	 the	complex	(data	not	shown).		Instead	of	omitting	this	step	in	the	purification,	he	lowered	the	salt	 concentration	 and	 proceeded.	 	 However,	 if	 he	 tried	 to	 separate	 the	 complex	 further	using	 ion	 exchange	 chromatography,	 Taf2,	 Taf8	 and	 Taf14	 would	 dissociate	 from	 the	complex.		This	particular	result	was	quite	illuminating	to	me	because	TFIID	purified	using	anti-HA	 immunopurification	 can	 be	 subjected	 to	 ion	 exchange	 chromatography	 without	disrupting	complex	integrity	(Sanders	et	al.,	2002a).		Based	on	this	body	of	data,	I		
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Figure	2.8:		Alternative	Taf1-TAP	Purification	Protocol	Yields	Intact	TFIID.		A.		S.	cerevisiae	cells	expressing	Taf1-TAP	were	lysed	and	extracts	bound	to	IgG	sepharose	and	eluted	via	TEV	cleavage.		The	 TEV	 eluate	 was	 then	 bound	 to	 a	 cation	 exchange	 column,	 washed	 and	 eluted	 with	 a	 linear	gradient	 (300mM	 to	 1M)	 of	 potassium	 acetate.	 	 The	 fractions	 were	 analyzed	 for	 conductivity	 to	determine	potassium	acetate	concentration	as	well	as	analyzed	by	immunoblot	using	anti-Taf	IgGs.		Input=	TEV	eluate,	FT	Fxns=	Flow	Through	(unbound)	fractions.	 	B.	SyproRuby	stained	gel	of	Taf1-TAP	TFIID	purified	with	alternative	TAP	purification	protocol.	hypothesized	 that	 the	 step	 that	 was	 disrupting	 complex	 integrity	 was	 the	 calmodulin	sepharose	binding	step.		Therefore,	if	this	step	were	removed,	TFIID	would	remain	intact.	For	 simplicity,	 I	 utilized	 the	 buffer	 system	 and	 initial	 purification	 steps	developed	 by	 graduate	 student	 Steven	 Sanders	 (unpublished	 data;	 outlined	 in	 Methods	section).	 	 After	 optimizing	 the	 volume	 of	 beads	 required	 for	 IgG	 sepharose	 binding	 and	concentration	of	TEV	protease	required	to	elute	Taf1-TAP	TFIID,	instead	of	proceeding	to	the	calmodulin	sepharose	step,	I	immediately	bound	the	TEV	eluate	to	the	cation	exchange	column	 that	 our	 lab	 routinely	uses	 following	HA1-Taf1-TFIID	 anti-HA	 immunpurification.		The	column	was	developed	with	a	 linear	potassium	acetate	salt	gradient	 from	300mM	to	1M	and	the	resulting	fractions	were	immunoblotted	for	TFIID	subunits,	including	Taf8	as	a	surrogate	for	the	putative	Taf2,	Taf8	and	Taf14	subcomplex	(Figure	2.13).		In	addition,	the	TFIID	peak	fraction	was	analyzed	by	SyproRuby	gel	stain.	 	These	analyses	suggested	that	
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my	hypothesis	was	correct.		Following	a	protocol	that	omitted	the	calmodulin	binding	step	allowed	me	 to	 separate	 the	 IgG	 sepharose	purified	Taf1-TAP	TFIID	on	a	 cation	exchange	column	without	resulting	in	dissociation	of	Taf8	from	the	rest	of	the	complex.		In	fact,	the	TFIID	complex	eluted	at	approximately	650mM	potassium	acetate,	the	same	elution	point	observed	for	cation	exchange	chromatography	of	anti-HA	immunopurified	TFIID	(data	not	shown).	 	 Based	 on	 these	 results,	 omitting	 the	 calmodulin	 binding	 step	 makes	 the	 TAP	purification	procedure	more	reliable	at	producing	TFIID	with	the	correct	stoichiometry	of	Taf2,	Taf8	and	Taf14.				 	DISCUSSION		In	 this	 chapter,	 I	 document	 attempts	 to	 purify	 soluble	 full	 length	 Taf2	 and	 to	identify	alternative	methods	for	efficient	TFIID	purification.	 	Successful	purification	of	full	length	Taf2	would	enable	to	me	to	perform	in	vitro	biochemical	assays	to	identify	functions	of	Taf2.	 	These	functions	could	then	be	genetically	and	biochemically	dissected	to	identify	loss-	 or	 gain-of-function	 variants.	 	 Loss-	 and	 gain-of-function	 reagents	 are	 key	 for	understanding	protein	functions	in	vivo	and	the	identification	of	such	reagents	would	allow	me	 to	 determine	 the	 role	 of	 Taf2	 in	 TFIID-dependent	 transcription	 regulation.		Additionally,	developing	an	efficient	and	robust	method	for	the	purification	of	TFIID	in	both	yeast	 and	 humans	 is	 an	 urgent	 need	 for	 scientists	 studying	 transcription	 initiation	mechanism	 in	 vitro.	 	 Such	 a	 method	 would	 enable	 more	 laboratories	 to	 analyze	 the	structure	 and	 function	 of	 the	 TFIID	 complex	 in	 vitro.	 	 Ultimately,	 the	 ability	 to	 generate	recombinant	TFIID	would	lead	to	the	generation	of	mutant	TFIID	variants,	important	tools	
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for	dissecting	its	mechanism	of	action	regarding	its	promoter	recognition	and	co-activator	function.	 	 Currently,	 only	 one	 laboratory	 has	 ever	 published	 biochemical	 analysis	 of	purified	 mutant	 TFIID	 forms	 (Lauberth	 et	 al.,	 2013)	 and	 their	 results	 have	 provided	important	 insights	 into	 how	TFIID	 engages	 chromatinized	DNA.	 	 This	 study	 underscores	the	need	for	innovation	in	TFIID	purification	in	order	to	advance	TFIID	research.			Attempts	 to	 express	 recombinant	 Taf2	 in	 both	E.	 coli	and	 Sf9	 cells	 resulted	 in	similar	and	potentially	informative	results.		In	E.	coli,	I	was	able	to	successfully	express,	in	large	quantities,	 soluble	Taf2	 fragments	 that	did	not	 include	 the	Taf2	C-terminus	 (Figure	2.2a).	 	 However,	 I	 was	 not	 able	 to	 produce	 soluble	 full	 length	 Taf2	 at	 all	 or	 significant	quantities	of	fragments	of	Taf2	that	contained	the	Taf2	C-terminus.		In	Sf9	cells,	attempts	at	expression	and	purification	of	full	length	Taf2	led	to	a	C-terminally	truncated	version	of	the	protein	(Figure	2.2b).	 	Taken	together,	 it	 is	possible	 that	 the	C-terminus	of	Taf2	adopts	a	conformation	 that	 renders	 it	 insoluble	 in	 E.	 coli	 and	 causes	 proteolysis	 in	 Sf9	 cells.		Consistent	with	this	hypothesis,	Kabani	et	al.	reported	that	their	attempts	to	express	a	Taf2	C-terminal	 fragment	 in	 E.coli	 resulted	 in	 an	 insoluble	 protein	 (Kabani	 et	 al.,	 2005).	 	 In	addition,	 this	 region	 of	 yeast	 Taf2	 corresponds	 to	 the	 predicted	 intrinsically	 disordered	region	 of	 metazoan	 Taf2	 (Zhang	 et	 al.,	 2015)	 which	 could	 play	 a	 role	 in	 the	 proteins	solubility	or	integrity	in	exogenous	expression	systems.	I	 was	 able	 to	 resolve	 the	 issues	 of	 solubility	 and	 C-terminal	 truncation	 by	overexpressing	Taf2	in	and	purifying	from	S.	cerevisiae	(Figure	2.2d,c,e).		Expressing	MBP-Taf2	 using	 a	 high	 copy	 plasmid	 with	 the	 GAL1	 inducible	 promoter	 produced	 significant	amounts	of	protein	that	could	be	subsequently	purified	using	amylose	resin.		In	general,	the	amylose	 resin	 does	 not	 appear	 to	 specifically	 bind	 endogenous	 yeast	 cell	 proteins.	 	 As	 a	
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result,	 a	 one	 step	 amylose	 resin	purification	of	MBP-Taf2	 yields	highly	pure	material	 for	subsequent	biochemical	analysis.	In	order	to	generate	recombinant	TFIID,	I	employed	two	similar	overexpression	strategies.	 	First,	I	attempted	to	infect	Sf9	cells	with	baculovirus	encoding	TFIID	subunits.	Using	this	method,	I	was	able	to	individually	overexpress	the	full-length	versions	of	every	TFIID	 subunit	 with	 the	 exception	 of	 Taf2	 (Figure	 2.3a).	 	 Then,	 I	 used	 these	 viruses	 to	express	 and	 purify	 Taf	 subcomplexes	 containing	 up	 to	 9	 subunits	 (Figure	 2.4a).		Importantly,	I	also	demonstrated	that	yeast	Tafs	4,	5,	6,	9	and	12	can	form	the	TFIID	core	complex	in	a	similar	manner	to	what	has	been	published	for	the	human	TFIID	core	complex	(Figure	2.3b-d).		The	existence	of	this	core	structure	strengthens	the	conclusion	that	yeast	TFIID	is	highly	evolutionarily	conserved	at	the	amino	acid,	structural	and	functional	level.				The	 main	 hurdle	 that	 I	 could	 not	 clear	 with	 regard	 to	 growing	 this	 complex	beyond	9	subunits	was	the	inability	to	efficiently	overexpress	both	Taf1	and	Taf2	when	the	rest	 of	 the	 other	 TFIID	 subunits	 were	 overexpressed	 (Figure	 2.4b).	 	 Our	 lab	 has	demonstrated	that	even	when	the	ability	of	Taf1	to	interact	with	holo-TFIID	is	disrupted,	it	still	maintains	its	ability	to	bind	Taf7	(Singh	et	al.,	2004).		In	addition,	we	have	also	shown	the	Taf1	TAND	directly	interacts	with	TBP	(Bai	et	al.,	1997).		Thus,	if	Taf1	is	not	expressed,	it	 is	 unlikely	 that	 either	 Taf7	 or	 TBP	 stably	 associate	 with	 the	 complex.	 	 At	 the	 time	 I	performed	this	study,	the	finding	that	a	Taf2-Taf8-Taf10	subcomplex	existed	had	not	been	published	 (Trowitzsch	 et	 al.,	 2015).	 	 In	 addition,	 the	 fact	 that	 the	 Taf1-TAP	 TFIID	purification	 protocol	 resulted	 in	 a	 preparation	with	 not	 only	 substoichiometric	 levels	 of	Taf2	but	also	substoichiometric	levels	Taf8	and	Taf14	had	escaped	my	attention	(Papai	et	al.,	2009).		Together	with	the	fact	that	a	mutant	form	of	Taf1	can	co-precipitate	the	entire	
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TFIID	complex	with	the	exception	of	Taf2,	Taf8	and	Taf14	(Singh	et	al.,	2004),	 these	data	suggest	 that	 in	 the	 absence	 of	 Taf1	 and	 Taf2,	 neither	 Taf8	 nor	 Taf14	 should	 properly	associate	with	 the	TFIID	 complex.	 	Therefore,	 it	 is	my	 supposition	 that	 in	 the	absence	of	Taf1	and	Taf2,	at	least	some	of	the	binding	surfaces	required	for	Tafs	7,	8	and	14	as	well	as	TBP	are	missing	such	that	these	subunits	cannot	stably	associate	with	the	remaining	TFIID	subunits.			The	fact	that	a	Taf8-Taf10	subcomplex	could	co-purify	with	the	5-Taf	TFIID	core	but	in	an	aggregated	state	is	puzzling.	 	It	is	possible	that	this	aggregated	state	reflects	the	conformational	change	proposed	by	the	Schultz	and	Berger	labs	insofar	as	binding	of	Taf8	and	 Taf10	 to	 the	 5-Taf	 TFIID	 core	 results	 in	 the	 exposure	 of	 surfaces	 that	 result	 in	aggregation	if	the	appropriate	TFIID	subunit	is	not	available	to	bind	them.		Alternatively,	it	is	possible	that	Taf10	mediates	the	association	of	the	5-Taf	TFIID	core	with	the	Taf8-Taf10	subcomplex,	 and	 as	 a	 result,	 in	 the	 absence	 of	 Taf2,	 Taf8	 facilitates	 protein	 aggregation.		Considering	full	length	Taf2	could	not	be	efficiently	expressed	in	Sf9	cells,	this	hypothesis	could	not	be	tested,	at	least	within	an	Sf9	co-expression	paradigm.	The	 other	 method	 I	 employed	 to	 generate	 recombinant	 TFIID	 was	 through	simultaneous	 overexpression	 of	 every	 TFIID	 subunit	 in	 yeast	 by	 Gal	 induction.	 	 This	method	was	exceptionally	 tantalizing	because	 I	had	demonstrated	 that	 I	 could	massively	overexpress	and	purify	Taf2	 in	 this	manner	(Figure	2.2b,c,e).	 In	addition,	 the	Burgers	 lab	utilized	this	approach	to	co-express	and	purify	the	5-subunit	replication	factor	C	complex	(Gerik	 et	 al.,	 1997).	 	 Even	 though	 the	 15-subunit	 TFIID	 complex	 is	 significantly	 more	complicated,	in	theory	overexpression	of	every	TFIID	subunit	in	yeast	should	be	possible.			
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I	 successfully	 designed,	 constructed	 and	 implemented	 a	 multi-ORF	overexpression	 system	 with	 significant	 success.	 	 The	 dual	 ORF	 expression	 cassettes	dramatically	overexpressed	all	TFIID	subunits	tested	(Figure	2.5).		In	addition,	I	was	able	to	transform	 a	 single	 strain	 with	 multiple	 co-expression	 plasmids,	 each	 of	 which	 drove	overexpression	 of	 the	 encoded	 subunits	 in	 the	 same	 strain.	 	 As	 a	 result,	 this	 system	 can	massively	overexpress	up	to	6	individual	TFIID	subunits	all	at	once.		Attempts	to	massively	overexpress	 all	 of	 the	 TFIID	 subunits	 in	 the	 same	 strain	 at	 the	 same	 time	 were	 not	successful	for	two	reasons	(Figure	2.7).		First,	Taf2	was	not	overexpressed	when	all	of	the	TFIID	subunits	were	expressed	at	the	same	time.		Second,	as	the	number	of	TFIID	subunit	ORFs	 included	 in	 a	 single	 overexpression	 vector	 increased,	 the	 total	 amount	 of	 protein	produced	 decreased.	 	 Even	 if	 Taf2	 were	 overexpressed	 to	 similar	 levels	 of	 the	 other	proteins,	without	dramatic	overexpression,	the	utility	of	this	approach	is	diminished.		Despite	being	unable	to	reconstitute	TFIID	in	Sf9	yeast	cells	through	concurrent	overexpression	and	purification,	the	overexpression	systems	described	in	this	chapter	still	have	the	potential	for	TFIID	reconstitution.		Instead	of	trying	to	reconstitute	TFIID	all	at	the	same	time,	Taf	subcomplexes	could	be	used	to	reconstitute	 the	complex	 in	vitro.	 	Sf9	and	(likely)	yeast	cells	readily	express	the	5-Taf	TFIID	core	complex.	 	In	addition,	I	am	able	to	overexpress	 full-length	 versions	 of	 every	 additional	 TFIID	 subunit	 in	 yeast.	 	 By	 iterative	overexpression	 and	 pull-down,	 it	 is	 likely	 that	 I	would	 be	 able	 to	 identify	 additional	 Taf	subcomplexes	 that	 could	 be	 mixed	 with	 the	 5-Taf	 TFIID	 core	 resulting	 in	 recombinant	TFIID.	 	 This	method	was	 employed	by	 the	Berger,	Tora	 and	Schultz	 labs	 to	 form	a	8-Taf	complex	composed	of	Tafs	2,	4,	5,	6,	8,	9,	10	and	12	(Trowitzsch	et	al.,	2015).		The	first	such	complex	I	would	attempt	to	reconstitute	is	a	Taf2,	Taf8,	Taf10	and	Taf14	complex.		In	yeast,	
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there	is	evidence	that	Taf2,	Taf8	and	Taf14	form	a	subcomplex	(Papai	et	al.,	2009;	Singh	et	al.,	 2004).	 	 In	 addition,	 the	 yeast	 Taf8	 and	 Taf10	 histone	 fold	 domains	 directly	 interact	(Gangloff	 et	 al.,	 2001b).	 	 Therefore,	 it	 is	 likely	 that	 through	 co-expression	 of	 all	 four	subunits,	I	would	be	able	to	purify	this	subcomplex	in	a	soluble	form.		Similar	approaches	have	been	 successful	 in	 reconstituting	 the	modules	of	 the	Mediator	 co-activator	 complex	(Baumli	et	al.,	2005;	Imasaki	et	al.,	2011;	Koschubs	et	al.,	2010,	2009,	Larivière	et	al.,	2012,	2008,	 2006;	 Takagi	 et	 al.,	 2006).	 	 In	 fact,	 the	 Cramer	 laboratory	 has	 reconstituted	 a	 15-subunit	Mediator	 complex	 that	 is	 active	 for	 in	vitro	 transcription	 assays	 (Plaschka	 et	 al.,	2015).	 	 Alternatively,	 considering	 I	 am	 able	 to	 overexpress	 all	 of	 the	 TFIID	 subunits	 in	different	 yeast	 strains,	 it	 may	 be	 possible	 to	 mix	 lysates	 containing	 massively	overexpressed	 TFIID	 subunits,	 allow	 TFIID	 to	 form	 in	 the	 extract	 and	 then	 purify	 the	complex.	 	 I	 am	 hopeful	 that	 through	 persistence,	 reconstitution	 of	 TFIID	 using	 the	methodology	developed	herein	is	possible.	When	 I	 was	 unable	 to	 produce	 recombinant	 TFIID	 through	 overexpression	techniques,	I	hypothesized	that	if	I	could	optimize	the	Taf1-TAP	TFIID	purification	protocol,	I	 could	 at	 least	make	 strides	 in	making	 TFIID	more	 accessible	 to	 scientists	 interested	 in	transcription	 initiation	mechanism.	 	 The	 TAP	 tag	 purification	 procedure	 is	 widely	 used,	having	been	cited	over	900	times	 in	PubMed	(Rigaut	et	al.,	1999).	 	Our	 lab	had	preferred	not	to	use	the	TAP-tag	protocol	because	the	quality	of	TFIID	was	not	as	high	compared	to	TFIID	 purified	 by	 our	 anti-HA	 immunopurification	 protocol.	 	 After	 examining	 old	unpublished	 data	 from	 our	 laboratory,	 I	 surmised	 that	 I	 could	 improve	 the	 TAP-tag	purification	 protocol,	 with	 regard	 to	 TFIID,	 by	 eliminating	 the	 calmodulin	 sepharose	binding	 step.	 	By	 removing	 this	 step,	 I	was	able	 to	 eliminate	 the	dissociation	of	 subunits	
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Taf2,	Taf8	and	Taf14	our	lab	had	observed	when	purifying	TFIID	by	TAP	tag	(Figure	2.8).		This	alternative,	 two-step	TFIID	purification	protocol	does	effectively	purify	TFIID,	albeit	not	to	the	same	purity	achieved	by	our	standard	anti-HA	immunopurification.		In	addition,	the	yield	is	not	as	robust	and	the	amount	of	IgG	sepharose	required	for	purification	can	be	quite	 expensive,	 even	 if	 the	 IgG	 sepharose	 is	 generated	 in	 the	 laboratory	 rather	 than	purchased	commercially.	 	Thus,	 in	order	for	this	protocol	to	be	an	improvement	over	our	current	anti-HA	immunopurification	protocol,	 the	protocol	must	be	optimized	to	 increase	yield	and	purity.		 	 I	believe	the	Taf1-TAP	protocol	can	be	improved	in	the	following	ways.	 	First,	I	never	optimized	cell	lysis	conditions	for	the	Taf1-TAP	protocol.		The	lysis	buffer	I	used	for	the	TAP	purification	procedure	was	dramatically	different	 than	the	protocol	used	 for	our	standard	HA1-Taf1	TFIID	purification	protocol.		The	primary	difference	between	these	two	buffers	is	salt	concentration.		The	salt	concentration	is	considerably	higher	in	the	HA1-Taf1	TFIID	purification	protocol,	which	may	 lead	 to	 increased	TFIID	extraction	 from	 the	 cells.		Second,	 the	 HA1-Taf1	 TFIID	 purification	 protocol	 includes	 an	 ammonium	 sulfate	precipitation	 step	 that	 concentrates	 the	 protein	 up	 to	 5-fold.	 	 It	 is	 possible	 that	 by	performing	 this	 step,	 I	 could	use	a	 smaller	volume	of	beads	 to	 capture	as	much	TFIID	as	possible.		This	would	reduce	the	cost	and	technical	difficulty	of	the	purification	and	make	it	more	accessible	to	other	researchers.	 	Third,	the	BioRex70	ion	exchange	chromatography	step	is	exceptionally	good	at	depleting	TFIID	from	yeast	extract	and	results	in	a	roughly	10-fold	purification	of	TFIID	(Poon	and	Weil,	1993).		Thus,	it	may	be	prudent	to	pre-fractionate	the	yeast	extract	on	the	BioRex70	column	prior	to	IgG	sepharose	binding.	 	This	may	both	increase	yield	as	well	as	improve	the	purity	of	the	final	preparation.	 	Ultimately,	I	believe	
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that	the	Taf1-TAP	TFIID	protocol	is	a	viable	method	for	the	purification	of	TFIID	and,	with	minor	modifications,	may	become	the	dominant	and	reliable	method	used	by	laboratories	wishing	to	study	the	biochemistry	of	this	important	complex.																					
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CHAPTER	III		THE	C-TERMINUS	OF	TAF2	MEDIATES	STABLE	ASSOCIATION	OF	TAF14	INTO	THE	YEAST	TFIID	COMPLEX		Considerations	to	Deciphering	the	Role	Taf2	Plays	in	TFIID-dependent	Transcription	Regulation	As	 described	 in	 Chapter	 I,	 while	 significant	 similarities	 exist	 between	 yeast	 and	metazoan	 TFIID,	 yeast	 display	 some	 significant	 differences	 to	 its	metazoan	 counterparts	with	regard	to	TFIID	structure	and	promoter	architecture.		First,	the	metazoan	Taf1	double	bromodomain	 and	 the	Taf3	 plant	 homeobox	 domain	 (PHD)	 finger,	 domains	 that	 directly	interact	 with	 modified	 chromatin,	 are	 missing	 from	 the	 yeast	 homologs	 (Gangloff	 et	 al.,	2001b;	Poon	et	al.,	1995;	Reese	et	al.,	1994).	 	 Second,	yeast	TFIID	contains	an	additional	subunit,	Taf14	(Henry	et	al.,	1994;	Sanders	et	al.,	2002a).		Third,	in	metazoan	TFIID,	Tafs	1	and	 2	 bind	 to	 the	 initiator	 (INR)	 core	 promoter	 element	 (Chalkley	 and	 Verrijzer,	 1999;	Verrijzer	et	al.,	1995,	1994)	and	Tafs	6	and	9	bind	 to	 the	downstream	promoter	element	(DPE)	 (Burke	 and	 Kadonaga,	 1997).	 	 Neither	 the	 INR	 nor	 the	 DPE	 have	 been	unambiguously	identified	in	the	yeast	system	(Hahn	and	Young,	2011).		Despite	 these	 differences,	 yeast	 have	 evolved	 mechanisms	 to	 achieve	 similar	 TFIID	promoter-DNA	binding	 and	 chromatin	 recognition	 activities.	 	 Instead	 of	 having	 a	 double	bromodomain	 covalently	 attached	 to	 Taf1,	 the	 double	 bromodomain	 protein	 Bdf1	 is	 a	TFIID	 associated	 protein	 (Ladurner	 et	 al.,	 2003;	 Matangkasombut	 et	 al.,	 2000)	 and	 its	occupancy	 in	 genome-wide	 analyses	 correlates	 with	 Taf1	 occupancy	 (Rhee	 and	 Pugh,	
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2012).	 While	 not	 conserved	 as	 a	 TFIID	 subunit,	 Taf14	 is	 conserved	 through	 its	 YEATS	domain	(Schulze	et	al.,	2009).	 	This	domain,	which	is	also	present	in	the	super	elongation	complex	 proteins	AF-9	 and	 ENL	 (Cairns	 et	 al.,	 1996;	 Lin	 et	 al.,	 2010;	Welch	 and	Drubin,	1994),	 	was	recently	shown	to	bind	to	acetylated	and	crotonylated	lysine	9	of	histone	H3	(H3K9)	 (Andrews	 et	 al.,	 2016;	 Shanle	 et	 al.,	 2015),	 marks	 associated	 with	 active	transcription	 (Bonnet	 et	 al.,	 2014;	 Li	 et	 al.,	 2016).	 	 In	 regards	 to	 S.	 cereivisae	 (Sc)	 TFIID	promoter	 recognition,	 footprinting	 analyses	 have	 demonstrated	 that	 both	metazoan	 and	ScTFIID	display	extended	footprints	with	contacts	spanning	nearly	100bp	(Cianfrocco	et	al.,	2013;	 Oelgeschläger	 et	 al.,	 1996;	 Sanders	 et	 al.,	 2002a).	 	 ScTFIID	 histone	 fold	 pairs	Taf4/Taf12	and	Taf6/Taf9	also	display	in	vitro	DNA	binding	activities,	although	binding	has	not	been	shown	to	be	sequence	specific	(Shao	et	al.,	2005).		In	addition,	structural	analyses	with	 ScTFIID-TFIIA-activator	 in	 complex	with	 enhancer/promoter-DNA	positions	DNA	 in	contact	with	the	C-terminus	of	Taf2	(Papai	et	al.,	2010).		Taken	together,	these	observations	demonstrate	that	TFIID	promoter-DNA	and	chromatin	interaction	activities	are	maintained	in	the	yeast	system.		Yet,	how	these	activities	contribute	to	TFIID	transcriptional	activation	function	remains	undefined.	In	addition	to	its	role	in	TFIID,	Taf14	is	also	a	subunit	or	associated	protein	of	six	other	transcription-related	complexes	(Cairns	et	al.,	1996;	Henry	et	al.,	1994;	Kabani	et	al.,	2005;	Sanders	et	al.,	2002b).		While	Tafs	1	through	13	are	essential	for	life	(Klebanow	et	al.,	1997,	1996;	Moqtaderi	et	al.,	1996;	Poon	et	al.,	1995;	Ray	et	al.,	1991;	Sanders	and	Weil,	2000),	
taf14	null	cells	display	temperature	sensitive	(Ts)	growth	and	defects	in	expression	of	GAL	and	DNA	repair	genes	(Cairns	et	al.,	1996;	Shanle	et	al.,	2015).	Still,	how	Taf14	contributes	to	 TFIID	 structure	 or	 function	 remains	 poorly	 understood	 because	 mutations	 in	 TAF14	
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could	 impact	 the	 function	 of	 all	 of	 the	 transcription	 related	 complexes	 with	 which	 it	associates.	 	 To	 begin	 to	 understand	TAF14	 function	 in	 vivo,	 we	 need	 true	 separation-of-function	 variants	 that	 can	 specifically	 dissociate	 Taf14	 from	 a	 single	 complex	 without	disrupting	its	ability	to	perform	its	other	functions.			We,	as	a	field,	have	minimal	understanding	of	Taf2	function,	despite	the	fact	that	it	was	the	first	yeast	Taf	discovered	(Poon	et	al.,	1995;	Ray	et	al.,	1991;	Verrijzer	et	al.,	1994).		Our	lab	was	 the	 first	 to	 discover	 the	 location	 of	 Taf2	within	 the	 TFIID	 complex	 (Papai	 et	 al.,	2009).		In	addition	to	its	INR	binding	function,	metazoan	Taf2	directly	interacts	with	Taf8	and	this	 interaction	is	critical	 for	Taf2	to	localize	to	the	nucleus	(Trowitzsch	et	al.,	2015).	For	 RNA	 polymerase	 II	 to	 clear	 the	 promoter	 and	 begin	 productive	 elongation,	 TFIID	appears	 to	 isomerize	 in	 a	 Taf2-dependent	 manner	 to	 release	 TFIID	 from	 downstream	promoter	sequences	(Yakovchuk	et	al.,	2010;	Zhang	et	al.,	2015).	However,	none	of	 these	biochemical	 activities	 have	 been	 genetically	 dissected.	 	 In	 fact,	 Taf2	 has	 never	 been	subjected	 to	 structure-function	 analysis	 in	 any	 system.	 	 During	 the	 execution	 of	 this	dissertation	project,	a	cryoEM	structure	of	human	TFIID	allowed	Louder	et	al.	to	describe	the	structure	of	Taf2	in	molecular	detail	(Louder	et	al.,	2016).		But,	this	structure	was	not	interrogated	 genetically	 or	biochemically.	 Consequently,	we	have	minimal	understanding	of	how	Taf2	contributes	to	TFIID-dependent	transcription	in	vivo.	In	this	chapter,	I	describe	a	systematic	molecular	genetic	dissection	of	Taf2	to	address	this	gap	in	knowledge.	 	These	analyses	identified	a	genetic	 interaction	between	TAF2	and	
TAF14.	 	 I	demonstrate	that	these	two	subunits	directly	interact	and	define	the	interaction	domains	 in	 both	 subunits.	 	 Despite	 Taf14	 being	 present	 in	 multiple	 copies	 per	 TFIID	subunit,	mutation	in	Taf2	can	completely	disrupt	the	ability	of	Taf14	to	associate	with	the	
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TFIID	complex.		Taf14-less	TFIID	containing	cells	display	defects	in	growth	and	transcript	abundance	for	the	highly	transcribed	TFIID-dominated	ribosomal	protein-encoding	genes.		Furthermore,	my	data	indicate	that	the	Taf14	YEATS	domain	contributes	to	TFIID	function.		 METHODS	
	 Yeast	Expression	Vector	Construction	and	Cell	Manipulations	All	 general	 cloning	 techniques	 (i.e.	 ligations,	 transformation,	 PCR	 with	proofreading	 polymerases	 and	 addition	 of	 restriction	 ends	 by	 PCR)	 were	 performed	 as	described	in	Chapter	II	Methods.	 	Site-directed	mutants	were	generated	by	PCR	using	the	gene	 sequence	 overlap	 extension	 method	 (Ho	 et	 al.,	 1989)	 and	 ligated	 into	 Taf2	 using	either	 the	 engineered	 5’-SpeI	 or	 3’	 SalI	 restriction	 sites	 or	 the	 natural	 restriction	 sites	located	within	the	body	of	the	TAF2	coding	sequence	(EcoRI,	EcoRV,	BamHI,	XhoI,	HindIII).		The	site-directed	mutants	were	cloned	into	the	p415ADH	expression	plasmid	(Mumberg	et	al.,	 1995)	 containing	 an	 N-terminal	 HA3-SV40	 Large	 T	 antigen	 nuclear	 localization	sequence	 (NLS)-tag	 (HA3NLS).	 Each	 TFIID	 subunit	 ORF	 (DNA	 fragments	 described	 in	Chapter	II	Methods)	was	cloned	into	p413GPD	MCS	using	compatible	restriction	ends.		For	all	DNA	fragments	containing	a	3’	KpnI	restriction	end,	the	fragment	overhang	was	filled	in	with	Klenow	fragment	(NEB)	and	blunt-end	 ligated	 into	 the	EcoRV	restriction	site	within	the	MCS.	 	 Furthermore,	 a	 5’XbaI-ClaI-FLAG2-NLS-SpeI-3’	 fragment	 was	 cloned	 5’	 and	 in-frame	of	 the	TAF14	ORF	 in	p413GPD	TAF14	 and	all	TAF14	 site-directed	mutant	variants.		The	TAF2-TAF14	chimeras	were	generated	by	PCR-based	sequence	overlap	extension	(Ho	et	al.,	1989).	 	The	chimeras	were	engineered	to	contain	three	glycine	residues	separating	
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the	TAF2	 sequence	 from	 the	TAF14	 sequence.	 	 The	 fragment	was	 designed	 as	 a	 5’-SpeI-
TAF2-Gly3-TAF14-SalI-3’	 fragment	 and	 ligated	 into	 the	 corresponding	 restriction	 sites	within	p415ADH	HA3NLS	plasmid.	All	constructs	were	sequence	verified.			Cell	 growth	 and	 transformation	 protocols	 were	 performed	 as	 described	 in	Chapter	II	Methods.	 	For	plasmid	shuffle	assays,	cells	were	grown	on	SC	-Leu,	His	or	both	including	0.1%	5-fluoroorotic	(5-FOA)	acid	(Boeke	et	al.,	1987).	All	 strains	 generated	 for	 this	 chapter	were	 derivatives	 of	 BY4741.	 	 A	 taf2	 null	strain	 (JFTAF2del)	 was	 generated	 by	 co-transforming	 BY4741	 with	 a	 p416ADH	 TAF2	covering	 plasmid	 and	 a	 linearized	 TAF2	 deletion	 cassette.	 The	 TAF2	 deletion	 cassette	replaced	-233	to	+4224	relative	to	the	start	codon	of	the	TAF2	ORF	with	the	hygromycin	B	resistance	cassette	 from	pAG32	(Goldstein	and	McCusker,	1999).	 	Co-transformants	were	sequentially	plated	on	SC-Ura	followed	by	replica	plating	to	YPD	+	300mg/mL	hygromycin	B.	 	 	 Hygromycin	 B+	 and	 Ura+	 clonal	 isolates	 were	 confirmed	 as	 taf2	 null	 using	 plasmid	shuffle	 genetic	 complementation.	 An	 HA1-TAF1	 strain	 (JFHATAF1)	 was	 generated	 using	ends-in	integration	of	a	HA1-TAF1	N-terminal	tagging	cassette	into	the	TAF1	 locus	using	a	similar	 strategy	 described	 previously	 for	Mot1	 (Poon	 et	 al.,	 1994).	 	 The	 resulting	 strain	harbors	 a	 G418R	 cassette	 and	 an	 N-terminal	 MYPYDVPDYAGVE	 tag	 (HA	 epitope	underlined)	 at	 the	 TAF1	 chromosomal	 locus	 (additional	 details	 upon	 request).	JFHAT1T2delC	was	generated	by	applying	PCR-based	homologous	recombination	methods	to	TAF2	 deleting	 sequences	 coding	 for	 amino	acids	1261-1407	at	 its	 chromosomal	 locus.	The	Taf2-ΔC	deletion	was	confirmed	by	PCR	and	immunoblotting.			
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I-TASSER	Structural	Prediction	and	TAF2	Site-Directed	Mutagenesis	Primary	 amino	 acid	 sequences	 for	 Saccharomyces	 cerevisiae	 (yeast)	 Taf2,	
Drosophila	melanogaster	(fly)	Taf2	and	Homo	sapiens	(human)	Taf2	were	submitted	to	the	I-TASSER	server	for	3-D	structure	prediction	(Yang	and	Zhang,	2015).		Resulting	3D	models	of	yeast,	fly	and	human	were	imported	into	Pymol,	displayed	in	cartoon	format	and	colored	based	on	secondary	structure.	The	first	of	five	models	generated	for	yeast	Taf2	was	used	to	define	solvent	exposed	residues.		 To	assess	amino	acid	conservation,	yeast,	fly	and	human	Taf2	primary	sequences	were	 aligned	 in	MacVector	 using	 ClustalW.	 	 Fifty-eight	mutants	were	 designed	 based	 on	solvent	accessibility	and	proximity	to	amino	acids	that	are	either	similar	or	identical	among	yeast,	fly	and	human	Taf2.		Twenty-nine	additional	mutants	were	designed	based	on	amino	acids	predicted	to	be	solvent	inaccessible	but	highly	conserved	among	yeast,	fly	and	human	Taf2.		All	mutations	were	arbitrarily	limited	to	a	maximum	of	8	contiguous	amino	acids.		A	list	of	the	mutants	is	provided	(Table	3.3).		 Plasmid	Shuffle	and	Overexpression	Suppression	All	 TAF2	 site-directed	 mutants,	 deletion	 mutants	 and	 TAF2-TAF14	 chimeras	were	 expressed	 from	 p415ADH	 with	 an	 N-terminal	 HA3NLS	 tag.	 	 For	 plasmid	 shuffle	analyses,	JFTAF2del	was	transformed	with	an	empty	p415ADH	plasmid,	a	p415ADH	TAF2	plasmid,	a	p415ADH	HA3NLS	TAF2	plasmid	or	a	p415ADH	HA3NLS	TAF2	mutant	plasmid	and	transformants	were	grown	on	SC-Leu	plates.	 	Leu+	colonies	were	grown	to	saturation	in	SC-Leu	at	30o,	serially	diluted	1/4	in	sterile	ddH2O,	spotted	to	SC-Leu	or	SC-Leu	+	5-FOA	15cm	plates	using	a	pinning	tool	and	grown	at	various	temperatures	(20o,	25o,	30o,	34o	and	
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37o)	to	assess	temperature	sensitive	growth.		Duration	of	growth	ranged	from	48	hours	to	96	hours,	as	indicated.			For	overexpression	suppression	screening	of	all	TFIID	subunits,	plasmid	shuffle	analyses	were	performed	essentially	as	above	with	the	following	exception.		JFTAF2del	was	co-transformed	 with	 LEU2-marked	 TAF2	plasmids	 and	 an	 empty	 p413GPD	 or	 p413GPD	containing	 the	ORF	 for	 each	 of	 the	 TFIID	 subunits	 and	 grown	 on	 SC-His,Leu	 plates.	 	 For	each	LEU2-marked	TAF2	and	p413GPD	TFIID	subunit	combination,	two	His+,Leu+	colonies	were	spotted	undiluted	to	SC-His,-Leu	or	SC-His,-Leu	+	5-FOA.		TFIID	subunits	that	scored	positive	 for	 overexpression	 suppression	 displayed	 uniformly	 improved	 growth	 for	 both	colonies	tested.				 Immunoblotting	and	Co-immunoprecipitation	For	 steady-state	 protein	 immunoblotting,	 protein	 was	 extracted	 from	 approx.	1.2x107	 cells	 of	 early	 to	 mid-log	 grown	 culture	 using	 sodium	 hydroxide	 based	 lysis	(Kushnirov,	 2000).	 	 For	 co-immunoprecipitations,	 JFTAF2del	 strains	 were	 grown	 as	pseudodiploids	 containing	both	 a	wild-type	URA3-marked	TAF2	 gene	 as	well	 as	 a	WT	or	mutant	LEU2-marked	TAF2	gene.		In	these	analyses,	50mL	of	yeast	cells	were	grown	at	30o	to	early	to	mid-log	phase	(approx.	2.4-3.6	x	107	cells/mL),	harvested	by	centrifugation	and	lysed	in	Co-IP	buffer	(20mM	HEPES-KOH	pH	7.9,	200mM	potassium	acetate,	10%	glycerol,	0.1%	 NP40	 substitute	 (Sigma-Aldrich),	 1mM	 DTT	 +	 1X	 protease	 inhibitors)	 using	 glass	bead	beating.	 	Soluble	protein	was	separated	from	insoluble	material	by	centrifugation	at	14k	rpm	for	15min	in	table-top	mini-centrifuge.	 	Protein	concentrations	were	determined	using	a	BSA	standard	curve	with	Bio-Rad	Protein	Assay.		Two	milligrams	of	soluble	protein	
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extract	were	incubated	with	2.5µg	of	anti-HA	12CA5	mAb	and	50ng/µL	ethidium	bromide	in	a	total	volume	of	412µL	at	4o	for	2	hours.		Immunecomplexes	were	captured	with	10µL	of	 proteinA	 sepharose	 beads	 (Life	 Technologies)	 for	 30min	with	mixing	 at	 4o.	 	 Captured	protein	complexes	were	washed	two	times	with	1mL	ice-cold	Co-IP	buffer	and	eluted	with	2x	LDS-NuPAGE	Sample	Buffer	(Life	Technologies)	and	heating	at	75o	for	10min.		Proteins	for	both	steady-state	immunoblotting	and	co-immunoprecipations	were	separated	via	SDS-PAGE	 and	 processed	 for	 immunoblotting	 as	 described	 in	 Chapter	 II	Methods.	 	 Anti-actin	(mAb8224)	was	procured	from	Abcam.		Horse	anti-mouse	IgG	HRP	conjugate	was	procured	from	Cell	Signaling.		For	immunoblot	loading	controls,	the	blot	was	stained	with	Ponceau-S	(0.5%	w/v	 1%	 v/v	 glacial	 acetic	 acid)	 following	 the	 electro-transfer	 and	 destained	with	ddH2O	prior	to	imaging.		 Protein	Overexpression	and	Purification	All	His6-tagged	proteins	were	expressed	from	pET28a	(Novagen).		All	His6-GST-tagged	proteins	were	plasmid	generated	from	pBG101	in	Rosetta2	(DE3)	E.	coli	(Novagen).		His6-Taf14	 and	 Taf2	 fragments	 were	 N-terminally	 tagged	 with	MGSSHHHHHHSSGLVPAGSHMAS	 (bold	 indicating	 hexa-histidine	 tag).	 E.	 coli	 expression	strains	were	grown	and	induced	with	IPTG	as	described	in	Chapter	II	Methods.		His6-Taf14,	His6-GST,	His6-GST-Taf14	aa	1-244,	His6-GST-Taf14	aa	1-123	and	His6-GST-Taf14	aa	124-244	were	purified	as	described	in	Chapter	II	Methods.	 	Taf2	fragments	were	purified	in	a	similar	fashion	with	modifications	for	denaturing	purification.	Approximately	200mg	of	E.	
coli	pellet	was	lysed	in	6mL	of	denaturing	lysis	buffer	(20mM	Tris-HCl	pH	7.9,	1x	PBS,	6M	guanidinium	HCl,	10mM	imidazole).		Denatured	cell	extract	was	mixed	with	200µL	of	Ni2+-
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NTA	agarose	for	2	hours	at	20o.	 	Ni2+-NTA	agarose	and	bound	proteins	were	washed	with	>10	column	volumes	of	 freshly	made	denaturing	wash	buffer	 (20mM	Tris-HCl	pH	7.9,	1x	PBS,	 7M	 urea,	 10mM	 imidazole).	 	 His6-Taf2	 fragments	 were	 eluted	 with	 freshly	 made	denaturing	 elution	 buffer	 (denaturing	 wash	 buffer	 except	 200mM	 imidazole).	 	 For	 all	purified	proteins,	protein	concentration	was	determined	via	in-gel	quantitation	using	a	BSA	standard	curve.			MBP,	 MBP-Taf2	 and	 MBP-Taf2ΔC	 were	 expressed	 in	 S.	 cerevisiae	 using	 Gal	induction	and	purified	as	described	in	Chapter	II	Methods	with	the	exception	that	MBP	was	not	subjected	to	MonoQ	ion	exchange	chromatography.				 Taf2/Taf14	Co-expression	Solubilization	Analyses	For	 Taf2	 and	 Taf14	 co-expression,	 a	 bi-cistronic	 expression	 plasmid	 was	generated	 by	 cloning	 in	 order	 either	 full	 length	 Taf14	 or	 Taf14	 aa	 164-244,	 an	 internal	ribosome	binding	sequence	(RBS)	(Lutzmann	et	al.,	2002)	and	Taf2	C-terminal	 fragments	(aa	1301-1407)	into	pET28a.	Taf14	full	length	and	aa	164-244	fragments	were	engineered	through	 PCR	 to	 contain	 5’	 NcoI	 and	 3’	 XhoI	 restriction	 ends.	 	 The	 internal	 RBS	 double	stranded	DNA	 insert	was	 generated	 by	 annealing	 complementary	 oligos,	 as	 described	 in	Chapter	 II	 Methods.	 	 The	 RBS	 insert	 included	 a	 5’	 XhoI	 compatible	 end	 and	 3’	 SpeI	compatible	end.		The	Taf2	C-terminal	fragments	were	generated	by	PCR	and	engineered	to	contain	a	5’	SpeI	compatible	end,	no	stop	codon	and	a	3’	HindIII	compatible	end.		The	final	plasmid	was	generated	by	performing	a	4-piece	ligation	containing	pET28a	digested	with	NcoI-HF	 and	 HindIII-HF	 restriction	 endonucleases	 (NEB)	 and	 the	 three	 inserts	 (5’-NcoI-
TAF14	(full-length	or	aa	164-244)-XhoI-3’	+	5’-XhoI-internal	RBS-SpeI-3’	+	5’	SpeI-TAF2	aa	
	 106	
1301-1407-(No	 STOP)-3’	 HindIII).	 	 For	 all	 cloning	 of	 all	 additional	 TAF2	 C-terminal	fragments,	 the	 resulting	 pET28a	 TAF14-TAF2	 co-expression	 plasmid	 (either	 TAF14	 full	length	or	aa164-244)	was	digested	with	SpeI-HF	and	HindIII-HF	restriction	endonucleases	to	 dropout	 the	 TAF2	 aa1301-1407	 fragment.	 	 This	 fragment	 was	 subsequently	 replaced	with	a	 family	of	TAF2	C-terminal	 fragment	N-	and	C-terminal	 truncation	variants.	 	 	 	 	The	removal	of	the	stop	codon	made	the	coding	sequence	of	the	TAF2	C-terminal	fragments	in-frame	 with	 the	 His6-tag	 (KLAAALEHHHHHH(STOP))	 encoded	 in	 the	 pET28a	 backbone.		Taf2/Taf14	co-expression	solubilization	assays	were	performed	by	growing	6mL	of	E.	coli	expression	 strains	 at	 37o	shaking	 at	 250rpm	 to	 an	 OD600	 =	 0.6-0.9,	 shifted	 to	 30o	 and	induced	 for	 2	 hours	 with	 1mM	 IPTG.	 	 One-sixth	 of	 the	 cell	 pellet	 was	 lysed	 in	 E.	 coli	denaturing	wash	buffer	 for	 total	 cellular	 protein.	 	 The	 remaining	 cell	 pellet	was	 lysed	 in	1mL	E.	coli	lysis	buffer	with	lysozyme	as	described	above.		Soluble	protein	was	mixed	with	7.5µL	of	Q-Sepharose	to	remove	nucleic	acids	for	30min	at	4o.		The	flow-through	was	mixed	with	20µL	of	Ni2+-NTA	agarose	 for	2	hours	 at	 4o.	 	 Bound	proteins	were	washed	2X	with	500µL	of	E.	coli	 lysis	buffer	and	eluted	with	200µL	of	E.	coli	elution	buffer.	 	Total	cellular	protein	 and	 purified	 Taf2/Taf14	 complexes	 were	 separated	 via	 SDS-PAGE	 as	 described	above	 except	 run	 with	 1X	 MES	 buffer	 (Life	 Technologies)	 to	 separate	 smaller	 protein	species.		The	proteins	were	visualized	using	coomassie	brilliant	blue.		 TFIID	Purification	HA1-Taf1	 TFIID,	HA1-Taf1	 Taf2-ΔC	TFIID	 and	Taf1-Tap	TFIID	were	 purified	 as	described	in	Chapter	II	Methods.	 	To	determine	relative	subunit	stoichiometry	of	purified	HA1-Taf1	TFIID	and	HA1-Taf1	Taf2-ΔC	TFIID,	the	peak	fractions	of	each	TFIID	variant	were	
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analyzed	by	SDS-PAGE	and	SyproRuby	gel	staining.	 	The	gel	was	scanned	using	PharosFX	scanner	 (Bio-Rad),	 band	peak	 intensity	was	 calculated	 in	QuantityOne	 (Bio-Rad)	 and	 the	values	were	graphed	in	GraphPad	Prism.		Relative	subunit	stoichiometry	between	the	HA1-Taf1	TFIID	and	 the	HA1-Taf1	Taf2-ΔC	TFIID	was	calculated	based	on	calculating	 the	area	under	 the	 curve	 using	 ImageJ	 software	 and	 normalizing	 to	 the	 Taf6	 signal	 within	 each	preparation.	
	 Far-western	Blotting			0.5pmol	of	Taf1-TAP	TFIID,	5pmol	purified	MBP,	1pmol	MBP-Taf2	and	between	1	and	5pmol	Taf2	truncation	variants	were	subjected	to	Far-western	analysis	with	a	His6-Taf14	 overlay	 essentially	 as	 described	 (Garbett	 et	 al.,	 2007)	 with	 the	 following	modifications.		For	all	analyses,	proteins	samples	were	subjected	to	SDS-PAGE	in	triplicate:		one	gel	 for	SyproRuby	gel	staining,	one	mock	overlay	control	and	one	His6-Taf14	binding	assay.	 	 During	 the	 blotting	 process,	 all	 binding	 steps	 and	 washes	 were	 performed	 in	renaturation	 buffer:	 	 20mM	 HEPES-KOH	 pH	 7.6,	 75mM	 potassium	 chloride,	 2.5mM	magnesium	chloride,	0.25mM	EDTA	and	0.05%	Triton	X-100	with	1mM	DTT	freshly	added.	The	overlay	was	performed	with	7nM	His6-Taf14	with	1%	BSA	as	a	non-specific	competitor	or	with	just	the	BSA	competitor	for	the	mock	control.		Bound	His6-Taf14	was	detected	using	a	standard	immunoblotting	protocol	(primary	antibody:	antigen	affinity	purified	anti-Taf14	polyclonal	 rabbit	 IgG	 at	 a	 concentration	 of	 0.1ng/mL	 and	 secondary	 antibody:	 goat-anti-rabbit	 Fc-HRP	 used	 per	 manufacturers	 instructions).	 	 Prior	 to	 treatment	 with	 ECL	 and	exposure	to	film,	the	blots	were	washed	once	with	tris-buffered	saline.			
	
	 108	
GST	Pull	Down	Assays		 Typically,	binding	reactions	were	performed	 in	a	 total	volume	of	200mL	in	 the	following	 reaction	 buffer:	 20mM	 HEPES-KOH	 pH	 7.9,	 300mM	 potassium	 acetate,	 10%	glycerol,	 1mM	 DTT,	 0.1%	 NP40	 substitute,	 0.1mg/mL	 BSA.	 MBP-Taf2	 and	 MBP-Taf2-ΔC	GST-pull	downs	were	performed	twice,	either	with	2pmol	His6-GST-Taf14	or	5pmol	His6-GST-Taf14	and	twice	that	amount	with	His6-GST	only	pull-downs.		Between	1pmol	and	32	pmol	of	MBP-Taf2	or	MBP-Taf2-ΔC	were	used	to	generate	dose	response	curves.		For	Taf2	binding	assays,	16pmol	His6-GST,	8pmol	His6-GST-Taf14,	12pmol	His6-GST-Taf14	aa	1-123	and	12pmol	His6-GST-Taf14	aa	124-244	were	used.		These	proteins	were	mixed	with	either	no	 Taf2	 or	 between	 0.78pmol	 and	 6.25pmol	 Taf2.	 	 Binding	 reactions	 were	 allowed	 to	proceed	 at	 20o	 for	 1hour	 followed	 by	 30min	 capture	 at	 20o	 with	 10mL	 1:1	 slurry	 of	glutathione	agarose	Fast-Flow	(GE	Healthcare)	equilibrated	in	reaction	buffer.		Glutathione	agarose	 bound	 complexes	 were	 pelleted	 by	 centrifugation	 and	 the	 supernatant	 was	discarded.		The	pellet	was	washed	with	500mL	binding	buffer	sans	BSA,	pelleted	again	and	the	wash	 buffer	was	 discarded.	 	 Bound	 proteins	were	 eluted	with	 2x	 LDS	 sample	 buffer	with	 100mM	 DTT	 and	 heating	 at	 75o	 for	 10min.	 	 Proteins	 were	 separated	 with	 4-12%	NuPAGE	Bis-Tris	gradient	gels	(Life	Technologies),	run	with	1X	MOPS	running	buffer	and	stained	 with	 SyproRuby	 per	 manufacturers	 instructions.	 	 Proteins	 were	 imaged	 with	PharosFX	Scanner	(Bio-Rad).		 Quantitative	Reverse	Transcription	PCR	(qRT-PCR)	For	all	RNA	analyses,	JFTAF2del	was	used	as	the	parent	strain.		For	temperature	shift	 experiments,	 this	 strain	 was	 co-transformed	 with	 p415ADH-HA3NLS-TAF2	 or	
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p415ADH-HA3NLS-taf2-ts7	 and	 either	 p413GPD	or	 p413GPD-	FLAG2NLS-TAF14.	 	 Leu+His+	colonies	 were	 subjected	 to	 plasmid	 shuffle	 on	 SC-His,Leu	 +	 5-FOA.	 	 For	 each	 co-transformed	 shuffled	 strain,	 two	 independent	 colonies	 were	 grown	 in	 SC-His,Leu	 at	 25o	until	they	reached	a	cell	density	of	~1.2x107	cells/mL	and	then	abruptly	shifted	to	37o	by	adding	an	equal	volume	of	50o	heated	SC-His,-Leu	and	then	grown	at	37o	for	2	hours.		Cells	were	 harvested	 by	 centrifugation	 and	pellets	were	 stored	 at	 -80o.	 	 For	 steady-state	RNA	experiments,	 JFTAF2del	 was	 transformed	 with	 either	 p415ADH-HA3NLS-TAF2	 or	p415ADH-HA3NLS-taf2-DC.	 	Leu+	colonies	were	subjected	to	plasmid	shuffle	by	growth	on	SC-Leu	+	5-FOA.	 	For	each	shuffled	strain,	 four	 independent	colonies	were	grown	 in	YPD	until	the	cells	reached	~2.4x107	cells/mL	and	harvested	by	filtration.		 For	all	samples,	RNA	was	extracted	using	hot	acidic	phenol	as	described	(Schmitt	et	al.,	1990).	Reverse	transcription	was	performed	with	1µg	of	total	RNA	using	Superscript	III	 according	 to	manufacturers	 instructions.	 	 cDNA	was	 generated	 using	 oligo	 dT-16	 and	1pmol	 each	 of	 gene	 specific	 reverse	 primers	 for	 U3,	 RDN58	 and	 SNR6.	 	 The	 primer	sequences	 used	 in	 these	 analyses	 are	 as	 follows:	 (U3-F:	 CAAAAGAGCCACTGAATCCAACT-TGG),	 (U3-R:	 GTACCCACCCATAGAGCCCTATCCCTTC),	 (RDN58-F:	 AACGGATCTCTTGGTTC-TCG),	 (RDN58-R:	 GTGCGTTCAAAGATTCGATG),	 (SNR6-F:	 CGAAGTAACCCTTCGTGGAC),	(SNR6-R:	 TCATCCTTATGCAGGGGAAC)	 (Bonnet	 et	 al.,	 2014),	 (RPS3-F:	 TACGGTGTCG-TCAGATACG),	 (RPS3-R:	 GACCAGAGTGAATCAAGAAACC),	 (RPS5-F:	 GGATGCTTCTTT-GGTTGACTAC),	 (RPS5-R:	 GGACATTGAGCCTTTCTGAATCTC),	 (RPS8A-F:	 AAAGATCCG-CTACCGGTGCCAAG),	 (RPS8A-R:	 TCTTGGAGATACCTTCAGAAGCCC),	 (RPS9B-F:	 CGGT-TTGAAGAACAAGAGA),	 (RPS9B-R:	 GCATTACCTTCGAACAATC),	 (PGK1-F:	 TGCTGCTT-
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TGCCAACCATC),	 	 (PGK1-R:	 GTGACATCCTTACCCAACAATG),	 (PYK1-F:	 CCAACCTCCA-CCACCGAAAC),	(PYK1-R:	GGGCTTCAACATCATCAGTCCA)	(Garbett	et	al.,	2007).		 Quantitative	 PCR	 was	 performed	 using	 Sybr	 Green	 Supermix	 (Bio-Rad)	according	 to	 manufacturers	 instructions.	 	 Samples	 were	 quantified	 using	 the	 relative	standard	curve	method,	normalized	to	U3	and	expressed	as	a	percentage	of	the	average	of	the	HA-TAF2	strain.	 	The	standard	curve	was	generated	by	mixing	equal	amounts	of	RNA	from	 each	 of	 the	 samples	 tested	 prior	 to	 reverse	 transcription.	 	 This	 RNA	mix	was	 used	both	 as	 the	 standard	 curve	 and	 as	 the	 no	 RT	 control.	 	 Three	 values	were	 used	 for	 each	standard	curve	based	on	the	dilution	of	 the	cDNA.	 	For	example,	 if	a	dilution	of	1:50	was	used	 to	measure	 the	experimental	 cDNA	samples,	 then	a	 standard	curve	of	1:5,	1:50	and	1:500	was	used.		The	no	RT	reactions	displayed	either	no	observable	signal	or	required	an	additional	 10	Ct	 values	 above	 the	+RT	 samples	 to	 achieve	measureable	 signal.	 	 Thus,	we	concluded	 that	contaminating	genomic	DNA	was	negligible	 in	 the	samples.	 	The	dilutions	used	for	each	gene	are	as	follows:		1:50	for	RPS3,	RPS5,	RPS8A,	RPS9B,	and	SNR6;	1:1000	for	
PGK1,	 PYK1	 and	 U3;	 and	 1:20,000	 for	 RDN58.	 	 All	 qPCR	 reactions	 were	 performed	 in	triplicate.		Individual	technical	replicates	were	only	discarded	as	outliers	if	Ct	values	were	different	 from	 the	 other	 technical	 replicates	 by	 greater	 than	 a	 full	 Ct	 value	 and	 the	amplification	trace	displayed	apparent	aberrations	in	amplification	efficiency.	
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RESULTS	
	 I-TASSER	Prediction	of	Taf2	Structures	To	 understand	 the	 role	 of	 Taf2	 in	 TFIID	 function,	 I	 initially	 pursued	 classical	approaches	that	have	been	successfully	used	to	identify	TFIID	subunit	functional	domains.	First,	primary	amino	acid	sequences	 from	S.	cerevisiae	(yeast),	H.	sapiens	 (human)	and	D.	
melanogaster	 (fly)	 Taf2	 were	 subjected	 to	 ClustalW	 sequence	 alignment	 to	 identify	“hotspots”	of	amino	acid	sequence	homology	that	we	could	target	for	mutagenesis.		These	analyses	have	been	successfully	applied	to	the	histone	fold	domain	containing	Tafs	as	well	as	the	conserved	TBP	C-terminus	(Gangloff	et	al.,	2001b;	Klebanow	et	al.,	1997,	1996;	Poon	et	al.,	1991;	Sanders	and	Weil,	2000).	 	Yeast	Taf2,	which	encodes	a	1407	aa	protein,	only	displays	 weak	 sequence	 conservation	 with	 human	 (1199	 aa’s)	 and	 fly	 (1221	 aa’s)	 Taf2,	~15%	sequence	identity	and	~32%	sequence	similarity	(Figure	3.1a	and	3.1c).		In	addition,	the	amino	acids	that	are	conserved	do	not	cluster	in	“hotspots”	but	instead	are	distributed	throughout	the	amino	acid	sequence.		Second,	I	performed	systematic	~100	amino	acid	N-terminal,	C-terminal	and	internal	deletion	mutagenesis	as	previously	described	(Bai	et	al.,	1997;	Garbett	 et	 al.,	 2007;	 Layer	 et	 al.,	 2010;	 Singh	 et	 al.,	 2004)	 to	 generate	 49	deletion	variants.		TAF2	is	a	single-copy	essential	gene.		Thus,	to	perform	genetic	complementation	assays,	 I	used	a	pseudodiploid	TAF2	WT	strain	 for	plasmid	shuffle	analysis,	as	previously	described	 (Gangloff	 et	 al.,	2001b;	Garbett	et	al.,	2007;	Layer	et	al.,	2010;	Layer	and	Weil,	2013).	Forty-eight	of	these	variants	were	unable	to	complement	a	taf2	null	strain	and	failed	to	stably	incorporate	into	the	TFIID	complex	(summarized	in	Table	3.1).		The	single	variant	that	could	complement	a	taf2	null	strain	(Taf2	aa	1-1307)	displayed	no	discernable	adverse		
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Table	3.1
TAF2	VARIANT taf2Δ	COMPLEMENTATION STEADY-STATE	PROTEIN	LEVELS ABILITY	TO	CO-IP	TFIID		
Deletion	Analyses (Taf1	and	Taf4	scored)
WT	Taf2 YES;	no	growth	defects (++) YES
Taf2	aa	1-1307 YES;	no	growth	defects (+++) YES
Taf2	aa	1-1207 NO,	inviable (+) NO
Taf2	aa	1-1107 NO,	inviable (+/-) NO
Taf2	aa	1-1007 NO,	inviable (++++) NO
Taf2	aa	1-907 NO,	inviable Protein	Not	Detectable NO
Taf2	aa	1-807 NO,	inviable Protein	Not	Detectable NO
Taf2	aa	1-707 NO,	inviable Protein	Not	Detectable NO
Taf2	aa	1-607 NO,	inviable (++) NO
Taf2	aa	1-507 NO,	inviable Protein	Not	Detectable NO
Taf2	aa	1-407 NO,	inviable (++++) NO
Taf2	aa	1-307 NO,	inviable (++) NO
Taf2	aa	1-207 NO,	inviable Protein	Not	Detectable NO
Taf2	aa	1-107 NO,	inviable Protein	Not	Detectable NO
Taf2	aa	1301-1407 NO,	inviable (++) NO
Taf2	aa	1201-1407 NO,	inviable Protein	Not	Detectable NO
Taf2	aa	1101-1407 NO,	inviable Protein	Not	Detectable NO
Taf2	aa	1001-1407 NO,	inviable Protein	Not	Detectable NO
Taf2	aa	901-1407 NO,	inviable Protein	Not	Detectable NO
Taf2	aa	801-1407 NO,	inviable Protein	Not	Detectable NO
Taf2	aa	701-1407 NO,	inviable Protein	Not	Detectable NO
Taf2	aa	601-1407 NO,	inviable Protein	Not	Detectable NO
Taf2	aa	501-1407 NO,	inviable Protein	Not	Detectable NO
Taf2	aa	401-1407 NO,	inviable (+) NO
Taf2	aa	301-1407 NO,	inviable (+) NO
Taf2	aa	201-1407 NO,	inviable (+) NO
Taf2	aa	101-1407 NO,	inviable (+) NO
Taf2	1-93,304-1407 NO,	inviable (+/-) NO
Taf2	1-193,304-1407 NO,	inviable (+/-) NO
Taf2	1-293,304-1407 NO,	inviable (+/-) NO
Taf2	1-396,	497-1407 NO,	inviable (+/-) NO
Taf2	1-396,	597-1407 NO,	inviable (+/-) NO
Taf2	1-396,	697-1407 NO,	inviable (+/-) NO
Taf2	1-443,744-1407 NO,	inviable (+/-) NO
Taf2	1-543,744-1407 NO,	inviable (+/-) NO
Taf2	1-643,744-1407 NO,	inviable (+/-) NO
Taf2	1-746,847-1407 NO,	inviable (+/-) NO
Taf2	1-746,947-1407 NO,	inviable (+/-) NO
Taf2	1-746,1047-1407 NO,	inviable (+/-) NO
Taf2	1-800,	1101-1407 NO,	inviable (+/-) NO
Taf2	1-900,1101-1407 NO,	inviable (+/-) NO
Taf2	1-1000,1101-1407 NO,	inviable (+/-) NO
Taf2	1-1102,1203-1407 NO,	inviable (+/-) NO
Taf2	1-1102,1303-1407 NO,	inviable (+/-) NO
Taf2	101-1307 NO,	inviable (+/-) NO
Taf2	201-1207 NO,	inviable (+/-) NO
Taf2	301-1107 NO,	inviable (+/-) NO
Taf2	401-1007 NO,	inviable (++) NO
Taf2	501-907 NO,	inviable Protein	Not	Detectable NO
Taf2	601-807 NO,	inviable Protein	Not	Detectable NO
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	growth,	 steady-state	 protein	 levels	 or	TFIID	 stable	 incorporation	 phenotypes.		Third,	 I	 created	 a	 hydroxylamine	mutagenized	TAF2	plasmid	mutant	library	(Klebanow	 et	 al.,	 1996)	 to	 generate	 taf2ts	variants	 (summarized	 in	 Table	 3.2).		However,	none	of	 the	 twenty	 taf2ts	 alleles	identified	 in	 a	 plate	 growth-based	 screen	displayed	 acute	 loss-of-function	 in	 liquid	culture	 when	 shifted	 to	 the	 non-permissive	 temperature	 (37o)	 (data	 not	shown)	as	has	been	shown	to	occur	for	Ts	alleles	 for	 every	 essential	 yeast	 Taf	 (Shen	et	al.,	2003).		 To	 overcome	 these	 technical	hurdles,	 I	 hypothesized	 that	 a	 structure-guided	 site-directed	mutagenesis	 strategy	would	 successfully	 identify	 Taf2	 amino	acids	 critical	 for	 Taf2	 function.	 	 However,	at	the	time	of	this	study,	no	3-D	structural	information	 existed	 for	 Taf2.	 	 Thus,	 to	generate	a	putative	3-D	model	for	Taf2,	I	employed	the	3-D	structural	prediction	program	I-TASSER	to	generate	models	for	yeast,	human	and	drosophila	Taf2	structures	(Figure	3.1a,	
	
Figure	 3.1:	 3-D Structural Prediction of Taf2 
Homologs Suggests Similar Structures Despite 
Low Overall Sequence Conservation.  A-C.  The 
primary amino acid sequences of A. S. cerevisiae 
Taf2, B. H. sapiens Taf2 and C. D. melanogaster 
Taf2 were analyzed using ClustalW sequence 
alignment algorithm and the 3-D structural 
prediction program I-TASSER. Evolutionary 
sequence conservation and predicted 3-D structural 
models indicating secondary structure (pink = b-
strand, cyan = a-helix and tan = random coil) are 
shown.  Amino (N)- and carboxy (C)- termini are 
labeled.  Sequence alignment similarity score of H. 
sapiens and D. melanogaster compared to S. 
cerevisiae displayed next to the predicted 
structures in B. and C., respectively. 
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3.1b	and	3.1c,	respectively)	(Yang	and	Zhang,	2015).		I-TASSER	has	been	successfully	used	in	the	gene	regulation	field	to	model	structurally	intractable	proteins	(Louder	et	al.,	2016;	Plaschka	 et	 al.,	 2016;	 Reiss	 and	Mobley,	 2011).	 	 Despite	 the	weak	 amino	 acid	 sequence	conservation,	 I-TASSER	 predicts	 that	 the	 Taf2	 structures	 from	 these	 three	 different	organisms	 display	 the	 same	 general	 features.	 	 Particularly,	 the	 N-terminus	 of	 Taf2	 is	predicted	 to	 contain	 a	β-sheet	motif,	 the	 central	 portion	 and	majority	 of	 the	molecule	 is	composed	of	HEAT	repeats	and	the	C-terminus	is	predicted	to	form	another	β-sheet	motif	along	with	 an	 unstructured	 region.	 	 This	 putative	 C-terminal	 unstructured	 region	 is	 also	predicted	 to	 be	 an	 intrinsically	 disordered	 region	 in	metazoans	 (Zhang	 et	 al.,	 2015).	 	 As	noted	 above,	 while	 this	 manuscript	 was	 in	 preparation,	 a	 high-resolution	 cryo-EM	structure	 of	 human	 Taf2	 was	 described	 and	 it	 exhibits	 the	 same	 general	 architecture	predicted	 by	 our	 analysis	 (Louder	 et	 al.,	 2016).	 	 Given	 the	 similarities	 among	 the	 yeast,	human	and	drosophila	Taf2	predicted	structures,	 I	 concluded	 that	our	 in	silico	 generated	yeast	 Taf2	 structure	 was	 a	 suitable	model	 from	which	 to	 design	 a	 structure-based	 site-directed	mutagenesis	screen.		 Site-directed	Mutagenesis	of	TAF2	To	 further	 genetically	 interrogate	 yTAF2,	 I	 designed	 two	 classes	 of	TAF2	 site-directed	variants	comprising	eighty-seven	mutants.	 	These	variants	primarily	consisted	of	ala	 block	 substitution	mutations	 but	 also	 included	 charge	 reversal	mutations	 (see	 Table	3.3).	 Class	 I	mutants,	 designed	based	 on	predicted	 solvent	 accessibility	 and	proximity	 to	evolutionarily	conserved	residues,	contained	fifty-eight	variants.	Class	II	mutants,	designed	based	on	predicted	solvent	inaccessibility	and	included	mutations	of	groups	of	conserved		
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Table	3.3	
TAF2	VARIANT taf2Δ	COMPLEMENTATION STEADY-STATE	PROTEIN	LEVELS ABILITY	TO	CO-IP	TFIID	
Site-Directed	Mutagenesis (@P=	permissive	25C,	@NP=nonpermissive	37C) 	(Taf7	and	Taf8	scored)
Class	I	Mutants:	Solvent	Accessible
taf2-m1	ala	25-28 YES,	no	defect Similar	to	WT Not	Tested
taf2-m2	ala	29-30,32 (@P	=	Slow,	@NP	=	very	slow	growth) Similar	to	WT Loss	of	Function
taf2-m3	ala	34,36,38 YES,	no	defect Similar	to	WT Not	Tested
taf2-m4	ala	45,47,49 YES,	no	defect Similar	to	WT Not	Tested
taf2-m5	ala	72-77 No,	inviable Similar	to	WT Loss	of	Function
taf2-m6	ala	120,123-127 YES,	no	defect Similar	to	WT Not	Tested
taf2-m7	ala	139-143 YES,	no	defect Similar	to	WT Not	Tested
taf2-m8	ala	145,	147-150,	152 YES,	no	defect Similar	to	WT Not	Tested
taf2-m9	ala	230-231,	233 YES,	no	defect Similar	to	WT Not	Tested
taf2-m10	ala	236,	238 YES,	no	defect Similar	to	WT Not	Tested
taf2-m11	ala	243-246,	248 YES,	no	defect Similar	to	WT Not	Tested
taf2-m12	ala	364-368 NO,	inviable Similar	to	WT Loss	of	Function
taf2-m13	ala	370-374 YES,	no	defect Similar	to	WT Not	Tested
taf2-m14	ala	394-398 YES,	no	defect Similar	to	WT Not	Tested
taf2-m15	ala	439-445 YES,	no	defect Similar	to	WT Not	Tested
taf2-m16	ala	449-452 (@P=	No	defect,	@NP=Slow	Growth) Similar	to	WT Not	Tested
taf2-m17	ala	454-458 YES,	no	defect Similar	to	WT Not	Tested
taf2-m18	ala	462-466 (@P	=	very	slow	growth,	@NP	=	No	growth) Similar	to	WT Loss	of	Function
taf2-m19	ala	469,	471-474 (@P	=	very	slow	growth,	@NP	=	No	growth) Similar	to	WT Loss	of	Function
taf2-m20	ala	554-557,	559 (@P=	No	defect,	@NP=Slow	Growth) Similar	to	WT Not	Tested
taf2-m21	ala	563-564 YES,	no	defect Similar	to	WT Not	Tested
taf2-m22	ala	588,	592-592,	594-595 YES,	no	defect Similar	to	WT Not	Tested
taf2-m23	ala	633-634,	637-639 YES,	no	defect Similar	to	WT Not	Tested
taf2-m24	ala	640-644 (@P	=	slow	growth,	@NP	=	No	growth) Similar	to	WT Loss	of	Function
taf2-m25	ala	671-672,	675 (@P	=	slow	growth,	@NP	=	No	growth) Similar	to	WT Loss	of	Function
taf2-m26	ala	693-696 (@P	=	slow	growth,	@NP	=very	slow	growth) Similar	to	WT Loss	of	Function
taf2-m27	ala	710-717 YES,	no	defect Similar	to	WT Not	Tested
taf2-m28	ala	727-733 YES,	no	defect Similar	to	WT Not	Tested
taf2-m29	ala	746-747,	751-753 YES,	no	defect Similar	to	WT Not	Tested
taf2-m30	ala	754,	756-758 (@P=	No	defect,	@NP=Slow	Growth) Similar	to	WT Not	Tested
taf2-m32	ala	775-780 Slow	at	all	temperatures Similar	to	WT Similar	to	WT
taf2-m33	E829K YES,	no	defect Similar	to	WT Not	Tested
taf2-m34	ala	833-837 YES,	no	defect Similar	to	WT Not	Tested
taf2-m35	D848K,	E850K (@P	=	slow	growth,	@NP	=	No	growth) Similar	to	WT Loss	of	Function
taf2-m36	ala	858-859 YES,	no	defect Similar	to	WT Not	Tested
taf2-m37	ala	861-863,	866 YES,	no	defect Similar	to	WT Not	Tested
taf2-m38	ala	867-871,	873-874 No,	inviable Similar	to	WT Loss	of	Function
taf2-m39	ala	R910E YES,	no	defect Similar	to	WT Not	Tested
taf2-m40	ala	917,	921	gly	918-919,922 No,	inviable Similar	to	WT Loss	of	Function
taf2-m41	ala	924-925,	927-929 YES,	no	defect Similar	to	WT Not	Tested
taf2-m42	ala	947-952 (@P=	No	defect,	@NP=Slow	Growth) Similar	to	WT Not	Tested
taf2-m43	ala	953-958 YES,	no	defect Similar	to	WT Not	Tested
taf2-m44	ala	965-966,	968-971 (@P=	No	defect,	@NP=Slow	Growth) Similar	to	WT Not	Tested
taf2-m46	ala	999,	1001,	1003,	1005 YES,	no	defect Similar	to	WT Not	Tested
taf2-m47	ala	1006-1007,	1010 YES,	no	defect Similar	to	WT Not	Tested
taf2-m48	ala	1027-1032 (@P=	No	defect,	@NP=Slow	Growth) Similar	to	WT Not	Tested
taf2-m49	ala	1036-1037,	1039-1041 YES,	no	defect Similar	to	WT Not	Tested
taf2-m50	ala	1043-1044,	1047-1049 YES,	no	defect Similar	to	WT Not	Tested
taf2-m51	ala	1051-1055 YES,	no	defect Similar	to	WT Not	Tested
taf2-m52	ala	1077-1080 YES,	no	defect Similar	to	WT Not	Tested
taf2-m53	ala	1084,	1086-1088 YES,	no	defect Similar	to	WT Not	Tested
taf2-m54	ala	1090-1091,	1093-1094 YES,	no	defect Similar	to	WT Not	Tested
taf2-m55	ala	1105-1107,	1112 (@P	=	slow	growth,	@NP	=	No	growth) Slight	Reduction Loss	of	Function
taf2-m56	ala	1136-1140 No,	inviable Similar	to	WT Loss	of	Function
taf2-m57	ala	1143-1144,	1146-1149 (@P	=	slow	growth,	@NP	=	No	growth) Similar	to	WT Loss	of	Function
taf2-m58	ala	1151-1155 YES,	no	defect Similar	to	WT Not	Tested
taf2-m59	ala	1181-1188 YES,	no	defect Similar	to	WT Not	Tested
taf2-m60	ala	1238-1242 (@P=	No	defect,	@NP=Slow	Growth) Similar	to	WT Not	Tested
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	amino	acids,	 contained	 twenty-nine	variants.	 	All	variants	were	engineered	 to	contain	an	HA3NLS	(HA)	N-terminal	tag.		Importantly,	HA-Taf2	phenocopies	untagged-Taf2	in	genetic	complementation	assays	and	can	efficiently	and	stably	incorporate	into	the	TFIID	complex	(Figure	3.2a	and	3.2b).	Every	variant	was	scored	for	its	ability	to	genetically	complement	a	
taf2	null	strain	at	both	permissive	(25o)	and	non-permissive	temperatures	(37o)	as	well	as	by	anti-HA	 immunoblotting	 to	ensure	each	variant	accumulated	 to	 levels	 similar	 to	wild-type	(WT)	Taf2.			Results	 for	 these	analyses	are	described	 in	detail	 in	Table	3.3.	 	 In	summary,	of	the	 Class	 I	 variants,	 thirty-six	 percent	 displayed	 a	 genetic	 complementation	 defect	including	 five	 that	were	 inviable	 and	 eight	 variants	 that	were	 both	 slow	 growing	 at	 the	permissive	temperature	and	Ts	at	the	non-permissive	temperature	(Figure	3.2;	taf2-ts1		
Table	3.3,	continued
TAF2	VARIANT taf2Δ	COMPLEMENTATION STEADY-STATE	PROTEIN	LEVELS ABILITY	TO	CO-IP	TFIID	
Site-Directed	Mutagenesis (@P=	permissive	25C,	@NP=nonpermissive	37C) 	(Taf7	and	Taf8	scored)
Class	II	Mutants:		Solvent	Inaccessible
taf2-m67	ala	129-133 YES,	no	defect Similar	to	WT Not	Tested
taf2-m68	ala	134-138 YES,	no	defect Similar	to	WT Not	Tested
taf2-m69	ala	180-185 No,	inviable Similar	to	WT Loss	of	Function
taf2-m70	ala	186-190 YES,	no	defect Similar	to	WT Not	Tested
taf2-m71	ala	191-195 No,	inviable Similar	to	WT Loss	of	Function
taf2-m72	ala	218,	220-223 (@P=	No	defect,	@NP=Slow	Growth) Similar	to	WT Loss	of	Function
taf2-m73	ala	225-229 (@P=	Slow,	@NP=Slow	Growth) Similar	to	WT Loss	of	Function
taf2-m74	ala	239-241 No,	inviable Similar	to	WT Loss	of	Function
taf2-m76	ala	358-363 YES,	no	defect Similar	to	WT Not	Tested
taf2-m77	ala	375,	377-380 (@P=	Slow,	@NP=No	growth) Similar	to	WT Loss	of	Function
taf2-m79	ala	388-393 YES,	no	defect Similar	to	WT Not	Tested
taf2-m80	ala	434-438 No,	inviable Similar	to	WT Loss	of	Function
taf2-m81	ala	475-480 No,	inviable Similar	to	WT Loss	of	Function
taf2-m82	ala	490,	493-495 No,	inviable Similar	to	WT Loss	of	Function
taf2-m83	ala	506-509 YES,	no	defect Similar	to	WT Not	Tested
taf2-m84	ala	517,	519,	521,	523-524 No,	inviable Similar	to	WT Not	Tested
taf2-m85	ala	537-542 No,	inviable Similar	to	WT Loss	of	Function
taf2-m86	ala	543-544,546-548 No,	inviable Similar	to	WT Loss	of	Function
taf2-m87	ala	842-846 No,	inviable Similar	to	WT Loss	of	Function
taf2-m88	ala	909-913 (@P=	Slow,	@NP=No	growth) Similar	to	WT Loss	of	Function
taf2-m89	ala	914-917 (@P=	Slow,	@NP=No	growth) Slight	Reduction Loss	of	Function
taf2-m90	ala	972-976 (@P=	No	defect,	@NP=Slow	Growth) Similar	to	WT Similar	to	WT
taf2-m91	ala	978-983 YES,	no	defect Similar	to	WT Not	Tested
taf2-m92	ala	984-990 (@P=	No	defect,	@NP=Slow	Growth) Similar	to	WT Similar	to	WT
taf2-m94	ala	1016-1020 (@P=	No	defect,	@NP=Slow	Growth) Similar	to	WT Similar	to	WT
taf2-m95	ala	1021-1024,	1026 YES,	no	defect Similar	to	WT Not	Tested
taf2-m96	ala	1056-1061 YES,	no	defect Similar	to	WT Not	Tested
taf2-m97	ala	1062-1065,	1067 YES,	no	defect Similar	to	WT Not	Tested
taf2-m98	ala	1068-1074 YES,	no	defect Similar	to	WT Not	Tested
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Figure	 3.2:	 Identification	 of	 taf2ts	 Alleles	 Using	 Structural	 Prediction	 and	 Amino	 Acid	
Conservation-Guided	 Site-Directed	 Mutagenesis.	 	 A.	 Genetic	 complementation	 assay.	 taf2	 null	cells	harboring	both	URA3-marked	TAF2	and	LEU2-marked	TAF2*	plasmids	were	serially	diluted	1:4	from	 left	 to	 right	 and	 spotted	 with	 a	 pinning	 tool	 onto	 either	 synthetic	 complete	 (SC)	 medium	without	leucine	(-L)	(Pre-Shuffle)	or	SC-L	+	5-FluorOrotic	Acid	(5-FOA)	to	select	for	cells	that	have	spontaneously	lost	the	URA3-marked	TAF2	plasmid	(Post-Shuffle).		Plates	were	grown	for	72	hours	at	37oC	or	96	hours	at	25oC	prior	to	imaging.	TAF2*	=	Test	gene,	either	no	ORF	(--),	TAF2,	HA3NLS-
TAF2	 or	 various	 HA3NLS-tagged	 taf2-temperature	 sensitive	 (Ts)	 alleles	 (HA3NLS-taf2-ts1	 through	
ts12).	 	 The	 variant	 amino	 acids	 in	 the	 taf2ts	 alleles	 are	 shown	 in	 the	Allele	Key	 to	 the	 right	 (taf2ts	Variants).	 Representative	 plate	 images	 from	 at	 least	 two	 biological	 replicates	 are	 presented.		HAx3NLS-tag	labeled	as	HA	in	all	figures.	B.	Taf2-TFIID	Co-Immunoprecipitation	(CoIP).	 	Whole	cell	extracts	 derived	 from	 the	 strains	 containing	 TAF2*:	 TAF2,	 HAx3NLS-TAF2,	 taf2-ts1	 through	 ts12	described	 in	 panel	A.	were	 used	 for	 immunoprecipitation	with	 the	 anti-HA	mAb	 12CA5	 IgG.	 	 One	percent	 of	 the	 lysate	 (Input)	 and	33%	of	 the	 pellet	 (Immunoprecipitate)	were	 separated	 via	 SDS-PAGE,	blotted	to	PVDF	membrane	and	probed	with	anti-HA	(α-HA(Taf2))	and	the	indicated	anti-Taf	IgGs	 (α-Taf7,	 α-Taf8	 and	 α-Taf14).	 	 Representative	 immunoblots	 from	 at	 least	 two	 biological	replicates	are	presented.			
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through	 taf2-ts8).	 	 Of	 the	 Class	 II	 variants,	 sixty-two	 percent	 displayed	 a	 genetic	complementation	defect	including	ten	that	were	inviable	and	four	variants	that	were	both	slow	 growing	 at	 the	 permissive	 temperature	 and	 Ts	 at	 the	 non-permissive	 temperature	(Figure	3.2;	taf2-ts9	through	taf2-ts12).	 	Of	note,	none	of	the	variants	displayed	dominant	negative	 phenotypes.	 Surprisingly,	 none	 of	 the	 variants	 displayed	 drastic	 reduction	 in	steady-state	 protein	 levels	 (>2x),	 even	 variants	 that	 could	 not	 complement	 the	 taf2	 null	strain.		 To	 assess	 the	 mechanism	 by	 which	 the	 loss-of-function	 Taf2	 variants	 fail	 to	complement	the	taf2	null	strain,	inviable	and	taf2ts	variants	were	subjected	to	anti-HA	Co-ImmunoPrecipitation	 (Co-IP)	 (Figure	 3.2b	 and	 Table	 3.2).	 	 A	 strain	 expressing	 untagged	WT	Taf2	was	used	as	a	negative	control.			Despite	similar	steady-state	protein	levels	and	IP	efficiency,	 none	 of	 the	 loss-of-function	 taf2	 mutant	 variants	 tested	 could	 co-precipitate	either	the	TFIID-specific	subunits	Taf7	and	Taf8	or	Taf14	as	efficiently	as	HA-Taf2.		These	results	suggest	that	these	mutations	disrupt	Taf2-TFIID	subunit	interactions,	contributing	to	growth	defects.	
	
TAF14	Overexpression	Suppresses	Select	taf2ts	Growth	Phenotypes	Considering	 all	 of	 the	 loss-of-function	 taf2	 variants	 display	 defects	 in	 stable	incorporation	into	the	TFIID	complex,	likely	as	a	result	of	disruption	of	specific	Taf2-TFIID	subunit	interactions,	I	hypothesized	that	artificially	driving	Taf2-TFIID	stable	incorporation	would	suppress	the	taf2ts-associated	growth	defects.		Ideally,	if	a	taf2ts	mutant	variant	has	a	reduction	 in	 binding	 affinity	 to	 a	TFIID	 subunit,	 increasing	 concentration	 of	 that	 subunit	could	drive	complex	formation	and	rescue	the	ability	of	Taf2	to	stably	associate	with	TFIID.	
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To	 this	 end,	 I	 individually	 overexpressed	 every	 TFIID	 subunit	 (Figure	 3.3a)	 in	 strains	harboring	 the	 taf2ts	variants.	 	Our	 lab	has	previously	shown	that	overexpression	of	TFIID	subunits	TAF4	and	TAF11	have	displayed	positive	genetic	interactions	with	TOA2,	a	protein	that	 directly	 interacts	 with	 the	 TFIID	 complex,	 demonstrating	 that	 overexpression	 of	individual	TFIID	subunits	is	a	viable	method	for	identifying	genetic	interactions	(Layer	and	Weil,	2013).			Overexpression	 of	 TAF1,	 TAF3,	 TAF7,	 TAF8	 and	 TAF14	 resulted	 in	 dominant	negative	growth	phenotypes,	consistent	with	published	results	(Yoshikawa	et	al.,	2011).		As	expected,	overexpression	of	TAF2	 could	complement	growth	 for	all	 taf2ts	variants	 (Figure	3.3b,	data	not	shown).		In	addition,	I	observed	strong	taf2ts	allele-specific	suppression	when	I	overexpressed	TAF14	but	not	for	any	of	the	other	non-TAF2	TFIID	subunits	(Figure	3.3b	and	3.3c;	see	taf2-ts6	vs.	taf2-ts7	and	ts8).	TAF14	overexpression	suppression	of	 the	taf2-
ts7-associated	 growth	 phenotype	 was	 particularly	 potent,	 rescuing	 growth	 to	 near	 WT	levels	at	both	permissive	and	non-permissive	temperatures.		While	 five	 of	 the	 twelve	 taf2ts	 variants	 displayed	 mild	 growth	 improvement,	
TAF14	overexpression	suppression	of	taf2-ts7	and	ts8	significantly	improved	growth	at	all	temperatures	 tested.	 	 The	 amino	 acids	 mutated	 in	 the	 taf2-ts7	 and	 ts8	 variants	 map	 to	adjacent	α-helixes	in	the	yTaf2	predicted	structure	whereas	taf2-ts6	is	predicted	to	reside	on	the	opposite	side	of	the	molecule	(Figure	3.3d).		These	results	suggest	that	amino	acids	mutated	in	the	taf2-ts7	and	ts8	form	a	domain	that	is	likely	involved	in	Taf2-TFIID	subunit	physical	interactions,	potentially	Taf2-Taf14	interaction.	Due	to	the	potency	of	the	genetic	interaction	 between	 TAF14	 and	 taf2-ts7,	 further	 molecular	 and	 genetic	 analyses	 were	performed	with	taf2-ts7.			
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TAF14	Overexpression	Suppresses	Defects	in	Ribosomal	Protein	Gene	Transcript	Abundance	Associated	with	taf2-ts7	I	 hypothesized	 strong	 taf2-ts7	growth	defects	likely	result	in	a	reduction	in	ribosomal	 protein-encoding	 gene	 (RPG)	transcript	abundance,	a	class	of	genes	that	is	TFIID-dominated	 (Basehoar	 et	 al.,	 2004;	Huisinga	 and	 Pugh,	 2004;	 Li	 et	 al.,	 2000;	Rhee	and	Pugh,	2012;	Shen	et	al.,	2003).	To	assess	 RPG	 transcripts,	 log	 phase	 growing	yeast	strains,	harboring	either	TAF2	or	taf2-
ts7	 and	 containing	 either	 an	 empty	overexpression	 vector	 or	 a	 TAF14	overexpression	 vector,	 were	 abruptly	shifted	 to	 the	 non-permissive	 temperature	for	 two	 hours	 followed	 by	 RNA	 extraction	and	 quantitative	 reverse	 transcription	 PCR	(qRT-PCR).	 	 Our	 lab	 has	 assessed	 RPG	transcript	 abundance	 using	 this	temperature	 shift	 paradigm	 using	 Ts	variants	for	TAF1	through	TAF13,	TOA1	and	
TOA2	 (Garbett	 et	 al.,	 2007;	 Layer	 et	 al.,	
	
Figure	 3.4:	 	 Overexpression	 of	 TAF14	
Suppresses	 the	 Ribosomal	 Protein	 Gene	
Transcription	 Defect	 Associated	 with	 taf2-
ts7.	 	A-C.		Analysis	of	RNAs	from	cells	shifted	to	the	 non-permissive	 temperature.	 	 	 Shuffled	strains	harboring	HA3NLS-TAF2	or	HA3NLS-taf2-
ts7	 with	 either	 an	 empty	 HIS3-marked	overexpression	 (OE)	plasmid	or	 a	HIS3-marked	OE	 plasmid	 containing	 an	 N-terminally	FLAG2NLS	 tagged	 TAF14	 cDNA	 were	 grown	 at	25o	 to	 early-mid-log	 phase	 and	 then	 shifted	 to	the	 non-permissive	 temperature	 (37o)	 for	 2	hours.	 	 RNAs	 were	 extracted	 and	 analyzed	 by	qRT-PCR	scoring	for	A.	RNA	Pol	 II,	B.	RNA	Pol	 I	and	C.	RNA	Pol	III	transcribed	genes.		Data	were	generated	 from	 two	 biological	 replicates.	 	 Each	data	point	in	the	graph	represents	one	biological	replicate	 and	 is	 generated	 from	 the	 average	 of	three	 technical	 replicates.	 Results	 were	statistically	analyzed	using	a	2-way	ANOVA	with	Dunnett’s	multiple	 comparisons	 test	 (GraphPad	Prism).	 	Mean	±	SD	depicted.	 	*	=	p<0.05.	 	Dark	Gray	=	HA3NLS-TAF2,	Light	Gray	=	HA3NLS-TAF2	+	 OE	TAF14,	 Red	 =	HA3NLS-taf2-ts7	 and	 Blue	 =	
HA3NLS-taf2-ts7	+	OE	TAF14.			
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2010;	Layer	and	Weil,	2013).			I	 found	 that	 taf2-ts7	 without	 TAF14	 overexpression	 displays	 a	 statistically	significant	~3-fold	reduction	compared	to	TAF2	in	TFIID-dominated	RPG	transcripts	(RPS3,	
RPS5,	RPS8A	and	RPS9B;	Figure	3.4a)	without	a	concomitant	significant	decrease	in	SAGA-dominated	 transcripts	 (PGK1	 and	 PYK1;	 Figure	 3.4a),	 RNA	 polymerase	 I	 transcripts	(RDN58;	Figure	3.4b)	or	RNA	polymerase	III	transcripts	(SNR6;	Figure	3.4c)	(Bonnet	et	al.,	2014).	 	 The	RPG	 transcript	 defects	were	 ameliorated	when	TAF14	was	 overexpressed	 in	the	taf2-ts7	strain.		These	data	suggest	the	ability	of	taf2-ts7	to	appropriately	regulate	RPG	transcript	abundance	is	aided	by	elevated	TAF14	levels.		Taf2	and	Taf14	Directly	Interact	in	vitro	The	simplest	model	 for	 the	genetic	 interaction	between	Taf2	and	Taf14	 is	 that	these	two	proteins	directly	interact.		Consistent	with	this	hypothesis,	Taf2	was	identified	as	a	 Taf14	 interacting	 protein	 in	 a	 genome-wide	 yeast	 two-hybrid	 screen	 but	 was	 not	authenticated	as	a	direct	interaction	(Kabani	et	al.,	2005).		To	determine	if	Taf2	and	Taf14	directly	 interact,	Taf1-TAP	purified	TFIID,	maltose	binding	protein	 (MBP)	and	MBP-Taf2,	all	purified	from	yeast,	were	subjected	to	Far-Western	blotting	with	and	without	purified	recombinant	 His6-Taf14	 (Figure	 3.5a).	 	 His6-Taf14	 bound	 proteins	 were	 detected	 with	antigen	 affinity	 purified	 anti-Taf14	 IgG	 (Sanders	 et	 al.,	 2002b).	 	 When	 His6-Taf14	 was	omitted	from	the	Far-Western	blot,	the	only	signals	observed	were	for	purified	Taf14	from	the	 TFIID	 complex	 as	 well	 as	 trace	 amounts	 of	 Taf14	 that	 co-purify	 with	 the	 yeast	generated	MBP-Taf2.	 	Upon	overlay	with	His6-Taf14,	His6-Taf14	bound	to	both	Taf2	 from	TFIID	as	well	as	MBP-Taf2,	but	not	MBP	or	other	TFIID	subunits.		To	extend	these	analyses		
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Figure	 3.5:	 	 Taf2	 and	 Taf14	 Directly	 Interact	 in	 vitro.	 A.	 Far-Western	 Blotting.	 	 Approx.	 500	nanograms	of	Taf1-TAP	purified	TFIID,	200	nanograms	of	recombinant	MBP	and	200	nanograms	of	recombinant	MBP-Taf2	were	separated	via	SDS-PAGE	in	triplicate.		One	gel	was	stained	with	Sypro	Ruby	 gel	 stain	 while	 the	 other	 two	were	 analyzed	 by	 anti-Taf14	 blotting,	 with	 and	 without	 7nM	overlay	of	purified	recombinant	His6-Taf14.		Representative	image	presented	from	more	than	three	technical	 replicates.	 	 B.	 	 Glutathione	 S-Transferase	 (GST)	 Pull-Downs.	 	 Either	 four	 picomoles	 of	purified	recombinant	His6-GST	or	two	picomoles	of	His6-GST-Taf14	were	mixed	with	0.1mg/mL	BSA	and	either	no	MBP-Taf2	or	between	2	and	32pmol	of	MBP-Taf2.		His6-GST	or	His6-GST-Taf14	bound	proteins	were	pulled-down	with	glutathione	agarose,	washed	with	binding	buffer,	analyzed	via	SDS-PAGE	and	stained	with	Sypro	Ruby	gel	stain.		One	picomole	of	purified	MBP-Taf2	(lane	1)	was	loaded	to	demonstrate	purity	of	input	material.	One	technical	replicate	was	performed.		to	solution	binding	assays,	increasing	concentrations	of	MBP-Taf2	were	mixed	with	either	purified	recombinant	His6-GST	or	His6-GST-Taf14,	in	the	presence	of	BSA	as	a	non-specific	competitor,	and	subjected	to	GST	pull-down.		His6-GST-Taf14	specifically	bound	MBP-Taf2	in	a	dose-dependent	and	saturable	manner	(Figure	3.5b).		Thus,	I	have	shown	through	two	independent	methods	that	Taf2	and	Taf14	specifically	and	directly	interact	in	vitro.		 	
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The	Taf2	C-terminus	Is	Necessary	and	Sufficient	for	Binding	Taf14	in	vitro	and	in	vivo	Using	 the	Far-Western	 assay,	 I	 determined	 the	domain	of	Taf2	where	Taf2	 and	Taf14	directly	interact	(Figure	3.6).		To	this	end,	purified	MBP-Taf2	(lane	1),	His6-Taf2	aa	1-407	(lane	2),	His6-Taf2	aa	401-1007	(lane	3),	His6-Taf2	aa	1001-1407	(lane	4),	His6-Taf2	aa	1001-1207	 (lane	5)	and	His6-Taf2	aa	1201-1407	 (lane	6)	were	 subjected	 to	Far	Western	blotting,	as	described	above	(Taf2	purified	forms	Figure	3.6a	Left,	constructs	diagrammed	in	3.6b).	 	When	His6-Taf14	was	omitted	from	the	overlay,	the	only	signal	present	was	the	co-purifying	Taf14	in	the	MBP-Taf2	sample.		Upon	His6-Taf14	overlay,	His6-Taf14	bound	to	MBP-Taf2	(lane1),	His6-Taf2	aa	1001-1407	(lane	4)	and	His6-Taf2	aa	1201-1407	(lane	6).		These	results	suggest	that	the	Taf14	binding	domain	resides	in	Taf2	aa	1201-1407.		 As	described	above,	my	systematic	100aa	TAF2	truncation	analysis	showed	that	Taf2	aa	1-1307	could	complement	a	taf2	null	strain	and	stably	incorporate	into	the	TFIID	complex	 whereas	 Taf2	 aa	 1-1207	 could	 do	 neither	 (Table	 3.1).	 	 Since	 these	 C-terminal	amino	 acids	 contain	 the	 Taf14	 binding	 domain,	 I	 hypothesized	 that	 a	 finer	 truncation	analysis	of	the	Taf2	C-terminus	may	define	the	amino	acids	necessary	for	Taf14	binding	in	
vivo.	TAF2	was	subjected	to	10	aa	serial	truncations	of	its	C-terminus.		These	variants	were	analyzed	for	their	ability	to	complement	a	taf2	null	strain,	steady-state	protein	levels	and	ability	to	coIP	TFIID	subunits	(Figure	3.6c	and	3.6d).		I	found	that	Taf2	aa	1-1250	could	not	complement	 a	 taf2	 null	 strain,	 had	 reduced	 steady-state	 protein	 levels	 compared	 to	HA-Taf2	and	could	not	coIP	TFIID	subunits	Taf4,	Taf7,	Taf8,	Taf9	or	Taf14.		Smaller	truncations	(Taf2	aa	1-1260	to	1300),	still	maintained	their	ability	to	complement	the	taf2	null	strain,	displayed	elevated	steady-state	protein	levels	compared	to	HA-Taf2	and	could	coIP	TFIID	subunits	Taf4,	Taf7,	Taf8	and	Taf9.		In	regards	to	Taf14	coIP,	Taf2	aa	1-1280,	Taf2	aa	1-	
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Figure	3.6:	The	Taf2	C-terminus	Is	Necessary	and	Sufficient	for	Binding	to	Taf14	in	vitro	and	
in	vivo.	A.	 	Far	Western-Blotting.			 	Purified	Taf2	forms	were	analyzed	in	triplicate	as	in	Figure	3.5,	one	 replicate	 analyzed	 by	 Sypro	 Ruby	 gel	 stain	 (shown	 in	 A,	 Left)	 while	 the	 other	 two	 were	analyzed	 by	 anti-Taf14	 Far-Western	 blotting,	 with	 and	without	 His6-Taf14	 overlay	 (shown	 in	A,	
Right).	 	 Two	 technical	 replicates	were	performed.	 	B.	 	 Schematic	 of	Taf2	 forms	used	 in	panel	A;	numbers	refer	to	the	proteins	loaded	in	Lanes	1-7	panel	A.	C,D.		Plasmid	Shuffle	Complementation	and	Taf2-TFIID	Co-IP.		Taf2	C-terminal	truncation	variants	(TAF2*:	no	ORF	(--),	TAF2	full	length	aa	1-1407,	HA3NLS-TAF2	full	length,	and	successive	HA3NLS-TAF2	truncation	variants	ranging	from	aa	1-1251	to	aa	1-1300)	were	analyzed	for	their	ability	to	complement	a	taf2	null	strain	via	plasmid	shuffle	 (D.)	and	 to	coIP	TFIID	subunits,	as	described	 in	Figure	3.2.	 	Additional	anti-Taf	 IgGs	were	used	in	these	analyses	(α-Taf4,	α-Taf9).			
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1290	and	Taf2	aa	1-1300	all	maintained	the	ability	to	co-precipitate	Taf14	at	levels	similar	to	WT.	 	However,	Taf2	aa	1-1270	showed	a	mild	reduction	in	the	ability	to	co-precipitate	Taf14	and	Taf2	aa	1-1260	(hereafter	referred	to	as	Taf2-ΔC)	completely	lost	the	ability	to	coIP	Taf14.		Based	on	this	data,	I	conclude	that	Taf2	aa	1261-1407	are	necessary	for	Taf2-Taf14	interaction	in	vivo.				 Purified	MBP-Taf2-DC	was	tested	for	its	ability	to	directly	interact	with	Taf14	in	
vitro.	MBP-Taf2-DC	was	subjected	to	both	Far	Western	blotting	(Figure	3.6a	lane	7)	as	well	as	 GST-pull	 downs	 (Figure	 3.6e),	 as	 described	 above.	 	 MBP-Taf2-ΔC	 displayed	 no	observable	binding	to	His6-Taf14	in	the	Far	Western	blot	or	His6-GST-Taf14	in	the	GST-pull	down.		Thus,	Taf2	aa	1261-1407	are	necessary	for	Taf14	binding	in	vitro.		 To	 assess	 if	 the	 Taf2	 C-terminus	 is	 sufficient	 for	 binding	 to	 Taf14	 in	 vivo,	untagged	 Taf2,	 HA-Taf2,	 HA-Taf2-ΔC	 and	 HA-Taf2	 C-terminal	 fragments	 (aa	 1261-1407,	1271-1407,	 1281-1407,	 1291-1407	 and	 1301-1407)	 were	 subjected	 to	 anti-HA	 coIP,	 as	described	above	(Figure	3.6f).		As	expected,	HA-Taf2	could	co-IP	Taf7,	Taf8	and	Taf14	while	HA-Taf2-ΔC	could	coIP	Taf7	and	Taf8	but	could	not	coIP	Taf14.		Surprisingly,	all	of	the	Taf2	C-terminal	fragments	displayed	the	ability	to	coIP	Taf14.		Despite	Taf2	aa	1261-1407	being	necessary	for	binding	to	Taf14	in	vivo,	aa	1261-1407	and	smaller	C-terminal	fragments	are	sufficient	for	binding	to	Taf14	in	vivo.		Considering	TFIID	contains	multiple	copies	of	Taf14	
Figure	3.6	Continued:	
E.	 	GST	Pull-downs.		Similar	to	Figure	5B	except	5	picomole	of	His6-GST-Taf14	was	incubated	with	0.1mg/mL	BSA	and	between	1	and	32	pmol	MBP-Taf2	or	MBP-Taf2-ΔC.		Two	independent	binding	assays	were	performed,	once	with	2	pmol	His6-GST-Taf14	and	once	with	5	pmol	His6-GST-Taf14,	both	displaying	high	affinity	saturable	binding	for	MBP-Taf2	and	a	lack	of	specific	binding	to	MBP-Taf2-ΔC.	 	 One	 picomole	 of	 purified	MBP-Taf2	 and	 one	 picomole	 of	 purified	MBP-Taf2-ΔC	were	loaded	to	demonstrate	purity	of	input	material.	 	F.	 	Taf2-TFIID	Co-IP.	 	Performed	as	described	in	Figure	 3.2.	 	 Black	 line	 depicts	 non-contiguous	 lanes	 from	 the	 same	 SDS-PAGE	 gel	 and	 from	 the	same	film	exposures.		One	technical	replicate	was	performed.		ΔC	=	Taf2	aa	1-1260.		
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per	TFIID	molecule	(Sanders	et	al.,	2002a),	these	data	allowed	me	to	hypothesize	that	the	Taf2	C-terminus	contains	multiple	Taf14	binding	domains	that	are	independently	capable	of	promoting	Taf14-TFIID	association.		 Defining	the	Minimal	Taf2	Interaction	Domain	in	Taf14	In	parallel	 to	my	 analyses	 to	map	 the	Taf14	 interaction	domain	 in	Taf2,	 I	 also	subjected	 TAF14	 to	 systematic	 truncation	 mutagenesis	 to	 identify	 the	 Taf14	 domain	operative	 in	 suppressing	 the	 taf2-ts7	 Ts	 phenotype.	 	 Previous	Taf14	 studies	 have	 shown	that	 the	 N-terminus	 contains	 the	 YEATS	 domain	 while	 the	 Taf14	 C-terminus	 can	 both	complement	the	growth	deficiencies	associated	with	a	taf14	null	strain	and	associate	with	transcription	related	complexes	such	as	TFIID	and	TFIIF	 in	vivo	 (Schulze	et	al.,	2010).	 	 In	addition,	C-terminally-tagged	Taf14	variants	display	defects	 in	growth,	 likely	because	 the	tag	negatively	impacts	the	ability	of	Taf14	to	interact	with	transcription-related	complexes	(Kabani	et	al.,	2005).			In	strains	harboring	taf2-ts7,	Taf14	full	length	(aa	1-244),	the	Taf14	N-terminus	(aa	1-123)	 and	 the	 Taf14	 C-terminus	 (aa	 124-244)	 were	 overexpressed	 to	 determine	 if	 these	fragments	 could	 suppress	 the	 Ts	 phenotype	 (Figure	 3.7a).	 	 All	 variants	 were	 expressed	with	 a	 FLAG2-NLS	 N-terminal	 tag.	 	 While	 Taf14	 aa	 1-244	 displayed	 the	 most	 robust	suppression	of	the	taf2-ts7	Ts	phenotype,	Taf14	aa	124-244	also	suppressed	the	taf2-ts7	Ts	phenotype.	 	 The	 N-terminal	 YEATS	 domain-containing	 fragment	 (aa	 1-123)	 could	 not	suppress	 the	 taf2-ts7	 Ts	 phenotype.	 	 I	 further	 dissected	 the	 Taf14	 C-terminus	 in	 this	overexpression	suppression	assay	by	performing	systematic	N-	and	C-terminal	truncations	of	Taf14	aa	124-244	(Figure	3.7a	and	data	not	shown).	These	analyses	identified	that	the		
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Figure	3.7:		The	Taf14	C-terminus	Physically	and	Functionally	Interacts	with	Taf2.		A.		TAF14	Overexpression	Suppression	of	taf2-ts7.		(Upper)	Plasmid	shuffle	performed	as	in	Figure	3.3C.	taf2	null	cells	harboring	a	URA3-marked	TAF2	plasmid,	a	LEU2-marked	HA3NLS-taf2-ts7	plasmid	and	a	
HIS3-marked	 TAF14*	 overexpression	 plasmid	 (TAF14	 and	 TAF14	 N-	 and	 C-terminal	 truncation	fragments;	 all	 TAF14	 forms	 contained	 an	 N-terminal	 FLAG2NLS-tag)	 were	 spotted	 on	 SC-L,-H	medium	 (pre-shuffle)	 or	 SC-L,-H	 +5-FOA	 (post-shuffle)	medium	 and	 grown	 for	 72	 hours	 at	 34o.		Representative	image	of	two	biological	replicates	is	presented.		(Lower)	Schematic	represents	the	domain	 structure	 of	 Taf14.	 	 Coordinates	 for	 YEATS	 domain	 derived	 from	 (Shanle	 et	 al.,	 2015).		Coordinates	 for	 Taf2	 Binding	 Domain	 (BD)	 defined	 in	 this	 study.	 B.	 Glutathione	 S-Transferase	(GST)	Pull-Downs.	16pmol	of	purified	recombinant	His6-GST,	8pmol	of	His6-GST-Taf14,	12pmol	of	His6-GST-Taf14	 aa	 1-123	 or	 12pmol	 of	 His6-GST-Taf14	 aa	 124-244	were	mixed	with	 0.1mg/mL	BSA	and	either	no	Taf2	or	0.78pmol	Taf2,	1.56pmol	Taf2,	3.125pmol	Taf2	and	6.25pmol	of	Taf2.		His6-GST	or	His6-GST-Taf14	variant	bound	proteins	were	pulled-down	with	glutathione	agarose,	washed	with	binding	buffer,	 analyzed	via	SDS-PAGE	and	stained	with	Sypro	Ruby	gel	 stain.	One	technical	 replicate	 was	 performed.	 C.	 Summary	 of	 overexpression	 suppression	 of	 taf2-ts7	 with	
FLAG2NLS-TAF14	 ala	 scan	 variants.	 	 Horizontal	 lines	 separate	 non-contiguous	 mutant	 variants.		Results	 were	 derived	 from	 serial	 dilution	 spot	 assays	 as	 described	 in	 A	 (not	 shown).	 	 Two	biological	replicates	were	performed.	
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domain	minimally	required	for	suppression	of	the	taf2-ts7	Ts	phenotype	lies	within	Taf14	aa	164-244.		 Again,	the	simplest	model	for	the	ability	of	the	Taf14	C-terminus	to	suppress	the	
taf2-ts7	Ts	phenotype	is	that	the	C-terminus	of	Taf14	directly	interacts	with	Taf2.			To	test	this	hypothesis,	purified	 recombinant	His6-GST,	His6-GST-Taf14	aa	1-244,	His6-GST-Taf14	aa	 1-123	 and	 His6-GST-Taf14	 aa	 124-244	 were	 mixed	 with	 purified	 Taf2	 and,	 in	 the	presence	of	BSA,	subjected	to	GST-pull	down,	as	described	above	(Figure	3.7b).		His6-GST-Taf14	aa	1-244	and	His6-GST-Taf14	aa	124-244	were	able	to	pull-down	purified	Taf2	in	a	dose-dependent	manner	whereas	His6-GST	and	His6-GST-Taf14	aa	1-123	did	not	pull-down	any	detectable	Taf2.	 	These	data	confirm	that	 the	Taf14	C-terminus,	 the	domain	required	for	 suppression	 of	 the	 taf2-ts7	 Ts	 phenotype,	 is	 necessary	 and	 sufficient	 for	 direct	interaction	with	Taf2	in	vitro.		 To	 identify	 point	 mutants	 that	 disrupt	 the	 TAF2-TAF14	 genetic	 interaction,	 I	performed	3ala	scan	mutagenesis	with	one	aa	overlap	of	Taf14	aa	164-244.		These	variants	were	overexpressed	in	the	context	of	full	length	Taf14	to	determine	if	they	could	suppress	the	 taf2-ts7	 Ts	 growth	 phenotype.	 	 Of	 the	 39	 ala	 variants	 generated,	 I	 identified	 11	 that	displayed	 defects	 in	 the	 ability	 to	 suppress	 the	 taf2-ts7-associated	 Ts	 phenotype	 at	 37o.		The	results	of	the	suppression	analyses	for	these	11	taf14-ala	variants	are	summarized	in	Figure	 3.7c.	 	 A	 particularly	 sensitive	 hotspot	 was	 identified	 between	 Taf14	 aa	 218-230	where	 every	mutant	 variant	 (m5	 through	m10)	 displayed	 a	 defect	 in	 taf2-ts7	 Ts	 growth	suppression.		These	amino	acids	are	likely	critical	for	the	function	of	the	Taf14	C-terminus.			 	
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Fine	Mapping	of	the	Taf2	C-terminus	Reveals	Two	Taf14	Interaction	Domains	A	previous	study	reported	that	the	Taf2	C-terminus	is	insoluble	when	expressed	in	E.	coli	(Kabani	et	al.,	2005).		My	studies	confirm	this	observation.		Expression	of	Taf2	aa	1301-1407-His6	 is	 largely	 insoluble	 and	 refractory	 to	 native	 purification	 with	 Ni2+-NTA	agarose	 (Figure	 3.8c,	 lane	 1).	 	 Our	 lab	 previously	 demonstrated	 that	 co-expression	 of	insoluble	Tafs	with	 their	cognate	binding	partner	results	 in	solubilization	(Gangloff	et	al.,	2001b).	 	Therefore,	 I	hypothesized	 that	 co-expression	of	 the	Taf2	C-terminus	with	either	full	length	Taf14	or	Taf14	aa	164-244	would	result	in	solubilization	of	the	Taf2	C-terminal	fragment.	To	this	end,	I	co-expressed	Taf2	aa	1301-1407-His6	with	either	Taf14	aa	1-244	or	Taf14	aa	164-244	and	subjected	 these	complexes	 to	Ni2+-NTA	agarose	purification.	Using	this	strategy,	I	could	generate	soluble	Taf2-Taf14	complexes	in	milligram	quantities/liter	of	
E.	 coli	 culture	 (Figure	 3.8a	 and	 3.8b,	 respectively).	 	 I	 also	 attempted	 to	 co-express	 full	length	Taf2	with	Taf14	aa	164-244	in	E.	coli	but	these	attempts	were	unsuccessful	(data	not	shown).		 I	then	employed	this	co-purification	assay	to	fine	map	the	Taf14	binding	domain	within	Taf2	aa	1301-1407.		N-	and	C-terminal	truncations	of	Taf2	aa	1301-1407-His6	were	co-expressed	 with	 Taf14	 aa	 164-244	 in	 E.	 coli	 and	 subjected	 to	 Ni2+-NTA	 agarose	purification	(Figure	3.8c,	diagrammed	in	3.8d).		These	analyses	revealed	that	Taf2	aa	1381-1407	were	sufficient	for	Taf14	co-purification	while	Taf2	aa	1362-1407	were	necessary	for	Taf14	 co-purification.	 	 Henceforth,	 I	 will	 refer	 to	 Taf2	 aa	 1363-1407	 as	 Domain	 1.		Surprisingly,	Domain	1	not	only	binds	 to	Taf14	but	also	contributes	 to	 the	 insolubility	of	the	Taf2	1301-1407	fragment	since	fragments	deleted	for	Domain	1	can	be	purified	from	E.	
coli	without	co-purifying	Taf14.			
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Figure	3.8:	 	 Taf2	Amino	Acids	1261-1407	Contain	Two	Domains	 that	 Contribute	 to	Taf14	
Binding.	 	A,B.	 	Co-purification	of	Taf2	and	Taf14.		Taf2	aa	1301-1407-His6	was	co-expressed	in	E.	
coli	with	either	Taf14	aa	1-244	or	Taf14	aa	164-244	and	purified	using	Ni2+-NTA	agarose.		Purified	Taf2	 aa	 1301-1407/Taf14	 aa	 1-244	 (shown	 in	 A.)	 and	 Taf2	 aa	 1301-1407/Taf14	 aa	 164-244	(shown	in	B.)	were	separated	via	SDS-PAGE	and	stained	with	coomassie	blue.		C,D.	 	Fine	mapping	of	the	Taf14	interaction	domain	in	Taf2	aa	1301-1407.		C-terminally	hexa-histidine	tagged	Taf2	aa	1301-1407	and	N-	and	C-terminal	 truncation	variants	of	Taf2	aa	1301-1407	(diagrammed	in	D.)	were	 co-expressed	 with	 Taf14	 aa	 164-244	 in	 E.	 coli.	 	 As	 a	 negative	 control,	 C-terminally	 hexa-histidine	tagged	Taf2	aa	1301-1407	was	expressed	alone.	 	Denatured	whole	cell	extracts	or	Ni2+-NTA	agarose	purified	 complexes	were	 separated	on	SDS-PAGE	and	 stained	with	 coomassie	blue	(C.).	 	 Samples	 that	co-purify	Taf14	aa	164-244	are	shown	 in	black	while	samples	 that	 fail	 to	co-purify	 Taf14	 aa	 164-244	 are	 shown	 in	 red.	 	 A	 representative	 image	 is	 shown	 of	 two	 technical	replicates.	 	 E.	 	 Taf2-TFIID	 Co-IP.	 	 Performed	 as	 described	 in	 Figure	 3.2.	 	 All	 deletion	 variants	contain	an	HAx3NLS-tag.	 	Black	lines	separate	non-contiguous	lanes	from	the	same	SDS-PAGE	gel	and	from	the	same	film	exposures.		One	technical	replicate	was	performed.		ΔC	=	deletion	of	Taf2	aa	1261-1407.		Δ1	=	deletion	of	Taf2	aa	1363-1407.		Δ2	=	deletion	of	Taf2	aa	1261-1300.	
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	 To	assess	the	relevance	of	Taf2	Domain	1	to	binding	to	Taf14	in	vivo,	I	performed	anti-HA	coIPs	with	a	series	of	Taf2	C-terminal	deletion	variants,	as	described	above	(Figure	3.8e).		Considering	Taf2-ΔC	(aa	1-1260)	fails	to	interact	with	Taf14	in	vivo	and	in	vitro	and	the	 Taf2	 aa	 1301-1362-His6	 fragment	 fails	 to	 co-purify	 Taf14,	 I	 reasoned	 that	 a	 second	Taf14	 binding	 domain	 likely	 resides	 within	 Taf2	 aa	 1261-1300	 (hereafter,	 Domain	 2).		Deletion	of	either	Domain	1	(Δ1)	or	Domain	2	(Δ2)	had	no	impact	on	the	ability	of	Taf2	to	co-precipitate	TFIID	subunits	Taf7,	Taf8	or	Taf14.		However,	a	Taf2	double	deletion	variant	(Δ1+Δ2)	 could	 co-precipitate	 Taf7	 and	 Taf8	 but	 failed	 to	 co-precipitate	 Taf14.		Furthermore,	 successively	 smaller	 deletion	 within	 Domain	 2	 (Δ1261-1291,	 Δ1261-1281	and	Δ1261-1271),	when	 combined	with	Δ1,	displayed	 strong	defects	 in	 the	 ability	 to	 co-precipitate	 Taf14.	 	 Taken	 together,	 these	 data	 are	 consistent	 with	 the	 Taf2	 C-terminus	containing	at	least	two	distinct	domains	that	can	independently	facilitate	incorporation	of	Taf14	into	the	TFIID	complex.		Thus,	to	completely	abrogate	association	of	Taf14	with	the	TFIID	complex,	both	of	these	domains	must	be	disrupted.		The	Taf14	Binding	Domains	in	Taf2	are	Necessary	for	TAF14	Overexpression	Suppression	of	the	taf2-ts7	Growth	Defect	My	overarching	hypothesis	has	been	that	TAF14	overexpression	suppression	of	the	taf2-ts7	Ts	phenotype	occurs	via	a	Taf2-Taf14	direct	interaction.		By	extension,	if	Taf2	and	Taf14	could	no	longer	physically	interact,	then	TAF14	overexpression	would	no	longer	be	able	to	suppress	the	taf2-ts7	Ts	phenotype.			To	test	this	hypothesis,	I	performed	genetic	complementation	assays	with	TAF2,	
taf2-ΔC,	taf2-ts7	and	taf2-ts7-ΔC,	with	or	without	TAF14	overexpression	(Figure	3.9a).		As		
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shown	 before,	 overexpression	 of	
TAF14	did	not	have	a	strong	impact	on	growth	 of	 strains	 harboring	 TAF2.		However,	 overexpression	 of	 TAF14	 in	strains	harboring	taf2-ΔC	resulted	in	a	synthetic	 slow	 growth	 phenotype.		Similarly,	while	TAF14	 overexpression	suppressed	 the	 taf2-ts7	 Ts	 phenotype,	it	 did	 not	 suppress	 the	 taf2-ts7-ΔC	phenotype	 but,	 instead,	 caused	synthetic	lethality.		Consistent	with	my	hypothesis,	the	Taf14	binding	domains	in	the	Taf2	C-terminus	are	required	for	suppression	 of	 the	 taf2-ts7	 Ts	phenotype.	Furthermore,	my	hypothesis	also	 predicts	 TAF14	 overexpression	drives	 Taf2-Taf14	 complex	 formation	resulting	 in	 stable	 incorporation	 into	the	 TFIID	 complex.	 	 To	 test	 this	hypothesis,	I	performed	anti-HA	coIP	analysis,	as	described	above,	to	determine	the	impact	of	 TAF14	 overexpression	 on	 the	 ability	 of	 Taf2,	 taf2-ΔC,	 taf2-ts7	 and	 taf2-ts7-ΔC	 to	 co-precipitate	 TFIID	 subunits	 (Figure	 3.9b).	 	 The	 strains	 used	 for	 these	 analyses	 were	
	
Figure	3.9:	 	The	Taf14	Binding	Domain	in	Taf2	is	
Necessary	 for	 TAF14	 Overexpression-Mediated	
Suppression	 of	 taf2-ts7.	 A.	 Intragenic	 TAF2	Synthetic	Genetics.		Plasmid	Shuffle	complementation	assays	 performed	 as	 described	 in	 Figure	 3C.	 	 Cells	were	 grown	 for	 72	 hours	 at	 25o	 prior	 to	 imaging.		Representative	 images	 from	 at	 least	 two	 biological	replicates	 are	 presented.	 	TAF2*:	 no	 ORF	 (--),	TAF2,	
HA3NLS-TAF2,	HA3NLS-TAF2-ΔC,	HA3NLS-taf2-ts7	and	
HA3NLS-taf2-ts7-ΔC.	 B.	 Taf2-TFIID	 Co-immunoprecipitation.	 	 Performed	 as	 described	 in	Figure	 3.2	 except	 strains	 also	 contained	 either	 an	empty	 HIS3-marked	 overexpression	 plasmid	 or	 a	
FLAG2NLS-TAF14	 cDNA	 containing	 HIS3-marked	overexpression	 plasmid.	 Representative	 image	 of	 at	least	 two	 biological	 replicates.	 	 TAF2*:	 no	 ORF	 (--),	
TAF2,	 HA3NLS-TAF2,	 HA3NLS-TAF2-ΔC,	 HA3NLS-taf2-
ts7	 and	 HA3NLS-taf2-ts7-ΔC.	 	 Taf14	 WT	 labeled	 14;	FLAG2NLS-Taf14	labeled	F14.		
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pseudodiploid	 for	 both	 TAF2,	 containing	 WT	 and	 a	 test	 TAF2	 allele	 (TAF2*),	 as	 well	 as	
TAF14,	 containing	 genomically-encoded	WT	 TAF14	 and	 either	 an	 empty	 overexpression	plasmid	 or	 an	 expression	 plasmid	 containing	 FLAG2-NLS-tagged	 TAF14.	 	 TAF14	overexpression	had	no	impact	on	the	ability	of	Taf2	to	coIP	Taf7	and	Taf8;	however,	Taf2	co-precipitated	elevated	levels	of	Taf14,	compared	to	the	no	TAF14	overexpression	strain.		Consistent	 with	 the	 synthetic	 sick	 growth	 phenotype,	 taf2-ΔC	 reproducibly	 displayed	 a	modest	reduction	in	the	ability	to	coIP	Taf7	and	Taf8	in	strains	that	overexpressed	TAF14.		Validating	 my	 hypothesis,	 TAF14	 overexpression	 rescued	 the	 ability	 of	 taf2-ts7	 to	 coIP	TFIID	subunits	Taf7,	Taf8	and	Taf14.	 	However,	 taf2-ts7-ΔC	was	not	responsive	to	TAF14	overexpression	and	still	failed	to	efficiently	coIP	TFIID	subunits	Taf7,	Taf8	and	Taf14.		 Replacing	the	Taf14	Binding	Domain	in	Taf2	with	Taf14	via	Gene	Fusion	Partially	Suppresses	the	taf2-ts7-associated	Growth	Defects	My	data	suggests	 that	 the	domain	necessary	 for	Taf2-Taf14	 interaction	resides	within	 Taf2	 aa	 1261-1407	while	 the	 location	 of	 the	mutations	 in	 taf2-ts7	 and	 ts8	 reside	between	 Taf2	 aa	 1100-1150.	 	 Based	 on	 this	 discrepancy,	 I	 conceived	 of	 two	 possible	mechanisms	 through	which	TAF14	 overexpression	 can	 suppress	 the	 growth	 phenotypes	associated	with	these	Ts	mutants.		First,	saturating	the	C-terminus	of	taf2-ts7	and	ts8	with	Taf14	induces	a	conformational	change	that	allows	these	variants	to	more	stably	associate	with	the	TFIID	complex.	 	Second,	when	at	saturating	 levels,	Taf14	can	tether	taf2-ts7	and	ts8	 to	 the	 TFIID	 complex,	 likely	 through	 direct	 interaction	 between	 Taf14	 and	 another	TFIID	subunit(s).		The	first	model	inherently	requires	a	binding	event	where	Taf14	binding		
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Figure	3.10:	 	Replacing	 the	Taf14	Binding	Domain	 in	Taf2	with	Taf14	Partially	Suppresses	
the	taf2-ts7	growth	defect.		A.		Plasmid	Shuffle	Genetic	Complementation.		Performed	as	described	in	 Figure	 3.2.	 	 Cells	 were	 grown	 for	 60	 hours	 at	 25o	 and	 30o	 prior	 to	 imaging.	 	 Plate	 images	representative	 of	 at	 least	 two	 biological	 replicates.	 	 TAF2*:	 	 no	 ORF	 (--),	 TAF2,	 HA3NLS-TAF2,	
HA3NLS-TAF2-ΔC,	 HA3NLS-TAF2-ΔC-TAF14	 chimeric	 fusion,	 HA3NLS-taf2-ts7,	 HA3NLS-taf2-ts7-ΔC,	
HA3NLS-taf2-ts7-ΔC-TAF14	chimeric	 fusion,	HA3NLS-taf2-ts7-ΔC-taf14	m3	chimeric	 fusion,	HA3NLS-
taf2-ts7-ΔC-taf14-W81A	 chimeric	 fusion	 and	 HA3NLS-taf2-ts7-ΔC-taf14-G80K	 chimeric	 fusion.	 	 B.	Steady-State	 Protein	 Immunoblot.	 	 Total	 cell	 protein	 was	 fractionated	 via	 SDS-PAGE	 and	transferred	 to	 PVDF	membrane.	 	 High	molecular	weight	 part	 of	 the	membrane	was	 probed	with	anti-HA	 antibody	 and	 total	 protein	 on	 the	 lower	 molecular	 weight	 part	 of	 the	 membrane	 was	visualized	with	Ponceau-S	as	a	loading	control.	to	 taf2-ts7	 or	 ts8	 induces	 a	 conformational	 change.	 	 The	 second	 model	 involves	 Taf14	playing	a	role	outside	of	simply	Taf2	binding.		 To	 distinguish	 between	 these	 two	models,	 I	 constructed	 Taf2-Taf14	 chimeras	where	 taf2-ΔC	 and	 taf2-ts7-ΔC	 were	 fused	 to	 the	 TAF14	 ORF.	 	 Ideally,	 these	 chimeric	fusions	would	bypass	 the	need	 for	TAF14	overexpression	 to	achieve	saturable	binding	 to	the	 Taf2	 C-terminus	 since	 these	 chimeras	 contain	 covalently	 attached	 Taf14.	 	 These	
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chimeras	were	 tested	 to	see	 if	 they	could	complement	a	 taf2	null	strain	(Figure	3.10a).	A	“WT”	chimera	(taf2-ΔC-Taf14)	supported	growth	at	a	 level	similar	to	TAF2	suggesting	the	chimera	 does	 not	 negatively	 impact	 Taf2	 function.	 	 This	 taf2-ts7-ΔC-TAF14	 chimera	suppressed	the	slow	growth	phenotype	at	30o	associated	with	taf2-ts7	and	taf2-ts7-ΔC.			I	 then	sought	 to	determine	 if	 this	 suppression	was	Taf14-dependent	and,	 if	 so,	which	 domain(s)	 was	 involved.	 	 To	 this	 end,	 I	 made	 taf2-ts7-ΔC-taf14	 chimeras	 with	mutations	either	in	the	Taf2	Binding	Domain	of	Taf14	(taf14-m3:	L186A,	T187A,	K188A)	or	in	 the	 Taf14	 YEATS	 domain	 that	 disrupt	 its	 ability	 to	 bind	 to	 acetylated	 or	 crotonylated	H3K9	(taf14-W81A	and	taf14-G80K)	(Andrews	et	al.,	2016;	Shanle	et	al.,	2015).		Mutations	in	 the	Taf14	C-terminus	 completely	 abrogated	 the	 ability	 of	 the	 chimera	 to	 suppress	 the	growth	defect	 associated	with	 taf2-ts7-ΔC.	 In	addition,	while	both	YEATS	domain	mutant	fusions	displayed	some	reduction	in	the	ability	to	suppress	the	growth	defects	associated	with	taf2-ts7-ΔC,	 the	G80K	mutation	displayed	a	significant	loss	in	the	ability	to	suppress.	The	 loss	of	suppression	cannot	be	attributed	to	a	reduction	 in	steady-state	protein	 levels	since	all	constructs	were	expressed	at	least	as	well	as	WT	Taf2	(Figure	3.10b).			Taf14-less	TFIID	Mutant	Cells	Display	a	Slow	Growth	Phenotype	and	Defects	in	RPG	Transcript	Abundance	My	results	suggest	that	the	Taf2	C-terminus	is	not	only	required	for	Taf2-Taf14	interaction	but	it	is	also	required	for	association	of	Taf14	with	the	TFIID	complex.		To	test	this	hypothesis,	 I	engineered	two	strains:	one	that	genomically	encodes	an	HA1-tag	at	the	N-terminus	of	Taf1	for	anti-HA	immunopurification	and	one	that	encodes	both	an	HA1-Taf1	and	genomic	deletion	of	Taf2	aa	1261-1407.		TFIID	was	purified	from	these	two	strains	as		
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Figure	3.11:		Taf14-less	TFIID	Mutant	Cells	Display	a	Slow	Growth	Phenotype	and	Defects	
in	 Ribosomal	 Protein	 Gene	 Transcription.	 A.	 Purified	 TFIID	 Forms.	 	 Between	 300	 and	 600	nanograms	of	HA1-Taf1	purified	TFIID	and	HA1-Taf1	Taf2-ΔC	purified	TFIID	were	separated	via	SDS-PAGE	and	stained	with	Sypro	Ruby	gel	stain.		Peak	traces	were	generated	using	Quantity	One	(Bio-Rad).	 	 TFIID	 subunit	 peaks	 were	 quantified	 in	 ImageJ	 by	 calculating	 the	 area	 under	 the	curve.	 	The	signal	 intensity	of	Taf6	was	used	to	normalize	each	TFIID	preparation	to	determine	relative	 subunit	 stoichiometry	 for	 each	 peak.	 	 Mean	 ±	 SD	 is	 depicted.	 	 Quantitation	 generated	from	 two	 technical	 replicates.	 B.	 	 Growth	 Rate	 Analysis.	 	 Log	 phase	 growing	 taf2	 null	 cells	shuffled	to	contain	either	plasmid-borne	HA3NLS-TAF2	or	plasmid-borne	HA3NLS-TAF2-ΔC	were	diluted	 to	an	optical	density	 (OD)	at	600nm=	~0.2	 (HA3NLS-TAF2,	 average	 start	OD600	=	0.229;	
HA3NLS-TAF2-ΔC,	 average	 start	 OD600	 =	 0.239),	 grown	 at	 30o	 and	 OD600	 was	 measured	approximately	every	hour	until	the	strains	reached	stationary	phase	growth.		Doubling	time	was	calculated	using	a	non-linear	exponential	growth	fit	(GraphPad	Prism)	for	the	early	phase	of	the	growth	curve	(first	7	time	points).		Growth	curve	was	performed	with	four	biological	replicates.		Experimental	error	in	doubling	time	is	derived	from	S.E.M.				
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described	 in	 Chapter	 II,III	 Methods	 and	 then	 subjected	 to	 SDS-PAGE	 and	 gel	 staining	 to	score	TFIID	subunit	composition	and	stoichiometry	(Figure	3.11a).	 	When	comparing	 the	TFIID	variants,	two	differences	were	apparent.		First,	in	the	Taf2-ΔC	TFIID,	the	size	of	Taf2	was	 reduced	 reflecting	 the	 genomic	 Taf2	 C-terminal	 deletion.	 	 However,	 Taf2-ΔC	 is	maintained	at	an	apparent	1:1	Taf2-TFIID	stoichiometric	ratio	relative	 to	Taf1,	 similar	 to	HA1-Taf1	TFIID,	indicating	that	the	deletion	does	not	negatively	impact	the	stability	of	Taf2	in	the	TFIID	complex.		Second,	in	the	Taf2-ΔC	TFIID,	Taf14	is	completely	absent,	consistent	with	 our	 Taf2	 C-terminus	 truncation	 analyses.	 	 Quantitation	 of	 these	 TFIID	 preparations	demonstrates	that	the	stoichiometry	for	the	rest	of	the	TFIID	subunits	 is	similar	between	the	 two	 TFIID	 forms.	 	 Based	 on	 these	 data,	 I	 can	 conclude	 that	 Taf2	 aa	 1261-1407	 are	necessary	 for	Taf14	 stable	 incorporation	 into	 the	TFIID	 complex	and	 that	 strains	 lacking	Taf2	aa	1261-1407	have	TFIID	devoid	of	Taf14	(Taf14-less	TFIID).		 When	 I	 streaked	 these	 TFIID	 purification	 strains	 onto	 rich	 medium	 to	 isolate	single	colonies,	I	found	that	the	Taf14-less	TFIID	strain	displayed	a	reduced	growth	rate	as	measured	by	 colony	 size	 (data	not	 shown).	 	To	determine	 if	 this	phenotype	was	directly	attributable	 to	 the	 Taf2-ΔC	 variant,	 growth	 curves	were	 performed	 in	 yeast	 strains	 that	contain	only	HA-TAF2	or	HA-taf2-ΔC.		These	growth	curves	revealed	that	strains	harboring	
Figure	3.11	Continued:	
C,D,E.		qRT-PCR.		Steady-state	RNA	was	analyzed	by	qRT-PCR	scoring	for	C.	RNA	Pol	II,	D.	RNA	Pol	I	and	E.	RNA	Pol	 III	 transcribed	genes.	 	Data	were	generated	 from	 four	biological	 replicates.	 	Each	data	 point	 in	 the	 graph	 represents	 one	 biological	 replicate	 and	 is	 generated	 from	 the	 average	 of	three	 technical	 replicates.	 Results	were	 statistically	 analyzed	 using	 a	 2-way	 ANOVA	with	 Sidak’s	multiple	 comparisons	 test	 (GraphPad	 Prism).	 Mean	 ±	 SD	 is	 depicted.	 *=	 p<0.05,	 ***=	 p≤0.0001.		Blue	 =	 shuffled	 strain	 harboring	 plasmid-borne	 HA3NLS-TAF2,	 Red	 =	 shuffled	 strains	 harboring	plasmid-borne	HA3NLS-TAF2-ΔC.	
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HA-TAF2-ΔC	 displayed	 a	 14.5	 min	 (15.6%)	 slower	 growth	 rate	 during	 log	 phase	 at	 30o	(Figure	3.11b).		 I	 then	 assessed	 steady-state	 transcript	 abundance	 for	 these	 two	 strains.	 	 RNA	was	 extracted	 from	 mid-log	 phase	 cells	 growing	 at	 25o	 and	 analyzed	 using	 qRT-PCR.		Despite	 no	 reduction	 in	 transcript	 abundance	 for	 RNA	 polymerase	 I	 transcribed	RDN58	(Figure	 3.11d)	 and	 RNA	 polymerase	 III	 transcribed	 SNR6	 (Figure	 3.11e),	 I	 reproducibly	observed	 a	 statistically	 significant	~2-fold	 reduction	 in	RPG	 transcript	 abundance	 (RPS5,	
RPS9B,	RPS8A,	RPS3)	 (Figure	3.11c).	 	 In	addition,	 I	observed	a	moderate	(~25%),	 though	not	statistically	significant	 for	both	genes,	reduction	 in	steady-state	 transcript	abundance	for	the	SAGA-dominated	glycolytic	PGK1	and	PYK1	genes.		Although	the	glycolytic	genes	are	not	considered	TFIID-dependent,	my	data	are	consistent	with	previously	observed	modest	reductions	in	PGK1	steady-state	transcripts	in	taf4ts	variants	(Layer	and	Weil,	2013).				 DISCUSSION	
	 Multiple	 structural	 and	 biochemical	 studies	 have	 attributed	 specific	 Tafs	 with	promoter-DNA	 or	 modified	 chromatin-binding	 capabilities	 (Andrews	 et	 al.,	 2016;	 Burke	and	Kadonaga,	1997;	Chalkley	and	Verrijzer,	1999;	Gazit	et	al.,	2009;	Jacobson	et	al.,	2000;	Kaufmann	et	al.,	1998,	1996;	Lauberth	et	al.,	2013;	Oelgeschläger	et	al.,	1996;	Shanle	et	al.,	2015;	 Shao	 et	 al.,	 2005;	 Verrijzer	 et	 al.,	 1994).	 	 These	 activities	 provide	 convenient	mechanisms	 through	 which	 TFIID	 can	 engage	 with	 genes	 to	 facilitate	 PIC	 formation.		Indeed,	an	activator-TFIID-TFIIA	promoter	DNA	quaternary	complex,	with	distinct	TFIID-DNA	 interactions,	 displays	 a	 locked	 DNA	 conformational	 state	 that	 likely	 serves	 as	 a	
	 141	
platform	 for	 general	 transcription	 factor	 and	Pol	 II	 binding	 (Andrews	et	 al.,	 2016;	Burke	and	Kadonaga,	1997;	Chalkley	and	Verrijzer,	1999;	Gazit	et	al.,	2009;	Jacobson	et	al.,	2000;	Kaufmann	et	al.,	1998,	1996;	Lauberth	et	al.,	2013;	Oelgeschläger	et	al.,	1996;	Shanle	et	al.,	2015;	Shao	et	al.,	2005;	Verrijzer	et	al.,	1994).		However,	these	many	biochemical	activities	have	rarely	been	interrogated	genetically	to	establish	their	importance	in	vivo	(Lauberth	et	al.,	 2013).	 	 This	 lack	 of	 knowledge	 was	 the	 impetus	 for	 the	 work	 reported	 in	 this	dissertation.				Specifically,	 the	 functional	 role	 of	 Taf2	 in	 vivo	 was	 largely	 unknown,	 despite	longstanding	 evidence	 for	 its	 in	vitro	 INR	 binding	 activity	 (Chalkley	 and	Verrijzer,	 1999;	Kaufmann	et	al.,	1998,	1996).		A	lack	of	Taf2	molecular	genetic	studies	is	likely	a	result	of	technical	 challenges.	 	 In	 addition	 to	 being	 essential	 for	 life,	 Taf2	 is	 a	 large	 protein	 and	particularly	 labile	 in	 ScTFIID	 purifications	 (Papai	 et	 al.,	 2009;	 Ray	 et	 al.,	 1991).	 	 As	 this	chapter	 demonstrates,	 systematic	 deletion	 analyses	 largely	 disrupt	 Taf2	 protein	 stability	and	 the	 ability	 of	 Taf2	 to	 stably	 incorporate	 into	 the	 TFIID	 complex,	 precluding	conventional	 methods	 of	 genetically	 interrogating	 large	 proteins	 (Table	 3.1)	 (Bai	 et	 al.,	1997;	 Knutson	 and	 Hahn,	 2011;	 Singh	 et	 al.,	 2004).	 	 Our	 site-directed	 mutagenesis	approach	 generated	 variants	 that	 displayed	 similar	 TFIID-incorporation	 defects,	 limiting	our	ability	 to	 interpret	 their	precise	molecular	 functions	(Figure	3.2).	 	Of	note,	while	 this	manuscript	was	in	preparation,	specific	amino	acids	were	predicted	to	be	important	for	the	INR	 binding	 function	 of	 Taf2	 (Louder	 et	 al.,	 2016).	 	 One	 of	 the	 site-directed	 mutants	generated	in	this	study,	taf2-m32,	targeted	a	subset	of	these	residues	but	displayed	only	a	mild	 slow	 growth	 phenotype	 and	 was	 not	 further	 pursued	 (Table	 3.2).	 	 Genetic	
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interrogation	of	this	putative	INR	binding	domain	will	 likely	shed	insights	into	the	role	of	INR	binding	in	TFIID	transcriptional	activation.	The	key	finding	in	this	chapter	is	the	discovery	of	a	genetic	interaction	between	
TAF2	 and	 TAF14.	 Individual	 overexpression	 of	 each	 TFIID	 subunit	 identified	 TAF14	overexpression	as	a	mechanism	to	achieve	suppression	of	select	taf2ts	alleles	(taf2-ts7	and	
ts8).		The	location	of	the	residues	mutated	in	these	Ts	variants	is	suggestive	of	a	functional	domain.	 	 Furthermore,	 I	 demonstrated	 that	 Taf2	 and	 Taf14	 directly	 interact.	 Molecular	genetic	 dissection	 of	 both	 Taf2	 and	 Taf14	 led	 to	 the	 identification	 of	 the	 domains	responsible	for	physical	and	functional	interaction	in	vivo	and	in	vitro.			Our	 lab’s	 previous	 structural	 and	 biochemical	 characterization	 of	 the	 TFIID	complex	 identified	 the	 stoichiometry	 and	 location	 of	 all	 of	 the	 TFIID	 subunits	 with	 the	exception	of	Taf14	 (Leurent	 et	 al.,	 2004,	 2002;	 Papai	 et	 al.,	 2009;	 Sanders	 et	 al.,	 2002a).		Purified	TFIID	displays	a	stoichiometry	of	at	least	two	copies	of	Taf14	per	TFIID	molecule.		In	addition,	Taf14	 self-associates	 in	vivo.	 	However,	 gel	 staining	of	purified	SWI/SNF	and	TFIIF	show	one	copy	per	complex,	so	this	multi-copy	per	complex	phenotype	is	likely	to	be	specific	 to	 TFIID	 (Cairns	 et	 al.,	 1996;	 Henry	 et	 al.,	 1994).	 	While	 deletion	 of	 the	 Taf2	 C-terminus	completely	disrupts	association	of	Taf14	with	the	TFIID	complex,	fine	mapping	of	the	 Taf2	 C-terminus	 identified	 two	 domains	 that	 can	 independently	 facilitate	 Taf14	incorporation	 into	 the	TFIID	 complex.	 	 This	 data	 is	 consistent	with	 a	 genome	wide	 two-hybrid	screen,	which	identified	part	of	the	Taf2	C-terminus	as	a	Taf14	interacting	protein	(Kabani	 et	 al.,	 2005).	 Yet,	 Taf2	 variants	 that	 fail	 to	 stably	 incorporate	 into	 the	 TFIID	complex	as	well	as	Taf2	C-terminal	fragments	display	reductions	in	Taf14	co-precipitation	relative	to	WT	Taf2.		This	observation	suggests	that	when	Taf2	incorporates	into	the	TFIID	
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complex,	Taf14	binding	is	enhanced,	potentially	through	a	multivalent	binding	site	between	Taf2	and	another	TFIID	subunit(s).			Interestingly,	the	Taf2	domain	identified	to	directly	interact	with	Taf14	does	not	contain	the	amino	acids	mutated	in	taf2-ts7	or	ts8,	despite	this	domain	being	required	for	
TAF14	 overexpression	 suppression	 of	 these	 variants.	 	 To	 test	 the	 possibility	 of	 a	multivalent	Taf14	binding	site	between	Taf2	and	another	TFIID	subunit,	I	fused	TAF14	to	a	
taf2ts	variant	deleted	for	the	Taf14	binding	domain.	This	chimeric	fusion	improved	growth	in	a	TAF14-dependent	manner	consistent	with	the	existence	of	a	multivalent	binding	site.		The	TFIID	subunit	responsible	is	likely	to	be	Taf8.		Human	Taf2	directly	interacts	with	Taf8	(Trowitzsch	et	al.,	2015).		Taf1-TAP	purifications	of	TFIID	result	in	substoichiometric	levels	of	Taf2,	Taf8	and	Taf14	(Papai	et	al.,	2009).		Furthermore,	specific	deletions	in	Taf1	result	in	dissociation	of	Taf2,	Taf8	and	Taf14	from	the	TFIID	complex	suggesting	that	these	three	subunits	form	a	subcomplex	(Singh	et	al.,	2004).	 	As	with	human	TFIID,	the	association	of	Taf2	and	Taf8,	along	with	Taf14,	with	the	TFIID	core	may	stimulate	a	structural	transition	in	the	TFIID	assembly	pathway	(Bieniossek	et	al.,	2013).	The	 function	 of	 Taf14	 in	 transcription	 regulation	 has	 remained	 enigmatic.		Functional	 interpretation	 of	TAF14	mutant	 variants	 is	 limited	 because	 of	 its	 presence	 in	multiple	transcription-related	complex	assemblies	(Cairns	et	al.,	1996;	Henry	et	al.,	1994;	Kabani	 et	 al.,	 2005;	 Sanders	 et	 al.,	 2002b).	 	 Specifically,	 molecular	 defects	 in	 taf14	 null	strains	or	strains	harboring	taf14	mutant	variants	unable	to	bind	modified	H3K9	could	be	attributed	to	TFIID-promoter	 interactions,	 the	role	of	TFIIF	 in	PIC	or	elongation	function,	ATP-dependent	 chromatin	 remodeling	 or	 the	 myriad	 transcription	 related	 functions	associated	with	Mediator.		The	results	presented	in	this	chapter	begins	to	decipher	the	role	
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of	Taf14	 in	 transcription	regulation	through	the	 identification	of	taf2-ΔC,	a	separation-of-function	 Taf2	 variant	 that	 can	 stably	 incorporate	 into	 the	 TFIID	 complex	 but	 precludes	incorporation	 of	 Taf14.	 	 The	 existence	 of	 this	 variant	 is	 consistent	 with	 the	 model	presented	by	Kabani	et	al.	that	Taf14	has	a	particular	entry	point	protein	in	each	complex	with	 which	 it	 is	 associated	 (Kabani	 et	 al.,	 2005).	 	 Thus,	 it	 may	 be	 possible	 to	 generate	genetic	 reagents	 that	 specifically	 dissociate	 Taf14	 from	 the	 TFIIF,	 Ino80,	 Swi/Snf,	 NuA3,	Mediator	 and	 RSC	 without	 perturbing	 complex	 integrity	 or	 the	 other	 functions	 of	 the	complex.	 	 taf2-ΔC	 mutant	 cells	 display	 a	 modest	 slow-growth	 phenotype	 as	 well	 as	 a	reduction	in	transcript	abundance	for	the	TFIID-dominated	RPGs.		In	addition,	purification	of	 TFIID	 from	 strains	 harboring	 taf2-ΔC	 yields	 a	 Taf14-less	 TFIID	 complex.	 	 Structural	analyses	of	this	complex	in	contrast	with	WT	TFIID	may	yield	to	important	insights	into	the	location	 of	 Taf14	 in	 TFIID	 as	 well	 as	 the	mechanism	 by	which	 two	 copies	 of	 Taf14	 can	associate	with	a	single	TFIID	molecule.			My	 data	 suggests	 that	 taf2-ΔC	 is	 a	 true	 separation-of-function	 variant	 whose	cellular	 and	 molecular	 phenotypes	 reflect	 the	 contribution	 of	 Taf14	 to	 TFIID	 function	(Figure	3.12).		However,	the	mechanism	by	which	Taf14	contributes	to	TFIID	transcription	activation	 mechanism	 remains	 speculative.	 	 	 The	 Taf14	 YEATS	 domain	 responsible	 for	binding	 to	modified	 chromatin	 (Andrews	 et	 al.,	 2016;	 Shanle	 et	 al.,	 2015)	may	 enhance	TFIID	occupancy	of	active	genes	by	increasing	the	number	of	contact	points	between	TFIID	and	gene	promoters.		In	addition,	the	Taf2-Taf14	chimeric	fusion	analyses	suggest	that	the	YEATS	domain	does	contribute	to	TFIID	function,	likely	through	its	ability	to	interact	with	modified	chromatin.		This	hypothesis	is	consistent	with	the	observation	that	the	Taf3	PHD	finger	H3K4me3	binding	activity	stimulates	transcription,	especially	in	context	of	a	mutant		
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Figure	 3.12:	 	 Model	 of	 Taf2-Taf14	 Interaction	 in	 TFIID-Dependent	 Transcription.	 	 (Left)	Depicts	 role	 of	 Taf2	 C-terminus	 in	 facilitating	 incorporation	 of	 two	 Taf14	 molecules	 per	 TFIID	complex.	 	 Taf14	may	 then	 bind	 to	 active	 chromatin	 through	 its	 YEATS	 domain.	 	 Brown	 circles	 =	histone	octamer,	yellow	stars	=	modified	H3K9,	D1	=	 the	Taf2	Taf14	Binding	Domain	1,	D2	=	 the	Taf2	Taf14	Binding	Domain	2.	 (Right)	Taf14	 cannot	 incorporate	 into	 the	TFIID	 complex	and	as	 a	result	 TFIID	 may	 lose	 the	 ability	 communicate	 with	 active	 chromatin	 through	 the	 Taf14	 YEATS	domain.		TATA-box	 (Lauberth	 et	 al.,	 2013).	 	 Similar	 in	 vitro	 transcription	 experiments	 with	chromatin	 templates	 need	 to	 be	 performed	with	WT	 and	 Taf14-less	 TFIID	 to	 assess	 the	validity	 of	 this	model	 for	 ScTFIID	 considering	 the	 Taf3	 PHD	 finger	 is	 not	 present	 in	 the	yeast	system.		On	 the	 other	 hand,	 the	 Taf14	 YEATS	 domain	 is	 non-essential	 and	 displays	minimal	 growth	 defects	when	 deleted	whereas	 deletion	 of	 the	 Taf14	 C-terminal	 domain	phenocopies	the	taf14	null	strain	(Schulze	et	al.,	2010).		Considering	the	Taf14	C-terminal	domain	 is	 responsible	 for	 the	 interaction	 with	 Taf14-associated	 complexes,	 this	 domain	could	mediate	 interactions	among	 these	complexes	 that	have	 thus	 far	not	been	explored.		We	 do	 not	 know	 if	 a	 single	 Taf14	 molecule	 can	 bind	 to	 multiple	 transcription-related	complexes	 at	 the	 same	 time	 or	 if	 binding	 of	 Taf14	 to	 TFIID	 or	 TFIIF,	 for	 example,	 are	mutually	exclusive.		If	these	interactions	are	not	mutually	exclusive,	Taf14	could	serve	as	a	
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bridge	between	the	transcription	machinery	that	could	play	a	key	role	in	the	transcription	process.		 In	summary,	 through	systematic	mutagenesis	of	 the	TFIID	subunit	Taf2,	 I	have	uncovered	important	physical	and	functional	interactions	between	Taf2	and	Taf14.		These	discoveries	have	shed	light	on	the	role	Taf14	plays	in	TFIID	function,	including	a	putative	role	 in	 TFIID-chromatin	 interaction.	 	 I	 believe	 this	 work	 could	 provide	 a	 model	 for	disambiguating	the	role	Taf14	plays	in	gene	regulatory	mechanisms.				 													
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CHAPTER	IV		 FUTURE	DIRECTIONS		 Summary		 	 The	work	presented	thus	far,	at	its	nature,	reflects	my	desire	to	understand	the	structural	 organization	 and	 function	 of	 the	 TFIID	 general	 transcription	 factor	 and	 co-activator	 complex.	 	 In	 particular,	 when	 I	 started	 as	 a	 graduate	 student	 in	 the	 Weil	laboratory,	our	knowledge	of	the	largest	TFIID	subunit	in	yeast	and	second	largest	subunit	in	 metazoans,	 Taf2,	 was	 woefully	 incomplete.	 My	 systematic	 genetic	 and	 biochemical	dissection	of	Taf2	helped	 to	define	 the	 interaction	domains	between	Taf2	and	Taf14	and	the	 importance	 of	 this	 interaction	 to	 Taf2-TFIID	 association	 and	 ribosomal	 protein-encoding	gene	transcription.		Yet,	there	is	still	much	to	learn	about	Taf2	and	TFIID	function.	The	findings	described	in	this	dissertation	will	serve	as	the	foundation	onto	which	multiple	avenues	of	study	could	be	built.			Specifically,	 our	 understanding	 of	 TAF2	 function	 within	 the	 TFIID	 complex	remains	poorly	understood	in	vivo.		I	will	describe	additional	studies	that	have	allowed	me	to	 generate	 taf2ts	 variants	 that	 could	be	used	 to	 acutely	 disrupt	 the	 stable	 association	of	Taf2	with	 the	TFIID	 complex.	 	The	 implications	 for	proposed	 future	 studies	utilizing	 this	type	of	mutant	variant	are	discussed.	 	 	 	Alternatively,	the	recent	structural	data	of	Taf2	in	complex	with	promoter	DNA	make	very	specific	predictions	regarding	which	Taf2	amino	acids	are	critical	for	this	function	(Louder	et	al.,	2016).		Mutation	of	these	amino	acids	may	prove	 insightful	 regarding	 Taf2/TFIID	 DNA	 binding	 activity	 and	 its	 role	 in	 transcription	
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activation	 in	 vivo.	 	 In	 addition,	 the	 link	 between	 the	 Taf14	H3K9ac-	 or	 H3K9cr-modified	chromatin	binding	activity	and	TFIID	function	remains	to	be	defined.		The	identification	of	the	taf2-ΔC	mutant	variant	and	Taf14-less	TFIID	will	likely	be	useful	for	addressing	the	role	of	Taf14	chromatin	binding	in	TFIID-dependent	transcription	activation	in	vitro.		 	 Attempts	 at	 reconstituting	 TFIID	 in	 cells	 using	 recombinant	 protein	overexpression,	 while	 unsuccessful,	 have	 provided	 an	 important	 framework	 for	 probing	TFIID	submodule	assembly	and	structure.	 	 I	will	discuss	ideas	to	utilize	the	multi-subunit	Gal	 inducible	overexpression	system	I	have	developed	to	define	the	organizing	principles	for	 TFIID	 assembly	 as	 well	 as	 methods	 to	 identify	 the	 existence	 of	 TFIID	 assembly	intermediates	in	vivo.		 What	is	the	Fate	of	TFIID	Without	Taf2?		 	 The	 initial	 site-directed	 mutagenesis	 screen	 I	 performed	 on	 Taf2	 yielded	 a	number	 of	 Ts	 and	 inviable	 mutant	 variants.	 	 While	 I	 was	 able	 to	 glean	 information	regarding	Taf2-Taf14	interaction	through	genetic	analyses	(Chapter	3),	the	fact	that	all	of	the	mutant	variants	that	displayed	significant	negative	growth	phenotypes	also	displayed	a	reduction	 in	 the	 ability	 of	 Taf2	 to	 stably	 incorporate	 into	 the	 TFIID	 complex	 was	disheartening.	 	Ideally,	the	goal	of	my	mutagenesis	strategy	was	to	generate	a	separation-of-function	mutation	whereby	Taf2	stability	 in	 the	TFIID	complex	 is	unperturbed	but	 the	biochemical	 function	 (i.e.	 DNA	 or	 transcription	 factor	 binding	 or	 ability	 to	 undergo	 a	conformational	change)	of	Taf2	and	the	TFIID	complex	is	disrupted.		I	hypothesized	that	I	was	 not	 able	 to	 identify	 any	 of	 these	 separation-of-function	 variants	 through	 my	 first	mutagenesis	 screen	 because	 the	 majority	 of	 variants	 involved	 ala	 block	 mutations	 that	
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were	quite	 large	and	potentially	disruptive	to	 local	domain	folding.	To	rectify	this	 issue,	 I	was	intent	on	performing	saturation	3ala	(primarily)	block	mutagenesis,	in	the	sense	that	every	 single	 residue	 would	 be	 mutated,	 on	 the	 N-terminus	 of	 Taf2	 (Table	 4.1).	 The	 N-terminus	was	chosen	because	a	 large	number	of	 the	Ts	or	 lethal	variants	 I	derived	 in	my	first	screen	localized	to	the	N-terminal	β-sheet	motifs.		 	 Through	these	analyses,	 I	 identified	an	additional	9	taf2	variants	that	display	a	growth	defect	at	the	permissive	temperature	and	are	Ts	at	the	non-permissive	temperature	as	well	as	6	taf2	variants	that	are	inviable	(summarized	in	Table	4.1).	 	Unfortunately,	as	I	observed	with	my	original	screen,	all	of	these	variants	were	unable	to	stably	associate	with	the	TFIID	complex	as	well	as	WT	Taf2.		In	light	of	these	results,	I	began	contemplating	what	experiments	 one	 could	 do	 if	 s/he	 had	 a	 taf2	 tight	 temperature	 sensitive	 variant	 whose	obvious	 molecular	 phenotype	 was	 a	 disruption	 in	 the	 ability	 to	 interact	 with	 the	 TFIID	complex.			Answering	 this	 question	 requires	 an	 in-depth	 explanation	 to	 how	 I	 have	 been	performing	my	co-IP	assays,	which	I	 like	to	call	competition	coIPs.	 	First,	when	I	perform	the	coIP	to	test	these	variants,	I	use	pseudodiploid	strains	expressing	both	an	untagged	WT	Taf2	and	the	tagged	Taf2	test	variant.	 	Furthermore,	both	versions	are	driven	off	the	ADH	promoter,	which	overexpresses	Taf2	relative	 to	 its	endogenous	chromosomal	 locus	 (data	not	 shown).	 	 Thus,	 the	 amount	 of	 both	 versions	 of	 Taf2	 are	 likely	 in	 excess	 to	 what	 is	required	 to	 associate	 with	 TFIID	 at	 normal	 physiological	 levels.	 	 In	 this	 instance,	 if	 the	mutant	 version	of	Taf2	 can	 associate	with	TFIID	as	well	 as	 the	WT	version	of	Taf2,	 coIP	efficiencies	will	remain	the	same.		However,	if	the	mutant	version	does	not	associate	with		
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Table	4.1 TAF2	SD	mutants	Round	2	-	N-terminal	Saturation	Mutagenesis
AA	Targeted Sequence Mutations Growth	Phenotype CoIP	Phenotype
29-31 RVA AAA WT	Growth Not	Tested
32-34 HEK AAA WT	Growth Not	Tested
35-37 ISL AAA WT	Growth Not	Tested
38-40 DID AAA WT	Growth Not	Tested
41-43 LAT AAA WT	Growth Not	Tested
44-46 HCI AAA WT	Growth Not	Tested
47-49 TGS AAA WT	Growth Not	Tested
50-52 ATI AAA WT	Growth Not	Tested
53-55 III AAA WT	Growth Not	Tested
56-58 PLI AAA WT	Growth Not	Tested
59-61 QNL AAA WT	Growth Not	Tested
62-64 EYV AAA Slow	Growth	and	Ts Not	Tested
65-67 TFD AAA Very	Slow	Growth	and	Ts Failed	to	CoIP	TFIID	Subunits
68-70 CKE AAA WT	Growth Not	Tested
71-73 MTI AAA Very	Slow	Growth	and	Ts Failed	to	CoIP	TFIID	Subunits
74-76 KDV AAA WT	Growth Not	Tested
77-80 LVEN AAAA WT	Growth Not	Tested
105-108 LYSD AAAA WT	Growth Not	Tested
109-112 NSIE AAAA WT	Growth Not	Tested
113-116 QSHF AAAA WT	Growth Not	Tested
117-119 LRS AAA WT	Growth Not	Tested
121 F A WT	Growth Not	Tested
128 P A WT	Growth Not	Tested
144,146 IKI AKA WT	Growth Not	Tested
154-155 LS AA WT	Growth Not	Tested
156-176 Deletion (GGG)	insert WT	Growth Not	Tested
177-179 PIT AAA WT	Growth Not	Tested
180-182 LQI AAA Inviable Failed	to	CoIP	TFIID	Subunits
183-185 EYE AAA Very	Slow	Growth	and	Ts Failed	to	CoIP	TFIID	Subunits
191-193 SGI AAA WT	Growth Not	Tested
194-196 KFD AAA Inviable Failed	to	CoIP	TFIID	Subunits
197-199 TVY AAA WT	Growth Not	Tested
201-203 DKP AAA WT	Growth Not	Tested
204-206 WLW AAA WT	Growth Not	Tested
207-209 NVY AAA WT	Growth Not	Tested
210-212 TSN AAA WT	Growth Not	Tested
213-215 GEI AAA WT	Growth Not	Tested
216-218 CSS AAA WT	Growth Not	Tested
220-222 SYW AAA Near	WT	@	Permssive,	Mild	Ts Not	Tested
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Table	4.1	continued TAF2	SD	mutants	Round	2	-	N-terminal	Saturation	Mutagenesis
AA	Targeted Sequence Mutations Growth	Phenotype CoIP	Phenotype
223-225 VPC AAA Near	WT	@	Permssive,	Mild	Ts Not	Tested
226-229 VDLL AAA Near	WT	@	Permssive,	Mild	Ts Not	Tested
232-234 KST AAA Near	WT	@	Permssive,	Mild	Ts Not	Tested
235-237 WEL AAA Inviable Failed	to	CoIP	TFIID	Subunits
239-240 FS AA WT	Growth Not	Tested
241-242 VP AA WT	Growth Not	Tested
247-250 NIGT AAAA WT	Growth Not	Tested
251-253 SKL AAA WT	Growth Not	Tested
254-257 IGQN AAAA WT	Growth Not	Tested
258-363 Deletion (GGG)	insert Inviable Failed	to	CoIP	TFIID	Subunits
364-365 KK AA Slow	Growth	and	Ts Failed	to	CoIP	TFIID	Subunits
366-368 KCI AAA WT	Growth Not	Tested
374-376 PVA AAA WT	Growth Not	Tested
377-379 PHH AAA WT	Growth Not	Tested
380-382 IGW AAA Inviable Failed	to	CoIP	TFIID	Subunits
383-387 AIGAF AAAAA Slow	Growth	and	Ts Failed	to	CoIP	TFIID	Subunits
393-432 Deletion (GGG)	insert WT	Growth Not	Tested
433-435 PIQ AAA WT	Growth Not	Tested
436-438 IFT AAA WT	Growth Not	Tested
446-448 ELT AAA WT	Growth Not	Tested
449-450 VI AA WT	Growth Not	Tested
451-453 NST AAA WT	Growth Not	Tested
459-461 IID AAA WT	Growth Not	Tested
462-464 FYS AAA Near	WT	@	Permssive,	Mild	Ts Not	Tested
465-467 KEF AAA Near	WT	@	Permssive,	Mild	Ts Not	Tested
468-470 GSY AAA WT	Growth Not	Tested
471-473 PFT AAA Slow	Growth	and	Ts Failed	to	CoIP	TFIID	Subunits
474-476 CYS AAA Slow	Growth	and	Ts Failed	to	CoIP	TFIID	Subunits
477-479 MVF AAA Slow	Growth	and	Ts Failed	to	CoIP	TFIID	Subunits
480-482 LPT AAA Very	Slow	Growth	and	Ts Failed	to	CoIP	TFIID	Subunits
483-485 APS AAA WT	Growth Not	Tested
486-488 KHM AAA Near	WT	@	Permssive,	Mild	Ts Not	Tested
489-491 DFA AAA WT	Growth Not	Tested
492-494 ALG AAA WT	Growth Not	Tested
495-497 ICN AAA Inviable Failed	to	CoIP	TFIID	Subunits
498-501 TRLL AAAA Near	WT	@	Permssive,	Tight	Ts Not	Tested
502-505 YPLE AAAA WT	Growth Not	Tested
783-817 Deletion no	insert Near	WT	@	Permssive,	Tight	Ts Not	Tested
**	Note:		All	mutants	displayed	steady-state	protein	levels	similar	to	WT.
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the	 TFIID	 complex	 as	 well	 as	 WT	 Taf2,	 the	 mutant	 will	 display	 a	 reduction	 in	 coIP	efficiency.	 	 This	 does	 not	 mean	 that	 the	 mutant	 variant	 cannot	 associate	 with	 TFIID.		Indeed,	 in	 shuffled	 strains	 containing	 only	 a	mutant	 taf2	 variant	 that	 does	 not	 associate	with	TFIID	 as	well	 as	WT,	 I	 am	able	 to	 observe	 co-precipitation	 of	Tafs	 at	 levels	 greater	than	observed	for	that	mutant	variant	in	the	“competition”	coIP	(data	not	shown).			Based	on	this	rationale,	it	is	my	supposition	that	these	taf2ts	variants	can	weakly	but	 productively	 associate	 with	 TFIID	 at	 the	 permissive	 temperature,	 allowing	 them	 to	grow	at	least	to	a	certain	extent.		However,	upon	shift	to	the	non-permissive	temperature,	Taf2	 can	 no	 longer	 associate	 with	 the	 TFIID	 complex	 resulting	 in	 a	 loss	 of	 appropriate	transcription	regulation	 for	 the	genes	 that	 require	Taf2	 function.	 	 In	addition,	 in	an	 ideal	mutant,	this	loss	of	interaction	between	the	taf2	variant	and	TFIID	would	likely	manifest	as	an	abrupt	growth	arrest	when	acutely	shifted	to	the	non-permissive	growth	temperature.		As	mentioned	above,	the	problem	with	my	initial	random	mutagnesis	screen	was	that	none	of	the	mutants	I	generated	could	arrest	growth	in	liquid	culture	following	shift	to	the	non-permissive	temperature.	 	 I	 tested	four	of	the	mutant	variants	derived	from	my	saturation	mutagenesis	 screen	of	 the	Taf2	N-terminus	 for	 the	 ability	 to	 arrest	 following	 shift	 to	 the	non-permissive	 temperature.	 	 All	 of	 these	 variants	 quickly	 arrested	 growth,	 including	 a	variant	with	only	2ala	block	mutation	(taf2-ts148;	Figure	4.1).		To	 confirm	my	 hypothesis	 that	 these	 taf2ts	 variants	 dissociate	 from	 the	 TFIID	complex	 following	 shift	 to	 the	 non-permissive	 temperature,	 coIP	 analyses	 of	 shuffled	strains	harboring	 these	variants	would	need	 to	be	performed	pre-	 and	post-temperature	shift.		In	lieu	of	these	data,	I	believe	this	type	of	Taf2	mutant	variant	could	be	useful	for	two	major	lines	of	inquiry.		First,	upon	disruption	of	Taf2	from	the	TFIID	complex,	what	is	the	
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state	of	the	rest	of	the	TFIID	complex?		Both	genetic	and	biochemical	 perturbations	related	 to	 Taf1	demonstrate	 that	 a	 TFIID	subcomplex	 can	 form	containing	 all	 of	 the	 TFIID	subunits	 sans	 Taf2,	 Taf8	and	 Taf14	 (Papai	 et	 al.,	2009;	 Singh	 et	 al.,	 2004).		Would	this	subcomplex		form	 in	 strains	 harboring	these	taf2ts	variants	upon	shift	to	the	non-permissive	temperature?		If	so,	how	would	TFIID	occupancy	change	on	gene	promoters?	 	More	 importantly,	how	would	gene	 transcription	change?			 With	current	methodologies,	all	of	these	questions	could	be	answered	in	a	rather	straightforward	manner.		For	example,	ChIP-exo	can	be	used	to	measure	TFIID	occupancy	genome-wide	by	scoring	Taf1	occupancy	(Rhee	and	Pugh,	2012).	 	In	addition,	ChiP-exo	of	Pol	 II	 can	 serve	 as	 a	 surrogate	 for	 active	mRNA	gene	 transcription.	 	 In	 the	 case	 that	my	hypothesis	 is	not	correct	and	shift	 to	 the	non-permissive	temperature	does	not	alter	Taf-TFIID	 association,	 I	 would	 employ	 the	 auxin	 inducible	 degron	 system	 to	 conditionally	deplete	Taf2	from	the	cell	(Nishimura	et	al.,	2009).		Assuming	the	stability	of	the	rest	of	the	TFIID	Tafs	is	not	altered	by	targeted	degradation	of	Taf2,	the	end	result	would	likely	be	the	
	
Figure	 4.1:	 	 taf2ts	 Mutants	 Arrest	 Growth	 Upon	 Shift	 to	 the	
Non-permissive	 Temperature.	 	 S.	 cerevisiae	 harboring	 taf2ts	variants	containing	2-	or	3ala	block	mutations	were	grown	at	25o	prior	 to	abrupt	shift	 to	37o.	 	Following	the	 temperature	shift,	 cell	density	 (OD600)	 was	 measured	 over	 time.	 	 Results	 are	 plotted	above.	
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formation	of	a	similar	putative	TFIID	subcomplex.		Ultimately,	I	would	hope	that	this	TFIID	subcomplex	 could	 still	 effectively	 drive	 transcription	 for	 a	 subset	 of	 genes.	 	 In	 this	 case,	these	 experiments	 would	 identify	 the	 group	 of	 genes	 that	 are	 reliant	 on	 Taf2	 function.		Similarities	 between	 these	 genes	 such	 as	 trans-activator	 binding	 sites,	 sequences	 of	 the	core	promoter	or	even	the	gene	product	could	provide	insights	into	the	role	of	Taf2	in	gene	regulation	in	S.	cerevisiae.		 Dissection	of	the	Putative	Taf2	DNA	Binding	Domain		 	 The	structural	model	of	TFIID	bound	to	promoter	DNA	published	by	the	Nogales	lab	may	lead	to	novel	insights	into	the	function	of	Taf2	within	TFIID	(Louder	et	al.,	2016).		Using	 docking	 of	 endoplasmic	 reticulum	 aminopeptidase-1,	 a	 homologous	 structure	 to	Taf2,	 Louder	 et	 al.	 was	 able	 to	 determine	 the	 structure	 of	 Taf2	 to	 atomic	 resolution,	including	key	evolutionarily	 conserved	amino	acids	 that	are	predicted	 to	directly	 contact	DNA.	 	 From	 a	 genetic	 perspective,	 these	 residues	would	 serve	 as	 fertile	 ground	 for	 site-directed	mutagenesis	to	determine	if	mutation	of	this	putative	DNA	binding	domain	results	in	a	growth	defects	in	yeast.		 	 While	 I	 was	 performing	 my	 original	 site-directed	 mutagenesis	 screen,	 I	 did	identify	 one	 variant	 with	 mutations	 that	 correspond	 to	 this	 putative	 Taf2	 DNA	 binding	domain	that	also	contained	a	growth	defect,	taf2-m32	(ala	block	mutation	of	aa	775-780).		Strains	 harboring	 taf2-m32	 displayed	 a	mild	 slow	 growth	phenotype	 at	 all	 temperatures	tested.		In	addition,	coIP	analyses	demonstrate	that	this	variant	can	stably	incorporate	into	the	TFIID	complex	(Figure	4.2b).		Based	on	my	model	generated	in	Chapter	3	(Figure	3.12),		
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Figure	4.2:		Growth,	CoIP	and	RNA	Analysis	of	the	m32	+	ΔC	taf2	Combination	Mutant.		A,B.		Plasmid	 shuffle	 complementation	 and	 coIP	 analyses	 performed	 as	 described	 in	 Figure	 3.2.	 	 C.		Steady-state	RNA	measurements	using	qRT-PCR	as	described	in	Figure	3.4.	 	Data	generated	from	two	biological	replicates.		Error	bars	represent	standard	deviation.	I	 proposed	 that	 Taf14	 binding	 to	 active	 chromatin	 marks	 served	 as	 another	 contact	between	TFIID	and	gene	promoters.	 	 Interestingly,	 cells	 containing	Taf14-less	TFIID	also	display	 a	 mild	 slow	 growth	 phenotype	 at	 all	 temperatures	 tested,	 although	 it	 is	 more	apparent	at	lower	temperatures.	 	This	led	me	to	hypothesize	that	if	I	were	to	disrupt	two	putative	contact	points	between	TFIID	and	the	promoter,	by	disrupting	Taf14-TFIID	stable	association	and	by	mutating	the	putative	Taf2	DNA	binding	domain,	then	I	would	observe	a	synthetic-sick	phenotype.			Indeed,	when	I	combined	the	mutations	 in	 taf2-m32	with	 the	 taf2-ΔC	mutation	(taf2-m32-ΔC),	strains	harboring	this	double	mutant	showed	significantly	reduced	growth	
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at	 the	 permissive	 temperature	 and	 a	 Ts	 phenotype	 at	 the	 non-permissive	 temperature	(Figure	 4.2a).	 	 Immunoblot	 analysis	 of	 these	 strains	 demonstrated	 that	 taf2-m32-ΔC	protein	was	made	and	stable	at	levels	even	greater	than	WT	Taf2	but	comparable	to	taf2-
ΔC	(Figure	4.2b).		Importantly,	this	taf2-m32-ΔC	variant	could	immunoprecipiate	TFIID	at	levels	comparable	to	WT	Taf2	(immunoprecipitation	of	taf2-ts7	included	as	a	reference	for	a	taf2	mutant	that	fails	to	coIP	TFIID	efficiently).		qRT-PCR	analyses	were	performed	with	RNA	extracted	from	cells	grown	at	the	permissive	temperature	and	harboring	TAF2,	taf2-
m32,	 taf2-ΔC	 or	 taf2-m32-ΔC.	 	 Consistent	with	data	 shown	 in	Figure	3.11,	RNA	extracted	from	taf2-ΔC	mutant	cells	shows	a	roughly	2-fold	reduction	in	transcripts	derived	from	the	ribosomal	protein-encoding	genes	 (RPS3,	RPS5,	RPS8A	and	RPS9B)	without	a	 comparable	reduction	in	the	glycolytic	genes	(PGK1	and	PYK1).	 	RNA	extracted	from	taf2-m32	mutant	essentially	shows	the	same	steady-state	RNA	phenotype	as	taf2-ΔC	mutant	cells.		However,	
taf2-m32-ΔC	 mutant	 cells	 display	 a	 ~10	 fold	 reduction	 in	 steady-state	 RNA	 from	 the	ribosomal	protein-encoding	genes.		But,	these	cells	also	display	a	~2-3-fold	reduction	in	the	glycolytic	genes	(Figure	4.3c).	 	These	data	demonstrate	that	the	mutations	in	taf2-m32	do	compromise	Taf2	 function,	 especially	when	 combined	with	mutations	 that	 disrupt	Taf14	stable	association	with	TFIID.	It	would	also	be	informative	to	perform	the	same	ChIP-exo	analysis	as	described	above	 to	 determine	 on	which	 genes	 TFIID	 and	 Pol	 II	 occupancy	 is	 impacted.	 	 For	 these	experiments,	 I	 think	 it	would	be	 imperative	 to	use	 the	 auxin	 inducible	degron	 system	 to	accurately	 interpret	 the	results.	 	Specifically,	cells	would	be	pseudodiploid	 for	a	WT	Taf2	copy	that	could	be	targeted	for	degradation	and	a	second	test	variant	of	Taf2	(either	WT,	taf2-ΔC,	taf2-m32	or	taf2-m32-ΔC)	that	would	be	unaffected	by	inducible	depletion.		Under	
	 157	
normal	 growth	 conditions,	 all	 of	 the	 cells	 would	 grow	 similarly	 to	WT	 because	 none	 of	these	mutant	alleles	are	dominant.		However,	upon	depletion	of	the	WT	copy,	the	molecular	phenotype	 would	 reflect	 the	 test	 version	 of	 Taf2	 without	 the	 complication	 of	 indirect	effects	associated	with	working	with	shuffled	yeast	strains	(Sun	et	al.,	2013,	2012).		Again,	these	types	of	experiments	could	 inform	us	as	to	which	genes	Taf2	function	is	critical	 for	TFIID-dependent	gene	regulation.	While	 these	 in	 vivo	 molecular	 phenotypes	 are	 promising,	 the	 main	 hurdle	 to	advancing	this	work	is	an	assay	that	measures	Taf2-DNA	binding.		Despite	significant	effort,	I	was	only	 able	 to	 observe	 a	 small,	 inconsistent	 amount	of	Taf2-DNA	binding	when	Taf2	was	in	vast	excess		(>100-fold)	to	DNA	(data	not	shown).		Alternatively,	it	is	likely	that	Taf2	plays	 an	 important	 role	 in	TFIID-DNA	binding	 that	 I	 have	not	been	 able	 to	 observe	with	pure	Taf2	alone.	 	Therefore,	 in	order	to	determine	 if	 the	taf2-m32	mutations	 impact	DNA	binding,	I	propose	that	TFIID-DNA	enzymatic	and	chemical	footprinting	be	performed	with	WT	and	taf2-m32	mutant	forms	of	TFIID.		The	results	of	these	footprinting	analyses	could	be	informative	regarding	the	impact	of	a	Taf2-DNA	binding	defective	mutant	on	TFIID-DNA	binding	affinity	or	on	the	sequences	protected	from	digestion.		Either	result	would	support	the	 findings	 observed	 in	 vivo	 and	 further	 establish	 Taf2-DNA	 binding	 as	 a	 key	 accepted	activity	for	TFIID-dependent	transcription	regulation.		 The	Role	of	Taf14	in	Chromatin	Transcription	The	 experiments	 detailed	 in	 Chapter	 III	 cemented	 the	 Taf2	 C-terminus	 as	 a	critical	 domain	 for	 the	 stable	 association	 of	 Taf14	with	 the	 TFIID	 complex.	 	 In	 addition,	biochemical	 and	 structural	 studies	 have	 demonstrated	 that	 Taf14	 can	 bind	 acetylated	 or	
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crotonylated	 histone	marks	 (Andrews	 et	 al.,	 2016;	 Shanle	 et	 al.,	 2015).	 	 Together,	 these	data	 led	 me	 to	 put	 forth	 a	 model	 (Figure	 3.12)	 that	 predicts	 that	 yeast	 TFIID	 makes	multiple	 promoter	 contacts	 through	 DNA	 and	 active	 histone	 marks,	 both	 of	 which	 are	important	for	TFIID	function.	To	test	this	model,	especially	pertaining	to	the	role	of	Taf14	in	TFIID	promoter	binding,	 I	 would	 need	 to	 perform	 both	 binding	 studies	 and	 in	 vitro	 transcription	 with	chromatinized	 templates.	 	 For	 in	vitro	 binding	 studies,	 I	would	 prepare	 end-biotinylated	positioned	 mononucleosomal	 templates	 for	 immobilization	 on	 streptavidin	 beads	(Gaykalova	et	al.,	2009).		This	template	would	be	designed	to	mimic	the	structure	of	the	+1	nucleosome	at	a	TFIID-dominated	promoter.	In	addition,	these	mononucleosomes	could	be	acetylated	 in	 vitro	 using	 purified	 SAGA	 and/or	 NuA4.	 	 I	 would	 then	 perform	 pull-down	assays	with	WT	or	taf2-ΔC	mutant	TFIID,	with	or	without	TFIIA.		If	my	model	were	correct,	TFIID-template	 binding	 would	 be	 stimulated	 in	 the	 presence	 of	 acetylated	 histones.		Furthermore,	this	stimulation	would	be	blunted,	if	not	eliminated	in	the	absence	of	Taf14.		These	 pull-down	 assays	 could	 also	 be	 supplemented	 with	 footprinting	 analysis	 to	determine	 if	 stimulating	 binding	 to	 a	 nucleosomal	 template	 enhances	 or	 changes	 TFIID-DNA	binding	properties.			Similarly,	 I	 would	 perform	 in	 vitro	 transcription	 assays	 with	 purified	 in	 vivo	assembled	 chromatin	 templates,	 using	 either	 of	 one	 of	 the	 methods	 developed	 by	 the	Kornberg	laboratory	(Griesenbeck	et	al.,	2003)	or	the	Tsukiyama	laboratory	(Unnikrishnan	et	 al.,	 2012).	 	 I	 would	 use	 these	 chromatinized	 templates	 for	 in	 vitro	 transcription	with	extracts	 (Woontner	 et	 al.,	 1991)	 that	 were	 immunodepleted	 for	 TFIID	 and	 then	reconstituted	with	either	WT	TFIID	or		taf2-ΔC	mutant	TFIID	(Sanders	et	al.,	2002a).		Again,	
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I	 would	 expect	 to	 see	 a	 reconstitution	 of	 activity	 with	 WT	 TFIID	 that	 would	 not	 be	observed,	 at	 least	 to	 the	 same	 extent,	 with	 taf2-ΔC	mutant	 TFIID.	 	 Similar	 results	 were	observed	by	the	Roeder	lab	with	regard	to	Taf3	PHD	finger-mutant	TFIID	and	transcription	from	H3K4me3-modified	chromatin	templates	(Lauberth	et	al.,	2013).	These	studies	would	support	my	model	regarding	the	role	Taf14	plays	in	TFIID-promoter	association.	 	 In	addition,	 these	studies	would	help	reinforce	the	 idea	that	while	yeast	 and	metazoan	TFIID	have	differences	 regarding	promoter	 structure	 and	 chromatin	binding	domains,	the	general	mechanisms	through	which	TFIID	engages	the	promoter	are	conserved.		 Biochemical	and	Structural	Analysis	of	TFIID	Submodules		 	 I	spent	a	significant	amount	of	time	and	energy	during	my	dissertation	research	attempting	 to	 reconstitute	 TFIID	 using	 recombinant	 overexpression	 methods.	 	 While	 I	made	progress	 in	replicating	published	data	(Bieniossek	et	al.,	2013),	 I	was	never	able	to	fully	reconstitute	the	complex.	 	Nonetheless,	I	believe	that	my	efforts	have	paved	the	way	for	an	 iterative	expression	and	 immunopurification	strategy	where	each	TFIID	subunit	 is	expressed	 in	 combination	 with	 other	 TFIID	 subunits	 in	 the	 hopes	 of	 forming	 TFIID	submodules.	 	 Alternatively,	 I	 have	 identified	 a	 genetic	 reagent	 that	 could	 help	 drive	formation	 of	 TFIID	 submodules	 in	 vivo	 and	 help	 to	 identify	 how	 yeast	 Tafs	 assemble	 in	vivo.	 	Using	 either	method,	 the	 identification	of	 these	 submodules	 could	 then	be	used	 to	assemble	 the	holoTFIID	 complex.	 	 In	 addition,	 submodules	 could	be	analyzed	by	 cryoEM	and/or	X-ray	crystallography	for	structural	determination.	
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	 	 The	 multi-ORF	 overexpression	 system	 in	 S.	 cerevisiae	 was	 highly	 effective	 at	expressing	between	one	and	six	distinct	TFIID	subunits	at	the	same	time	in	the	same	cell.		Using	this	methodology,	the	first	complex	I	would	attempt	to	reconstitute	is	the	Taf2-Taf8-Taf10-Taf14	 complex.	 	When	 the	Berger,	 Tora	 and	 Schultz	 labs	 identified	 the	 Taf2-Taf8-Taf10	complex,	I	had	already	transitioned	away	from	reconstituting	TFIID	and	was	intent	on	dissecting	the	interactions	between	Taf2	and	Taf14	(Trowitzsch	et	al.,	2015).		Given	my	knowledge	of	the	interaction	between	Taf14	and	Taf2,	I	strongly	believe	that	I	could	form	this	 Taf2-Taf8-Taf10-Taf14	 complex.	 	 In	 addition,	 I	 hypothesize	 that	 this	 complex	 will	solubilize	Taf8	in	a	manner	that	heretofore	I	have	been	unable	to	do	through	my	attempts	to	form	Taf	subcomplexes	in	Sf9	cells.		Through	collaboration,	the	structures	of	these	TFIID	subcomplexes	 could	 be	 analyzed	 with	 cryoEM	 and	 computational	 docking	 methods	 to	model	 the	 structure	 of	 these	 four	 subunits.	 	 New	 EM	 detectors	 have	 allowed	 structural	biologists	 to	 resolve	 cryoEM	 structures	 to	 atomic	 resolution,	 revolutionizing	 the	 field	 of	structural	 biology	 of	 large	 complexes	 (Callaway,	 2015).	 	 Additionally,	 I	 would	 perform	cryoEM	 analysis	 for	 every	 TFIID	 subcomplex	 that	 I	 generate,	 especially	 if	 I	were	 able	 to	iteratively	build	the	TFIID	complex	one	subunit	or	heterodimer	at	a	time.	 	This	step-wise	approach	could	be	used	to	map	protein	interfaces,	potential	conformational	changes	upon	protein-protein	 interactions	and	 the	 locations	of	new	proteins	 as	 they	are	 added	 in	 each	step	of	the	TFIID	complex	building	process.		 	 An	entirely	different	question	is	whether	these	TFIID	subcomplexes	exist	in	cells	(other	 than	the	Taf2-Taf8-Taf10	complex).	 	When	I	was	attempting	to	reconstitute	 the	5-Taf	 TFIID	 core	 complex	 +	 the	 Taf8-Taf10	 heterodimer,	 I	 hypothesized	 that	 extra	 yeast	specific	domains	of	Taf8	may	be	 the	cause	of	 the	aggregation	phenotype	 I	was	observing	
	 161	
(yeast	Taf8	 is	200aa	 larger	than	 metazoan	 Taf8,	 see	Figure	 1.7).	 	 In	 an	 attempt	to	solubilize	Taf8,	I	deleted	some	 of	 the	 yeast	 specific	
TAF8	 sequence	 to	determine	 if	 it	 was	essential	 for	 viability.	 	 One	of	 the	 variants	 I	 generated	(TAF8	Δ215-332)	displayed	a	mildly	dominant	negative	phenotype	 (Figure	 4.3a,	left;	 compare	 growth	 to	strain	 Pre-Shuffle).	 	 In	addition,	 this	 variant	 could	not	 support	 viability	(Figure	4.3a,	right).		I	then	performed	my	customary	steady-state	immunoblotting	and	coIP	analyses	 and	 found	 that	 this	 variant	 of	 Taf8	 could	 efficiently	 coIP	 many	 of	 the	 TFIID	subunits,	but	failed	to	coIP	others	(Figure	4.3b).		Interestingly,	the	subunits	Taf8	Δ215-332	could	co-precipitate	corresponded	very	well	to	the	5-Taf	TFIID	core	(Taf4,	Taf5,	Taf6,	Taf9,	Taf12)	 with	 the	 addition	 of	 Taf10.	 	 However,	 the	 Taf8	 Δ215-332	 variant	 could	 not	efficiently	coIP	Tafs	1,	2,	7	and	14.		
	
Figure	 4.3:	 	 Identification	 of	 a	 TAF8	 Deletion	 Variant	 that	
Facilitate	Formation	of	a	TFIID	Subcomplex	in	vivo.			A.		Plasmid	shuffle	 analyses	 performed	 as	 described	 in	 Chapter	 III	 Methods	and	Figure	3.2a	with	the	exception	that	the	strain	used	is	taf8	null	with	a	URA3-marked	TAF8	covering	plasmid	(YSLS58,	(Gangloff	et	al.,	 2001b)).	 	 The	 expression	 plasmids	 encoding	 the	 test	 TAF8	alleles	 were	 derived	 from	 p415ADH.	 	 HA=HA3NLS.	 	 B.	 Co-IP	analyses	 as	 described	 in	 Chapter	 III	methods	 and	 in	 Figure	 3.2b.		For	these	experiments,	either	untagged	or	HA-tagged	Taf8	and	the	HA-tagged	Taf8	Δ215-332	variant	were	immunoprecipitated	out	of	cell	extracts	rather	than	Taf2	forms.	
	 162	
Preliminary	data	suggests	that	Taf3,	Taf11	and	Taf13	also	fail	 to	coIP	with	this	complex	(data	not	shown).	 	The	 idea	 that	Tafs	3,	11	and	13	could	not	associate	with	 this	complex	is	in	conflict	with	my	Sf9	cell	co-expression	analyses	(Figure	2.4a).		However,	as	I	described	above,	 the	 stoichiometry	observed	within	 the	Sf9	 cell-generated	7Taf	and	9Taf	complexes	did	not	reflect	the	stoichiometry	observed	for	TFIID	purified	from	S.	cerevisiae.		Thus,	it	is	possible	that	association	of	Tafs	3,	11	and	13	with	the	overexpressed	5-Taf	TFIID	core	is	an	artifact	that	does	not	reflect	the	true	nature	of	TFIID.		Indeed,	through	personal	communication	with	 the	Berger	and	Schultz	 labs,	 I	was	 informed	that	association	of	Taf3	with	 the	 5-Taf	 core	 resulted	 in	what	 they	 described	 as	 a	 dead-end	 complex,	meaning	 it	could	not	associate	with	any	additional	TFIID	subunits.	Furthermore,	 this	 complex	was	 also	 able	 to	 co-precipitate	 TBP.	 	 This	 result	 is	interesting	because	it	also	conflicts	with	my	Sf9	cell	co-expression	data	where	TBP	was	not	effectively	 precipitated	when	 I	 tried	 to	 co-express	 every	TFIID	 subunit	 at	 the	 same	 time	(Figure	2.4b).		In	that	TFIID	co-expression	experiment,	I	was	able	to	see	co-precipitation	of	the	entire	5-Taf	core	+	Taf8-10	by	immunoblotting	(Figure	2.4	and	data	not	shown).		While	this	result	is	perplexing,	it	made	me	consider	the	differences	between	TFIID	and	SAGA.		In	the	Schultz	and	Berger	model,	the	binding	of	Taf8	and	Taf10	to	the	5-Taf	TFIID	core	results	in	 a	 conformational	 change	 that	 would	 facilitate	 the	 association	 of	 the	 remaining	 TFIID	subunits.	 	 What	 would	 then	 happen	 if	 the	 domains	 of	 Taf8	 that	 were	 required	 for	 this	conformational	 changes	were	 not	 present	 or	 functional?	 	 Could	 SAGA	 subunits	 associate	with	the	5-Taf	core	in	the	absence	of	this	conformational	change	resulting	in	TBP	binding?		At	this	point,	this	is	all	conjecture;	however,	the	TAF8	Δ215-332	mutant	could	be	useful	for	exploring	 what	 the	 fate	 of	 the	 remaining	 TFIID	 subunits	 if	 the	 5-Taf	 TFIID	 core	 cannot	
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undergo	 the	 Taf8-induced	 conformational	 change	 in	 vivo	 (Figure	 4.4;	 model	 of	 TFIID	assembly	and	theoretical	submodule).						 	 My	 results	 suggest	 that	 the	 subunits	 that	Taf8	Δ215-332	 cannot	 co-precipitate	are	Taf1,	Taf2,	Taf3,	Taf7,	Taf11	and	Taf13.		Could	these	subunits	form	a	submodule	in	the	absence	 of	 the	 TFIID	 5-Taf	 core	 or	 do	 they	 just	 individually	 assemble	 onto	 5-Taf	 core	 +	Taf8-Taf10	complex?	 	To	address	 this	question,	 I	would	engineer	a	strain	 to	express	 two	forms	 of	 Taf8:	 a	 conditional	 WT	 Taf8	 variant	 that	 could	 be	 depleted	 using	 the	 auxin	inducible	degron	 system	and	 the	Taf8	Δ215-332	variant.	 	 Following	depletion	of	 the	WT	Taf8	protein,	my	hypothesis	is	that	Taf8	Δ215-332	would	block	the	conformational	change	of	 the	5-Taf	TFIID	core	and,	as	a	 result,	 the	 rest	of	 the	TFIID	subunits	may	be	prevented	from	 properly	 associating	 with	 the	 TFIID	 complex.	 I	 would	 then	 individually	immunoprecipitate	Tafs	1,	2,	3,	11	and	13	and	immunoblot	for	all	of	these	subunits	to	see	if	any	 form	 subcomplexes.	 	 Currently,	 we	 have	 a	 poor	 understanding	 of	 the	 interaction	network	and	structure	of	 this	 lobe	of	 the	TFIID	complex	 (Taf1,	Taf3,	Taf11	and	Taf13	all	map	to	the	A	lobe	of	TFIID,	Figure	1.6).			These	above	proposed	experiments	could	address	this	deficiency.	If	immunopreciptiation	of	Taf1	(or	any	of	the	A	lobe	Tafs)	were	to	still	result	in	co-precipitation	of	 the	5-Taf	core	 in	strains	containing	only	Taf8	Δ215-332,	 then	 I	would	instead	 individually	 deplete	 every	 single	TFIID	 subunit	 using	 the	 auxin	 inducible	 degron	system	 (Nishimura	 et	 al.,	 2009).	 	 Following	 depletion,	 I	 would	 perform	 coIP	 analysis,	forming	 immunoprecipitates	 using	 antibodies	 against	 several	 different	 TFIID	 subunits	 to	determine	which	subcomplexes	remain.		This	approach	was	employed,	to	a	certain	extent,	by	the	Tjian	laboratory	where	they	used	siRNA	to	individually	knockdown	many	of	the		
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Figure	 4.4:	 	 Model	 of	 TFIID	 Assembly	 Based	 on	 Submodules	 Revealed	 by	 Taf8	 Δ215-332.		Schematic	 of	 TFIID	 assembly	 starting	 with	 the	 5-Taf	 TFIID	 core	 complex.	 	 Modular	 assembly	proceeds	through	step-wise	association	TFIID	submodules	with	the	5-Taf	core.		Binding	of	Tafs	2,	8,	10	and	14	to	the	5-Taf	core	results	in	a	conformational	change	that	enables	association	of	the	rest	of	the	TFIID	subunits.		In	the	presence	of	Taf8	Δ215-332,	association	of	Taf2	and	Taf14	are	disrupted	from	binding	to	the	5-Taf	core	resulting	in	the	accumulation	of	putative	TFIID	submodules.			
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TFIID	subunits	and	then	monitored	steady-state	protein	levels	of	the	other	TFIID	subunits	(Wright	et	al.,	2006).		Through	this	knockdown	paradigm,	they	were	the	first	to	suggest	the	existence	of	the	5-Taf	TFIID	core	complex.		However,	these	analyses	were	not	performed	on	all	of	 the	TFIID	subunits.	 	 In	addition,	 following	knockdown,	Tjian	and	colleagues	did	not	follow	 up	 by	 performing	 multiple	 distinct	 coIP	 reactions	 to	 identify	 the	 residual	subcomplexes.		 	 Taken	 together,	 I	 have	 described	 several	 distinct	 approaches	 that	 attack	 the	problem	 of	 identifying	 stable	 subcomplexes	 within	 holoTFIID,	 if	 they	 exist.	 	 These	subcomplexes	 could	 then	 be	 used	 to	 assemble	 the	 holoTFIID	 complex	 in	 vitro.	 	 If	 TFIID	subcomplexes	can	be	produced	efficiently	and	in	high	abundance,	this	method	could	easily	be	 used	 to	make	mutant	 forms	 of	 TFIID	 that	 would	 allow	 for	 in-depth	 biochemical	 and	structural	characterization	of	the	TFIID	complex.		 	 	 										
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